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Preface
This manual has been prepared for clinicians, researchers, public health 
professionals, and other personnel who wish to conduct epidemiologic studies of 
reproductive health issues. It is intended to be used in a two-week workshop that 
includes an introduction to epidemiologic methods, the unique applications of 
these methods to reproductive health research, and the development of research 
proposals. The manual is not intended to replace the many excellent resources 
and texts presently available on these subjects. Course participants use the 
teaching materials to develop research proposals about reproductive health 
problems that are of interest to them or to the organizations they represent. 
Representatives from funding agencies attend the final session of the workshop to 
observe presentations of the research proposals prepared during the workshop and 
to make recommendations about further development of the projects and possible 
funding.
The evolution of this workshop and manual has been extensive. Many 
organizations and individuals have contributed to this project over a long period 
of time. In November 1980 while working in Asia, Drs. Linda Atkinson and 
Oscar (Bud) Harkavy, Program Officers at the Ford Foundation, and Dr. Roger 
Rochat from the Centers for Disease Control (CDC) discussed the need to 
support capacity-building in epidemiologic research in developing countries, 
particularly in the area of contraceptive safety (broadly defined to include the 
health consequences of not contracepting as well as maternal mortality). 
Discussions with health personnel at The United States Agency for International 
Development (USAID) (Jim Shelton, Tony Boni), the Ford Foundation (Lincoln 
Chen, Tony Measham), the Population Council (Jarrett Clinton), and the 
International Development Research Council (Marjorie Koblinsky) provided the 
impetus to increase the number and quality of contraceptive safety studies being 
implemented internationally. Training in epidemiology, research methodology, 
and proposal development were used to accomplish this objective. As a result, 
five contraceptive safety workshops were developed for presentation in 
Southeast Asia.
These first workshops were a collaborative effort by the Division of 
Reproductive Health at CDC, the Population Council, and the Ford Foundation. 
The objectives for these first workshops included the following:
• To increase the knowledge of health professionals in Southeast Asia about 
the principles of epidemiology.
• To assist workshop participants in developing research proposals for 
conducting contraceptive safety studies.
• To increase the number and quality of epidemiologic studies on 
contraceptive safety conducted in Southeast Asia.
Each of the first five workshops was scheduled to last one week. Didactic 
sessions and group exercises were the primary approaches used for the
xvii
presentation of materials. To supplement the lecture materials, a training manual 
was developed and included information on the principles of epidemiology and 
research design, examples of epidemiologic studies from the literature (from 
Southeast Asia whenever possible), case studies, and practice exercises. Other 
teaching materials included epidemiology textbooks, statistical monographs, and 
publications from the medical and epidemiologic literature on contraceptive 
safety. Participants worked in groups of 4 to 8 persons to develop research 
proposals on studies of contraceptive safety. The research proposals were 
presented on the last day of the workshop to a panel of health professionals 
familiar with contraceptive safety concerns in the region. Feedback was provided 
by the panel regarding the relevance of the problem selected, the suitability of the 
selected study design, and the feasibility of implementing the study. These 
presentations helped to formalize the learning experiences of the participants 
from the workshop and to publicize to potential funding agencies the research 
hypotheses and methodologies for contraceptive safety studies that the participants 
hoped to eventually conduct.
To evaluate the success of the workshop and to help the workshop participants 
assess their progress during the workshop, tests on the principles of epidemiology 
were administered on the first day and last days of the workshop. The same test 
was administered on both days. In general, test scores at the conclusion of the 
workshop were approximately twice as high as test scores on the pretest.
The first workshop was planned and developed during the summer of 1981 by 
George Rubin (CDC) and Christine Zahniser (CDC) and conducted on 
September 21-28, 1981, in Bangkok, Thailand. Andrew Fisher (The Population 
Council) managed the logistics, including the selection of the workshop 
participants. David Brandling-Bennett from the World Health Organization 
(WHO), Andrew Fisher, George Rubin, and Christine Zahniser were workshop 
instructors. The first workshop trained 12 workshop participants from four 
countries in Southeast Asia. Three additional workshops were conducted in 
Bangkok during February 1982, October 1982, and March 1983; additional 
instructors from CDC included Carlos Huezo and Peter Layde.
After the first Bangkok workshop, CDC received a request for a national 
workshop in Bangladesh. This workshop was a collaborative effort by CDC, the 
Program for the Introduction and Adaptation of Contraceptive Technology 
(PIACT), and The Population Council/International Center for Diarrhoeal 
Disease Research. David Grimes and Christine Zahniser conducted the first 
national workshop in Dhaka, Bangladesh, in March 1982. Atiqur Rahman Khan 
(PIACT), a regional resource person for the September 1981 workshop in 
Thailand, and Yusef Choudhury (PIACT) arranged the Bangladesh workshop. 
PIACT received grant monies from the Ford Foundation for contraceptive safety 
research in Bangladesh that ultimately were used to support research initiated 
during the workshop.
The series of national workshops in Bangkok stimulated substantial interest 
among the participants, private organizations, and government organizations 
such as USAID, WHO, the Ford Foundation, the Population Council, and the
Johns Hopkins Program for International Education in Gynecology and Obstetrics 
(JHPIEGO) for conducting additional workshops. Furthermore, the newly 
developed technical expertise of selected participants proved useful for 
implementing research and future workshops.
Beginning in 1983, Family Health International (FHI) provided technical 
assistance to an epidemiologic training program implemented by the Instituto de 
Investigación Científica of the Universidad Juarez, Durango, Mexico. With 
support from FHI and the United Nations Family Planning Assistance (UNFPA), 
the Instituto trained and funded investigators from Mexico and other countries in 
Latin America to conduct epidemiologic studies of reproductive health issues.
The training was provided annually to approximately 10 students during a three- 
week workshop in Durango. Materials used in the workshop evolved from those 
developed by the Division of Reproductive Health at CDC and were prepared in 
a self-instructional format in both English and Spanish.
As an outgrowth of the epidemiology training program supported by FHI and 
UNFPA at the Instituto, the Mexican Interuniversity Group for Epidemiologic 
Research in Reproductive Health (GIMIESAR) was formed in 1984. GIMIESAR 
is based in Durango and includes representatives from Mexican universities and 
medical schools who received training in the Durango workshops. GIMIESAR 
has embellished the training materials originally developed in collaboration with 
FHI and has been responsible for organizing and presenting the annual workshop 
since 1985. Later workshops were coordinated by the Mexican Institute of Social 
Security (IMSS), WHO, and CDC and were conducted during March and 
November 1990. Jose Becerra, Daniel Hernandez, Octavio Mojarro, Holly 
Shulman, and Phyllis Wingo from CDC were workshop instructors.
The first regional workshop in Africa was conducted in Mombassa, Kenya, in 
1983 by Ronald Burkman, Michael Dalmat, David Grimes, Peter Lamptey, 
Japheth Mati, Hamid Rushwan, and Kenneth Schulz. For this workshop, the 
instructional materials were expanded to include randomized clinical trials, 
surveys, and sample size and power estimation. The length of the workshop was 
extended to two weeks, a recommendation that had been made during the 
Southeast Asia workshops. JHPIEGO managed the administrative functions for 
this workshop and paid all participant costs. Representatives from potential 
funding agencies participated in a grant application review process during the last 
two days of the workshop, and three research projects were funded. The results 
of a randomized clinical trial of the efficacy of prophylactic antibiotics 
administered when an intrauterine device was inserted were recently published. 
The need to train additional reproductive health professionals resulted in a 
national workshop conducted in 1985 by Barbara Janowitz, John Repke, George 
Rubin, Kenneth Schulz, and Charles Warren.
Another regional workshop in Africa was sponsored by the Special Programme 
on Human Reproduction (WHO) and was conducted in Yaounde, Cameroon, in 
September 1987 by Robert Anda, Nancy Binkin, Barbara Maciak, and Phyllis 
Wingo. Boniface Nasah (Centre Universitaire pour la Science et la Sante and 
Centre Hospitalier Universitaire) facilitated the presentation of the workshop.
The collaboration among CDC, FHI, and WHO that resulted in the preparation 
of the present version of the manual evolved from this workshop. Carol Hogue 
supported the completion of this project through steady encouragement and the 
provision of program resources and protected time.
The first national workshop in China, a collaborative effort between the CDC 
and the Beijing Medical College, was conducted in October 1983 by Charles 
Chen, Carol Hogue, George Rubin, and Roger Rochat. A  participant at the 
fourth regional workshop in Thailand, Qiao Geng-Mei (Beijing Medical 
University), was instrumental in arranging the first China workshop. The second 
workshop in China was requested through WHO and conducted by Jonathan Liff, 
Wong-Ho Chow, Raymond Bain, and Roger Rochat from Emory University, 
Atlanta, Georgia, in 1986. For both workshops, the manual was translated into 
Chinese. All lectures were conducted in English and simultaneously were 
translated into Chinese.
The first national workshop in Indonesia was coordinated by the Indonesian 
National Family Planning Board (BKKBN), Yayasan Kusuma Buana (YKB), the 
Ford Foundation of Indonesia, and the CDC. The workshop was conducted in 
January 1987 by Nancy Lee, Edmond Maes, and Phyllis Wingo. An Indonesian 
researcher, Joedo Prihartono (YKB), a participant at the first regional workshop 
in Thailand, arranged for the participants to attend the workshop and managed 
the administrative functions of the workshop. The manual was translated into 
Bahasa Indonesian. The proposal to conduct a case-control study of the possible 
association between hepatocellular adenoma and the use of oral contraceptives 
received funding for further development. Although participants ultimately 
established a surveillance system for identifying biopsy-proven cases of 
hepatocellular adenoma, the case-control study has not yet been implemented.
A  total of 14 workshops have been conducted in eight countries during 1981- 
1990, including six regional and eight national workshops. More than 300 
clinicians, researchers, and public health professionals have participated. CDC 
continues to receive requests for regional and national workshops on 
epidemiologic approaches to reproductive health. This training program should 
complement the Field Epidemiology Training Program supported by CDC and 
WHO as well as the training program for clinicians that is supported by The 
Rockefeller Foundation. The paucity of medical and epidemiologic literature on 
reproductive health issues in developing countries indicate that this training 
program is unique in at least three aspects:
• This program lasts two weeks while most epidemiology training programs 
last 6 months to 2 years.
• This program provides the training in the developing countries whereas most 
other programs provide training at institutions in developed countries. 
Conducting short-term workshops in reproductive health epidemiology at 
regional or national levels may allow a greater number of individuals to 
benefit from this training.
xx
• When representatives from funding agencies attend the presentations of the 
proposals developed during the workshop, workshop participants have the 






1 Reproductive Health Epidemiology
Introduction
This workbook is designed to train public health professionals 
to use epidemiologic methods to answer questions about reproduc­
tive health. It serves as the text for the Centers for Disease 
Control, Family Health International, and the World Health 
Organization’s Reproductive Health Epidemiology Workshop and 
should provide the user with the necessary skills to develop a 
protocol for conducting epidemiologic research. Specific skills 
include basic quantitative measures used in reproductive health 
epidemiology, epidemiologic study design (descriptive and 
analytic), sample size and power estimation, survey sample design, 
and scientific statements of research questions and hypotheses.
Epidemiology can be defined as the study of patterns of human 
diseases, health, and behaviors. Epidemiologists answer research 
questions by classifying individuals into one or more discrete 
groups and assessing the differences between these groups.
Reproductive health epidemiology applies this system of study 
to questions about maximizing the reproductive health of men and 
women. Human reproductive health begins with sexual growth 
and development that is manifest at puberty, continues throughout 
life for men, and ends at menopause for women. Reproductive 
health is influenced by fertility and by decisions related to sexual 
activity, pregnancy, and contraception.
History
Origins of Reproductive Epidemiology
Reproductive epidemiology dates back to 19th century Vienna 
when Ignaz Semmelweis discovered that deaths from puerperal 
(childbed) fever were higher among women whose babies were













delivered in the hospital by medical students than among women 
whose babies were delivered by midwives. He correctly attributed 
this difference to the midwives’ practice of washing their hands 
between deliveries (MacMahon and Pugh, 1970).
Modern reproductive epidemiology has evolved substantially during 
the 20th century. The advent of birth and death registries, which 
were established in the United States during the early part of this 
century and in Europe during the 18th and 19th centuries, gave health 
officials a means of identifying risk factors for maternal and infant 
mortality. Public health measures could then be designed to reduce 
these factors. For example, milk stations, which provided milk to 
nursing mothers, were established when a relationship was found 
between infant mortality, sanitation, and nutrition (Holland et al.,
1984). This and similar measures led to a 95% decrease in maternal 
mortality in the United States from 1915 to 1965 (Hogue CJR, 
personal communication). In Sweden, the infant mortality rate 
declined from 200 deaths per 1,000 live births in the 1750s to less 
than 20 per 1,000 in the 1950s (United Nations, 1963).
Influence of Demography and Epidemiology
Reproductive epidemiology also has origins in demography, a 
discipline that evolved during the 19th century from studies of parish 
registries in England. Historical changes in the population 
(demographic transitions) and related changes in the patterns of 
health and disease (epidemiologic transitions) directly affect mortality, 
fertility, birthrates, and other measures of reproductive health. These 
changes also affect the health and status of women, children, and the 
family.
The original theory of demographic transition (Notestein, 1945) 
describes three stages of population growth that accompanied 
economic development in Western countries.
High growth potential. During this stage, rates for births and 
deaths, although high, are at similar levels, so population growth is 
minimal. If mortality were to decline at this stage without a 




Transition. This stage begins with a decline in mortality while 
fertility remains high, and shifts to a decline in fertility until both 
rates are at similarly low levels. During the first part of this stage, 
the high growth potential is realized; during the latter part, 
population growth declines.
Incipient decline. During this final stage, rates for births and 
deaths are at low and relatively stable levels. Sometimes, 
however, fertility rates decrease to levels lower than death rates 
and produce a decline in population.
Although demographic transition provides a perspective for 
interpreting historical changes in Western populations, the theory 
does not completely describe or explain patterns of population 
change in non-Western societies or those in developing countries 
where external factors have affected a dramatic decline in the 
mortality rate without a concomitant decline in the birthrate 
(Hauser and Duncan, 1959; Notestein and Segal, 1963).
Epidemiologic transition theory describes changes in patterns of 
health and disease by focusing on mortality and fertility rates and 
on the interaction of social, economic, demographic, and health 
variables (Omran, 1974). The three stages of epidemiologic 
transition parallel and influence the three stages of demographic 
transition.
Age o f pestilence and famine. During this stage, the prevalence 
of endemic diseases is high, nutrition is poor, and infectious 
diseases and famine are rampant. The rates for births and deaths 
are high, and population growth minimal. Extended family struc­
tures with large family size, multiple-generation households, and 
home-centered lifestyles are dominant. Women function as 
mothers with no rights or responsibilities outside the home 
(Omran, 1974).
Age o f receding pandemics. At this stage, disease and famine 
decrease, mortality rates decline, birthrates increase, and 
populations grow. Large extended families are predominant, 
especially in rural areas, but nuclear family units become more 
common in urban centers. Women begin to become involved in 






Age o f degenerative and man-made diseases. During this period, 
social, economic, and environmental conditions improve; infectious 
diseases and conditions related to poor nutrition decline. Birth and 
death rates are low, and population size is stable. Chronic diseases 
(e.g., cardiovascular disease, cancer, stroke, diseases caused by 
occupational exposures, etc.) are the primary causes of death. Small 
nuclear families become the norm. Women are increasingly 
emancipated from traditional roles and become better educated and 
more career-oriented (Omran, 1974).
Status Of Reproductive Health
Substantial variation in maternal and infant mortality rates exist 
throughout the world today. Among the ten most populous countries, 
maternal mortality rates vary from 1,500/100,000 live births to less 
than 15/100,000 live births, a 100-fold range. Infant mortality varies 
from 140 to 5 per 1,000 live births (Table 1.1).
In the United States, epidemiologists are seeking explanations for 
the diminishing decline in U.S. maternal and infant mortality rates, 
while these rates continue to decrease in other developed countries. 
They are also concerned about the excess mortality among minorities 
in the United States. For example, infant mortality is twice as high 
among blacks as among whites, and maternal mortality is more than 
two times higher among black women than among white women 
(Hogue et al., 1987; Rochat et al., 1988).
Population growth rates also vary considerably. At the current rate 
of growth, three of the ten most populous countries—Bangladesh, 
Nigeria, and Pakistan—will double in population in less than 30 years 
(Hatcher et al., 1989). By comparison, the two most populous 
countries with the lowest growth rates—Japan and the United 
States—will double in 133 and 99 years, respectively. In Nigeria and 
Bangladesh, the two countries with the highest total fertility rates, 
births per 1,000 females aged 15 to 19 years exceed 200.
In the ten most populous countries, the prevalence of contraceptive 
use among married women aged 15 to 44 years varies from less than 
10% to more than 80% (Hatcher et al., 1989). In all but one of these 
countries, 10% or fewer of the couples of reproductive age use 
condoms, which provide both contraception and protection from HIV 




Reproductive Health Around the World
China 1087 21 7 1.4 49 2.1 55 44 44 66 50 58.5
India 817 33 13 2.0 35 3.7 31 101 400 -500 54 61 43.5
U.S.S.R 286 20 10 1.0 68 2.4 0 25 • ■ 69 19 77.0
United States 246 16 9 0.7 99 1.9 5 11 14 75 8 82.5
Indonesia 177 27 10 1.7 40 3.5 36 88 357 -800 58 62 46.5
Brazil 144 28 8 2:0 34 3.5 26 63 87 -154 65 50 54.5
Japan 123 11 6 0.5 133 1.8 14 5 16 78 11 68.5
Nigeria 112 46 17 2.9 24 7.1 0 124 1500 47 80 29.0
Bangladesh 110 43 17 2.7 26 5.5 21 140 623 50 79 21.5
Pakistan 108 43 15 2.9 24 5.3 18 125 400 -600 54 73 28.0
Mexico 84 30 6 2.4 29 4.0 38 50 92 66 47 61.5
United Kingdom 57 13 12 0.2 408 1.8 14 9 12 75 12 74.5
Egypt 53 38 9 2.8 24 4.3 22 93 269 59 55 38.0
Turkey 53 31 9 2.2 32 3.7 33 92 207 63 55 52.5
World 5128 28 10 1.7 40 3.3 25 81 390 63 55 • ■




China 81 5 32 30 9 3 — — — 1 1 84
India 39 5 4 26(combined) 4 — — — — • ■ 64
U.S.S.R 75
United States 68 14 5 17 11 10 — 1 3 7 • • 83
Indonesia 46 14 13 3 — 2 10 ■ • ■ • 4 • m 67
Brazil 65 25 1 27 1 2 — 5 4 1 m m 56
Japan 64 1 4 8 3 43 — 1 4 ■ • 1 63
Nigeria 5 1 1 3 21
Bangladesh 25 5 1 8 2 2 1 1 4 — 1 64
Pakistan 8 1 1 2 — 2 1 1 — — — 29
Mexico 53 10 11 19 1 2 3 • • ■ • • ■ 8 72
United Kingdom 833 24 7 14 14 17 — 6 2 3 — 97
Egypt 30 17 8 2 — 1 — — 1 1 1 37
Turkey 62 9 9 1 — 5 - - 30 1 3 3 39




Abortion Breastfeeding Adolescent Pregnancy & Determinants
China 1 490 • • 56 55 12 23 4 35 34
India II 247 98 90 79 41 19 57 20 25
U.S.S.R. 1 2080 16 • ■ 27 77 2
United States 1 422 58 36 22 53 22 8 92 1
Indonesia IV • ■ 97 93 92 31 16 37 24 42
Brazil IV 250-12005 91 56 31 81 22 18 35 28
Japan II 382 -1492 75 ■ ■ ■ ■ 3 25 1 93 1
Nigeria III • ■ 100 100 89 213 19 44 16 77
Bangladesh II! 45 99 98 97 237 16 63 6 87
Pakistan Ill • ■ 97 • • 91 141 21 38 7 87
Mexico IV • ■ 87 78 52 80 18 19 49 • •
United Kingdom II 223 51 15 9 28 23 5 84 ■ ■
Egypt III • a 95 91 86 99 21 22 45 75













These data highlight the urgent need worldwide for improved 
family planning and maternal and child health services. The 
availability of existing contraceptives should also be improved, and 
new methods should be developed and tested. Epidemiologic 
research has an important role in improving each of these areas.
Uses of Epidemiologic Methods in 
Reproductive Health Practice
Epidemiologic methods are used to define reproductive health 
problems, to elucidate the causes of these problems, to test 
interventions, and to evaluate programs (Table 1.2). Problem 
definition involves describing the population affected, the etiology of 
the health problem, identifying the alterable risk factors, and 
conducting ongoing surveillance to detect trends in the problem. 
Reduction of risk factors through intervention depends on accurate 
assessment of the comparative safety and efficacy of proposed 
interventions and treatments. Analytic epidemiology is used to test 
such interventions. Epidemiologic methods and results are used to 
assess whether a program is based on the appropriate interventions 
and treatments and whether the interventions and treatments are 
being properly used. Cost-benefit analysis is applied to determine 
whether interventions make the best use of available resources.
Example 1
The Shunyi Risk Approach Project in Perinatal Health (Yan et al., 
1989), which was conducted in Shunyi County, People’s Republic of 
China, shows how epidemiologic methods are applied to problem 
definition, intervention and testing, and program evaluation. The 
project used the risk approach in an attempt to improve perinatal 
health services. It began in 1983 and continued for five years.
Problem definition. Investigators collected data on 1,914 pregnant 
women and their 1,928 infants, and on 50 cases of perinatal mortality. 
Among other problems, the investigators found that 151 per 1,000 
women suffered from hypertensive disorders during pregnancy, and 1 
per 1,000 suffered from eclampsia. The perinatal mortality rate for
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the infants born to these women was elevated. For example, the 
perinatal mortality rate for infants born to women who 
experienced mild to severe hypertension that improved during 
pregnancy was 4.6 per 1,000 deliveries, or more than twice the rate 
for pregnancies uncomplicated by these disorders. The rate for 
infants born to women with hypertensive disorders that worsened 
or remained severe throughout pregnancy was 10.8 per 1,000 
deliveries.
Table 1.2
Uses of Epidemiologic Methods in Reproductive Health Practice
Uses Problems Addressed
Problem definition Population affected 
Risk factor identification 
Surveillance
Intervention and testing Comparative safety of treatments 
Comparative efficacy of treatments
Program evaluation Risk approach 
Cost-effectiveness
Intervention and testing. To reduce the incidence of pre­
eclampsia, eclampsia, and perinatal mortality associated with 
hypertensive disorders of pregnancy, the investigators initiated a 
number of interventions in 1985. They educated patients about 
the need for rest, proper nutrition, and the signs and symptoms of 
eclampsia. High-risk women were informed about the need for 
weekly or biweekly blood pressure measurements. The investiga­
tors also provided training to health care providers and taught 
village doctors to measure blood pressure and to check their 
equipment. Practitioners in the township hospital were taught how 
to diagnose and treat hypertensive disorders, to make proper 
referrals to the county hospital, and to follow a set protocol for 
monitoring all pregnant women.
Program evaluation. The investigators conducted epidemiologic 
surveillance to assess the impact of these interventions. From
Reproductive Health Epidemiology
Surveillance 





1984 to 1986, the incidence of preeclampsia and eclampsia decreased 
from 1.8% to 0.4%, and the perinatal mortality rate for pregnancies 
complicated by these disorders declined from 10.8 per 1,000 deliveries 
to 0. The team of investigators concluded that the interventions had 
been highly successful in reducing maternal and infant morbidity and 
mortality related to hypertensive disorders of pregnancy.
Example 2
Another example of epidemiologic problem definition and 
intervention is the surveillance of maternal smoking and pregnancy 
outcome and the study of effective smoking cessation programs.
Problem definition. Over the last three decades, a relationship 
between maternal smoking and pregnancy outcome has been 
established through numerous analytic epidemiologic studies. For 
example, MacMahon et al. (1966) reported that infants born to 
women who smoked were approximately 200 g lighter than infants 
born to nonsmoking women. Since then, virtually all studies of 
maternal smoking and birthweight have confirmed this finding. A 
dose-response relationship also exists between the number of 
cigarettes smoked and infant birthweight, regardless of gestational age 
at birth (Hogue et al., 1987). Descriptive epidemiologic studies have 
revealed that one in three women in the United States are smokers 
when they conceive, and one in four women continue to smoke 
throughout pregnancy (Prager et al., 1984). Worldwide, the 
prevalence of smoking among women varies considerably. In general, 
the prevalence of smoking increases with economic development. 
Using analytic epidemiology, Kleinman et al. (1988) estimated that 
10% of infant mortality in the United States could be eliminated if 
maternal smoking were no longer a risk factor. In the United States, 
epidemiologic surveillance of maternal smoking has been conducted 
through the analysis of birth certificates in Missouri since 1979, 
through the Pregnancy Risk Assessment Monitoring System in six 
states since 1988, and in the future for all states adopting the revised 
birth certificate of 1989.
Intervention and testing. Experimental epidemiology has been used 
to test the effectiveness of smoking cessation counseling to help 
women who want to stop smoking and to assess the impact on
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improved pregnancy outcome for women who do stop smoking. 
Well-conducted clinical trials have found that some women can 
stop smoking with counseling assistance. The results of these trials 
show that the birthweights of the infants born to women who stop 
smoking by the fifth month of pregnancy are similar to the 
birthweights of the infants bom to women who never smoked 
during their pregnancy (Sexton and Hebei, 1984; Windsor et al.,
1985).
Program Evaluation. Using analytic epidemiologic studies as 
the data source, Marks et al. (1990) estimated that a national 
smoking cessation program could save over $5 in care for low- 
birthweight infants for every $1 spent on the intervention, and that 
program costs would amount to $69,542 for each of the 338 deaths 
prevented.
Scope of Epidemiologic Research 
in Reproductive Health
Epidemiologists have conducted investigations into virtually 
every aspect of reproductive health, including sexual development, 
sexual activity, contraception, contraceptive methods, fertility, 
unintended pregnancy, induced abortion, maternal and infant 
morbidity and mortality, male and female problems with the 
reproductive tract, and the delivery of maternal and child health 
and family planning services. In this workbook, we have selected 
examples from epidemiologic studies that have been conducted in 
many countries to illustrate the usefulness of epidemiology in 
answering important public health questions on reproductive 
health issues. During the workshop, we will discuss this research 
to provide a framework for developing research protocols. The 
examples we provide should not be considered comprehensive or 
exhaustive because epidemiologic methods can be applied to many 
areas of human reproductive health.
Reproductive Health Epidemiology
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Learning Objectives - Chapter 2
After completing this chapter you should be able to:
1. Write an abstract of a research proposal.
2. Use the literature to identify a research problem.
3. Define a research problem.
4. Write a justification for a proposed study.
5. Write an ultimate goal for a proposed study.
6. Write research objectives for a proposed study.
7. Write research questions or hypotheses for descriptive and analytic research.
8. Distinguish four types of study designs.
9. Recognize parts of each of the following that must be included in all research 
plans and outlined in a research proposal:
research methods 
analysis of data 
interpretation of findings 
reporting the findings 
logistics 
work schedule
10. Design a research proposal following guidelines given.
2 Developing a Research Proposal
Introduction
Research is conducted in response to a problem, such as an 
epidemic or an unexpected health outcome, or in response to a 
need to plan or change a program or a course of action, to test a 
hypothesis, or to further study recent research findings. Inquiries 
from politicians or journalists and scientific or medical curiosity 
also stimulate research.
Having decided to pursue a research project, the researcher 
needs to develop a plan or protocol as a guide for the study. A 
plan written to seek approval for research from a supervisor or 
organization is called a research proposal.
The format and content of research proposals vary widely. This 
chapter defines the standard information usually included in a 
research proposal. The order in which this information is 
presented can vary.
The Proposal Abstract
The abstract is a summary of the proposed study. Although it 
usually appears as the first section of the proposal, it is not written 
until all other sections are completed. The abstract should be 
brief—approximately 200 words—and should answer as many of 
the following questions as possible:
A  protocol is 
developed as 
guide for a 
study.
Abstract
• What is the problem to be studied?
• What are the research questions or hypotheses?
• What are the expected implications of the study?
• Who will conduct the study (data collection and/or 
analysis)?
• When will the study be conducted (data collection and/or 
analysis)?
• Where will the data collection be conducted?
Developing a Research Proposal
• What methods will be used to collect and/or analyze the data?
• What resources are required to conduct the study?
Examples 2.1 and 2.2 provide hypothetical abstracts for study 
proposals.
Example 2.1
Abstract for a Case-Control Study 
of Adolescent Pregnancy
Adolescents constitute a higher percentage (15%-20%) of pregnant 
women admitted to clinics in Central state than in the southern parts of the 
country. They also account for a disproportionately high rate of morbidity, 
maternal mortality, and perinatal mortality in the state. Because of this 
situation, the Ministry of Health wishes to determine the major differences in 
attitudes toward and practice of contraception between younger and older 
women.
This descriptive, case-control study in Central state will be conducted 
between January and December 1995 by the Ministry of Health with technical 
assistance from the Centers for Disease Control. It will compare the 
knowledge, attitudes, and practices of fertility control among (1) primigravidae 
less than 18 years of age and their husbands and (2) primigravidae 18 years of 
age and older and their husbands.
A  sample size of 800 couples will be selected for each group from 
antenatal clinics (assuming a rate of ignorance of contraception of 70% in the 
under 17 group and 60% in the 17 and over group, a power of 90%, and a 
confidence level of 0.1). These couples will be interviewed by highly trained 
interviewers using precoded questionnaires.
Information from the study will help the government and officials 
responsible for managing health care delivery systems to find appropriate 
ways of preventing pregnancies in this high-risk group and thereby reduce the 
costs to the health care delivery system. Information will be disseminated 
through:
• A seminar on adolescent pregnancy problems sponsored by the 
Congressional Committee on Health.
• Health Management Board.
• Women’s health associations.
• Educators.
• Community leaders.




Abstract for a Randomized Clinical Trial 
of Malaria Prophylaxis in Pregnancy
Pregnancies complicated by malaria are becoming an increasingly 
important problem in Country Y and in many other developing countries. 
Adverse outcomes include fetal death as well as maternal mortality and 
morbidity. Routine prophylaxis against malaria in pregnancy might help to 
prevent these adverse outcomes, and yet the value of prophylaxis has not been 
established in Country Y.
A randomized clinical trial will be conducted by a research team from 
State University during 1991-1992. The study will compare the use of weekly 
prophylaxis against malaria for 2,500 pregnant women with the weekly use of 
a placebo for 2^00 pregnant controls. Patients will be enrolled from the 
obstetric population of State University and Western University clinics.
The research hypothesis of this study is that weekly prophylaxis will reduce 
the incidence of intrauterine fetal death from 5%. to 3%. The sample size will 
provide 90% power with a p value of 0.05.
Although the primary focus of the study is to reduce intrauterine fetal 
death, other complications of malaria, such as morbidity, anemia, and 
congenital malaria, will also be studied.
The findings will be incorporated into the existing program plans of the 
Ministry of Health.
Problem Identification and Definition
This section of the proposal depends upon information from 
previous research and the literature. It should therefore contain 
the literature review. Before writing this section, you should:
1. Search the literature thoroughly for information about the 
problem you are researching. Establish whether or not 
others are currently engaged in similar or related research.
2. Classify key literature on the subject. It is often useful to do 
this in tabular form (Table 2.3).
3. Identify critical areas for research (i.e., shortcomings of 
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After careful examination, the medical and epidemiologic literature 
may be used to identify and define the problem under study.
Table 2.3
Literature Review of 





Procedure* Controlled Variables Results
Japan
1971
Cross-sectional Mostly D&C Age, duration o f marriage Gravidity was similar 
for those reporting and 




Abortion cohort Mostly VA Contraceptive use Pregnancy-to-conception 
intervals were signif­




Case-control Illegal D&C Age, parity, education For secondary infertility 
>  18 months, relative risk
(RR) =  1.1 <95% Cl =  
0.6, 1.9).
Illegal D&C Age, parity, education, 
spontaneous abortion history
RR =  12.5
(95% C l =  2 .3 ,6 6 .9 )
Denmark
1967-1975
Pregnancy cohort Mostly VA Age, parity, socioeconomic 
status, regular menstrual 
cycle, contraceptive use
For pregnant women, the 
outcome o f (he preceding 
pregnancy did not signif­
icantly affect the length 




Case-control Mostly VA Age, gravidity, race or ethnic 
status, marital status, 
socioeconomic status
For secondary infertility 
> 1 2  months, RR =  1.3 
(95% Cl =  0.1, 2.4)
Mostly VA Age, gravidity, race or ethnic 
status, marital status, socio­
economic status, spontaneous 
abortion history
RR =  1.2
(95% Cl =  0.4, 3.0)
Hawaii Abortion cohort Mostly VA Age, gravidity, menstrual 
1970*1979 regularity, contraceptive use
"D&C =  dilatation and curettage; VA =  vacuum aspiration.
Several analytic 
techniques resulted in the 
conclusion that induced 
abortion had not impaired 
ability to conceive.
(Hogue et al., 1982)
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Chapter 2
Identify the problem: State why you think the problem requires 
study. Problem identification for analytic epidemiologic research 
must proceed from the following three conditions:
1. Indicate the discrepancy between the real or observed 
situation (what is) and the ideal, desired, or theoretical 
situation (what should be).
2. Indicate the alternative solutions or explanations for the 
discrepancy.
3. Indicate which of the alternatives you believe is the most 
likely to be correct and why.
For exploratory or descriptive research, only the first condition 
is required. Conditions 2 and 3 may or may not apply.
Example 2.4 illustrates three hypothetical problem identification 
statements. The what is is indicated in bold text, and the what 
should be is noted in italics.
Example 2.4  
Three Problem Identification Statements
Infant Mortality (Analytic Study): Infant mortality is higher in Village A 
than in neighboring villages. There should be no difference in infant mortality 
between these villages. Possible explanations are that Village A has (a) lower 
nutrition levels, (b) lower levels of breast-feeding, (c) poorer sanitary 
conditions, (d) lower maternal literacy. Our knowledge of lifestyles in these 
villages leads us to believe that infant mortality is higher in Village A because 
sanitary conditions are poorer than those in surrounding villages.
Increase in Vasectomies (Analytic Study): Thirty vasectomies were 
performed in region A over the past six months. This number constitutes an 
abnormal increase, since the region usually averages two vasectomies a month. 
This increase may be due to support for this procedure from local community 
leaders or it may be due to a new promotional campaign undertaken by 
family planning clinics in Region A. Our team believes the primary influence 
is the new promotional campaign.
Adolescent Fertility (Descriptive Study): Fertility is higher among 
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Example 2.4 (continued)
health officials felt the fertility rate for adolescents should be lower. In response to 
this concern, we propose to study the factors associated with adolescent pregnancy 
in order to identify high-risk groups and to begin formulating hypotheses 
regarding interventions for further study.
Define the problem: Summarize current research and list issues 
needing further study. Problem definition may include information 
on:
• Magnitude. What is the incidence and prevalence of the 
problem?
• Time frame. When does it occur? Is it current?
• Geographic area. Where does the problem generally occur?
• Population. Does the problem affect certain groups of people? 
If so, what are their characteristics?
• Why? What are the probable reasons for the problem? Is 
there agreement or conflict over these reasons?
• Solutions. What solutions have already been tried? How 
successful have they been? What untried solutions might there 
be?
• Unanswered questions. What parts of the problem need further 
research?
Example 2.5 illustrates a hypothetical problem identification and 
definition.
Example 2.5
Problem Identißcation and Definition 
Family Planning Services in Country X
Problem Identification
• Country X has a shortage of trained health professionals to provide 
intrauterine devices (IUDs) to women in rural regions.
• Therefore, the government initiated a program in 1985 to provide two 
months of training in family planning to traditional midwives.
• A study will be conducted to.determine IUD retention rates for village 
women who received IUDs from rural midwives and those who received





Trained health professionals are currently (time frame) in short supply 
(magnitude of the problem) in rural areas of Country X (geographic area). 
Consequently, women residing in rural areas (population) have not adopted 
effective methods of birth control.
In many developing countries, and particularly in rural areas, where there 
are few trained health providers, auxiliary personnel serve as health care 
providers. Thus, since 1985, traditional midwives have been providing family 
planning services to rural women in Country X (solution).
The traditional midwives are well accepted as paramedics in rural areas. 
Their traditional tasks of delivery and care of the mother and child permit 
them to easily provide family planning services to those mothers who wish 
them (elaboration).
The effect of traditional midwives on people’s decisions to use 
contraceptives and their continued use in rural Country X has never been 
evaluated (unanswered questions).
In addition, this problem needs to be studied in the context of previous 
studies about IUD insertion performed by rural midwives versus insertion by 
physicians and trained nurse-midwives.
Justification
The justification of the research topic is an important part of 
any research proposal. Research is often expensive and time 
consuming, and most funding agencies are reluctant to support 
studies unless the results have direct program implications. When 
funds are limited (as they almost always are), it is especially 
important for the research investigator to justify the proposed 
study carefully. In doing so, the investigator should place himself 
or herself in the position of the approving official and should 
consider what criteria would be used to select the study if there 
were funds to support only one of several proposed studies.
In writing the justification, it is usually helpful to consider the 
following questions and then arrange the answers to these 
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• Is the problem a current and timely one? In other words, does 
the problem exist now? Current problems are more likely than 
past problems to receive funding.
• Does the problem have life-threatening or serious morbidity 
consequences? Poor surgical technique during sterilization can 
have life-threatening or serious morbidity consequences for the 
patient, whereas occasional spotting from IUD use generally 
does not have serious consequences.
• Does the problem affect, or potentially affect, a large number of 
people? Some problems, such as thromboembolism from 
contraceptive pill use, are life threatening, but of all the people 
who use oral contraceptives, relatively few are affected. In 
countries where sterilization is widely used, other problems, 
such as anesthesia overdose, tetanus, and intraperitoneal 
hemorrhage, may affect a large number of people.
• Does the problem relate to on-going program activities? That 
is, does the problem have implications for current programs?
For example, a study comparing failure rates and complications 
of different IUDs is not likely to have major program 
implications in a country where the IUD is not commonly used.
• Does the problem have broad social, economic, political, or 
health implications? Some studies may impact many different 
activities. For example, using nonmedical personnel to provide 
contraceptive methods may lower maternal mortality and 
fertility rates and thus have broad social, economic, and political 
ramifications.
• Is the problem viewed as a concern by many different people?
A research problem that evokes the concern of many different 
people—administrators, politicians, health professionals, the 
general public—is more likely to receive priority funding than 
one that only a small group of researchers view as a concern.
• Have many studies already addressed the problem? For some 
reproductive health issues study has been extensive, and much is 
already known about the etiologies of the problems. For
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example, the complications and failure rates of different 
IUDs have been widely studied. Would another IUD study 
add significant new information?
Example 2.6 illustrates problem justification.
Example 2.6
Problem Justification: Prophylactic Use of 
Antibiotics at the Time of Intrauterine Device Insertion
The Ministry of Health and the Women’s Development Movement have 
completed negotiations with an international donor for a $5 million loan that 
will be distributed over the next 5 years. The funding will be used to double 
the existing network of family planning clinics in an effort to increase 
contraceptive prevalence from 12% to 35% by 19%.
Considerable controversy exists over whether or not to promote the use of 
IUDs in existing and future rural and urban family planning clinics because 
IUD use is associated with an increased incidence of pelvic inflammatory 
disease (PID) (Faulkner and Ory, 1976; Kaufman et al., 1980; Vessey et a l, 
1981). Two studies were conducted in Country X — one at the National 
Teaching Hospital in 1980 and one in three provincial hospitals in 1981. The 
findings indicated that between 28% and 35% of women examined in the 
obstetrics and gynecology wards had PID and suggested that PID may be a 
prevalent condition. PID is expensive and difficult to treat in most clinics. If 
untreated, PID can lead to infertility, a problem that is thought to be 
widespread in certain areas of Country X.
Thus, before the Ministry of Health can promote IUD use in these areas, 
methods for decreasing IUD-associated PID need to be identified. If IUDs 
can be used safely and if one-third of the new users of contraceptives used 
IUDs, the costs associated with family planning visits for resupply of oral pills 
and other contraceptives could be reduced by as much as 50%. Service 
providers could spend more time promoting family planning among unserved 
high-risk women and thus increase the likelihood of achieving the country’s 
goal for contraception.
A  recent study conducted in the United States concluded that IUDs were 
associated with PID only at times of insertion or reinsertion (Burkman et al., 
1981). Consequently, antibiotics given prophylactically to women at the time 
of IUD insertion may decrease the incidence of IUD-associated PID. 
However, no research has been conducted to test this hypothesis. The 
randomized clinical trial to be described is designed to test this hypothesis in 
rural and urban service delivery clinics in Country X.







Before a study is actually designed, the study’s ultimate, long-term, 
public health goal and its immediate, specific research objectives are 
written. Ultimate goals should be stated in terms of the potential 
impact or public health purpose of the study or service delivery 
program. Although goals are not as detailed as research objectives, 
they must be clear.
Goals are stated in terms of:
• Broad social, economic, or health concerns.
• Change in policy decisions, service delivery programs, or 
individual health behavior.
• Populations that may be affected.
Three hypothetical goals are presented in Example 2.7.
Example 2.7
Three Ultimate Goals
By 1995: To decrease by 40% the percentage of d ink or hospital 
deliveries among women who are at low risk for pregnancy-related 
complications.
By 1999: To decrease by 20% the death-to-case rate for vasectomies 
among rural males in Country X.
To improve use of health facilities by farmers in Province A.
Research objectives describe what will be demonstrated, tested, 
evaluated, confirmed, or compared. They communicate:
• What you plan to do.
• Who will do it.
• To whom it will be done.
• When it will be done.
• Where it will be done.
• What you hope to learn.
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Example 2.8 provides details of hypothetical research objectives 




The Department of Maternal and Child Health will conduct a cohort study 
over a two-year period (1993-1995) to compare the risk of complications 
associated with postpartum tubal sterilization and interval sterilization in 2,000 
women living in Central City.
What: Cohort study
By whom: Department of Maternal and Child Health
To whom: 2,000 women
When: 1990-1992
Where: Central City
Purpose: Risk of complications of postpartum and interval sterilization
Surveillance System
The Centers for Disease Control (CDC) will establish a surveillance 
system in Division A  by the end of 1995 to monitor all pregnancy-related 
deaths among women aged 15 to 44 years.
What: Surveillance system
By whom: Centers for Disease Control
To whom: Women aged 15 to 44 years
When: End of 1995
Where: Division A
Purpose: Monitor all pregnancy-related deaths
Descriptive Study
A  descriptive study will be conducted by the Health Department of 
District X from June to December 1992 to determine the demographic and 
social characteristics of the 4,300 women obtaining family planning services in 
government health clinics.
What: Descriptive study
By whom: Health Department
To whom: Women obtaining family planning services in government
health clinics 
When: June to December 1992
Where: District X
Purpose: Determine demographic and social characteristics
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The
hypothesis
Research Questions or Hypotheses
All proposals should contain a formal and explicit statement of the 
research question(s) to be studied or the research hypothesis(es) to be 
tested. Whether to use questions or hypotheses depends on the type 
of research. Exploratory or descriptive epidemiologic research does 
not involve hypothesis testing; it is based on underlying questions.
The research questions must be formally stated with clarity, 
specificity, and appropriate inclusiveness. Example 2.9 provides 
examples of research questions.
Example 2.9
Research Questions 
Exploratory or Descriptive Epidemiology
1. Why does Village Y have half the fertility rate of other populations in the 
region? Is the lower fertility rate due to more effective use of 
contraception, different breast-feeding practices or marriage patterns, or 
other unspecified social practices?
2. What are the levels of maternal and infant mortality in major cities of 
Country X?
Analytic epidemiologic research is designed to make predictions 
about the relationships between variables and therefore tests 
hypotheses. All proposals for analytic research must explicitly state 
the hypothesis(es) (Example 2.10).
A hypothesis is a statement (not a question) about an expected 
relationship between one or more independent variables and one 
dependent variable. The statement should proceed logically from the 
prior problem identification. In addition to stating the hypothesis(es), 
the proposal should also indicate:
• Under what conditions the hypothesis is expected to be true.
• All potential intervening variables that may affect the 
dependent variable.







1. Children who receive a sex-education course before entering their teens are 
more likely to use contraceptives at first intercourse than children who do 
not receive such a course.
2. In Country X, Catholic women have higher fertility rates than non-Catholic 
women.
3. Lower rates of smoking are expected among pregnant women who attend the 
prenatal clinic in District X than among women who do not attend.
At this point in the proposal, the null hypothesis is not stated. 
The null hypothesis is appropriate only in the section of the 
proposal that discusses the analytic methods to be used in the 
study.
Study Design
The study design or research design is determined, in part, by 
the primary purpose of the research. Therefore, the proposal 
should first indicate whether the study is descriptive or analytic.
A descriptive study is used when additional information is 
needed before being able to formulate specific hypotheses. 
Descriptive studies provide accurate baseline data on the 
occurrence or prevalence of a characteristic or event related to a 
health problem, and on the people who are affected and how they 
are affected.
An analytic, or explanatory, study is used to explain the 
relationship between two or more variables by testing causal 
hypotheses that specify the relationship between the variables.
Once the primary purpose of the research is identified, we can 
select the study design. The type of design we choose is 
influenced by the purpose, the cost, and the nature of the problem 
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• Cross-sectional design. Current or retrospective information is 
collected at one point in time from a sample of subjects from the 
target population. This design is appropriate for descriptive 
purposes because it does not always lend itself to temporal 
arrangement of independent and dependent variables. This type 
of study is discussed in Chapter 6.
• Experimental design (randomized clinical trials). The researcher 
manipulates the independent variable or study factor and 
controls allocation of subjects to the exposure under study. This 
design is ideal for analytic epidemiologic research; it is discussed 
in Chapter 8.
• Cohbrt design. Information is collected on the study population 
at one point in time. Then, at a later point in time the subjects 
are examined again to measure the outcome of interest. The 
temporal aspect of this design makes it the most appropriate 
nonexperimental design for analytic epidemiologic research. This 
design is discussed in Chapter 9.
• Case-control design. Typically a retrospective design that 
compares a group of cases and controls to examine the effect of 
a current or previous risk factor. The case-control design may 
also be a prospective design in which cases and controls are 
enrolled prospectively soon after a health problem is diagnosed 
or identified. The design is used for both descriptive and 
analytic research purposes; it is especially useful if the outcome 
or dependent variable is a rare event. Tliis design is discussed in 
Chapter 10.
Methods
Epidemiologic research involves a careful and systematic 
observation of people (subjects) and events. The methods used for 
such observation affect the quality of the data. Therefore, the 
investigator must provide a thorough description of the methodology 
for selecting the subjects and for collecting the data. The content of 
the proposal’s methods section will vary depending on the purpose of 
the research and study design, but this section should specify the study
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population, the type of data to be collected, and the data 
collection and quality control procedures. The Methods section 
should present step-by-step instructions for carrying out the 
research. A  brief outline for the Methods section follows:
1. Define the population, including political, geographic, social, 
economic, and demographic identifiers.
2. Describe the sampling process, if applicable.
• Identify the type of sample (e.g., simple random, 
systematic, cluster, multistage, nonprobability).
• Specify the sample size calculations.
• Describe the random assignment procedure for clinical 
trials.
3. Define the type of data to be collected.
• Define cases, controls, and comparison groups.
• List all variables (i.e., independent, dependent, control, 
exposure, treatment, outcome, confounders, effect 
modifiers) and state the conceptual and operational 
definitions (Example 2.11).
Example 2.11
Hypothetical Example of Conceptual and Operational Definitions 
for the Term Contraceptive Use
Current contraceptive use could be conceptually defined as any use of 
birth control by either the subject or her partner during the last month. 
Operationally, current contraceptive use could be defined as a subject 
indicating that she had used within a four-week period one of the 
contraceptive methods listed on an interview card. The list of methods could 
include tubal ligation; vasectomy; contraceptive pills; IUD; injection; condom; 
diaphragm; vaginal tablets, creams or jellies; rhythm; Billings method; and 
withdrawal.
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4. Describe the data collection procedure.
• Indicate data collection method(s) (e.g., structured or 
unstructured interview; focus groups; self-administered 
questionnaire; direct observation of behavior; service 
statistics; medical chart review; vital records, census data, 
or other secondary sources).
• Describe the data collection instrument (e.g., 
questionnaire, medical records’ abstract form, etc.). A first 
draft of the data collection instrument is typically 
developed after the research project has been approved.
The proposal may, however, indicate that individuals with 
experience in developing and using similar data collection 
instruments will be asked to critique and improve the 
draft. Other aids for developing a questionnaire, may also 
be mentioned (e.g., focus groups for clarifying concepts 
and terminology). If the study uses a preexisting 
instrument, a copy may be appended to the proposal.
• Discuss consent of participants and how it will be obtained. 
If an Informed Consent form is needed, a copy should be 
included in the proposal.
• Discuss confidentiality of the data and, if needed, how it 
will be maintained.
• Discuss human subjects review, if applicable.
5. Describe the procedures used to control data quality. The 
research proposal should include a discussion of any activities 
that are planned for maximizing the validity and reliability of 
the data.
• Pretest the data collection instrument. Field test on a 
limited basis in an area outside the study area (or without 
involving the study subjects). All the study procedures 
should be followed, including sampling, data collection 
(e.g., interviewing), supervising, coding, data entry, editing,
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and a limited analysis. Pretesting is useful to modify 
the data collection instrument as well as other data 
collection procedures.
Reinterview subgroups of respondents. This is a 
common technique for testing the reliability of the 
instrument.
Train interviewers and supervisors for data collection. 
Initially, data collection teams should be closely 
observed by a field coordinator or supervisors. Often, 
data collection does not go as planned and many 
problems can affect the validity or reliability of the 
data. When these problems occur, interviewers or 
other data collectors should consult a supervisor or the 
field coordinator so that decisions about how to 
proceed take into consideration the impact of the 
decision(s) on the entire study.
Describe plans for data control. Meticulous attention 
to detail is required on the part of supervisors so that 
1) all forms are completed according to the 
predesignated specifications, 2) errors are corrected, 
and 3) no forms are lost. The forms should be sent to 
a central location where they are counted and 
processed for tabulation.
Indicate multiple sources of information. Some studies 
may be structured to allow for more than one source of 
data. An interview, for example, may be supplemented 
with a medical record to obtain a medical history.
More than one source for the same information 
provides an excellent opportunity to check the validity 
of the primary source.
Describe all other data quality checks. For example, 
more than one question may be structured to ask the 
same information of the interviewee. Responses to 
these questions can be compared for consistency.






The analysis provides answers to the research questions. All 
proposals for epidemiologic studies contain plans for analysis. The 
analysis plan and data collection methods are so interdependent that 
defining one without the other is difficult. Although the analysis 
depends on the type of data collected, how the data are collected 
depends on the type of analysis anticipated. Sample size, for example, 
is a function of the type of analysis that will be performed. The 
sampling design is also frequently determined by the analytic needs. 
The analysis plan should deal with data preparation issues as well as 
data analysis.
Preparation of the Data
Before the actual analysis, the data must be checked for errors and 
put into a form that will allow it to be manipulated accurately and 
efficiently:
Tabulation. Indicate whether the data will be tabulated by hand, 
computer, or some other method.
Coding. The process of coding translates verbal responses into 
numerical codes that will facilitate data manipulation. Indicate 
whether coding is necessary and who will do it. If any of the key 
variables in the study are obtained with open-ended questions, the 
need to code the responses to these questions may be mentioned.
Editing or cleaning the data. Editing ensures that no question on a 
questionnaire is omitted erroneously, that no illegal codes have been 
used, and that logical inconsistencies in the recorded responses are 
noted. Data may be edited in the field during the collection phase or 
in a central office after the fieldwork is completed. Data may be 
edited by manually reviewing the questionnaires or forms on which 
responses were originally recorded, by using computer programs that 
find errors and inconsistencies in the data, or by reviewing tabulations 
produced by the computer. Computer editing may be structured to 
check each record as it is entered into the computer (this may be 
done in the field) or after all the records have been entered into
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the computer. The proposal should briefly state how the editing 
will be carried out.
Analysis of the Data
Any combination of the following may be required.
Variable transformations. These may include:
• Collapsing response categories for a particular variable into 
broader ones (e.g., age may be recorded by single years but 
collapsed into five-year age groups for a particular analysis).
• Creating new variables (e.g., create a variable denoting 
premarital conception by comparing age at marriage with 
age at first birth).
• Counting the responses to a number of questions (e.g., 
create a score that indicates the number of correct responses 
in a set of true and false questions).
• Constructing a scale or index that combines the responses to 
two or more questions (e.g., create a socioeconomic score 
using mother and father’s education, father’s occupation, and 
family income).
• Creating temporary mathematical transformations by 
converting original numerically scaled values of a variable to 
a different scale (e.g., square root, quadratic, or logarithmic) 
to better meet the assumptions of a particular statistical 
method.
Descriptive statistics. Descriptive statistics are used to describe 
data quantitatively. They may be univariate, bivariate, or 
multivariate:
• Univariate statistics include proportions, percentages, ratios, 
frequency distributions, and any graphic presentations.
Other univariate descriptive statistics measure central 
tendency (e.g., mean, median, mode), deciles, quartiles, and







measures of dispersion (e.g., range, mean deviation, standard 
deviation, coefficient of variation).
• Bivariate and multivariate statistics are used to describe the 
associations between variables. Such statistics are called 
measures of association and include lambda, gamma, Pearson’s 
correlation coefficients, relative risks, odds ratios, and others.
Even if the research objective is to test a hypothesis or generalize 
sample characteristics to a target population, a description of some 
basic quantitative characteristics of the sample may be of interest. 
More importantly, if a  total population is under study instead of a 
sample, descriptive statistics will be the form used to report the study 
results.
Inferential statistics. Most epidemiologic studies, and certainly 
those that are based on population samples, use statistical inference 
methods, which allow conclusions about a population to be made 
from results obtained in a sample. If the study is based on a sample, 
you should use not only descriptive statistics that describe 
characteristics or associations in the sample but also inferential 
statistics that estimate the effect of sampling error on the ability to 
infer population characteristics and associations from sample findings. 
Measures used in statistical inference include confidence levels, 
confidence intervals, and tests of statistical significance.
Table shells. A table shell contains all the elements of a data 
analysis table except the data. Some researchers find constructing 
table shells useful in planning the data collection instrument and in 
visualizing how the data will be organized for analysis. Table shells 
may be included in the proposal or in an appendix.
Plans for Interpretation
Although data have not been collected or analyzed yet, the 
literature review and study design provide guidelines and constraints 
for interpreting the research results. The proposal should describe 
plans to interpret the results. Considerations include:
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• Generalizability. The generalizability of a study is a function 
of sampling and analysis procedures. The proposal should 
indicate the target population and any other populations (in 
time or space) to which the results can be generalized.
• Limitations. No study is flawless. All studies will have some 
weaknesses, for example, in the sample selection, 
questionnaire design, measurement, or analysis. The 
researcher’s task is to keep these weaknesses at a minimum, 
to identify the limitations that do exist, and to inform the 
reader as to how the limitations preclude generalizability or 
how the problems may be overcome in future studies.
• Potential contributions. The proposal should also discuss the 
merits of the study, such as timeliness, public policy 
implications, contribution to scientific knowledge, and public 
health contribution.
Plans to Report Research Findings
The proposal should indicate what reports and other means of 
disseminating research findings are planned. Any or all of the 




• Seminars, workshops, and conferences
• Discussions with policymakers and program managers
Some of the questions that should be addressed when discussing 
dissemination of study results are:
• What specific parts of the research or data will be covered?
• At what stage in the study will the results be written, and by 
whom?
• How much time will be required to prepare the materials?
• Who will receive these materials?
Indicate how 
research 
findings will be 
disseminated
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The logistics are the resources, personnel, facilities, and budget 
required for the study. The proposal should indicate the anticipated 
cost of the study, the source of these funds, and how the funds will be 
allocated. The discussion about logistics should include:
• A description of the resources and facilities available for the 
study. For example, computer facilities, secretarial help, office 
space, library facilities, and vehicles. Indicate whether other 
institutions will contribute resources and what proportion of the 
principal investigator’s time will be devoted to the study (e.g., 
100%, 60%, 20%). Many funding agencies prefer joint research 
projects and look favorably on proposals that show contributions 
from the applicant’s home institution or other organizations.
• Any anticipated difficulty in obtaining scarce professional skills. 
Consultants or an advisory committee might be used if this need 
exists.
• A brief management plan that indicates who will be responsible 
for the budget, staff, field operations, data processing, analysis, 
and other components of the project. If several departments or 
institutions are collaborating on the project, indicate who will 
have overall responsibility for the project and what would be the 
roles or contributions of the different departments or institutions.
• A clearly outlined, realistic budget that lists each cost item and 
its components. For example, the cost of 10 interviewers might 
be shown as: Interviewers (10 @ $5 per day x  30 days) $1,500. 
Remember that different funding agencies have different rules 
for what they can fund in a project. (See World Health 
Organization, Preparing a Research Project Proposal: Guidelines 
and Forms, pages 15-17).
Arrange the cost items under major headings:








• Keypunchers and coders
• Clerical staff
• Other
Supplies and equipment, items under this heading might include:




• Computer time or purchase
• Report printing and distribution
Travel. This is a very limited category and should include only 
travel necessary to complete the study and to initially distribute 
the results. These costs might include:
• Vehicle rentals
• Gasoline
• Lodging for interviewers during fieldwork
Miscellaneous costs. Separate cost by year if the study will require 
more than one year. Also if the study will have a long duration, 
you may want to include a line item for inflation (A hypothetical 
proposal budget is shown in Example 2.12).
Work Schedule or Timeline
The steps and their sequence in the entire research process 
should be outlined. A corresponding calendar should indicate the 
amount of time each step will require (Example 2.13). The steps 
might include:
Developing a Research Proposal
Example 2.12
Hypothetical Budget for a Reproductive Health Survey
Personnel Salaries and Wages PESOS
1 Study Director @ 6 mos. x 141,000/mo.
1 Statistical Consultant @ 0.5 mo. x 130,000/mo. 
1 Field Coordinator @ 3.5 mos. x 117,500/mo.
4 Supervisors @ 3 mos. x 75,000/mo.
16 Interviewers @ 3 mos. x 55,000/mo.
1 Programmer/Analyst @ 2 mos. x 117,000/mo.
1 Coder @ 2 mos. x 94,000/mo.
2 Keypunchers @ 2 mos. x 50,000/mo.
1 Secretary @ 3 mos. x 40,000/mo.













2 IBM-XT computers @ 730,380/ea. 
1 IBM wide carriage printer 
Computer paper and supplies 
Printing
2500 Individual questionnaires 












2 Vehicle rentals @ 10 wks. x 50,000/wk. 






Total Project Cost 9,611,110
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• Selecting the sample
• Drafting the questionnaire
• Training interviewers and supervisors
• Pretesting the questionnaire
• Revising the questionnaire
• Printing the questionnaires
• Carrying out fieldwork (interviews)
• Coding the data
• Keypunching the data
• Editing the data
• Tabulating the data
• Analyzing the data
• Writing the final report
• Printing the final report
• Presenting the research findings at a conference
Example 2.13 
Hypothetical Work Schedule for a Household Survey
First Year Second Year




Prepare interviewer's manual 
Complete fieldwork maps 




Train interviewers tor pretest 
Pretest questionnaire 





supervisors for fieldwork 
Carry out fieldwork 
Code data




Prepare preliminary analysis 
and preliminary report 
Conduct detailed analysis 
Prepare final report
Phase V 
Print final report 
Organize and hold seminar to 
present final report 
Mail final report
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Special 
documents 
should be in 
the
appendices.
Bibliography for the Proposal
The proposal must include a bibliography that contains all the 
sources cited in the text of the proposal (these citations will be found 
primarily in the problem identification and justification or in the 
literature review). Important references that were not cited in the 
text may also be listed in the bibliography, including methodologic 
sources. Various styles exist for listing references in a bibliography. 
Any published journal or book can be used as an example for a 
bibliographic style (e.g., this manual). The important point is to be 
consistent and use the same style for each entry in the bibliography. 
Every reference should be checked against the original publication to 
ensure correct information.
Appendices to the Proposal
Many people believe that appendices are extras and that they are 
not read by proposal reviewers. This is not true. Documents such as 
curriculum vitae and questionnaires receive close scrutiny by 
reviewers. Therefore, careful attention should be given to the 
organization and presentation of documents that are not placed in the 
text of the proposal. These appended documents may include:
• Curriculum vitae of principal investigators
• Information on institutional affiliation of researchers
• Sample of data collection instrument
• Informed consent form
• Letters of endorsement for the study




1. Example 2.14 is part of a research proposal. After reading the example, write 
an abstract in the spaces provided. Your abstracts should answer these 
questions: 1) What is the research problem? 2) What is the research 
question or hypothesis? 3) What are the major expected implications? 4) 
Who will conduct the study? 5) When? 6) Where? 7) What methods will be 
used to collect and analyze the data? 8) What resources are required? If the 
example does not provide the information to answer one of these questions, 
provide your own hypothetical answer.
Example 2.14
Excerpts from a Proposal for a Descriptive Study of Prenatal Care in Puerto Rico 
Goal of the Study
The purpose of this study is to provide a descriptive analysis of the determinants of prenatal 
care in Puerto Rico by using data collected in the Puerto Rico Fertility and Family Planning 
Assessment (PRFFPA) survey.
This islandwide survey provides a unique data set to describe receipt of prenatal care in 
Puerto Rico. The initial descriptive analysis presented in this study should provide an impetus 
for more specific and in-depth studies concerning the determinants, components, quality, and 
benefits of prenatal care in Puerto Rico. This study may also offer insight into prenatal care 
behavior of Puerto Rican women who live in the United States.
Problem Identification
Research findings suggest that further substantial reduction in neonatal mortality is possible 
only if there is a decrease in the incidence of low-birthweight infants (Institute of Medicine,
1985). The general consensus in the United States and in other industrialized countries is that 
prenatal care can have a positive impact on an infant’s birthweight and thus improve the infant’s 
chance for survival.
However, all women do not receive prenatal care equally. In the United States, factors 
associated with a lack of appropriate prenatal care include low socioeconomic status, race other 
than white, unmarried status, very young or very old age at pregnancy, and first or third or 
higher order of birth.
In Puerto Rico, the infant mortality rate decreased dramatically, from a rate of 93.4 in 1945 
to 20.9 in 1975. Between 1975 and 1983, however, infant mortality declined only slightly to a rate 
of 173. This rate was higher than the infant mortality rate for any U.S. state (Rigau-Perez,
1986). Between 1980 and 1983, 9% of all live-born infants in Puerto Rico had low birthweights 
(Rigau-Perez, 1986; Becerra, 1989). In 1983,6.8% of all live-born infants in the United States 
had low birthweights (5.7% of white births, 12.6% of black births) (National Center for Health
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Statistics, 1983).
To date, the only information on prenatal care in Puerto Rico has come from birth 
certificates. In 1980, investigators analyzed the prenatal care information on the birth 
certificates, namely, the month prenatal care began and the total number of visits (Vazquez and 
Vazquez, 1982; Vazquez et al., 1983). Results indicate that 99% of women received some form 
of prenatal care, but only 63% began receiving care in the first trimester, and only 37% had at 
least ten visits. In comparison, U.S. vital statistics for the same period show that 73% of U.S. 
women began receiving prenatal care in the first trimester, and 53% had at least ten prenatal 
visits.
Justification
The PRFFPA, which collected information on many sociodemographic variables, offers a 
unique opportunity to further define and understand the level of prenatal care and the 
determinants of prenatal care in Puerto Rico. With more complete information on who receives 
and who does not receive care, prepared decision makers will be better able to respond to the 
discrepancies in prenatal care services. A  clear description of who lacks care is necessary to 
effect policy decisions that will close the gaps in receipt of prenatal care.
As services and care become more equitable, we expect to see a lower incidence of low- 
birthweight infants (especially if care includes services such as identifying high-risk women, 
advising pregnant women against smoking, and focusing on good nutrition) and thus a lower 
neonatal mortality rate. A  reduction of low-birthweight infants would lower the yearly costs of 
providing neonatal intensive care. Prenatal care programs can be a cost-effective approach to 
decreasing the incidence of low birthweight (Institute of Medicine, 1985).
Design
This study will be a descriptive analysis of the determinants and usage of prenatal care in 
Puerto Rico, It is based on a retrospective cross-sectional survey.
Methods
A. Definition of Terms
• Prenatal Care: At least one visit to a doctor, clinic, or other source for prenatal care 
during entire pregnancy.
•  Late prenatal care: First prenatal visit occurs after the first trimester.
• Inadequate care: Care that begins after the first trimester or less than seven visits to a 
prenatal care provider.
• Low birthweight: Birthweight that is less than 2,500 g (5.5 pounds), a criterion 
recommended by the American Academy of Pediatrics in 1935 and adopted by the World 
Health Organization in 1948. Low-birthweight infants may be premature (gestation less 




•  Very low birthweight: Birthweight that is less than 1,500 g.
•  Parity: The number of live births a woman has had.
B. Population
The population under study will be all women of reproductive age (15 to 49 years old) who 
have had at least one live birth and who were interviewed during the 1982 PRFFPA.
C. Data Source
This study will use data from the 1982 PRFFPA, a joint collaboration between the 
University of Puerto Rico, the Puerto Rico Department of Health, and the Division of 
Reproductive Health, Center for Chronic Disease Prevention and Health Promotion,
Centers for Disease Control (CDC). Financial support came from the National Institute of 
Child Health and Human Development, the Bureau of Community Health Services, and the 
CDC.
1. Sampling and Sample Size. The survey sample was chosen to be representative of the 
entire island. The sample was a two-stage, disproportionate, stratified cluster; housing 
units were the sampling units. These units did not include institutional housing, such as 
prisons, military reservations, and college dormitories. The study subjects were all 
women aged 15 to 49 years who lived in the selected housing units. The sample size 
necessary for the study was calculated to be 3,000 women. The survey obtained 3,175 
completed interviews.
The present study will consider only women who have had at least one live birth. Of the 
3,175 women interviewed, 2,012 women (63%) had had at least one live birth.
2. Data Collected. The individual questionnaire included basic social, economic, and 
demographic information and information on fertility, family planning, and maternal and 
child health. Each individual respondent was asked for complete retrospective histories 
on fertility, marriage, migration, education and employment, and contraceptive use since 
1978.
3. Data Collection. The data collection procedure for the PRFFPA involved two steps: 1) 
a household questionnaire was completed for each of the 30 housing units within 150 
sectors, and 2) an individual questionnaire was completed for all women aged 15 to 49 
years in each housing unit. For the household questionnaire, a total of 3,877 completed 
interviews were obtained from 4,500 units less 418 vacant units (95.0%), and for the 
individual questionnaire, a total of 3,175 completed interviews were obtained from 3,493 
eligible respondents (90.9%).
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4. Data Quality. Previous data quality checks for the PRFFPA survey involved: 1) 
examining the internal consistency of data from the household questionnaire and the 
individual questionnaire for age and marital status, 2) examining the internal consistency 
of the marriage and birth histories from the individual questionnaires, and 3) comparing 
the PRFFPA data, including age, marital status, fertility, and contraceptive use, with 
data from vital statistics, census, and other surveys.
The proposed study will carry out a validity check for the prenatal care data. Prenatal care 
data from the PRFFPA survey (specifically for the year 1980) and the results of Vazquez’s 
analysis of birth certificate data for that same year will be compared.
Interpretation
The sampling design of the study will allow the results to be generalizable to all Puerto 
Rican women aged 15 to 49 years in 1982. The findings may also be generalizable to Puerto 
Rican women living in the United States because these women move back and forth between the 
United States and Puerto Rico.
A  limitation of this study is that quality of care is unknown. In addition, because the present 
study will be limited to information from the PRFFPA survey, we will not be able to consider 
why women chose not to receive prenatal care, chose to receive care late, or chose not to 
continue care.
This study will be limited to women who have had one live birth. Prenatal care practices of 
women having other pregnancy outcomes, such as stillbirth or spontaneous abortion, will not be 
considered in this study. Thus, our results will not be representative of all pregnancies or 
persons eligible to receive prenatal care.
(Hammett, 1988)
1.1 What is the research problem?
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1.2 What is the research question or hypothesis?
1.3 What are the expected implications?
1.4 Who will conduct the study?
1.5 When will the study be conducted?
1.6 Where will the data be collected?
Developing a Research Proposal
1.7 What methods will be used to collect and analyze the data?
1.8 What resources are required?
2. For each of the following statements, indicate whether a problem is clearly 
identified. Does the statement include both a what is and a what should be 
component. If the statement is an analytic research problem, indicate 
alternative solutions for the problem and state the preferred solution. For a 
descriptive research problem, provide the appropriate responses.
2.1 Several different family planning methods have been distributed through 
rural clinics. The comparative continuation rates for these methods vary 
substantially in the Region Z  villages. Based on previous research, we 
would expect no variation in the continuation rates for the methods used in 
this region. Local health workers believe most of the variation is due to 
various side effects from the different methods. The Central Health 
Bureau believes the variation is related to traditional beliefs associated 
with different forms of contraception. The real reason(s) for the variation 
should be determined.
(a) Is this a clear problem statement? Yes/No
(b) Identify the what is:
(c) Identify the what should be:
(d) Are alternative explanations provided? Yes/No
(e) Is one explanation identified as the most likely?
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2.2 Five women had their IUDs removed last month because of excessive 
bleeding.
(a) Is this a clear problem statement? Yes/No
(b) Identify the what is:
(c) Identify the what should be:
(d) Are alternative explanations provided? Yes/No
(e) Is one explanation identified as the most likely? Yes/No
2.3 All hospitals that admit women for complications following induced 
abortions should accurately note the reason for admission on the medical 
record. However, because of the legal and ethical problems associated 
with abortion, information is frequently not recorded correctly.
(a) Is this a clear problem statement? Yes/No
(b) Identify the what is:
(c) Identify the what should be:
(d) Are alternative explanations provided? Yes/No
(e) Is one explanation identified as the most likely? Yes/No
2.4 Men should not die from infection following a vasectomy.
(a) Is this a clear problem statement? Yes/No
(b) Identify the what is:
(c) Identify the what should be:
(d) Are alternative explanations provided? Yes/No
(e) Is one explanation identified as the most likely? Yes/No
3. Select three reproductive health problems that are important in your country. 










4. Example 2.15 presents a hypothetical problem. Describe the following parts of 
the problem definition:
Example 2.15 
Problem Definition for a Family Planning Study
In Country X, the population growth rate is 3.8% per year. Because of recent economic 
trends, the average desired family size has fallen from 7.2 children in 1970 to 4.2 in 1980. Until 
the 1960s, the traditional segments of the population (80% of the total population) practiced 
postpartum abstinence and breast-feeding for two years after giving birth. Today, fewer than 
30% of women with newborn infants breast-feed for as long as 12 months, and 75% resume 
sexual activity three to five months after delivery. Modem methods of birth control have not yet 
compensated for the deterioration of traditional child-spacing practices. In 1980, contraceptive 
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5. Write a problem definition for each of the three reproductive health problems 
that you identified as important in your country.
(a) Health problem:
Problem definition:
(b) Health problem: 
Problem definition:




6. Example 2.16 describes a proposed study. Which form(s) of justification does 
the author use? Circle all justifications you find in the description below.
(a) Is the problem timely and current?
(b) Does it have serious consequences?
(c) Does it affect a large number of people?
(d) Does it have implications for current programs?
(e) Are there broad social, economic, or health implications?
(f) Who is concerned about the problem?
(g) What advances have already been made toward solving it?
Example 2.16
Justification for a Young Adult Reproductive Health Survey in Chile
Adolescent fertility has become an important concern in Latin America for various reasons, 
including a decline in age at first pregnancy, an increase in unintended pregnancies, and a 
relatively high rate of premarital conceptions among young women. This concern is tied to 
evidence that women who have their first birth at a young age will subsequendy have shorter 
birth intervals, more unplanned pregnancies and illegitimate births, and lower income levels than 
women who have their first birth at older ages. The health consequences of adolescent 
pregnancy are a growing concern worldwide. The evidence from surveys confirms that mortality 
rates are higher for infants and children bom to young mothers. For example, a study using 
World Fertility Survey (WFS) data from 29 countries showed that the infant mortality rate was 
33% higher for infants born to mothers less than 20 years old than for infants bora to mothers 
aged 20 to 29 years.
Despite the public health community’s awareness of the health risks and social problems 
associated with early pregnancy and childbearing, representative sample surveys designed to 
document the attitudes toward sexual activity and sex education, history of sexual experience, and 
use of contraception among young people in Latin America have been rare. Many investigators 
have drawn samples of adolescents and young adults from dinic or school populations, groups 
that are not representative of the total population of young people. To address the need for 
representadve data, Mexico City, Guatemala City, and the island of Jamaica reproductive health 
surveys using representative samples of young men and women were recently conducted.
In Chile, statistics reveal that the dramatic decline in age-specific fertility rates over the past 
two decades did not occur among 15 to 19 year olds. For example, women aged 15 to 19 years 
had fertility rates of 71.8 per 1,000 in 1969; 61.1 in 1979; and 64.1 in 1984. These fairly stable 
rates contrast sharply with the 24% decline in fertility rates among women aged 25 to 29 years 
and the 29% decline among women aged 30 to 34 years over the same period. This situation 
indicates a need for information on the reproductive knowledge and practices of the young adult 
population in Chile.
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Example 2.16 (continued)
A more significant change among young Chilean adults in recent years has been the 
pronounced increase of births among unmarried adolescent women. In 1970, 44% of the infants 
born to younger women (<20 years old), were born to unmarried women. By 1985, this 
percentage had steadily increased to 55%.
To develop programs that address these critical fertility issues in Chile, specific information 
on sexual activity, reproductive knowledge and attitudes, and contraceptive use among young 
adults is needed to accurately describe this population.
(Valenzuela, 1988)
7. Using one of the three previously defined reproductive health problems, write a 
justification for the proposed research. If the exact statistics are not available, 
substitute an "X" for the real figures.
(a) Health Problem:
Justification:






(b) Health problem: 
Ultimate goal:
(c) Health problem: 
Ultimate goal:
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9. Read the examples below and pick out the key elements that go into the 
research objectives for each case.
9.1 From 1993 to 1995, the State University will conduct a case-control study 
in the northern region to determine whether an association between pelvic 








9.2 In 1993, a cohort study of 1,000 women will be conducted in Province X to 
determine if the risk of morbidity is greater among women whose tubal 
sterilizations were performed by nurse-midwives than among women whose 
tubal sterilizations were performed by physicians. The study will be 
conducted by the Ministry of Health with technical assistance from the 







9.3 From August to December 1993, a descriptive study will be conducted in 
Division A by the National Health Council. The study will determine the 
types of complications that occur among women who had tubal sterilization 
surgery performed in mobile clinics. A total of 500 women who had 
sterilization surgery from January to June 1993 in Division A will be 









10. Using one of your reproductive health problems and the ultimate goal
stated in Exercise 8, write three different statements of research objectives 
for the problem.
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11. For each of the three reproductive health problems selected earlier, decide on 




(b) Research question or hypothesis:
11.2 Health problem:
(a) Primary purpose:





(b) Research question or hypothesis:
12. From Exercise 11, select one problem that has a research hypothesis (not a 
question) and indicate:
(a) Conditions:
(b) All potential intervening variables:
(c) Operational definitions of variables:
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13. Using your three reproductive health problems, decide which of the four study 
designs is appropriate for each problem.
(a) Health problem:
Type of study design:
(b) Health problem: 
Type of study design:
(c) Health problem: 
Type of study design:
Chapter 2
14. Circle true (T) or false (F).
(a) T /F  Resources already available for the study, such as office space and
secretarial help, need to be discussed in the proposal.
(b) T /F  Statistical analysis methods need to be outlined in the proposal.
(c) T /F  Detailed time lines make a proposal too long.
(d) T /F  Proposals should include plans for checking for errors.
(e) T /F  Interviewer training, including supervision, should be outlined in the
proposal for a survey.
(f) T /F  The data collection instrument is usually included in the Methods
section of the proposal.
15. Multiple choice. Select one response.
15.1 All of the following are generally included in the Methods section of the 
proposal except:
(a) Sample selection description
(b) Definition of variables
(c) Hypothesis formulation
(d) Data collection procedure
(e) Quality control procedure
15.2 All of the following are generally included in the Analysis section of the 
proposal except:
(a) Data preparation plans
(b) Scales, indices, transformations
(c) Descriptive or analytic statistics
(d) Dummy tables
(e) Summary of results
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15.3 All of the following are generally included in the Logistics section of the 
proposal except:




(e) Justification of costs






(e) Write final report
15.5 All of the following are generally included in the Interpretation section 





(e) Public health implications
15.6 All of the following are generally included in the Plans to Report 





(e) Discussions with policymakers
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Suggested Answers to Practice Exercises
1. Write a proposal abstract.
1.1 What is the research problem? Puerto Rico has a higher infant 
mortality rate than any state in the United States, and a higher 
proportion of low-birthweight infants are born in Puerto Rico than in 
the United States. Because prenatal care can have a positive effect on 
birthweight and infant survival, we need to determine the extent to 
which prenatal care services are used and the subgroups in the 
population at greatest risk for inadequate care.
1.2 What is the research question or hypothesis? What is the level of 
prenatal care in Puerto Rico and what are the characteristics of women 
who are at greatest risk for no care or insufficient care?
1.3 What are the expected implications? Improved levels of prenatal care, 
which in turn would bring about a reduction in incidence of low- 
birthweight births.
1.4 Who will conduct the study? Data collection: University of Puerto 
Rico, Puerto Rico Health Department, and the Centers for Disease 
Control. Data Analysis: No information is given in the example, provide 
your own hypothetical who.
1.5 When will the study be conducted? Data collection: 1982. Data 
analysis: No information is given in the example, provide your own 
hypothetical when.
1.6 Where will the data collection be conducted? The island of Puerto 
Rico.
1.7 What methods will be used to collect and analyze the data? Cross- 
sectional, islandwide survey of 3,175 women aged 15 to 49 years who live 
in the sampled housing units. (Other methods of data collection, to be 
used as needed, can be found in the Methods section.)
1.8 What resources are required? Not available in example given. Provide 
your own hypothetical cost or other resources needed.
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2. Identify a problem.
2.1 (a) Yes
(b) Continuation rates for family planning methods vary substantially in 
Region Z  villages.











(b) Hospital admissions for complications following induced abortion 
frequently are not recorded on medical records.
(c) This information should be accurately recorded on medical records.
(d) Legal and ethical problems associated with abortion are preventing 




(c) Men should not die from infection following a vasectomy.
(d) No
(e) No
4. Describe parts of the problem definition.
(a) Countrywide high rate of population growth
(b) Current
(c) Country X
(d) Traditional segments of the population are more affected; that is, 80% 
of total population.
(e) Postpartum abstinence and breast-feeding use to last two years. Today, 
fewer than 30% of mothers breast-feed newborns for as long as 12
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months, and 75% of women resume sexual activity from 3 to 5 months 
after delivery.
(f) Modern methods of birth control should be substituted for the 
traditional abstinence and breast-feeding.
(g) Why is the prevalence of contraceptive use only 12%?
6. Justifying a proposed study.
a, b, c, d, e, and f 
9. Key elements of research objectives.
9.1 (a) A case-control study
(b) State University
(c) Women attending private clinics
(d) 1993 to 1995
(e) Northern region
(f) To determine whether an association exists between pelvic 
inflammatory disease and IUDs among women attending private 
clinics
9.2 (a) A  cohort study
(b) Ministry of Health with technical assistance from the United 
Nations Development Program
(c) 1,000 women obtaining tubal sterilization
(d) 1993
(e) Province X
(f) To determine if the risk of morbidity is greater for women 
obtaining sterilization performed by nurse-midwives versus 
sterilization performed by physicians
9.3 (a) A  descriptive study
(b) National Health Council
(c) 500 women who obtained a tubal sterilization from mobile clinics in 
Division A  from January to June 1993
(d) August to December 1993
(e) Division A
(f) To determine the type of complications occurring after the 
sterilization procedure
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14. True or false.
(a) T Logistics
(b) T Analysis Plan
(c) F Work Schedule or Timeline. No, Example 2.13 shows that a
detailed timeline can be put on one page.
(d) T Analysis Plan
(e) T Methods
(f) F Methods. No, the data collection instrument is not included in the
body of the proposal, but may be placed in an Appendix.
15. Multiple choice.
15.1 (c) Methods
15.2 (e) Analysis Plan. The proposal is the plan to do a study, and
therefore there are no results yet.
15.3 (e) Logistics
15.4 (a) Work Schedule or Timeline. Problem identification takes place
before writing the proposal and is included in the proposal. The 
time line outlines steps that will be taken to complete the study.
15.5 (c) Interpretation
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Learning Objectives - Chapter 3
After completing this chapter you should be able to:






proportional mortality ratio 




2. Identify reasons for adjusting rates.
3. Interpret adjusted rates.
4. Identify measures of reproductive health:
crude birthrate 
general fertility rate 
general pregnancy rate 
age-specific birthrate 
total fertility rate
induced termination of pregnancy ratio
induced termination of pregnancy rate I









3 M easures of Disease Frequency in Reproductive Health
Introduction
To understand the occurrence and pattern of reproductive 
health outcomes in populations, epidemiologists must use 
statistical and epidemiologic methods to compare disease 
frequencies among individuals and populations. Standardized 
definitions of health outcomes are necessary to make comparisons 
across time and for specified periods of time. This chapter 
introduces quantitative measures used to assess reproductive 
health outcomes.
To measure the amount and distribution of diseases, health 
outcomes, or deaths in a population, investigators need to relate 
individuals with a specified disease or outcome to a population 
base. Investigators must also know the size and source (e.g., 
hospital patients, community sample, census tract) of the 
population from which the cases are drawn and the time period in 
which the information was collected. When these components are 
combined as a rate or ratio, we can compare disease frequencies 
in two or more groups of individuals.
Rates and Ratios
Rates
A rate is a measure of the frequency of some event in a defined 
population. A rate is composed of a numerator (number of 
events); a denominator (average population at risk for the event); 
a specified time in which events occur; and a multiplier (10” ; n >_ 
1 ), which converts a fraction or decimal to a whole number.
Most rates are proportions—the numerator is a subset of the 
denominator. For instance, the case fatality rate is the number of 
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Ratio
defined
persons diagnosed with the problem during a specified time period. 
The result is a fraction that is usually expressed per hundreds, per 
thousands, etc.
(3.1.1)
Case Fatality R ate1 = Number of deaths related to health problem * 1Q.
Number of persons diagnosed with health problem
The numerator and denominator should reflect a similar 
population. If the numerator is confined to a certain age, sex, or 
racial group, the denominator should be similarly restricted (Example 
3.1).
Example 3.1
Rate of Oral Contraceptive Use Among Mexican-American Women 
in the United States-Mexico Border Survey, 1979
To determine the rate of oral contraceptive (OC) use among Mexican- 
American and non-Hispanic white women, we must calculate the rate of use 
for a defined population and time period. In this example, the population is 
the U.S.-Mexican border and the time period is the calendar year 1979.
Research Question
What proportion of Mexican-American and non-Hispanic white women 
in the U.S.-Mexico Border Survey used OCs in 1979?
575 Mexican-American women used PCs * 100 = 45.8%
1,255 Mexican-American women in the sample
482 non-Hispanic white women used OCs * 100 = 60.4%
798 non-Hispanic white women in the sample
(Smith et al., 1983)
Ratios
A ratio is an expression of the relationship between a numerator and a 
denominator regardless of the population base from which the numerator 
and denominator are derived. The numerator of a ratio is not necessarily 
a subset of the denominator. For example, the maternal mortality ratio
70 1 The asterisk (*) that appears in the formulas throughout this manual denotes multiplication.
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is calculated by dividing the number of maternal deaths regardless of 
pregnancy outcome (i.e., ectopic pregnancy, fetal death, live birth) by 
the number of live births in a defined population. This measure of 
disease frequency is a ratio and not a rate because the numerator 
includes maternal deaths that are not a subset of the denominator. 
Ideally, the maternal mortality rate should include all pregnancies (not 
just live births) in the denominator. In practice, measuring all 
pregnancies in a population is difficult, so the maternal mortality ratio 
is used as a proxy for the more accurate maternal mortality rate. 
Unfortunately, most textbooks refer to the maternal mortality ratio as 
the maternal mortality rate.
A ratio is simply the value obtained by dividing one quantity by 
another. Therefore, a rate is also a ratio but a ratio is not always a 
rate. For example, a frequently cited ratio is the proportion of 
persons with disease relative to the proportion of persons without 
disease. This ratio is called the odds of disease:
(3.1.2)
n , ,  t  tv  Proportion of persons with the health problemOdds of Disease = --------------------- ----------------------------------------------
Proportion of persons without the health problem
Another ratio is the proportion of persons exposed to a risk 
factor relative to the proportion of unexposed persons. This ratio
is called the odds of exposure. Because the numerator is not a
subset of the denominator, we cannot call an odds ratio a rate.
Proportional mortality (PM) measures the relative importance 
of a specific cause of death relative to all deaths in a population
(3.1.3). It is an estimate of the proportion of lives that may be 
saved by preventing a given cause of death.
(3.13)
Number of deaths from a specific cause
= _______________ within a specified time period_________  #
Total number of deaths within the specified time period
The proportional mortality ratio (PMR) is the ratio of two PMs. 
For instance, the proportional mortality of a given cause of death 
may be compared in two different populations (Example 3.2).
However, the PMR can be misleading. In this example, the 
PMR of 2.4 could have resulted because France had a higher 
infant mortality rate from birth defects than did Mauritius.
Maternal 
mortality rate
Odds o f disease 
ratio













Proportional Mortality Ratio of French and Mauritian 
Infants Who Died of Birth Defects
Of the 6,257 native French infants who died in 1986, 1,303 had birth 
defects. The proportional mortality for the infants with birth defects is 
20.8% (1,303/6,257 = 0.208 * 100).
Of the 463 native Mauritian infants who died in 1987, 40 had birth 
defects. The proportional mortality for the infants was 8.6% (40/463 = 
0.086 * 100).
The proportional mortality ratio (PMR) is calculated as:
PMR = 20.8 = 2.4
8.6
(World Health Organization, 1988)
However, a lower infant mortality in France would have produced the 
same result, particularly among infants who died of causes other than 
birth defects. In fact, in France only 80 out of every 10,000 live-born 
infants died within the first year of life, and 17 of every 10,000 live- 
born infants died from birth defects. In Mauritius, 242 of every 
10,000 live-born infants died within the first year of life and 21 of 
every 10,000 died from birth defects. Because the denominator of the 
PM does not reflect a population at risk, we cannot describe the risks 
of the individuals in the population who are dying from a health 
problem.
Prevalence and Incidence Rates
The measures of disease most frequently used in epidemiology are 
prevalence and incidence. The point prevalence rate (PR) is the 
proportion of the population that has the health problem under study.
(3.2.1)
Number of existing cases of the health 




We include all persons who have the health problem at a 
specified point in time in the numerator, regardless of the length 
of time the individuals have had the problem. The denominator 
includes the total population—all persons diagnosed with the 
health problem and all persons unaffected by the health problem 
(Example 3.3).
Example 3.3
Prevalence of Smoking Among Women in Puerto Rico in 1982
In the 1982 Puerto Rico Fertility and Family Planning Assessment, women 
15 to 49 years old were asked, "Do you currently smoke?" The point prevalence 
of smoking was:
PR = Women currently smoking at time of interview = 487 = 15.3% 
Total women in the sample 3,175
(Becerra et al., 1988)
In contrast, the incidence rate (IR) is the number of new cases 
of a health problem that occurs in a population at risk within a 
specified period of time (Example 3.4).
(33.1)
_ Number of new cases of disease during a specified period of time ^
Population at risk
The incidence rate shown in Example 3.4 is sometimes referred 
to as a cumulative incidence rate. This rate is based on the 
assumption that the entire population at risk is followed from the 
beginning of the observation period to the end of the observation 
period.
However, we may not always be able to record observations for 
the specified period of time. For example, participants may enter 
a study at different points in time, or some participants may not be 
available for follow-up. Consequently, the duration of 
observations will not be uniform for all participants. When the 
observation periods are not uniform, we must use a more precise 











Eight-Year Incidence of Vasectomy in the 
Framingham Offspring Study
During an eight-year follow-up period, forty-four men who participated in 
the Framingham Offspring Study had had a vasectomy.
IR = Number of men who had had a vasectomy = 44 = 11.1%
Number of men at risk for vasectomy 397
(Hubert et al., 1987)
estimate, the incidence density (ID), is calculated by using the exact 
amount of time each study participant is followed; it is considered the 
instantaneous rate at which a disease develops in a population:
(3.4.1)
jj-j _ Number of new cases of disease during a given period of time +
Total person -  time of observation
For the ID and the IR, the numerator is the number of new cases 
of disease in a population during a given period of time. The 
denominator for the ID, however, is the sum of the total time that 
each individual contributes to the observation period and remains 
disease-free. The units in the denominator must reflect time (i.e., 
person-days, person-months, person-years) (Figure 3.5).
In calculating an incidence rate, we must precisely define the 
denominator. The denominator should include only those people who 
are at risk of developing the health problem. Therefore, people who 
have the health problem or who have had the problem, as well as 
people who cannot develop the health problem, should not be 
included in the denominator. Sometimes we may have difficulty 
determining who should not be included in the denominator, but the 
magnitude of the problem depends on the proportion of the total 
population not at risk. If persons not at risk are included in the 
denominator, the incidence rate will underrepresent the true 
incidence of the health problem. In some situations, we must remove 
people who are not at risk because they make up a large proportion 
of the population. For example, we should remove women who have
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had a hysterectomy from the denominator when calculating 
incidence rates for endometrial cancer because these women are 
not at risk for this type of cancer (Nolan et al., 1982; Pokras, 
1989).
In Figure 3.5, the total amount of time contributed by all 
participants is the sum of all person-years, or 8.5 years. Two 
occurrences of the health problem occurred during the follow-up 
period. Therefore, the incidence density is:





Jan July Jan July Jan July Years
1989 1989 1990 1990 1991 1991 Contributed
A O • 1.5
B o 2.0
Population C o X 1.0
Member D O X 1.5
E o 2.5
O Initiation of observation
•  Loss-to-follow-up: study subject died from causes other than health 
problem or moved out of study area.
X Disease of interest detected
An underlying assumption in calculating the ID is that the risk 
of developing the health problem is constant over time across age 
groups. Because this may not be true, we must divide the time 
period into smaller segments and stratify the population by age.
By dividing and stratifying the population, our calculation may 
better reflect the ID over time and age. Certain age groups may 
also be more prone to being lost to follow-up. If loss to follow-up 
occurs equally among the various exposure groups, our bias 
problems will be minimized. However, because this is unlikely, we 
must carefully inspect the ID by time and age to assess the extent 














If the distribution of characteristics in a population (i.e., 
categorization by age or sex) and the mortality rates specific for each 
one of the characteristic categories (i.e., age-specific mortality rates) 
are known, we can always express the overall, or crude mortality rate 
as:
(3.5.1)
JU Total number of deathsV  c * r. = --------------------------------
m 1 1 Total population at risk
where C; = the proportion of the population in each category,
r; = category-specific mortality rates, and I = number of categories or
strata.
When populations are different from each other (i.e., by age or 
race distribution), we should not use crude rates to compare them. 
Rather, we must adjust or standardize the rate to remove the effect of 
differences between populations for comparison purposes. Age is the 
variable most often used for adjustment because of its effect on 
morbidity and mortality, although we can use other variables.
Basically, two methods are used to adjust for differences in 
demographic composition of two populations: the direct method and 
the indirect method (Mausner and Bahn, 1974). Regardless of the 
method used, we must identify a standard population. The standard 
population may be one of the populations being compared, a 
combination of the comparison populations, a different population 
altogether, or a theoretical population. Because we use the process of 
standardization to remove the effect of differences between 
populations for comparison purposes, the standard population we 
select is not important.
Direct method. Using this method of adjustment, we multiply the 
proportions of the standard population in each category (i.e., age 
groups) by the corresponding age-specific mortality rates of each of 





Direct Adjusted Rate = Cs * r.
i-1
where Q  = the proportion of the standard population in each 
category, i t = category-specific mortality rates in the study 
population, and I = number of strata.
Using this method, we obtain rates that would be expected in 
the standard population if the age-specific rates prevailed for each 
of the comparison populations. The directly adjusted rate is 
meaningless by itself because its absolute value will always depend 
on the standard population; it is useful, however, in comparing 
another similarly adjusted rate using the same standard population. 
In essence, the two comparison populations are similarly weighted 
by the adjusted characteristic (age).
In Example 3.6, the direct method was used to correct or adjust 
for differences in the age distribution of the two comparison 
populations, Argentina and Mexico. If only the crude rates had 
been cited, researchers would have concluded that Argentina (9.2 
deaths per 1,000) had a higher death rate than Mexico (6.4 deaths 
per 1,000). However, after adjusting the rates, we are presented 
with a different picture: Mexico has a higher death rate (7.3 
deaths per 1,000) than Argentina (6.6 deaths per 1,000). The 
difference is because Mexico has a younger population than 
Argentina and age-specific death rates are much lower in younger 
people than in older people. Therefore, when differences in the 
age distribution are considered, researchers would have concluded 
that Mexico had a slightly higher death rate than Argentina.
Indirect method. For this adjustment procedure, we multiply 
the category-specific mortality rates of the standard population by 
the corresponding number of individuals in each category in the 
study population. These products are then added up for each 
population. The result is usually expressed as a ratio of the 
observed number of deaths in a study population to the expected 
number of deaths if the study population had the category-specific 
mortality rates of the standard population. This ratio is called the 
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Example 3.6
Age-Adjusted Death Rates Using the Direct Method 
Argentina and Mexico, 1982
Argentina* Mexico* Standardt Argentina Mexico
Age in Death Death Expected Expected
vears % Rate* % Rate* % Deaths* Deaths*
(a) (b) (c) (d) (e) [b*e/H>0] [d*e/100]
< 1 2.4 33.2 3.3 38.0 3.0 1.01 1.15
01-04 9.3 1.5 13.2 2.5 12.1 0.18 0.30
05-14 18.9 0.5 28.9 0.8 26.1 0.14 0.20
15-24 16.6 1.2 20.4 23 19.3 0.22 0.45
25-34 15.0 1.7 13.2 3.8 13.7 0.23 0.52
35-44 11.9 3.7 8.4 6.1 9.4 0.35 0.57
45-54 10.6 9.3 5.7 9.8 7.1 0.66 0.70
55-64 8.0 20.4 3.7 17.7 4.9 1.00 0.87
>.65 7.2 64.6 3.2 58.0 4.4 2.82 2.52
Total1 100.0 (9.2)1 100.0 (6.4)1 100.0 6.60 7.28 
Adjusted Rates
* Males only; midyear population estimates (Argentina = 14,501,000;
Mexico = 36,647,000).
f Combined Argentina and Mexico population.
* Per 1,000 population.
1 Totals may not exactly add up due to rounding error.
I Average mortality weighted by the proportion of the population in each age 
category (crude death rates).
(Adapted from Pan American Health Organization, 1989)__________________
(3.6.1)
Standardized Mortality Ratio = Observed number of deaths „ m
Expected number of deaths
Suppose we want to compare the survival of infants in different 
hospitals who weigh less than 2,500 grams with the national average 
(the standard population). Because the survival of a newborn 
weighing 1,000 grams is dramatically different from the survival of a 
newborn weighing 2,000 grams and because hospitals have different
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referral patterns for high-risk newborns, we can adjust for 
birthweight. In this case, the number of births and deaths per 
birthweight category (usually in 500 gram increments) in a given 
hospital will probably be smaller than the aggregate national 
figure. Consequently, if we were to use the direct method, our 
estimates of birthweight-specific mortality for each hospital would 
be unstable and unreliable. The alternative is to use the indirect 
method to estimate the ratio of the observed number of deaths in 
a study hospital to the expected number of deaths if the hospital 
population had the birthweight-specific mortality of the national 
average.
In Example 3.7, Hospital A has the highest neonatal mortality 
in the country among newborns who weighed less than 2,500 
grams. However, if we adjust for birthweight, we may reach a 
different conclusion. For example, if Hospital A had the same 
neonatal mortality experience for each birthweight category as the 
national average, we would expect to see 275 neonatal deaths, or 
75 more deaths than the 200 that actually occurred. Therefore, 
after we adjust for birthweight, Hospital A  has better neonatal 
survival than the national average.
Example 3.7 
Indirect Standardization of Neonatal Mortality
In 1985, 1,000 infants who weighed less than 2,500 grams were delivered in 
Hospital A. The hospital reported that 200 of these infants died. The 
national neonatal mortality average for infants weighing less than 2,500 grams 
was 126 deaths per 1,000 live births. Hospital A  was identified as having the 
highest neonatal mortality in the country. A  study will be conducted to 
investigate this matter.
Live Births in National Expected Observed
Hospital A  Mortality Deaths Deaths
Birthweight (a) (b) [a*b]
500-999 g 300 0.750 225 168
1000-1499 g 250 0.125 31 20
1500-1999 g 250 0.060 15 10
2000-2500 g 200 0.020 4 2
Total 1000 275 200
SMR = 200 = 72.7% 
275









Reproductive Health Rates and Ratios
The definitions and formulas that we present in this chapter were 
adopted from the World Health Organization (WHO) International 
Classification of Diseases (ICD-9) definitions used in perinatal 
statistics (Health Care Financing Administration, 1980; Chiswick,
1986) and adapted, reviewed, and approved by representatives of the 
American Academy of Pediatrics (AAP), the American College of 
Obstetricians and Gynecologists (ACOG), the American Medical 
Association, the American Medical Record Association, and the 
Centers for Disease Control (1988). Adherence to standard and 
commonly agreed upon definitions is necessary to make meaningful 
comparisons. Recently the WHO finalized the ICD-10 definitions 
(see Appendix 2).
The definition of a live birth is the complete expulsion or extraction 
from the mother o f a product o f human conception, irrespective o f the 
duration o f pregnancy which, after such expulsion or extraction, breathes 
or shows any other evidence o f life, such as beating o f the heart, 
pulsation o f the umbilical cord, or definite movement o f voluntary 
muscles whether or not the umbilical cord has been cut or the placenta 
is attached. A fetal death is defined as death prior to the complete 
expulsion or extraction from the mother o f a product o f human 
conception, fetus and placenta, irrespective o f the duration o f pregnancy; 
the death is indicated by the fact that, after such expulsion or extraction, 
the fetus does not breathe or show any other evidence o f life, such as 
beating o f the heart, pulsation o f the umbilical cord, or definite 
movement o f voluntary muscles. Heartbeats are to be distinguished from  
transient cardiac contractions; respirations are to be distinguished from  
fleeting respiratory efforts or gasps. This definition excludes induced 
terminations o f pregnancy. Induced termination of pregnancy is 
defined as the purposeful interruption o f an intrauterine pregnancy with 
the intention other than to produce a livebom infant, and which does not 
result in a live birth. This definition excludes management o f prolonged 
retention o f products o f conception following fetal death.
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Live Birth Measures
The crude birthrate measures the impact of fertility on population 
growth by relating the total number of births to the total population 
(usually approximated by the midyear estimate) in a given year.
(3.7.1)
Number of live births to women of all ages
Crude Birthrate = ________ during â  calendar year - „ 1QQQ
Total estimated midyear population
The general fertility rate is also a measure of fertility that 
relates the number of births to women aged 15 through 44 years 
(childbearing ages). For this measure, the denominator is the 
population-at-risk.
(3.7.2)
Number of live births to women of all ages
General Fertility Rate -   t o i - g  .  calendar »car--------------  „ 1000
Estimated midyear population of women aged 
15 through 44 years
The general pregnancy rate is more inclusive than the general 
fertility rate. In addition to live births, this rate includes fetal 
deaths and induced terminations of pregnancy in the numerator.
(3.73)
Number of live births + number of fetal deaths + 
number of induced terminations of pregnancy 
General = during a calendar year #  ̂qqq
Pregnancy Rate Estimated midyear population of women
aged 15 through 44 years
Age-specific birthrate and the total fertility rate are rates that 
relate the number of births to women in a specific age group to 
the total number of women in that age group.
(3.7.4)
Number of live births to women within a 
A ge-Specific Birthrate = specific age group during acalendaryear + ^
Estimated midyear population of women 
within the same age -  specific group




Total Fertility Rate = The sum of the age-specific birthrates of women at each age
group 10-14 through 45-49 years. Because 5-year age 
groups are used, we multiply the sum by 5. This rate can 
also be calculated using single years of age.
= Sum of the Age-Specific Birthrates * 5
Maternal Mortality Definitions and Measures
These measures are designed to indicate the likelihood that a pregnant 
woman will die from complications o f pregnancy, childbirth, or the 
puerperium period. Maternal death is defined as the death o f a woman 
from any cause related to, or aggravated by, pregnancy or its 
management (regardless o f duration or site o f pregnancy). This 
definition does not include accidental or incidental causes.
A death that occurs during pregnancy or after a pregnancy is 
terminated from causes unrelated to the pregnancy, including 
complications and management of the condition, is not considered a 
maternal death. Nonmatemal deaths may result from accidental causes, 
such as an automobile accident or gunshot wound, or incidental causes, 
such as a concurrent malignancy.
Direct obstetric death. The death of a woman from obstetric 
complications of pregnancy, labor, or the puerperium; from 
interventions, omissions, or treatment; or from a chain of events 
resulting from any of these factors.
Indirect obstetric death. The death of a woman from a previously 
existing disease or a disease that develops during pregnancy, labor, or 
the puerperium. The disease(s) are not from direct obstetric causes, 
although the physiologic effects of pregnancy were partially responsible 
for the death.
Theoretically, the population at risk (the denominator) should include 
all pregnant women in a given time period. Because it is difficult to 
ascertain fetal deaths and pregnancies that are induced terminations, we 
usually use the number of live births in the denominator.
(3.7.6)
Number of deaths attributed to maternal 
Maternal _ conditions during a specified time period 
Mortality Ratio Number of live births during the same time period
100,000
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WHO currently recommends including maternal deaths that 
occur within 42 days of the end of the pregnancy. Some countries 
use other time periods (i.e., within one year) but are urged to use 
the WHO and the national definitions.
Although international comparisons are difficult to make 
because of variable reporting practices, we know that wide 
differences in maternal mortality exist worldwide (World Health 
Organization, 1985) (Example 3.8).
Example 3.8
Maternal Mortality Ratios in the World, 1985
In 1985, more than 500,000 maternal deaths occurred worldwide. 
Approximately 99% of these deaths occurred in developing countries. In 
1985, the maternal mortality ratio averaged 640 per 100,000 live births in 
Africa, 420 in Asia, and 270 in Latin America. In 1985, the U.S. maternal 
mortality ratio was 7.8 per 100,000 live births.
(World Health Organization, 1985)
Induced Termination of Pregnancy Measures
Induced termination o f pregnancy ratio I. Like the maternal 
mortality ratio, the population at risk for the measures of induced 
termination of pregnancy can be estimated by the number of live 
births in a time period as a surrogate measure of all pregnancies. 
Because this is not the actual total population at risk, the measure 
is considered a ratio.
(3.8.1)
Number of induced terminations 
Induced Termination of _ occurring during a specified time period ^  ̂
Pregnancy Ratio I Number of live births occurring ’
during the same time period
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Induced termination o f pregnancy rate. This measure uses live 





Number of induced terminations occurring 
during a specified time period 
Number of induced terminations + live births + 
reported fetal deaths during the same time period
Induced termination o f pregnancy ratio II. This is the probability 
that women of reproductive age will have an induced termination of 
pregnancy.
(3.8.3)
Number of induced terminations 
Induced Termination _ occurring during a specified time period  ̂  ̂^  
of Pregnancy Ratio II Female population aged 15 through 44 years ’
Fetal Mortality Measures
Fetal death measures indicate the likelihood that pregnancies in a 
population group would result in fetal death.. . .  The population at risk 
for fetal mortality is the number o f live births plus the number o f fetal 
deaths in a year. To obtain the fetal death ratio, we can use the 
number of live births as the population at risk. Because birthweight 
can be more accurately measured than gestational age, we 
recommend that this measurement include specific birthweight (e.g., 
fetal deaths of at least 1,000 g).
(3.8.4)
Number of fetal deaths during a
Petal Death Rate  ------ - -------  specified time period ,  y o o
Number of fetal deaths + number of live births 
during same time period
(3.8 5)
Number of fetal deaths during a
Fetal Death Ratio = _________  specified time p eriod ^   ♦ 1,000
Number of live births during same time period
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Perinatal Mortality Measures
These measures combine fetal deaths and live births which 
survive only briefly (up to a few days or weeks) on the assumption 
that similar factors are associated with the losses. The population-at- 
risk is the total number o f live births plus fetal deaths, or the number 
o f live births alone. Perinatal mortality measures can vary by age o f 
fetus and the infant. In general, perinatal mortality measures 
should be reported by specific birthweight rather than gestational 
age.
(3.8.6)
Number of deaths of infants less than  days old
P rinatal + num^er êta  ̂deaths (birthweight at least  g)
Mortality = _________during a specified time period___________ _ 100Q
Rate Number of live births + number of fetal deaths
(birthweight at least  g) during same time period
(3.8.7)
Number of deaths of infants less than  days old
Perinatal + num^cr °* êta* deaths (birthweight at least  g)
Mortality = _________ during a specified time period___________  * 1>000
Ratio Number of live births during same time period
When gestational age is used to calculate perinatal mortality 
rates and ratios, instead of birthweight, we generally use the 
following accepted categorizations:
(3.8.8)
Perinatal Period I = Number of deaths of infants less than seven days old;
gestation of 28 weeks or more.
(3.8.9)
Perinatal Period II = Number of deaths of infants less than 28 days old;
gestation of 20 weeks or more.
(3.8.10)
Perinatal Period III = Number of deaths of infants less than seven days old;
gestation of 20 weeks or more.




Measures of infant mortality are intended to show the likelihood 
that live births with certain characteristics will die during the first year of 
life. In general, the population at risk are live births that occur during 
the time period specified for the study. Infant deaths include any 
death at any time from birth up to, but not including, one year o f age 




Number of infant deaths (neonatal + postneonatal)
Infant . _ during a specified time period
Mortality Rate Number of live births during the same time period
(3.9.2)
Neonatal Period = Birth through 27 days, 23 hours, 59 minutes.
(3.9.3)
Postneonatal Period = End of 28th day through 364 days.
(3.9.4)
Number of neonatal deaths
Neonatal _ __________ during a specified time period________   +  ̂qqq
Mortality Rate Number of live births during the same time period
(3.9 5)
Number of postneonatal deaths 
Postneonatal _ during a specified time period + jqqq




Infant Mortality Rates, Worldwide, 1985
In 1985, approximately 40,000 infants died each day worldwide. In the 
United States, 40,000 infants died throughout the same year. Clearly, 
substantial disparities in infant mortality rates exist among countries. In 1985, 
Afghanistan, Mali, Sierra Leone, Malawi, Guinea, Ethiopia, Somalia, 
Mozambique, Burkina Faso, and Angola had infant mortality rates higher 
than 140 per 1,000 live births. On the other hand, Sweden, Finland,
Japan,Finland, Japan, Switzerland, Norway, Netherlands, Denmark, France, 
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Practice Exercises
1. Circle true (T) or false (F).
(a) T /F  If the numerator of a rate is confined to a certain age, the
denominator should relate to the general population.
(b) T /F  The numerator of a rate is always a subset of the denominator.
(c) T /F  The multiplier term in a rate could be 100,000.
(d) T /F  Ratios measure the relationship of one health outcome to another.
(e) T /F  The proportional mortality expresses the number of deaths from a
specific cause relative to the total number of people in the 
population.
(f) T /F  All ratios are rates.
(g) T /F  The point prevalence rate is the proportion of the population that
has an outcome or a risk factor at a specific point in time.
(h) T /F  The incidence rate is the number of new cases that develop in a
population at risk during a specific time interval.
(i) T /F  The cumulative incidence rate assumes that the entire population is
followed from the beginning of the study to the end of the study.
(j) T /F  Incidence density measures the exact amount of time each study 
participant is followed.
(k) T /F  Incidence density is an appropriate measure when the risk of 
developing the outcome of interest changes over time.
(1) T /F  Incidence density is useful when study subjects die from causes 
unrelated to the study question before the study is completed.




(n) T /F  If women who have had hysterectomies are included in calculating 
incidence density, our result will be an overestimation of the rate of 
endometrial cancer.
(o) T /F  Comparisons using crude rates are accurate when populations have 
similar distributions with respect to a risk factor.
(p) T /F  Adjusted rates are commonly used to correct for age differences 
between populations.
2. Define the following rates:
(a) Crude birthrate:
(b) Maternal mortality rate:
(c) Perinatal mortality rate (use Perinatal Period I):
(d) Infant mortality rate:
3. Qrcle true (T) or false (F).
(a) T /F  A surrogate for the population at risk is used when we measure the
induced termination of pregnancy rate.
(b) T /F  The induced termination of pregnancy rate gives the probability of
an induced termination of pregnancy among women in a specific 
age group.
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(c) T /F  WHO recommends no time limitation on maternal mortality ratio
calculations for geographic areas within the United States.
(d) T /F  The perinatal period I is number of deaths of infants less than
seven days, gestation of 28 weeks or more.
(e) T /F  Measures of infant mortality show the chances that live-born infants
will die within the first two years of life.
(f) T /F  The total fertility rate is the sum of age-specific birthrates.
(g) T /F  The denominator of the general fertility rate uses the total midyear
population.
4. Data were collected in Michigan from 1950 to 1964 on the incidence of 
Down’s syndrome by birth order and maternal age (Example 3.10).
Example 3.10














5 + 443,000 .00026
Total 2,826,000 Crude Rate: 
.00043
* Michigan Standard 














In this example, birth order is the confounding factor. Note that because the 
maternal age rates increment in different directions by birth order, the results are 
difficult to interpret.
(a) Complete the chart by computing the expected number of cases and the 
adjusted rates for both maternal age strata:
Age 20-24: Adjusted rate =
Age < 20: Adjusted rate =
(b) Was there a reversal from crude to adjusted rates?
(c) How might the results be interpreted?
91
Measures of Disease Frequency in Reproductive Health
Suggested Answers to Practice Exercises
1. True or false.
(a) F Rates. The numerator and denominator of a rate should reflect a
similar population; if the numerator is confined to a certain age, sex, 
or racial group, then the denominator should be similarly restricted.
(b) T Rates
(c) T  Rates
(d) T  Ratios
(e) F Ratios. The proportional mortality measures the relative importance
of a specific cause of death relative to all deaths in a population.
(f) F  Ratios. All rates are ratios, but the converse is not true because in










only those people considered to be at risk of developing the disease.
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(n) F  Prevalence and Incidence Rates. If women who have had a
hysterectomy are included in the denominator, the rate of 
endometrial cancer would be underestimated because they are not 
part of the population at risk of developing endometrial cancer.
(o) T Adjusted Rates
(p) T  Adjusted Rates
3. True or false.
(a) T  Induced Termination of Pregnancy Measures
(b) T  Induced Termination of Pregnancy Measures
(c) F  Maternal Mortality Measures
(d) T  Perinatal Mortality Measures
(e) F  Infant Mortality Measures. Measures of infant mortality are intended
to show the likelihood that live-born infants will die during the first 
year of life.
(f) F  Live Birth Measures
(g) F  liv e  Birth Measures
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4. Answers to Example 3.10.
Example 3.11
Maternal Age and Birth Order 
Exercise Answer
Michigan Maternal Age Maternal Age
Standard 20-24 Years Years < 20
Birth Population
Order at Risk -» ------- Expected - Expected
1 731,000 .00043 314.33 .00047 343.57
2 725,000 .00046 333.50 .00035 253.75
3 569,000 .00040 227.60 .00020 113.80
4 358,000 .00038 136.04 .00044 157.52
5 + 443,000 .00026 115.18 .00000 000.00
Total 2,826,000 Crude Rate: Crude Rate:
.00043 .00043
(Kleinbaum and Kleinbaum, 1979)
(a) Age 20-24: Adjusted rate = 1126.95 = .00039 or 39.9/100,000
2,826,000
Age < 20: Adjusted rate = 868.64 = .000307 or 30.7/100,000
2,826,000
(b) The crude rates are equal. The adjusted rates are different.
(c) Because no age group has consistently higher birth-order-specific rates,
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Chapter 4 - Learning Objectives
After completing this chapter, you should be able to:
1. Differentiate descriptive from analytic epidemiology.
2. Define the general concepts exposure and disease.




4. Identify strategies to eliminate bias.




6. Define sensitivity and specificity and their relationship to misclassification.
7. Identify the relationship of the p value to chance.
8. Distinguish effect modification and confounding.
9. Define reliability and internal validity.
10. Recognize limitations on the generalizability of epidemiologic findings.
11. Identify factors to consider when evaluating the epidemiologic evidence of a 
causal relationship between an exposure and a disease or health outcome.

4 Epidemiologic Study Design
Introduction
This section provides an overview of epidemiologic study 
designs, introduces epidemiologic terms, and distinguishes between 
analytic and descriptive epidemiology. In addition to the 
fundamentals of study design, estimation, and testing, we must be 
familiar with the limitations of epidemiologic studies before we 
can interpret the results of studies. These limitations express 
themselves through biases in the selection of participants, and the 
collection and analysis of data. Thus, this chapter also introduces 
the major types of bias and other threats to the reliability and 
validity of epidemiologic research. Finally, the chapter enumerates 
the major criteria used for assessing the causality of epidemiologic 
findings.
Analytic and Descriptive Epidemiology
Experimental and Nonexperimental Studies
Epidemiologic studies may be categorized into two general 
classes, experimental and nonexperimental. The difference 
between these classes is based on whether the researcher has any 
control over the exposure—the agent that may potentially cause or 
control a disease—that is being evaluated. In this chapter, we use 
the term disease to refer to the health problem or outcome of 
interest.
Experiments are the first major class of epidemiologic research. 
Because epidemiologists typically control the exposure in 
experimental studies, such studies should provide stronger 
evidence of an association or a lack of an association between an 
exposure and a health problem than would nonexperimental 
studies. Common examples of epidemiologic experiments are











clinic-based trials of new therapeutic agents (e.g., evaluation of AZT 
in the treatment of AIDS patients) or communitywide interventions of 
health education programs (e.g., media campaigns to encourage family 
planning).
The second major class of epidemiologic research, nonexperimental 
studies, comprises the majority of all epidemiologic studies. Non­
experimental epidemiology is further divided into two major subtypes, 
descriptive and analytic. Descriptive studies (described in Chapter 6) 
are performed when relatively little is known about the risk factors or 
natural history of a particular disease or condition. Typically, a 
descriptive study focuses on patterns of disease occurrence in relation 
to groups of persons, geographic places, or periods in time. For 
example, sudden infant death syndrome (SIDS), a major cause of 
postneonatal mortality, has a very poorly understood etiology. 
Descriptive studies designed to determine if SIDS occurs more 
frequently among certain ethnic groups, within certain geographic 
areas, or at certain times of the year could be instructive.
In contrast, analytic studies, sometimes referred to as etiologic 
studies, are performed to test specific hypotheses about a specific 
health problem. For example, if a particular ethnic group were to 
experience a relatively high frequency of SIDS deaths, the investigator 
might look for more specific risk factors within that ethnic group.
Overall, the difference between analytic and descriptive 
epidemiology is primarily one of emphasis rather than method 
(Kleinbaum et al., 1982). The major differences relate to the use of 
comparison groups, measures of effect or association, and hypothesis 
generation rather than hypothesis testing. Although descriptive 
studies typically do not select persons into formal comparison groups, 
investigators often form internal comparison groups after examining 
the initial descriptive statistics. For example, consider data collected 
on pregnancy history and contraceptive practices from a random 
sample of women. We could summarize the data using simple 
descriptive statistics of family size, types of contraception, and other 
factors. In another analysis, the same data could be reanalyzed by 
making internal comparison groups based on the choice of contracep­
tive method. We could then compare different characteristics (e.g., 
family size, ethnic distribution, etc.) in relation to choice of 
contraceptive method.
In general, the associations observed in descriptive studies are often 
the basis for gathering more specific data and testing hypotheses in
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additional studies. Conclusions concerning risk factors from 
nonexperimental research must usually be obtained in several 
studies before they receive widespread acceptance. Similarly, the 
biological plausibility of a particular finding affects its acceptability 
by the scientific community.
Study design is the protocol for selecting persons to study and 
the method in which data are collected. Study design constitutes 
the major difference between descriptive and analytic epidemio­
logy. Analytic epidemiology involves the selection and comparison 
of two or more groups of persons, based on either their exposure 
or disease status, to evaluate an association between exposure and 
disease. Although descriptive epidemiology does not typically 
select persons on the basis of exposure or disease, descriptive 
studies may divide participants into subgroups for comparison.
Exposure includes potential risk factors and interventions in the 
etiology of disease as well as therapies in the treatment of disease. 
Similarly, disease includes any health problem on the continuum 
from complete health to death. Thus, in the context of 
reproductive epidemiology, examples of exposure include maternal 
age, contraceptive methods, or surgical procedures; examples of 
disease include low birthweight, pelvic inflammatory disease, 
ectopic pregnancy, or surgical complications. Depending upon the 
question under study, a characteristic may be an exposure or a 
disease. For example, low birthweight is a risk factor for neonatal 
mortality, but low birthweight may also be a consequence of poor 
prenatal care. By definition, an exposure must antedate the 
occurrence of disease.
Second, analytic epidemiology focuses on measures of effect to 
quantify the magnitude of the association between the exposure 
and the health problem under study. These measures of effect are 
most commonly expressed as ratios of or differences between 
rates, probabilities, and proportions. In addition to measuring the 
magnitude of the etiologic (or preventive) effect of a particular 
exposure, some measures of effect indicate the proportion of 
disease occurrences caused (or averted) within a particular 
subgroup or population.
Finally, descriptive epidemiology emphasizes hypothesis 
generation, and analytic epidemiology typically emphasizes 
hypothesis testing; both study designs may use statistical tests. 
Descriptive epidemiologic studies might suggest potential risk
Exposure
defined




factors that can be altered to reduce or prevent disease. Ultimately, 
those clues could generate hypotheses that would be more explicitly 
tested in analytic studies. By hypothesis testing, analytic epidemiology 
seeks either to confirm (support) or to refute (reject) previously 
reported associations (Hennekens and Buring, 1987). Both hypothesis 
generation and hypothesis testing involve writing careful research 
hypotheses and questions that describe the association between the 
outcome under study and the exposure of interest expected to be seen 
at the conclusion of the study. In Example 4.1, the clinical trial was 
designed to test the research hypothesis that infection rates following 
intrauterine device (IUD) insertions by nurse-practitioners differed 
from infection rates following IUD insertions by gynecologists.
Example 4.1
Clinical Trial
Health Care Provider and Post-IUD Insertion Infection Rates
Problem: Do post-intrauterine device (IUD) insertion infection rates differ 
between nurse-practitioners and gynecologists?
Research Hypothesis: The rate of infection following IUD insertions by 
nurse-practitioners is different from the rate of infection following IUD  
insertions by gynecologists.
Study Design: Clinical trial
Eligibility Criteria: Women 30 to 45 years old with at least one prior 
pregnancy
Treated: Women with IUDs inserted by nurse-practitioners constitute the 
treatment group.
Not Treated: Women with IUDs inserted by gynecologists constitute the 
control group.
Outcome: Each group of women is followed up on a regular basis to monitor 
any development of infection. The same method of assessing infection should 
be used for the treatment and control groups.
Data Collection Methods: Regardless of who inserted the IUD, the patients 
are visited twice a week for six weeks by a nurse to determine whether 






Study design refers to the manner in which groups of persons 
with particular characteristics are assembled and compared to 
evaluate the association between a risk factor or exposure and a 
disease or outcome.
The ideal study design from the scientific point of view is an 
experiment. The distinguishing feature of an experiment is that 
the scientist determines the exposure status of each participant and 
then observes the occurrence of a particular event (for example, 
disease). The investigator also typically establishes eligibility 
criteria that study subjects must meet before they can be assigned 
to a particular exposure. In health research, experiments are most 
often used to evaluate a new clinical therapy. This design, 
referred to as a clinical trial, involves the assignment of individual 
persons to one of two or more therapeutic interventions.
Clinical trial designs may also involve the element of 
randomization (typically called a randomized clinical trial). The 
epidemiologist assigns study subjects to a particular treatment at 
random and relies on chance to distribute an equal number of 
study subjects to each treatment group. Example 4.1 describes an 
experiment designed to evaluate complications of IUD insertion 
performed by different types of health care providers. If 
nonrandom assignment were used in this example, clinic personnel 
might introduce some bias when assigning a provider (e.g., by 
assigning patients with more favorable prognosis to the nurse).
Under simple random assignment, each eligible study subject 
would have an equal chance to be treated by either health care 
provider. Random assignment is often accomplished by clinic 
personnel opening a sealed envelope containing the treatment 
assignment for each eligible person. Randomization minimizes the 
opportunity for bias and also provides the theoretical basis for the 
use of statistical models and hypothesis testing.
Nonexperimental
From an ethical point of view, most experimental studies of risk 
















observe the effect of passive smoking on birthweight would not 
randomly assign expectant mothers to environments where they either 
would or would not be exposed to cigarette smoke. The majority of 
epidemiologic studies are nonexperimental.
Although we cannot to assign exposure status, good nonexperi­
mental studies should emulate other characteristics of a good 
experiment. One of these characteristics is the nonbiased collection 
of data among all groups included in the study. Two ways to promote 
nonbiased data collection are to use the same standardized data 
collection forms for all groups under study and observers who do not 
know the group to which a study subject belongs. When the observer 
does not know the study subject’s group, the observer is considered to 
and be blinded. When neither the observer nor the participant knows the 
exposure status, the study is referred to as double-blinded. Similarly, 
nonexperimental studies should use the same questionnaire or 
laboratory procedure to gather data from all study subjects. 
Investigators using nonexperimental designs should attempt to use 
blinded observers for data collection, although this may not always be 
practical or possible.
Investigators who properly execute nonexperimental studies select 
subjects according to some predetermined, objective criteria. In this 
way, the study subjects should represent reproducible and comparable 
groups of persons.
Using nonexperimental study designs,r we select persons on the 
basis of either exposure status or disease status. Selection based on 
exposure is directly analogous to the experimental design in that the 
epidemiologist knows the level of exposure (or particular clinical 
therapy) and observes the subsequent occurrence (or prevention) of a 
health problem. This design is called a cohort or follow-up design.
In a cohort study, the epidemiologist follows up the cohort (a defined 
group of exposed persons) to ascertain the outcome of interest.
Most cohort studies are based on the enrollment of currently 
exposed and unexposed persons. A cohort study design that is based 
on current exposure status may be called a prospective cohort study.
In contrast, historical records of exposure among a group of persons 
may be used to select individuals for follow-up. This design has most 
often been used in occupational epidemiology, where job classification 




Example 4.2 illustrates a prospective cohort study designed to 
determine the association between passive smoking and respiratory 
infections in children. In this example, the epidemiologist must 
identify families with children younger than 12 years old who live 
at home. Children are considered exposed to smoking if at least 
one smoker lives in the same household and unexposed if no 
smokers live in the same household.
Example 4.2
Prospective Cohort Study 
Passive Smoking in Children and Respiratory Infections
Problem: Is passive exposure to tobacco smoke associated with increased 
respiratory infections in children?
Research Hypothesis: Passive exposure to tobacco smoke is associated with 
increased frequency of respiratory infections.
Study Design: Cohort study of children exposed and not exposed to tobacco 
smoke in their home.
Exposed: Children younger than 12 years old who live at home where at least 
one smoker resides.
Not Exposed: Children younger than 12 years old who live at home where no 
smokers reside.
Outcome: Outcome is respiratory infections in children. Families will be 
contacted on a monthly basis for one year to determine the frequency of 
respiratory infections. The method of assessing infection frequency should 
not vary according to smoking status.
When selection is based on current disease status rather than 
exposure status, the epidemiologist collects information on 
exposure history from diseased and nondiseased study subjects. 
Study subjects with disease are called cases and study subjects 
without disease are called controls. This design is called a 
case-control study, although some researchers prefer the name 
case-referent study. Example 4.3 illustrates a case-control study of 














Oral Contraceptive Use and Breast Cancer
Problem: Does use of oral contraceptives influence the development of 
breast cancer?
Research Hypothesis: Using oral contraceptives is associated with breast 
cancer.
Study Design: Hospital-based case-control study of women with newly 
diagnosed breast cancer.
Cases: Women are selected at time of initial diagnosis of breast cancer from 
several hospitals during a one-year period.
Controls: Women who do not have a history of cancer are selected from the 
same hospitals as the cases during the same one-year period.
Exposure: Both cases and controls receive a standardized personal interview 
to obtain information on previous use of oral contraceptives. Both groups of 
women must be questioned in the same manner.
When studying the etiology of a disease, investigators who use the 
case-control study should recruit persons with newly diagnosed disease 
(incident cases) rather than persons with a history of disease 
(prevalent cases). The study protocol must specify how persons with 
incident disease will be ascertained and how they will be distinguished 
from persons with previous disease. The causation of disease is 
related to factors present before the onset or incidence of disease. 
Persons with incident disease (incident cases) are more likely to 
represent the distribution of risk factors among individuals developing 
disease. In contrast, the prevalence (P) of disease is related to both 
disease incidence (I) and the average duration (D) of the disease 
(P = I * D). All persons with disease (prevalent cases) may 
overrepresent factors related to survival with disease rather than 
causation of disease. For example, women with ovarian cancer have a 
relatively short survival. Therefore, a case-control study that enrolled 
only women surviving with ovarian cancer would underrepresent
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women who died soon after diagnosis; consequently, the risk 
factors related to the rapid course of disease might be missed.
In summary, descriptive studies usually select persons who 
represent some segment of the population and do not necessarily 
select persons on the basis of exposure or disease status. Analytic 
designs select study subjects either on the basis of exposure status 
(persons are followed forward in time until a particular outcome 
occurs) or on the basis of disease status (data is obtained on 
exposures that occurred in the past).
Basic Formulas for 2 x 2 Tables
In the simplest terms, the goal of most epidemiologic studies is 
to complete a two-way table. Typically this table is a 2 x 2 table 
with exposure on one axis and disease (or outcome) status on the 
other (Figure 4.4). Data organized in this way can be used to 
calculate measures of association (e.g., risk ratios, rate differences, 
or odds ratios) and the appropriate statistical tests.
The risk difference (Rothman and Boice, 1979) is the arithmetic 
difference between two risks and is computed from Figure 4.4 as:
(4.4.1)
a + c b + d
« a — b
The confidence interval, using test-based procedures, is estimated 
as:
(4.4.2)
Confidence Interval for RD = RD + (1 ± z  /  x )
where z is the normal variate associated with the desired level of 
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Risk difference is also known as attributable risk. Using the 
attributable risk, it is possible to estimate the excess rate of disease in 
Population the total population attributable to the exposure. The population
attributable attributable risk (PAR) can be calculated by multiplying the
risk attributable risk by the proportion of exposed persons in the
population.
(4.4.4)
PAR = RD * proportion of exposed persons in the population
Cumulative The cumulative incidence relative risk (CIR) for a randomized 
incidence clinical trial or a cohort study is the ratio of the risk in the exposed
relative risk group relative to the risk in the unexposed group; it is computed from
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The confidence interval, using test-based procedures, is 
estimated as:
(4.4.6)
Confidence Interval for CIR = CIR ^  ± z /  X )
where z is a normal variate and x is defined in 4.4.3.
The odds ratio for a case-control study is the odds of disease in 
the exposed group relative to the odds of disease in the unexposed 
group; it is computed from Figure 4.4 as:
(4.4.7)
OR = a * ..d. 
b * c
The approximate confidence interval for the OR, using test- 
based interval estimation, is estimated as:
(4.4.8)
Confidence Interval for OR = OR ^  ^ z f  *  )
where z is a normal variate and x is defined as in 4.4.3.
Most examples in this manual are based on count or frequency 
data. With count data, all study participants are classified as 
exposed or unexposed and sick or well—these frequencies fill in 
the four cells of a 2 x 2 table. Count data from cohort studies 
enable us to estimate the proportion of persons who develop 
disease in two (or more) exposure groups after a given amount of 




















A measure of incidence that explicitly incorporates the amount of 
time a person is followed up until the outcome occurs is person-time 
incidence (also referred to as incidence density). Person-time data 
may be arranged in a two-way table in which the cells of the table (a 
and b in Figure 4.5) represent the number of cases observed among 
exposed and unexposed persons; the totals at the bottom of each 
exposure column (nj and n 0) represent the amount of person-time of 
follow-up for each exposure group. Person-time is accumulated by 
summing the amount of time (e.g., the number of days, months, or 
years) that an individual is exposed or unexposed until the person 
develops the outcome or drops out of the study, or the study is ended. 
(m t represents the total number of persons with the outcome; t 
represents the total amount of person-time.)
Outcome
Figure 4.5 
2 x 2  Table for Incidence Density Data
Exposure Status
Exposed Unexposed
Present a b m 1
Person-time n, no t
Person-time analysis permits us to incorporate more of the 
information obtained in cohort studies. We may include data on 
persons who are lost to follow-up until the time when their outcome 
status was last evaluated. Person-time data also forms the basis of 
life table analysis, which allows us to evaluate the rate of outcome at 
intervals within the total follow-up period. Formulas 4.4.1 - 4.4.2 and
4.4.4 - 4.4.6 are applicable for person-time data if we let n ! , n 0, and t
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represent person-time data instead of count data and let x be 
defined as:
(4.4.9)
a — m, * n, /  t 
\ j m , * n , * n0 /  t 2
Bias (Systematic Error)
In this section we will introduce the three major classes of bias 
and the general approaches used to minimize their effects. (More 
specific information on these biases will be provided for each study 
design covered in this workbook.)
In epidemiology, bias is a systematic deviation between the true 
value of a statistic (e.g., an estimate of the relative risk) and the 
value estimated by the epidemiologic study. Proper study design is 
primarily concerned with eliminating the influence of potential 
biases. Although many types of bias exist, biases are typically 
grouped into three major categories: selection, information, and 
confounding. In general, bias may be minimized by ensuring that 
the groups of study subjects (the exposed and unexposed persons 
in a clinical trial or cohort design, and the cases and controls in a 
case-control design) are comparably selected, interviewed (or 
otherwise provide data), and influenced by risk factors other than 
the one being studied,
Extraneous risk factors may weaken the comparability of the 
study groups. If we can measure these factors, we can adjust the 
analysis for their impact. Without additional participant 
enrollment or data collection, however, we may have difficulty 
adjusting for selection and information biases that have already 
occurred. Nevertheless, the analysis may incorporate various worst 
case scenarios to estimate the way in which selection and 
information biases may have distorted the results. Sensitivity 
analysis assesses the effects of worst case situations and evaluates 







Selection bias is the first major class of bias we consider. This 
group of biases concerns how individuals are selected for an 
epidemiologic study. To prevent selection bias, we must select all 
study subjects (cases and controls or exposed and unexposed persons) 
in a comparable manner from the same population.
In a clinical trial, the study subjects are assigned to a particular 
treatment group. Other than their treatment, all subjects should have 
a similar prognosis for the health problem or outcome of interest. 
Random assignment tends to produce similar groups with similar risks 
for the outcome of interest.
In a cohort study, an epidemiologist enrolls study subjects on the 
basis of their exposure status. The goal is to obtain two groups of 
persons who have similar risks for the health outcome of 
interest—except for the particular exposure under study. Selection 
bias often occurs in a cohort study when persons are lost to follow-up 
or when their participation is related to the outcome. Example 4.6 
describes a prospective cohort study on the effect of prenatal care on 
Bayley’s Mental Development Index (Bayley, 1969) at two years of 
age. Although information on prenatal care may be obtained from 
comparable groups of women who are giving birth, we may have 
difficulty maintaining contact with the women over the two-year study
Example 4.6
Prenatal Care and Bayley’s Mental Development Index
Problem: Is prenatal care associated with Bayley’s Mental Development 
Index at two years of age?
Research Hypothesis: Receipt of prenatal care is associated with increased 
index score.
Study Design: Cohort study, mothers are enrolled through hospital records. 
Unexposed: Mothers who received no prenatal care.
Exposed: Mothers who received prenatal care.
Outcome: The outcome of interest is the index score.
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period. Highly motivated parents may be more likely to maintain 
interest in the study; less motivated parents may tend to be lost to 
follow-up. At the end of two years, both groups of children may 
score similarly on the index. This outcome, however, could be 
attributed to differences in the home environment of children with 
motivated parents regardless of prenatal care.
Thus, selection bias occurs in a cohort study when participation 
is related to the outcome of the study. For example, the healthy 
worker effect is a selection bias by which employed persons tend 
to be healthier than unemployed persons (particularly if the work 
is physically demanding) and will therefore have a lower risk of 
disease than the general population.
In the case-control study, study subjects are selected on the 
basis of disease status. The goal is to obtain persons with incident 
disease (cases) and disease-free persons (controls) who represent 
the population from which the cases arose. Thus, other than their 
disease status, case and control persons would have a similar 
chance of having the exposure of interest. Example 4.7 shows how 
failure to enroll all newly diagnosed cases of cervical cancer can 
result in a form of selection bias called hospital admission bias. 
This bias occurs when the case subjects in a case-control study 
tend to be sicker than nonhospitalized cases, and consequently 
have different opportunities for previous exposures. Hospital 
admission bias may operate in a study of cervical cancer if only 
hospitalized case patients are selected because hospitalized 
patients are more likely than nonhospitalized patients to have 
advanced disease. When cervical cancer is detected early, as 
preinvasive disease, treatment may be given on an out-patient 
basis rather than on an inpatient basis. If Pap smears are 
associated with the detection of preinvasive cervical cancer, 
women with preinvasive cancer would be less available for 
inclusion in a study of hospitalized case patients. In Example 4.7, 
the table that includes all incident cases presents the hypothetical 
true relationship between Pap smear frequency and incident 
cervical cancer. Because 40% of case patients had a history of 
Pap smear and 60% of the controls patients had had Pap tests, we 
find that the odds ratio of 0.44 indicates that Pap smears are 
protective against invasive cancer.
If we could estimate the selection probabilities that limited the 








Hospital Admission Bias 
Pap Smear Screening and Cervical Cancer
Problem: Is clinically diagnosed cervical cancer associated with a history of 
Pap smear screening?
Research Hypothesis: History of Pap smear screening reduces the risk of 
clinically diagnosed cervical cancer.
Study Design: Hospital-based case-control study.
Cases: Women hospitalized for treatment of cervical cancer during the 
past year.
Controls: Women selected at random from all women without cervical 
cancer who received hospital care during the past year.
All Incident Cases Historv of Pan Smear
Yes Nq.
Cases 40 60 100
Controls 60 40 100
100 100 200
HosDitalized Cases Onlv Historv of Pan Smear
Yes No
Cases 20 45 65
Controls 39 26 65
59 71 130
Odds Ratio = 0.29
ratios may have been biased in the study. The table in Example 4.7 
that includes only hospitalized cases suggests that 65% of women with 
incident cervical cancer were hospitalized. Furthermore, 
hospitalization varies by Pap smear history. For example, only 50% 
of women with cancer and Pap smears were hospitalized (20/40 = .5), 
whereas 75% of women with cancer and no previous Pap smear were 
hospitalized (45/60 = .75). For simplicity, we have assumed that the 
control patients accurately reflect the frequency of Pap smears among
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women without cervical cancer. These results indicate a positive 
bias (an overestimation of the protective effect of Pap smears) 
because the data on the case patients underestimates the 
proportion of women with Pap smears (20/65 or 31%). Thus, the 
odds ratio based only on hospitalized cases is spuriously lower 
(0.29) than the odds ratio based on all incident cases (0.44). To 
reduce selection bias, the epidemiologist should obtain all newly 
diagnosed cases, regardless of hospitalization, for a specified 
period of time to ensure that women with less advanced disease 
are not excluded from the study. The controls should be 
representative of the population at risk of becoming cases.
Researchers have described several different types of selection 
bias (Sackett, 1979). The primary cause of selection bias varies 
with study design. For example, in cohort studies, selection bias 
occurs when factors associated with the health outcome influence 
study participation. In case-control studies, selection bias occurs 
when factors associated with exposure influence study participation 
(Rothman, 1986). When selection bias exists, the relationship, 
between exposure and the health outcome is different for the study 
participants than for the eligible nonparticipants. If factors are 
identified that accurately reflect the selection bias (for example, 
the impact of motivated parents on mental development in 
Example 4.6), we can adjust for this bias in the analysis (Rothman, 
1986).
Information Bias
Information bias (also known as observation, classification, or 
measurement bias) is the second major class of bias. This group 
of biases concerns the way in which information is obtained from 
or about study subjects. In the ideal study design, we collect 
information about all study subjects in a similar maimer.
Researchers have described several types of information bias 
(Sackett, 1979). The major types of information bias include 
ascertainment bias, recall bias, interviewer bias, missing data bias, 
and prevarication bias (study subject or data collection personnel 
intentionally distort the data). The distinguishing feature of 
information bias is that it occurs after the study subjects have been 
selected. Information bias results when the study subjects are 
misclassified with respect to exposure or disease or both. The














consequences of information bias depend on whether misclassification 
is random.
Ascertainment bias is a form of information bias that occurs if the 
outcome of interest is obtained by using different methods for each 
comparison group. In Example 4.7, ascertainment bias would occur if 
history of Pap smear was obtained by medical record review for case 
patients but by personal interview for control patients. Ascertainment 
bias could occur in Example 4.2 if respiratory infections among 
children exposed to cigarette smoke were measured by personal 
interviews of parents but infections among unexposed children were 
measured by self-administered questionnaires given to parents.
Depending on the information sought, the various forms of 
information bias result in differential misclassification. That is, the 
prevalence of a risk factor or outcome in one of the study groups is 
systematically underestimated or overestimated. Example 4.8 shows 
how the use of a different source of information for case subjects and 
control subjects can cause differential misclassification. Consider the 
possibility ¿hat control subjects were less likely to report previous 
diagnostic radiation than was shown in the medical records. Because 
the information from case subjects about previous exposure to 
radiation was obtained from medical records and the information 
from control subjects was obtained from personal interview, the use of 
diagnostic radiation among the control subjects might be under­
estimated. If radiation and breast cancer were truly not associated, 
the results from this study would show a positive association between 
radiation and breast cancer. To avoid differential misclassification, 
the epidemiologist should collect data from the comparison groups in 
the same manner. In Example 4.8, abstracting medical records for 
both groups would probably yield comparable data.
In contrast to differential misclassification, nondifferential 
misclassification will occur if data are poorly collected from all study 
subjects. For example, if a questionnaire has not been field-tested or 
validated, some proportion of the study subjects in each group may be 
misdassified. This bias will either falsely decrease a positive 
association or falsely decrease a negative association. By reducing the 
magnitude of the true association, nondifferential misclassification 
increases the chance of finding no association (Kleinbaum et al.,
1982).
We can illustrate nondifferential misclassification using the data in 




Diagnostic Radiation and Breast Cancer
Problem: Is breast cancer associated with a history of diagnostic radiation?
Research Hypothesis: Diagnostic radiation is associated with breast cancer.
Study Design: Case-control study
Cases: Women hospitalized with newly diagnosed breast cancer. A  
history of previous diagnostic radiation was obtained from a review of 
medical records.
Controls: A  random sample of women without breast cancer. Controls 
were selected from the communities served by the hospital that admitted 
women with breast cancer. A  history of previous diagnostic radiation was 
obtained from telephone interview.
Data Analysis: Diagnostic radiation: Reported results and true results
Yes N a Total
Cases 40 60 100
Controls 25 75 100
Total 65 135 200
True Results
Yes Na. Total
Cases 40 60 100
Controls 40 60 100




Pap Smear Screening and Cervical Cancer
True history of True Results
screening with Yes No Total
Pap smear
Cases 40 60 100 Odds Ratio = 0.44
Controls 60 40 100
Total 100 100 200




Cases 42 58 100 Odds Ratio=0.52
Controls 58 42 100
Total 100 100 200
screening with Pap smears and cervical cancer is 0.44. If 10% of all 
cases and 10% of all controls are misclassified with respect to Pap 
smear screening, regardless of their true screening status, we would 
obtain the results shown in the lower panel of Table 4.9. We obtain 
these results because 10% of the 40 case women who received 
screening are misclassified as not receiving screening, and 10% of the 
60 case women who received no screening are misclassified as having 
screening. The misclassification probabilities result in 42 case women 
who had been screened (40 -  (40 * 10%) + (60 * 10%)) and 58 who 
had not been screened (60 -  (60 * 10%) + (40 * 10%)). Using 
similar calculations we would obtain the results shown for controls. 
The new odds ratio of 0.52 is closer to the null value of 1.0 than the 
true odds ratio 0.44; and the strength of the association has been 
decreased.
Nondifferential misclassification introduces a conservative bias (i.e., 
it biases results toward the null value ̂ toward no association between 
the exposure and outcome). When estimating ratios, the bias will 
always adjust the estimate toward the value of 1.0—from either a 
positive association (e.g., from a relative risk of 2.0 to 1.7) or a 
negative association (e.g., from a relative risk of 0.42 to 0.76).When 
we estimate risk differences in a cohort study or clinical trial,
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nondifferential misclassification may reduce the size of the 
difference toward zero (Rothman, 1986).
Another way we can assess misclassification when collecting 
information is to evaluate the sensitivity and specificity of a 
particular question on a questionnaire. Although sensitivity and 
specificity are commonly used in describing the characteristics of a 
diagnostic screening test, these concepts may also describe data 
collection. The sensitivity of a screening test is the proportion of 
persons with disease whom the screening test classified as having 
the disease, and specificity is the proportion of persons whom the 
screening test classifies as being free from disease. For example, 
among women with cervical cancer, the Pap smear will correctly 
classify a certain proportion as being positive for cancer (i.e., that 
proportion is known as the Pap smear’s sensitivity for cervical 
cancer). Among women without cervical cancer, the Pap smear 
will correctly classify a certain proportion as being negative for 
cancer (i.e., that proportion is known as the Pap smear’s specificity 
for cervical cancer).
In data collection, sensitivity and specificity refer to the correct 
classification of an exposure or other risk factor as well as to the 
correct classification of a health problem or other outcome. In 
Example 4.10, we provide data to calculate the sensitivity of the 
original question "Have you ever smoked?" Because the question 
correctly classified 25 of 30 smokers, its sensitivity was 25/30 or 
83.3%. The original question correctly classified 55 of 70 
nonsmokers, and thus its specificity was 55/70, or 78.6%.
To increase the sensitivity and specificity of the question, we 
must clearly define the information of interest. The question must 
be explicit enough to obtain the desired information. Pilot testing 
and validating questions will make it possible to obtain more 
accurate data. Also, adopting questions previously tested and 
validated in other studies improves the quality of data collected 
and permits direct comparison of the results in the current study 
with previous studies.
Example 4.10 shows how sensitivity and specificity relate to 
misclassification of a risk factor common to many diseases— 
smoking. In a study where two or more groups are being 
compared, sensitivity and specificity may vary within the groups 
being compared. For example, mothers of low-birthweight babies 









Obtaining Information on Smoking History
Problem: Classify persons by whether they have previously smoked cigarettes.
Original Question: Have you ever smoked cigarettes? Some participants 
may say yes if they ever smoked even one cigarette but others may say no if 
they never smoked habitually, even though they smoked on a few occasions.
Information of Interest: Suppose you were only interested in finding out if 
people smoked a substantial amount. One standard way to determine this is 
to ask, "Have you smoked 100 or more cigarettes in your lifetime?" Because 
of the different interpretations of the original question, some participants who 
smoked less than 100 cigarettes would be misclassified as smokers and some 
participants who smoked more than 100 cigarettes would be misclassified as 
nonsmokers.
Information Obtained: Suppose we have data from 100 people, 30 of whom 
had smoked and 70 of whom had not smoked according to the 100 cigarette 
criterion. Suppose that 25 of the smokers and 15 of the nonsmokers said they 
had smoked. These numbers are displayed below. Note that the title of the 
table refers to the true (100 cigarette criterion) smoking history, as reflected 
in the numbers 30 and 70 on the bottom row of the table (30% smokers and 
70% nonsmokers).
Data Analysis: Misclassification of smoking history
True Smoking History 
Have smoked 100 or more cigarettes
Yes Nsl Tptal
"Have you ever Yes 25 15 40
smoked?" No 5 55 60
Total 30 70 100
normal-birthweight or high-birthweight babies may tend to 
underreport smoking history. When misclassification of a risk factor 
is the same in all groups being compared (the sensitivity and 
specificity are the same among study subjects with and without the 
disease or health outcome), nondifferential misclassification results. 
When misclassification varies among compared groups (the groups do 




If data are flawed but good estimates of the sources of 
misclassification can be obtained, we can make some simple 
adjustments to the tabular data. However, this is not practical 
when misclassification is contingent upon several factors 
(Kleinbaum et al., 1982).
Confounding Bias
Confounding bias occurs when the effects of two risk factors are 
mixed in the occurrence of the health problem under study. 
Specifically, a confounding factor must meet three criteria: 1) it 
must be an independent risk factor for the health problem or 
outcome of interest among the unexposed, 2) it must be associated 
with the exposure of interest in the data collected, and 3) it must 
not be an intermediary in the pathway between exposure and 
disease. Unlike selection and information biases, confounding bias 
may have an analytic solution—provided we can identify the 
presence of a particular confounder.
Regarding the relationship between prenatal care and 
birthweight, we know from previous studies that maternal cigarette 
smoking causes low birthweight. Suppose that women obtaining 
prenatal care are less likely to smoke cigarettes than women who 
do not obtain prenatal care. The cumulative incidence relative 
risk 3.7 (Table 4.11) indicates that low-birthweight babies are 3.7 
times more likely to be born to mothers who do not receive 
prenatal care than to mothers who do receive prenatal care.
Table 4.11 is a crude table. Crude indicates that the data are 
combined across levels of the additional risk factor (maternal 
cigarette smoking) ignoring the effect of that factor. If the study 
does not consider maternal smoking when estimating the effect of 
prenatal care on birthweight, the results may be confounded by 
smoking status. One strategy to eliminate this potential 
confounding is to collect sufficient information on maternal 
smoking behavior and then analyze the results separately for 
smokers and nonsmokers.
Table 4.12 displays the same data separated according to the 
smoking status of the mother. Typically, this presentation is called 
a stratified analysis, and each smoking category forms one stratum. 
Clearly, relative risk for the effect of prenatal care among smokers 







Maternal Smoking as a Confounder of the 
Effect of Prenatal Care on Low Birthweight
Stratum 1: Mothers Who Smoke Cigarettes
Exposure
Low-birthweieht Infant No Prenatal Care Prenatal Care Total
Yes 290 21 311
No 610 79 689
Total 900 100 1,000
CIR = 1.5
Stratum 2: Mothers Who Do Not Smoke Cigarettes
_____________ Exposure______________
Low-birthweight Infant No Prenatal Care Prenatal Care Total
Yes 10 60 70
No 90 840 930
Total 100 900 1,000
CIR = 1 . 5 ____________________________ __
Table 4.11
Crude Table
Confounding of the Effect of Prenatal Care on Low-Birthweight Infants
ExDOSure
Low-birthweteht Infant No Prenatal Care Prenatal Care Total
Yes 300 81 381
No 700 919 1,619




the crude relative risk. In fact, both strata yield the same relative 
risk of 1.5. If we adjust for the confounding of smoking, we would 
obtain an accurate summary relative risk of 1.5. The difference 
between the summary relative risk of 1.5 and the crude relative 
risk of 3.7 indicates the presence of confounding. An accurate 
summary relative risk, standardizing for the confounding of 
smoking, equals 1.5.
The Mantel-Haenszel relative risk or summary odds ratio is 
used in case-control studies and for cumulative incidence data in 
cohort studies to adjust for the effects of potentially confounding 
variables and is computed as (Rothman and Boice, 1979):
(4.12.1)
. E (ai * di / h )
E (bi* ci/ ti)
where a, b, c, d, and t are defined as in Table 4.4 and i represents 
the i* stratum (Mantel and Haenszel, 1959).
We can estimate the confidence interval for the Mantel- 
Haenszel relative risk (4.12.1) by using test-based procedures 
(Miettinen, 1976). The confidence interval is computed as:
(4.12.2)
(1 ±  z /  xMH )
Confidence Interval for R R MH = RR MH
where z is a normal variate, Xmh = t and 
(4.123)
v2 _ <E ai - Emn* nn / t. >2
Xmh E (mn * mm * nu * n« ) / (tf * (li “ !))
A summary estimate of relative risk is a weighted average of the 
stratum-specific relative risks, whereas a crude relative risk does 
not properly account for the distribution of persons among the 
strata. The formula given in 4.12.1 uses the odds ratio to 
approximate the relative risk—assuming a rare outcome; formula














in cohort studies, a different formula (Rothman, 1986) that relies on 
relative risk instead of the odds ratio approximation is:
(4.12.4)
J > . * ln (CIRj ) 
Ewi
CIRS = exp [ ±  —  ^  Ll]
, a. * b. * n.. * n„.
where Wj =
a. * di * n H + b, * c. * nw
The confidence interval for CIRS, using a test-based procedure, is 
computed as:
(4.12.5)
(1 ±  z  /  X )
Confidence Interval for CIRS -  CIRS
where z is a normal variate and x is defined as in (4.12.3).
To determine how the criteria for assessing confounding apply in 
Example 4.11, we must first decide if smoking is a risk factor for low 
birthweight among mothers who do receive prenatal care (the 
unexposed group). The risk of low birthweight was 21/100, or 0.210, 
among women who received prenatal care and smoked and 60/900, or
0.067, among women who received prenatal care but did not smoke. 
Because the probability of low birthweight varies according to 
smoking, we find that smoking is a risk factor among women who 
received prenatal care. Second, we must determine if smoking is 
associated with prenatal care in the data we have obtained. Among 
the women who did not receive prenatal care (the exposed group), 900 
out of 1,000 (90%) smoked cigarettes; among women who received 
prenatal care, only 100 out of 1,000 (10%) smoked. Assuming that 
this study obtained an accurate sample, we find that the difference 
between 90% and 10% is clear evidence that smoking is negatively 
associated with prenatal care. Finally, from substantive knowledge, 
we know that smoking is not an intermediate step in the pathway 
between prenatal care and low birthweight. That is, prenatal care is 
not a cause of smoking.
The Mantel-Haenszel procedure (4.12.1) and the CIRS estimate 
(4.12.4) adjust relative risk estimates for the effects of confounding
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variables. The formula that adjusts risk differences for potentially 
confounding variables for cumulative incidence data is:
(4.12.6)
Yv/.  * RD.
R D . = ±±—L_______ 1
where RD; is the risk difference in stratum i: 
a, b.
RD. =
a i + c, b. + d. 
a. b.
and w; is the weight for standardizing the stratum-specific 
estimates of risk difference:
w. =
a .*  c. b .* d.
The test-based confidence interval can be computed as 
(Rothman, 1986):
(4.12.7)
Confidence Interval for RD S = R D S * (1 ± z /  x )
Formulas 4.12.4 - 4.12.7 are applicable for person-time data, if 
we let n , , n 0, and t represent person-time. The w; in (4.12.6) 
simplifies to W; = l
Another strategy to remove confounding bias is to restrict 
participation in the study. In Example 4.12, the study could be 
restricted to women who did not smoke. Alternatively, if we are 
concerned about the effect of prenatal care among smokers, the 
study could be restricted to women who smoke. The principal 
issue in either scenario is that, regardless of prenatal care status,
Summary 











the comparison groups should have the same smoking status to ensure 
that smoking does not differentially influence the occurrence of low 
birthweight.
The final strategy to reduce confounding is to match study subjects 
for the presence of another risk factor. This strategy requires that 
matching be considered in the analysis, or else bias may result. 
Matching can be costly, particularly in follow-up studies (Rothman, 
1986). Also, matching has an additional implication—it precludes 
determining the magnitude of risk associated with the matching factor. 
For this reason we should first consider the strategies of restriction or 
increasing the size of the study groups as more efficient ways of 
obtaining information.
In summary, potential biases are best managed by anticipating 
them in the design phase of a study (Table 4.13). In particular, 
selection and information biases are not easily managed in the 
analysis unless additional information is collected or enrollment of 
participants is extended. Nevertheless, it may be helpful to consider 
sensitivity analysis to assess the effect of the biases or the results. 
Confounding has good analytic solutions if sufficient data are 
available for use in a tabular or regression-based analysis. Although 
no study is free from bias, the well-conducted randomized clinical trial 
is the study design that is most likely to have minimal bias.
Table 4.13
Strategies for Addressing Biases in the Design and 
Analysis Phases of an Epidemiologic Study
Tvpe of Bias Design Strategy Analysis Strategies
Selection • Enroll all incident cases 
from geographic areas 
(study group differs • Enroll controls from 
from target group) same area
• Avoid self-referral
• Increase frequency of 
contact during follow-up
• Blind assignment of 
exposure (clinical trial)
• Estimate selection or loss 
probabilities
• Conduct a sensitivity 
analysis
• Obtain data on selection 










(effect of exposure • 
is mixed with effect 
of an additional 
risk factor) •
Table 4.13 (continued)
Standardize the measure- • 
ment regardless of exposure 
and disease status 
Use blinded observers 
Use surrogate sources • 
rather than dropping 
participants from study •
Validate the measurement 
procedure
Obtain historical data in 
reference to time of disease 
onset
Collect information on •
potential confounders 
Restrict participation 
to persons with similar •
baseline risk of disease 
Match on major potential 
confounder(s) •
Estimate probabilities of 
misclassification 
based on validation 
study
Conduct a sensitivity 
analysis
Look for systematic 
differences between 
observers
Stratify on the basis of 
potential confounder 
in a tabular analysis 
Add a term for potential 
confounder in regression 
analysis
Use adjusted rates to 
adjust for confounding 
Stratify on matching 
term(s) in the analysis
Chance (Random Error)
Bias may introduce error at any stage of an investigation; its net 
effect is to produce results that differ systematically from the truth. 
Chance, another source of error, differs from bias in that chance 
represents random error. The primary way to reduce error 
attributable to chance is to increase the sample size of the study. 
However, this will be true only to the extent that more accurate 
information is obtained. Specifically, we must consider the 
distribution of exposure, disease or health status, and other 
individual risk factors to appreciate the amount of information 
present in a particular study. The more information that is 











The p  value
Influence o f 
randomness
Although increasing the sample size will reduce random error, the 
efficiency with which we collect the information from a given number 
of study participants will also affect random error. For example, a 
prospective cohort study of a rare disease (incidence of 1 case per
1,000 unexposed persons) that includes 1,000 exposed and 1,000 
unexposed persons would probably not be as informativeas a case- 
control study with 100 cases and 100 controls. Finally, the cost of 
collecting information will have an impact on both the study design 
and the number of persons selected. The best study design will yield 
the maximum information for the lowest cost.
Increasing sample size will reduce random error by reducing 
sampling error (lowering the p value) and by obtaining more 
information. Although a larger sample will lower the variance of the 
estimates, sample size alone will not overcome the effect of selection, 
information, or confounding biases.
The p value is the probability that chance alone is responsible for 
the differences observed between the comparison groups. For 
example, suppose a study was designed to evaluate the difference in 
the probability of infection between two groups of surgical patients 
treated with two different antibiotics (named A  and B). If the 
observed difference was significant at a p value of 0.05, then we had a 
5% chance of finding that difference when no difference actually 
existed. Note that the p value is a conditional probability; it assumes 
that the exposure is not associated with the outcome. For example, if 
all persons receiving antibiotics A and B truly have the same 
probability of infection, then a p value of 0.05 indicates that the study 
has a 5%  chance of selecting comparison groups with different 
infection probabilities. The p value is not, however, the probability 
that the tested hypothesis is true (Ahlbom and Norell, 1984).
The influence of chance or randomness may be viewed from either 
of two philosophical perspectives. From a deterministic view of 
reality, the appearance of randomness is really attributable to 
unmeasured and unknown causal factors affecting the exposure- 
disease association. If those unknown factors could be perfectly 
measured, the occurrence of disease would be predictable. From a 
nondeterministic view, randomness is in itself a real but unknowable 
source of causation. By this philosophy, we are always faced with 
some unpredictable influences. When conducting a study, we cannot 
distinguish between:these two potential sources of randomness. The
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epidemiologist must instead focus on the size of the group studied 
and on the quality of the information obtained (Rothman, 1986).
Effect Modification
Effect modification concerns how the presence of an additional 
risk factor changes the magnitude of the association between a 
given exposure and a health outcome. We assess effect 
modification by comparing the magnitude of two or more stratum- 
specific estimates of effect with each other (e.g., the relative risks 
for two strata of age). Effect modification exists when these 
estimates are "substantially" different from each other; that is, the 
additional risk factor modifies the effect of the exposure on the 
outcome. Determining whether the difference is substantial can 
be assessed with a statistical test, however, some authors prefer 
using a criterion of clinical or practical importance (Rothman and 
Boice, 1979).
To illustrate effect modification, we will consider the effect of 
prenatal care on birthweight and the use of risk difference (RD) 
(formula 4.4.1) as the measure of effect. In Table 4.14, women 
who do no receive prenatal care have 0.219 (or 21.9%) higher risk 
of delivering a low-birthweight child than women who receive 
prenatal care. However, the crude table obscures the effect of 
cigarette smoking. Therefore, we should examine the data 




The Effect of Prenatal Care on Low Birthweight
as Measured by the Risk Difference
Exnosure
Low-Birthweieht Infant No Prenatal Care Prenatal Care Total
Yes 300 81 381
No 700 919 1,619
Total 1,000 1,000 2,000





Because the RD for the effect of prenatal care is greater among 
mothers who smoke cigarettes (11.2%) than among mothers who do 
not smoke cigarettes (3.3%), we know that cigarette smoking modifies 
the effect of prenatal care (Table 4.15). When effect modification 
occurs, it is misleading to compute a single summary measure of the 
association (as in Table 4.14). The summary measure obscures the 
modifying effect of the additional factor, smoking. Also, depending 
upon the distribution of the modifier, the particular value of the 
summary measure will vary from study to study. For example, if the 
number of women without prenatal care in stratum 2 was increased 
from 100 to 200 (maintaining the same incidence), the summary RD 
would decrease from 0.060 to 0.050.
By comparing Tables 4.14 and 4.15, we observe that a factor 
that modifies the risk difference will not necessarily modify the
Table 4.15
Effect Modification and Confounding of the Effect of Prenatal Care on
Low Birthweight
Mothers Who Smoke Cigarettes: Stratum 1
ExDosure
Low-birthweieht Infant No Prenatal Care Prenatal Care Total
Yes 290 21 311
No 610 79 689
Total 900 100 1,000
Risk Difference = (290/900) - (21/100) = 0.322 - 0.210 = 0.112
Mothers Who Do Not Smoke Cigarettes: Stratum 2
ExDosure
Low-birthweieht Infant No Prenatal Care Prenatal Care Total
Yes 10 60 70
No 90 840 930
Total 100 900 1,000
Risk Difference = (10/100) - (60/900) = 0.100 - 0.067 = 0.033
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measures used. Effect modification, however, represents an 
relative risk. Thus, effect modification depends, in part, on the 
interaction between the exposure and the modifier; as such, we 
would expect the same modifier to appear in other studies of a 
given exposure and disease.
In contrast to effect modification, confounding factors do not 
depend upon a particular measure of effect nor would they 
necessarily be observed in other studies. It is possible, however, 
for a risk factor to be both a confounder and an effect modifier in 
a single study. As shown in Table 4.14, the crude RD is 0.219; 
using formula 4.12.1, the adjusted RD from Table 4.15 is 0.060. 
Thus, these data also illustrate that an effect modifier may also be 
a confounder.
Reliability
Reliability (or precision) concerns the degree to which the 
values obtained from repeated measurements of the same 
persons—under similar conditions—will yield the same result. For 
example, a large range in the distribution of averages implies a 
lack of reliability even though the average of several averages may 
equal the true value. We must be sure that the characteristic of 
the persons being measured is constant (e.g., height) and thus not 
a source of the variation. Reliability is distinguished from bias in 
that the average of several biased measurements will still differ 
from the true value.
Several situations are likely to produce low reliability. As 
described in the section on errors attributed to chance, small 
sample sizes may produce low reliability because of sampling 
error. Another source of low reliability is data collected within a 
nonstandardized or poorly structured manner. Examples of poorly 
structured data collection include poorly worded questions in a 
questionnaire, poorly trained interviewers, or poorly trained data 
abstractors. Poorly trained interviewers and abstractors probably 
would not obtain the same answer when collecting the data on a 
second attempt. Imprecision during data collection tends to 
produce nondifferential (random) misclassification of information, 
a type of information bias that reduces the chance of finding 











The validity (or accuracy) of a study concerns the extent to which 
inferences may be made from the study. Epidemiologists usually refer 
to two types of validity — internal and external.
Target shooting may be used as a simple illustration of the 
relationship between reliability and validity (Figure 4.16) (Ahlbom 
and Norell, 1984). A good marksman, unaware that the gun used was 
not aligned, would hit the target with minimum scatter (high 
reliability) but systematically off-center (low validity). TTie individual 
shots of another marksman could scatter the shots about the center 
(low reliability) but do so in an evenly distributed pattern (high 
validity).
Internal Validity
By internal validity, epidemiologists refer to the lack of bias among 
the groups compared within a given study. Except for random errors, 
an internally valid study accurately represents the effect of the 
exposure on the disease outcome among the study subjects. If any of 
the three major categories (selection, information, confounding) of 
bias exist, the internal validity of that study is decreased.
External Validity
External validity concerns the generaiizability of a study’s results 
beyond the particular groups participating in the study. As such, 
generaiizability primarily concerns how well the study population 
represents other populations. Before examining external validity, 
however, the study comparisons must be considered internally valid. 
Some degree of generaiizability which extends the limits of knowledge 
is typically the goal of scientific research. If, however, our particular 
study was primarily concerned with limited and unique populations, 
we might not be so concerned about broad generalizations.
Few studies, if any, are entirely free of bias. When evaluating the 
validity of a study, it is important both to identify biases and to 
estimate how they may have distorted the study’s findings. Although 
biases exist, they may not be serious enough to appreciably change 
the conclusions of a study. Sensitivity analysis is one way of assessing 




Target Shooting As an Example of 









In this context, sensitivity refers to the degree to which a study’s 
findings may be changed if certain parts of the obtained data were 
different.
In Example 4.17, 50% of mothers of low-birthweight infants 
reported a history of smoking, but only 20% of mothers with 
normal- or high-birthweight infants reported smoking; the resulting 
odds ratio was 4.0. If we believed that mothers of low-birthweight 
babies may have tended to overreport smoking, we could use an 




Maternai Smoking and Low Birthweight
Problem: Is maternai cigarette smoking associated with low birthweight?
Research Hypothesis: Maternal cigarette smoking increases the risk of low 
birthweight.
Study Design: Case-control study 
Outcome: Low-birthweight infant
Smoking Status as Originally Reported*
Maternal Smoking Status
Low-Birthweieht Infant Yes No Total
Yes 50 50 100
No 20 80 100
Total 70 130 200
OR * 4.0
* Reflects overreporting of smoking among 100 mothers with low-birthweight 
babies.
Sensitivity Analysis after Correcting Original Results t
Maternal Smoking Status
Low Birthweicht Infant Yes No Total
Yes 40 60 100
No 20 80 100
Total 60 140 200
OR = 2.7
t  Reflects corrected smoking status for the ten mothers who had low- 





the odds ratio (OR) would change. For example, if we estimated that 
10% of the mothers of low-birthweight babies incorrectly reported 
that they smoked (whereas the mothers of other babies accurately 
reported their smoking), the OR would change from 4.0 to 2.7. 
Although the results may have overestimated the effect of smoking, 
we would have found that low birthweight was still positively 
associated with smoking. By substituting worst case numerical 
estimates for the effect of potential biases, we can better understand 
how much the conclusions of a study may be changed by biases of a 
study.
Causality
Causality concerns judging whether a particular exposure causes a 
particular disease. This is a subjective process—particularly in 
epidemiology, where the epidemiologist typically has no control over 
the sequence of events in the natural history of a disease. In an 
attempt to establish a systematic way of determining causality, several 
authors have cited the following seven criteria for evaluating whether 
a particular exposure causes a particular outcome:
Proper temporal sequence. To have caused a particular outcome, 
an exposure must temporally precede that outcome. This tenet may 
be difficult to establish for chronic diseases or diseases with a long 
time interval between exposure and occurrence.
Experiment. Randomized assignment of an exposure results in a 
greater rate of the expected health outcome in the exposed group 
than in the unexposed group. Although this tenet provides the 
strongest evidence of causation, we can ethically use randomized 
assignment in only a few epidemiologic studies.
Dose-response. Higher levels of exposure are associated with 
higher rates of disease; for example, higher rates of lung cancer have 
been observed with an increasing number of cigarettes smoked daily.
Strength o f association. The larger the measure of effect, the more 
likely the relationship is causal. This tenet assumes that smaller 
measures of effect are more likely to be attributable to bias.
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Consistency o f association. Similar associations between exposure 
and disease are observed among different studies. If similar 
associations are repeatedly observed, it is unlikely that they are all 
spurious.
Collateral evidence and biological plausibility. The likelihood that 
an exposure causes a particular disease is supported by evidence such 
as trends in vital statistics and animal or human biological models.
Specificity o f association. Different studies report the same specific 
disease associated with a particular exposure.
Of these seven criteria, only the first is absolutely required for 
causation. All the remaining tenets support the attribution of 
causality but are not essential to causality (Kleinbaum et al., 1982; 
Hill, 1965). With a few exceptions, the last criterion is probably the 
least often fulfilled because most diseases have multifactorial etiology 





1. Circle true (T) or false (F).
(a) T /F  Analytic studies typically test hypotheses.
(b) T /F  The major difference in descriptive and analytic epidemiology is the
way study subjects are selected and data are collected.
(c) T /F  Descriptive epidemiology focuses on measures of effect.
(d) T /F  Analytic epidemiology emphasizes hypothesis testing as opposed to
hypothesis generation.
(e) T /F  Analytic epidemiology describes frequency of disease occurrence in
relation to person, place, and time.
2. Distinguish descriptive from analytic studies by putting a (D) for descriptive or 
an (A) for analytic next to each of the following:
  2.1 Etiologic
  2.2 Tests hypotheses
  2.3 Shows patterns regarding person, place, and time
  2.4 Compares two or more groups
  2.5 Generates hypotheses
  2.6 Evaluates the association between exposure and disease
2.7 Gives measures of effect
3. Select one response.
3.1 Any of the following may be included as an "exposure" in health research 
except:
(a) A potential risk factor
(b) The outcome being studied
(c) The treatment or therapy
(d) Any potential event before the disease
(e) A health problem
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3.2 Any of the following may be included as a disease or health outcome in 
health research except:





3.3 Which of the following strategies cannot be used in cohort and case- 
control studies to eliminate bias?
(a) Random selection process to select study subjects
(b) Same standardized instruments on both groups
(c) "Blind" observer who will do data collection
(d) Study subjects selected according to predetermined criteria
(e) Size of study groups increased
3.4 As a strategy to eliminate bias, you can make sure cases and controls are 
comparable with regard to all but one of the following:
(a) How they are selected
(b) How they are interviewed
(c) How they are exposed
(d) How they are influenced by other risk factors
3.5 Which of the following is not a strategy to eliminate bias?
(a) Use a validated questionnaire
(b) Use measures of effect
(c) Write a protocol for screening
(d) Restrict study subjects
(e) Use stratified analysis
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4. Matching. Select A (Clinical trial), B (Cohort), or C (Case-control) to indicate 
the type of study design that is being described.
  4.1 Collects information on diseased and nondiseased study subjects
  4.2 Selection is based on disease status.
  4.3 Assesses exposure of each study subject and then observes
occurrence of the health outcome
  4.4 Called a follow-up design because study subjects are followed to
determine outcome
  4.5 Randomized assignment of exposure is a characteristic of this type
of design.
  4.6 Uses selection based on exposure and then observes subsequent
occurrence of the health outcome
5. Circle true (T) or false (F).
(a) T /F  Misclassification may falsely increase a positive association.
(b) T /F  Misclassification may increase the chance of finding no association.
(c) T /F  A  confounding factor must be 1) an independent risk factor, 2)
associated with exposure, and 3) not in the pathway from exposure 
to disease.
(d) T /F  Confounding may be removed by opening up restrictions on
participation.





6. Matching. Select the appropriate letter to indicate the type of bias that is 






  6.1 Information is obtained from different study subjects by different
processes.
  6.2 Observation, classification, and measurement bias occurs.
  6.3 Has an effect on odds ratios, relative risks, and risk differences.
  6.4 Only a subset of potential study subjects survives to become
enrolled in the study (survival bias).
  6.5 Recall bias, interviewer bias, or bias attributable to missing data or
prevarication occurs.
  6.6 In case-control studies, factors associated with exposure influence
study participation.
  6.7 Shows how a third factor changes the true effect of exposure on
disease.
  6.8 The effects of two risk factors are mixed.
  6.9 If you can identify its presence, you can analyze and eliminate the
problem.
  6.10 One group provides information on questionnaires and the other
from medical records.
  6.11 Error in classification of study subjects occurs with regard to
exposure or disease or both.
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6.12 A difference between a crude result and a stratified result indicates 
its presence.
6.13 Repeated administration of the same questionnaire to the same 
person yields different answers.
7. Circle true (T) or false (F).
(a) T /F  The sensitivity is the proportion of people free of the disease who
will be classified correctly by the screening test.
(b) T /F  The specificity is the proportion of people who have the disease who
will be classified correctly by the screening test.
(c) T /F  When the sensitivity and specificity equal 1.0, misclassification
results.
(d) T /F  If p = 0.05, we have a 5% chance of finding a difference between
the comparison groups when no difference really exists.
(e) T /F  The p value is the probability that the tested hypothesis is true.
(f) T /F  Increasing sample size will increase the p value.
(g) T /F  Both effect modification and confounding concern the way a third
variable affects the relationship between exposure and disease.




8. Matching. Select the appropriate letter to match the descriptions on the left 
with the terms on the right. Suppose you take repeated measurements on the 






  8.1 Get the same result.
  8.2 Get the same result, but later find out the tool is inaccurate.
  8.3 Get different results, but the average measure is accurate.
9. Circle true (T) or false (F).
(a) T /F  A study with internal validity accurately reflects the effect of
exposure on disease outcome among study subjects.
(b) T /F  Bias increases the internal validity of a study.
(c) T /F  External validity depends on internal validity.
(d) T /F  External validity is less of a consideration when working with unique
populations.
(e) T /F  Because most epidemiologic studies contain bias, we are limited in
the generalizability of the findings from a single study.
(f) T /F  Numerical estimates can be given to biases to determine their
impact on the risk ratio or risk difference using sensitivity analysis.
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10. Matching. Match the descriptions in 10.1 - 10.5 with the single best choice of 
factors (a - f) to consider in evaluating evidence of a causal relationship in an 
epidemiologic study.
a. Proper temporal sequence
b. Dose-response
c. Strength of association
d. Consistency of association
e. Collateral evidence and biological plausibility
f. Specificity of association
 10.1 Absolutely required to show causality. .
 10.2 The larger the measure of effect, the more likely the relationship is
causal.
 10.3 Similar associations have been observed across numerous other
studies.
 10.4 Higher levels of exposure are associated with higher rates of
disease.
10.5 Least often fulfilled.
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Suggested Answers To Practice Exercises
1. True or false.
(a) T  Introduction
(b) F Study Design. No, descriptive studies generate hypotheses and
analytic studies test hypotheses.
(c) F  Study Design. No, analytic epidemiology focuses on measures of
effect.
(d) T  Study Design
(e) F Study Design. No, descriptive epidemiology describes the frequency
of disease occurrence in relation to person, place, and time.
2. Descriptive or analytic.
2.1 a Study Design
2.2 a Study Design
2.3 d Study Design
2.4 a, d Study Design
2.5 d Study Design
2.6 a Study Design
2.7 a Study Design
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Study Design. Case-control studies select subjects by disease 
status and then collect exposure data; however, a and b are also 
correct, since scientists collect data on disease status of 
participants for clinical trials and cohort studies.
Study Design
Study Design























































9. True or false.
9.1 T
9.2 F
Information Bias. No, the specificity is the proportion of 
people free of disease who will be classified correctly by the 
screening test.
Information Bias. No, the sensitivity is the proportion of 
people who have the disease who will be classified correctly by 
the screening test.
Information Bias. No, when the sensitivity and specificity are 
not equal to 1.0, misclassification results.
Chance
Chance. No, the p value is the probability of rejecting the null 
hypothesis when the null hypothesis is true (i.e., the probability 
of finding a difference when no difference exists).
Chance. No, increasing sample size will decrease the p value.
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Chapter 5 - Learning Objectives
After completing this chapter, you should be able to:
1. Identify constraints on the sample size of a study.
2. Identify the terms:
null hypothesis
alternative hypothesis
level of significance, Type I error, a
Type II error, 0
power of test, I -/3
3. Recognize the relationship between hypothesis testing and sample size and 
statistical power.
4. Identify purposes of sample size and power calculations.
5. Distinguish one-sided from two-sided comparisons.
6. Identify information needed for calculation of sample size for each type of study.
7. Calculate sample sizes for:
descriptive studies 
randomized clinical trials 
cohort studies 
case-control studies
8. Calculate statistical power for:
randomized clinical trials 
cohort studies 
case-control studies




One of the most important issues in designing a study is 
appropriate sample size. A sample size that is too small will limit 
the conclusions that can be made from the study, and a sample 
that is too large will result in unnecessary expenditures of time, 
money, and effort to reach conclusions that could have been made 
with fewer subjects. We can rely on statistical theory to compute 
the smallest sample size to properly achieve the objectives of the 
study. Because of practical considerations, the nature of the study, 
and the resources available, the sample size we ultimately choose 
will usually be a compromise between what is needed to satisfy the 
statistical requirements and what can realistically be accomplished.
When designing a study, we must apply statistical formulas to 
determine the required number of participants to achieve the 
specified statistical power or the reverse—to determine the 
statistical power provided by a specified sample size. Statistical 
hypothesis testing is the foundation for determining the sample 
size and for assessing statistical power.
Hypothesis Testing
The Null Hypothesis
To make inferences, researchers use the principles of hypothesis 
testing. Any study tries to prove or disprove a research hypothesis 
or hunch about exposures to potential risk factors or the efficacy 
of different treatments. To test the hypothesis, the researcher 
assumes that no difference exists between exposures to risk factors 
or treatments under study. This assumption is called the null 
hypothesis. Examples of null hypothesis statements for different 
types of studies are presented below:











• Randomized clinical trial: The new treatment has the same 
proportion of effectiveness as the control treatment.
• Cohort study: The proportion of the exposed individuals who 
develop the outcome of interest is the same as the proportion 
of unexposed individuals who develop the outcome of interest.
• Case-control study: The proportion of cases exposed to the 
potential risk factor under study is the same as the proportion 
of exposed controls.
The hypothesis test ascertains the validity of the null hypothesis 
against an alternative hypothesis from the evidence gathered in a 
study. For example, an alternative hypothesis for the cohort study 
cited above might state that the proportion of exposed individuals 
who develop the outcome of interest is higher than the proportion of 
unexposed persons who develop the outcome. Randomized clinical 
trials, case-control studies, and cohort studies are designed to seek 
evidence to either support or reject the null hypothesis in favor of the 
alternative hypothesis. The specifications of the null and alternative 






Decision making is an integral component of hypothesis testing.
The researcher must use the data gathered from the study to 
determine one of two possible decisions—to accept or to reject the 
null hypothesis. The researcher should be aware of two types of 
errors that can affect this decision (Table 5.1).
Type I  error. If we reject a null hypothesis that is actually true, but 
the study data indicate that it is false, we have made a type I error. 
The chance of making this error is called the level o f significance of 
the study, or the alpha (a) level.
Type II error. If we accept a null hypothesis that is actually false, 
but the study data indicate that it is true, we have made a type II 






Testing and Possible Outcomes
Study Null hvoothesis
Decision Trye False
Accept the Correct Type II
null hypothesis decision error
Reject the Type I Correct
null hypothesis error decision
Power and Confidence Level
The chance of correctly rejecting a null hypothesis when it is 
indeed false is called the statistical power ( i -/3) of the test of the 
hypothesis. Power is the probability of detecting a difference in 
exposure levels or treatments when a difference actually exists.
The probability of accepting the null hypothesis when it is true 
is often called the confidence level (1 — a) of the test. The 
confidence level is the probability of finding no difference in 
exposure levels or treatments when no difference exists.
When a decision is made to accept or reject the null hypothesis, 
the actual state of nature is not known. Regardless of how small a  
and 0 are set, we are always faced with an element of chance, and 
the possibility that we have made the wrong decision always exists. 
A decision to accept the null hypothesis does not prove that it is 
true; a decision to reject the null hypothesis does not prove that it 
is false.
Power defined
a - f o
Confidence 
level defined 
( 1 -  «)
Sample Size and Power
The null hypothesis is rejected when the significance level based 
on the study data exceeds the significance level (a) established to 
test the hypothesis. To guard against a type I error, the level of 
significance is typically set at a suitably small probability, such as 
a =.05. A  given statistical test is more likely to distinguish minor 
differences in treatments or exposure levels as the sample size 
increases; and hence, we are more likely to reject the null
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hypothesis. We should impose some limits on sample size to ensure 
that only meaningful or practical differences are detected by statistical 
testing.
Conversely, if the null hypothesis is actually false, the likelihood 
that we correctly reject it (i.e., the power of the test, 1 -j8) depends 
primarily on sample size. The larger the sample size, the more power 
a study has. A study with sufficient power enables us to detect a 
difference in treatments or exposure levels when a difference actually 
exists. If a study possesses inadequate power, a result that does not 
achieve significance (i.e., the null hypothesis is accepted) may just as 
well be attributed to the lack of power as to the fact that the null 
hypothesis is correct. Typically, the statistical power, 1 —/S, is chosen 
between .80 and .95.
The power of a study is the key factor in interpreting results that 
indicate there is not a clinically important difference in two 
treatments or exposure levels. What constitutes a clinically important 
difference is typically determined by the researcher and established at 
the onset of a study. In summary, both the significance level (a) and 
the power of the study (1-/3) are important in determining sample 
size.
Determining the Size of a Sample
One of the first questions typically asked when designing a 
reproductive health study is, "How many subjects should be selected 
for the study?" To answer this question, researchers must first answer 
other questions that provide information about what they expect to 
achieve from the study. In essence, the study must be set up in the 
framework of a hypothesis test. The sample size is then determined 
by applying statistical methodology that quantifies the relationship 
between the various parameters that describe the hypothesis test 
under consideration. The researchers must provide the parameters 
that will be used in the formulas.
In Example 5.2, we present the information required to calculate 
the sample size for a randomized clinical trial. From this information, 
the sample size we need for the clinical trial can be calculated with 
a = 0.05, 1-/3 = 0.90, po = 0.60, d = 0.10, f = 0. These statistical 
techniques will be described later in this chapter. Similar information 
needs to be provided for all study designs.
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A Two-Sided Comparison 
Required Information to Calculate the Sample Size for 
a Randomized Clinical Trial
Example 5.2
Estrogen has been associated with most of the undesirable side effects of 
the combined oral contraceptive (OC) pill. Lower doses of estrogen should 
decrease the frequency and duration of side effects, such as nausea, headache, 
and vomiting. A  randomized clinical trial was designed to compare the rate 
of continued use among women who took a standard-dose oral contraceptive 
(1.0 mg norethindrone with 50 meg mestranol) and the rate of continued use 
among women who took a low-dose oral contraceptive (1.0 mg norethindrone 
with 35 meg ethinyl estradiol). In designing the study, several questions were 
considered to determine the appropriate sample size.
What is the primary purpose of the study (Statement of hypothesis)?
To see if women who take a low-dose OC (new treatment) have a higher 
rate of continued use than women who take a standard-dose OC (control 
treatment). The reasons that women discontinue using OCs are of interest 
but are not the primary focus of the study. The null hypothesis states that 
there is no difference in the rate of continued use between low-dose users and 
standard-dose OC users.
What is the primary outcome measure?
Continued use of the assigned OC for the first 12 months of the study.
What level of outcome is expected with the standard-dose OC (proportion in 
control group, denoted p«)?
Previous studies have shown that at 12 months the rate of continued use 
for the control treatment is 60% (p0 = .60). The rate of discontinuation at 12 
months would therefore be 40%. For this example, we have chosen to discuss 
continued use, although discontinuation would have been just as appropriate.
How small a difference (d) in the outcome between treatments is it 
important to detect and with what statistical power?
An increase in the rate of continued use is anticipated for low-dose OC 
users. However, the rate may be lower for standard-dose users because low- 
dose users may experience breakthrough bleeding. We wish to detect as stat­
istically significant a difference in continuation rates of 10 percentage points 
(d = 0.10). That is, based on the expected rate of continued use of 60% for
Sample Size and Power
Example 5.2 (continued)
women in the standard-dose group, we wish to find the continuation rate for the 
low-dose users to be statistically significantly different as small as 50% or as large 
as 70%. Further, there should be a 0.90 (or 90%) chance (i.e., power of 1 -/?  = 
0.90) that a difference in continuation rates as great as 10 percentage points be 
detected as statistically significant.
If the two treatments really don’t differ with regard to outcome, what risk are we 
willing to take (a )  that the study will find the treatments to be significantly 
different?
We are willing to risk at most an a  = 0.05, or 5% chance, that a difference in 
the rates of continued use will be detected when a difference actually does not 
exist.
What proportion f of the women who are admitted to the study will drop out 
before the study ends for reasons other than the outcome under study?
Because continued use is the outcome under study, all reasons for leaving the 
study would be considered discontinuations of OC use.
(Adapted from Basnayake et al., 1983)
When comparing a new treatment and a control treatment, 
exposed and unexposed individuals, or case subjects and controls, 
researchers may only be interested in detecting differences in one 
One-sided direction. For example, we might want to determine if the new
and two- treatment is better than the control treatment, if exposure to the risk
sided factors under study increases the chances of developing the outcome
comparisons of interest, or if more cases than controls were exposed to the risk
factors. These examples illustrate one-sided comparisons. In some 
studies, researchers may be interested in detecting whether one group 
differs from the other by a certain level, regardless of the direction of 
the difference. This type of comparison is called a two-sided 
comparison. Example 5.2 illustrates a two-sided comparison: the 
researchers want to determine if the rate of continued use of oral 
contraceptives (OC) among women who take a low-dose oral 
contraceptive is greater than or less than the rate of continued use 
among women who take the standard-dose oral contraceptive. The 















sample size through the Z statistics. Table 5.3 provides the Z 
statistics for both one-sided and two-sided comparisons.
Adjusting the Sample Size for Nonresponse
If information will be collected directly from the study subjects, 
we must consider the issue of nonresponse when estimating sample 
sizes. Nonresponse may be attributed to a variety of reasons, 
including refusal to participate or to continue in the study, inability 
to locate the study participants, and incorrect information on 
sampling lists. Sample size formulas represent the number of 
subjects for whom complete information must be obtained and not 
the number of subjects who should be selected for the study. To 
satisfy the confidence level (1 -  a) and tolerance specified for the 
study, researchers should estimate the expected level of 
nonresponse and inflate the estimated sample size accordingly.
To adjust the sample size estimates for nonresponse, sample 
size formulas should be multiplied by a factor of:
(5.3.1)
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Other Considerations for Determining Sample Size
The statistical theory used to derive sample size estimates includes 
several assumptions. If some of these assumptions are not actually 
met, the formula for the sample size may not be valid. The sample 
size determination is most strongly influenced by two of these 
assumptions: 1) the population from which the sample is drawn is 
infinitely large, and 2) the sample is selected by a simple random 
sampling process. In reality, both of these assumptions are often 
violated. However, we can apply adjustments to correct the estimated 
sample size in studies for which one or both assumptions are violated.
Although the assumption of an infinitely large population from 
which to draw the sample will never be true, if the size of the 
population of interest is large relative to the sample size, we can use 
the standard sample size formulas to calculate accurate estimates of 
the required sample size. If the size of the population of interest is 
not large, the finite population correction (fpc) must be applied. As a 
general rule, the need only be applied if the sample comprises more 
than 5% to 10% of the population. The fpc, which yields the adjusted 
sample size n', is calculated as:
(5.3.2) 
fpc = n ' =
1 + n /N
where n = sample size and N = size of population of interest.
If the size of the population of interest is not precisely known, a 
guess about the size should be sufficient. Applying the fpc will reduce 
the sample size estimate. Therefore by ignoring the fpc when it is 
needed, researchers may be using a larger sample size than is actually 
required to achieve the desired accuracy. The fpc is applicable more 
often for descriptive studies and for the selection of controls in case- 
control designs.
The sample size formulas are derived under the assumption that 
simple random sampling is used to draw a sample from a population 
of interest. Because of practical concerns, such as cost, time, and the 
resources required to conduct the study, a simple random sample is 
seldom possible. Chapter 7 describes various types of sampling 
designs and discusses when each type should be used. If a sampling 
design other than simple random sampling is planned for a study, the
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specific design needs to be considered when computing sample 
size estimates. No simple formula is available for computing the 
design effect adjustment.
Types of Studies and 
Sample Size Requirements
Descriptive Studies
In a descriptive study, we are interested in obtaining an 
estimate of the proportion of the population that possesses or 
develops a particular health outcome or attribute. Assessing the 
total population is frequently not possible, so we must draw a 
sample from the population. If the sample is constructed by 
applying statistical principles, we can use statistical theory to make 
inferences about the proportion of the entire population with 
respect to some attribute or outcome based on the proportion of 
individuals from the sample who have the attribute or outcome.
In descriptive studies, we have no hypotheses to test. The only 
decision that would effect sample size is how accurate we want the 
estimate to be. In this situation an approach based on the concept 
of confidence intervals is applied to determine sample sizes.
Once a proportion is obtained from measuring the study 
sample, we can construct a confidence interval about the sample 
proportion. The researcher must specify a confidence level for the 
interval. The confidence level is the probability that the 
confidence interval contains the true population proportion. The 
higher the confidence level, the wider the confidence interval. 
Again, a denotes the probability of making an error (i.e., 
constructing an interval that does not contain the true proportion). 
Once these values are specified, we can apply statistical 
procedures, based on the concepts of confidence intervals, to 
calculate the appropriate sample size. The higher the confidence 
level, the larger the sample size.
The size of the sample depends on the following information: 
d = The distance (or tolerance) — how close to the





proportion of interest the estimate is desired to be (e.g., 
within 0.05).
l —o = The confidence level that our estimate is within distance
(d) of the proportion of interest (1 —a is expressed as a
decimal, for example, 0.95).
p = Proportion or a best guess about the value of the
proportion of interest. If we have no information about p, 
then p = 0.5 is a conservative estimate.
Using this information, the required sample size (n), for a 
descriptive study is calculated as:
(533)
n - p  * (1 -  p) * (Za /  d )2
where a -  (1 — confidence level).
Because the confidence interval extends for a distance (d) on both 
sides of the sample proportion, we may always find the value Z a for 
descriptive studies in the column of two-sided comparison (Table 5.3). 
In Example 5.4, if the investigators had been willing to be within 
0.001 of the actual proportion instead of 0.0005, the required sample 
size would have been n = 0.0045 * (0.9955) * (1.96/0.001)2 =
17,209.4 =  17,210. By allowing the estimate to be less precise, they 
could have lowered the number of medical records that needed to be 
sampled. In the actual study, the investigators sampled approximately
225,000 medical records.
Randomized Clinical Trials
In randomized clinical trials, we compare the proportion of 
participants with a specified outcome in a group that receives 
treatment A and the proportion of participants with the same 
outcome in a group that receives treatment B. These two treatments 
are referred to as the new treatment and the control treatment, which is 
also known as the standard treatment or the placebo treatment. The 




Computing the Sample Size for a Descriptive Study
A  study was designed to estimate and compare the 1970 and 1978 
cumulative incidence of ectopic pregnancy in the United States. A sample of 
medical records was reviewed to abstract demographic data, final diagnoses, 
and surgical procedures. In 1970, the cumulative incidence of ectopic 
pregnancy was estimated at 4.5 per 1,000, or 0.0045, reported pregnancies. 
The investigators wanted to have a confidence level of 0.95 that their estimate 
was within 0.0005 of the actual value. The required sample size for this study 
was calculated using the following information:
d = 0.0005
1 —a = 0.95, so « = 0.05. Therefore, Z a = 1.96 (see a  = 0.05 in Table 
53 under the two-sided comparison).
p = 0.0045, the proportion estimated in 1970 was chosen as a guess 
for the 1978 proportion.
then n = p * (1 -  p) * (Za /  d)2
= 0.0045 * 0.9955 * (1.96 /  0.0005)2 
= 68,837.6 «  68,838
p0 = The proportion of the participants in the control
treatment group who are expected (an educated guess) 
to exhibit the outcome of interest.
Pi = The proportion of the participants in the treatment 
group that are expected to exhibit the outcome of 
interest. This proportion is usually set relative to p 0. 
The investigator desires to detect p , as being different 
from p0.
For example, a commonly used spermidde had an annual failure 
rate of 16% (16 per 100 women who used the spermicide became 
pregnant, or 0.16). The researchers would like to compare this 
spermicide and a new spermicide to determine if the failure rate is 
reduced by half (i.e., to 8%).
Sample Size and Power
a  = The level of significance or type I error probability.
0,
1 —18 = /3 is the type II error probability and 1 —0 is the statistical
power of the comparison. Usually j8 or 1 - 0  is provided 
and either one may be calculated from the other.
f  = The proportion of study subjects who are expected to
leave the study for reasons other than the outcome under 
investigation, / i s  used to inflate the sample size to allow 
for individuals who drop out of the study before the end 
of the study period. The level of/ can often be estimated 
from prior experience with similar treatments and in 
similar research settings. The sample size adjustment 
factor for nonresponse or dropout is q = 1/(1  - f ).
Formula 5.4.1 determines the required number of participants for each 







(1 - f )
2 * ( Za +z * p * (i - p )
( Po -  p. ) 2
where
P = ( Po +  P i ) / 2
Z„ = value from Table 5.3
Z,, = value from Table 5.5
In Example 5.6, we used formula 5.4.1 to calculate the required 
sample size. For this randomized clinical trial, 520 women should 




Computing the Sample Size of a Randomized Clinical Trial
In Example 5.2, we compared the rates of continued use among women 
who used standard-dose oral contraceptives (OCs) and among those who used 
low-dose OCs. The following information was used to calculate the required 
sample size:
p0 = 0.6 of women will continue to use the standard-dose oral
contraceptive for 12 months.
P! = 0.5 or 0.7 of women will continue to use the low-dose oral
contraceptive for 12 months (two-sided comparison).
a  = 0.05
¡3 -  0.10, power = 1 — jS = 0.90
f = 0; all women who dropout are considered discontinuations.
With the two-sided comparison, we have two possible values for p , . To 
be certain that our sample size is sufficiently large, we always use the value of 
p , that is closest to 0.5 because this value will yield the larger sample size.
The required sample size for this randomized clinical trial is:
1 * f 2 * + 1.28)* * 0.55 * 0.45] itwiimn = -----------  *       = 520 per group
( 1 - 0 )  [  (0.6 -  0.5)2 J ^  5
Table 5.5
Z^for Sample Size Formulas for Selected


















Z a = 1.96 (see Table 53  under a  = 0.05 in the two-sided
comparison column)
Zp = 1.28 (see Table 5.5 under 0 = 0.10 or 1 - 0  = 0.90)
P = (p0 + P i)/2 = (°-6 + 0.5)/2  = 0.55
f = 0
Cohort Studies
In cohort studies, we compare the proportion of participants with a 
specified outcome who are exposed to a potential health risk 
(sometimes a potential health benefit) and the proportion of 
participants with the same outcome who are not exposed to the 
potential health risk. The two study groups are called the exposed 
and unexposed groups.
The sample size formula for cohort studies is similar to the 
formula used for clinical trials. The calculation depends on the 
following information:
po = The proportion of the participants in the unexposed group 
who are expected to exhibit the outcome of interest.
p, = The proportion of the participants in the exposed group w 
ho are expected to exhibit the outcome of interest. This 
proportion is usually set relative to p0, and the investigator 
desires to detect p , as being different from p0.
For example, we could compare women with dysmenorrhea after 
sterilization surgery and nonsterilized women with dysmenorrhea who 
use barrier methods. Previous studies indicate that dysmenorrhea is 
reported by about 10% of women who use barrier methods over a 
period of six months. The researchers would like to detect a doubling 
(i.e., 20%) of the risk of dysmenorrhea, if it exists, among the women 
who have had sterilization surgery.
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a = The level of significance, or type I error 
probability.
ft 1 -|8  = The type II error probability and power, 
respectively.
f  = The proportion of study subjects who are expected 
to leave the study for reasons other than the 
outcome under investigation q = 1/(1 -  f ).
A formula for determining the required number of participants 
for the exposed and for the unexposed group in a cohort study is 
calculated as:
Sample size 
formula for a 
cohort study
(5.6.1)
n = a  -  f>
2 * (Za + Z.?  * p * (1 -  P)
(Po -  Pi)2
where
P = (Po + Pi )/2
Z„ = See Table 5.3 
Z„ = See Table 5.5.
In Example 5.7, we used formula 5.6.1 to calculate the required 
sample size for this cohort study. The investigator must enroll 244 
women who had had sterilization surgeiy, and 244 nonsterilized 
women who had used barrier methods for contraception.
Case-Control Studies
As with cohort studies, case-control studies are designed to 
determine whether individuals who are exposed to a health risk 
are more likely to exhibit the outcome of interest than individuals 
who are not exposed to the health risk. In case-control studies, we 
compare the exposure histories of individuals who have had the 
outcome (cases) and individuals who have not had the outcome 
(controls).
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Example 5 .7  
Computing the Sample Size of a Cohort Study
We compared dysmenorrhea among women who had had sterilization 
surgery and nonsterilized women who had used barrier methods. Assume 
that dysmenorrhea occurs in about 10% of women who have used barrier 
methods. Further, suppose the investigator wants to be able to detect a 
doubling of this level, if it exists among sterilized women with a statistical 
power of 0.90. The level of significance is set at 0.05; up to 10% of the 
participants are expected to drop out. The required sample size for each 
group was calculated using formula 5.6.1:
1
(1 - 0.1)




P = (Po + P i ) / 2 = (0.10+0.20)/2  = 0.15 
a  = 0.05
0 = 0.10, power = 1 - / ? =  0.90
Z a = 1.65 (See Table 8.3 under a  = 0.05 in the one-sided comparison 
column)
Zp = 1.28 (See Table 8.5 under 0 = 0.10 or 1 — 0 = 0.90) 
f = 0.10
The sample size formula for case-control studies is similar to that 
used for clinical trials and cohort studies. To apply the sample size 
formula estimates, two quantities are needed: the proportion of 
individuals among the cases who are exposed (pj), and the proportion 
of individuals among the controls who are exposed (p0). Researchers 
should have some idea of the proportion of individuals in the control 
group who are exposed, since controls supposedly represent the 
general population. The two proportions are related; given an
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estimate of p0 and another value (the odds ratio [OR]), an 
estimate of p t can be obtained.
Formula 5.7.1 estimates the proportion of the cases who are 
exposed.
(5.7.1)
Pl = Po* OR /  [1 + Po* (OR - 1 ) ]  
where
p , = The estimate of the proportion of individuals among
the cases who were exposed.
Po = The proportion of individuals among the controls
whom we expect have been exposed.
OR = The odds of the outcome of interest among individuals 
who were exposed divided by the odds of the outcome 
of interest among individuals who were not exposed. 
The odds ratio that is to be tested as being statistically 
significant is specified by the researcher.
In Example 5.8, we consider the relationship between the 
intrauterine device (IUD) use and ectopic pregnancy. In this 
example, p , is estimated to be 0.095. After p, is estimated as a 
function of po and OR, the following additional information is 
required to calculate the sample size:
a = the level of significance or type I error probability.
jS, 1 — jS = the type II error probability and power,
respectively.
Formula 5.7.2 may be used to calculate the required number of 
participants for the case group and for the control group:
(5.7.2)
' 2 .  ( z . * z f r  * p -  ( i  - p ) "n = -----------“------ ---------------------------
( Po -  P i  ) 2
Proportion o f 
cases exposed
Sample size 
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where
P = ( P o +  P i )  /  2
Z a = value from Table 5.3 
Zp = value from Table 5.5
Example 5.8
Estimating the Proportion of Exposed Cases
The controls were nonpregnant women 18 to 44 years old who were 
admitted to surgical or medical services in selected hospitals. The investigator 
estimated that about 5% of the controls were using intrauterine devices 
(IUDs) at the time of their last menstrual periods. The cases were women 18 
to 44 years old who were admitted to the same hospitals with a diagnosis of 
ectopic pregnancy. The investigator wants to be able to detect a statistically 
significant level of ectopic pregnancy among IUD users. This level should be 
twice the level for non-IUD users, if such a relative difference exists. Using 
formula 5.7.1, the investigator estimated the proportion of exposed cases:
Pi = (0.05 * 2) /  [1 + 0.05 * (2 — 1)]
= 0.095
where
pQ = 0.05, estimate of proportion of controls that used IUDs
OR = 2 (i.e., investigator wants to detect twice as high an ectopic
pregnancy rate in IUD users as in non-IUD users)
In Example 5.9, the investigator assumes that about 5% of the 
controls had been using IUDs at the time of their last menstrual 
period. The investigator would like to detect, with statistical power of
0.95, a doubling in the level of ectopic pregnancy among IUD users, if 
it exists. The level of significance desired is 0.05. Before applying 
sample size formula 5.7.2, the investigator must obtain an estimate of 





Computing the Sample Size for a Case-Control Study
The required sample size for each group is calculated as:
2 » (1.65 + 1.65)2 * 0.0725 » 0.92751 .  m  
(0.05 — 0.095)2 J
where
p0 = 0.05 
p, = 0.095
P =  (Po +  p D/2 =  (0.05 +  0.095)/2 =  0.0725 
or = 0,05
¡3 = 0.05, power = 1 —0 = 0.95
Za = 1.65 (See Table 53 under a  = 0.05 in the one-sided 
comparison column)
Zp = 1.65 (See Table 5.5 under 0 = 0.05 or 1 —{} = 0.95)
Case-Control Studies with Unequal Group Sizes
One final consideration that applies particularly to case-control 
studies is the issue of a balanced design. Frequently, a study 
cannot be designed with equal numbers of cases and controls. If 
the outcome of interest is a rare phenomenon, we may not be able 
to enroll a large number of cases. Usually, more individuals are 
eligible to be controls than cases. To optimize the total number of 
participants in a study, we need a one-to-one ratio of the number 
of controls to the number of cases, sometimes referred to as a 
balanced design.
The formulas given in this chapter assume equal sample sizes in 
each group. A  slight modification to the formulas allows us to 




Sample Size and Power
Adjustment 
factor for 
ratio o fr  
controls to 
cases
ratio of r controls to cases. To compute the sample size for a given 
ratio of r controls to cases, we must modify the existing sample size 
formula (5.7.2) by a factor of:
(5.9.1)
fr  + l ) / ( 2 * r )
In Example 5.10, the investigator assumes that the occurrence of 
ectopic pregnancies is relatively infrequent and decides to enroll three 
controls for every woman enrolled with a diagnosis of ectopic 
pregnancy. The required number of cases is 413 and the required 
number of controls is 3 * 413 = 1,239 (total required study sample is 
1,239 + 413 = 1,652). Recall that the total study size for the 
balanced design (with an equal number of cases and controls) was 
1,448 (724 cases + 724 controls) (See Examples 5.8 and 5.9).
The value of p in Example 5.10 is no longer a simple average of p 0 
and p , but a weighted average of p 0 and p t . The resulting sample 
size, n, is for the case group. The size of the control group is r * n. 
Note that if r = 1, everything simplifies to a situation in which there 
are equal sample sizes for cases and controls.
Example 5.10
Computing the Sample Size of a Case-Control Study 
With Unequal Group Sizes
The number of study participants for a case-control study with unequal 
group sizes is calculated by multiplying formula 5.7.2 by formula 5.9.1:







p = (r * p0 + p , ) / ( r  + 1) = (0.15 + 0.095)/4 = 0.06125, a weighted 




a  = 0.05
0 = 0.05, power = 1 —/3 = 0.95
Z a = 1.65 (See Table 5.3 under or = 0.05 in the one-sided 
comparison column)
Zp = 1.65 (See Table 5.5 under 0 = 0.05 or 1 —/? = 0.95)
Assessing Statistical Power
For several reasons, assessing the statistical power that is 
provided by a particular sample size may be of interest. If the 
circumstances of the study limit the sample size, then knowledge 
of the statistical power available for the study is needed. Also, 
researchers can calculate statistical power when assessing the 
findings reported by others. The concept of statistical power does 
not apply to descriptive studies because they are not comparative 
(i.e., hypothesis testing is not involved).
Interpreting Power of Published Studies
Reporting power when reporting study results in the literature 
constitutes good epidemiologic practice. Many published studies 
do not mention power. It is usually possible to compute the power 
of a published study from the information provided by the authors. 
The power is the probability that the study data will indicate a 
difference in treatment or exposures when a difference truly exists. 
Power of a study is especially important for interpreting results 
that indicate there is no significant difference between the 
treatments or exposure levels under consideration. If the power is 
high, there is no reason to question the study conclusions.
However, if the study has insufficient power, a result of no 
significance (i.e., accepting the null hypothesis) may be attributed 
to the lack of power rather than to the possibility that the null 
hypothesis is correct. Published studies with inadequate power 
probably should not have been conducted.
Power defined
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A  study with inadequate power does not allow the researcher to 
test the hypothesis of interest. Researchers designing a study should 
consider the statistical power provided by a specified sample size. If 
the calculations reveal an inadequate level of power, the sample size 
can be increased until adequate power is achieved. If limitations on 
the sample size exist because of other considerations, such as cost, 
time, and limited resources, it may not be feasible to conduct the 
study.
Randomized Clinical Trials
Given the sample size for each group n, p , , p 0, and a , formula
5.10.1 provides the power associated with a randomized clinical trial:
(5.10.1)
V n * (1 -  f ) * |p0 -  p,| - z ,  * y/2  *  p * (1 -  p)
J 2 * p * (1 -  p)
where
n = sample size per group.
p 0 = estimated or observed proportion of individuals 
receiving the control treatment who had the 
outcome of interest.
Pt = estimated or observed proportion of individuals 
receiving the new treatment who had the outcome 
of interest.
P  =  ( P o +  P i )  / 2 .
| po — Pi | = the absolute difference between p 0and p , .
f = proportion of subjects expected to drop out.
Z 0 = determined from Table 5.3 based on the value of 
the level of significance a.
172
Z„ = calculated by formula 5.10.1. The statistical
power of the study, 1 - f t  may be found in Table
5.5 corresponding to this value of . Z^ value 
>0.0 indicates statistical power >0.50; a Z^ 
value <0.0 indicates a power <0.50.
In Example 5.11, is calculated as 0.14. By referring to the 
1 - f t  column of Table 5.5, we find that the statistical power (1 —0) 
of the study is between 0.5 and 0.6. Statistical power between 0.5 
and 0.6 is considered quite poor because there is only about one 
chance in two that the study could distinguish a 10% difference in 
continuation between the two oral contraceptive dosages.
Example 5.11
Calculating the Power for a 
Randomized Clinical Trial
In a clinical trial that compares the rates of continued use among low-dose 
oral contraceptive (OC) users and standard-dose OC users in Colombo, Sri 
Lanka, the investigators believed they would be able to recruit a total of only 
400 women for the study (200 women for each group). They wanted the level 
of significance to be or = 0.05 and knew from previous studies that about 70% 
of women who had taken a standard-dose OC continued to use this pill for at 
least one year. They wanted to determine if women who took a low-dose pill 
would have a one-year continuation as large as 10 percentage points different 
from the standard-dose users (i.e., £  60% or ^  80%). Using formula 5.10.1, 
the statistical power is:
z  = >/200 * 0.1 -  1.96 ♦ ^ 2  » 0.65 » 035
yj 2 * 0.65 * 035 = 0.14
where
n -  200
Po = 0.7
Pi = 0.6 (because this is a two-sided comparison, choose the
value of po closer to 0.5.)
P = (Po + P i) / 2  = 0.65






I Po -  Pi I = 0.1 
f  = 0  
a  = 0.05
Z a = 1.96 (see Table 8.3 under the two-sided comparison column)
The power (1-/3) is found in Table 5.5. For = 0.14, the corresponding 
power is between .5 and .6.
(Adapted from Basnayake et al., 1983)
Cohort Studies
The power calculation for cohort studies is similar to the 
calculation used for randomized clinical trials. The calculation uses 
the notation introduced in the section on determining the sample size 
for cohort studies:
(5.H.1),
z  = yfn * (1 ~  0  * IPo ~  Pil ~  z .  * y/2 * P * (1 ~  p)
/  2 * p * ( l  -  p)
where
n = sample size for each group.
p 0 = estimated or observed proportion of the unexposed 
group who developed the outcome of interest.
P! = estimated or observed proportion of the exposed 
group who developed the outcome of interest
P = ( Po + P i )  /  2.
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I Po - P i  I the absolute difference between p 0 and p i .
f = proportion of subjects expected to drop out.
Z a = determined from Table 5.3 based on the value 
of the level of significance, a, and on whether it 
is a one-sided or two-sided comparison.
Zp = calculated by the formula 5.11.1; used to
establish the statistical power of the study, 1 —0 
(Table 5.5). A Z fi value > 0.0 indicates 
statistical power > 0.50; a Z„ value < 0.0 
indicates a power < 0.50.
In Example 5.12, Z fi is calculated as 2.75. From the Z d 
column in Table 5.5, the statistical power 1 —0 exceeds 0.99. Thus, 
the investigator could reduce the sample size and still have good 
statistical power.
Example 5.12
Calculating the Power for a Cohort Study
In a study that compared the complication rate among women who had had 
an interval tubal sterilization by silastic band and the complication rate among 
women who had had an interval tubal sterilization by electrocoagulation, an 
investigator anticipated enrolling 4,000 participants. She estimated that 1% of 
the women who had been sterilized by silastic band would exhibit a 
complication. She would like to be able to detect as statistically different (for 
a  = 0.05) a complication percentage as large as 3% among the women who 
had been sterilized by electrocoagulation. She expects a 5% drop-out rate. 
Using formula 5.10.1, she calculates the statistical power of this study as:
Z = v/ 2,000 ♦ (1 ~  0-05) * 0-02 -  1.65 * y/ 2 » 0.02 * 0.98 _ 2?5
7  2 * 0.02 * 0.98
where
n = 2,000 
Po = 0.01
p i = 0.03; one-sided comparison___________________________









P = (  Po + P i )  /  2 = .02 
I Po “ P i l  = 0.02 
f = 0.05
a  = 0.05, so Z a = 1.65 (Sec Table 53, one-sided comparison 
column)
The power (1-0 ) is found in Table 5.5. For = 2.75, the corresponding 
power exceeds .99.
(Adapted from DeStefano et al., 1983)
Case-Control Studies
The power calculation for the case-control study is similar to that 
for the cohort study, but, as with sample size determination, it 
requires an estimate of p j (the value of the proportion of the cases 
that were exposed to the risk factor of interest). Recall that p , is 
estimated by the relation:
Pl = Po * OR /  [ l  + Po * (OR - l ) ]
where
p 0 = The proportion of participants in the control group who 
are expected to be exposed or who are observed to be 
exposed.
OR = The odds of the outcome of interest among the exposed 
divided by the odds of the outcome of interest among the 
unexposed that we wish to detect as being significantly 
different from 1.
Once an estimate of p , is calculated, the power of the study with 
equal or unequal case and control size is calculated by:
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Z = * n * I Po ~ Pil ~ Z° * + 1) * p * (X ~ P)
V (r + 1) * p * (1 -  p)
where
n = sample size of cases.
(5.12.1) _______
r = ratio of controls to cases; r = 1 for equal 
number of cases and controls.
P = (r * Po + Pi) /  (r + 1).
I Po _  Pi I = the absolute difference of p 0and p i .
Z a = determined from Table 5.3, it is based on the 
level of significance (a) and on whether the 
study tests a one-sided or two-sided comparison.
Z„ = calculated using formula 5.12.1, it is used to 
determine the power of the study from values 
shown in Table 5.5.
In Example 5.13, Z fi is calculated as -1.52; the statistical power 
is less than 50% (Table 5.5). Although the results of the statistical 
test indicate there is no significant difference in the proportion of 
women with and without breast cancer who had used depo- 
medroxyprogesterone acetate (DMPA), the power calculation 
indicates a less than 50% chance of detecting a difference of the 
specified magnitude if such a difference truly exists. A  result that 
indicates no significant difference exists between the study groups 
could be due to the lack of power rather than the possibility that 
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Example 5.13 
Calculating the Power of a Case-Control Study
Is the use of depo-medroxyprogesterone acetate (DMPA) associated with 
the risk of breast cancer? The cases were women attending a family p lanning 
clinic who developed breast cancer during a 13-year period (Greenspan et al., 
1980). The controls were women attending the same family planning clinic 
who did not develop breast cancer. The results of the study were as follows:
______ Exposure________
DMPA Did not
Outcome use use DMPA
Women who 5 25
developed breast cancer
Women without 32 147
breast cancer
OR « 0.9 (95% Cl: 0.3 - 2.6)
Women who used DMPA were at decreased risk of developing breast 
cancer than were women who did not use DMPA; the difference between the 
groups was not statistically significant at the 0.05 level.
What is the power for these results?
n - 30, r = 179/30 = 5.97 (from the table above)
a  = 0.05, Z a = 1.65 (one-sided comparison)
Pi = 0.17 (from the table above)
Po = 0.18 (from the table above)
P = ( P l +  r * P o ) / ( r + 1)
(0.17 + 5.97 * 0.18) /  (5.97 + 1) = 0.179
P o - P i l  = 0.01
^ 30 * 5.97 ♦ 0.01 -  1.65 * fë.91  * 0,179 ♦ 0.821 =
V 6.97 * 0.179 * 0.821
The power (1 - / ? )  is found in Table 5.5. F o r Z B= -1.52, the 












and assessing statistical power.
If the test fails to reach significance, it may be that the study has 
high power rather than that the null hypothesis is true.
In a general sense, the greater the sample size, the more accurate 
the results.
( )  Sample size for descriptive studies is based on hypothesis testing.
A  sample size that is too large will limit the conclusions that can 
be drawn from the study.
If the power is sufficient, failure to achieve significance may 
indicate a reasonable difference in the outcomes.
The proper interpretation of a test that fails to reach significance 
is based largely on the level of power of the study.
2. Matching. Match the definitions with the terms on the a. Type I error 
right.
b. Type II error
2. 1 ___ The risk that the investigator is willing to
make of committing a type I error; also c. a
called the significance level.
d. 0
2. 2 ___ The probability of rejecting the null
hypothesis when it is actually false; e. power of a test
equal to 1 — 0.
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2. 4  Affirms that there is no difference between the
populations being compared with 
respect to the parameter under study.
2. 5  When, as a result of a test of significance, a
null hypothesis is not rejected when it is false.
2. 6  When, as a result of a test of significance, a
null hypothesis is rejected when it should not have
been rejected because it is true.
3. Consider the problem of assessing the level of maternal mortality associated 
with cesarean delivery in a large network of hospitals. An estimate of the 
level can be obtained by reviewing a sample of medical records. Previous 
studies in similar hospital settings have estimated that the level of maternal 
mortality for all deliveries (cesarean and vaginal) was about 10 per 1,000. It is 
desired that the estimate be within two deaths per 1,000 of the actual level 
with 90% confidence.
(a) What size sample would be required? 
d
1 —a = 
a =





4. In Example 5.2, we compared the rate of continued use among women who 
used a standard-dose OC and the rate of continued use among women who 
used a low-dose OC. From this Example, we know the following information:
p 0 = 0.6 of women who use the standard-dose OC will continue to use 
this OC for 12 months.
P! = 0.5 or 0.7 (two-sided comparison) of women who use the low-dose 
OC will continue use for 12 months.
a  = 0.05.
/3 = 0.10, power = 1 — 0 = 0.90.
f = 0; all dropouts are considered discontinuations.
With the two-sided comparison, we have two possible values for p j . The 
value closer to 0.5 should be applied because it will always yield a larger 
sample size. In Example 5.2, p j = 0.5 yielded a sample size of 520 individuals 
per group.
(a) Calculate the sample size using p t = 0.7 with all the other values the 
same as in the first calculation.
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5. A case-control study is being designed to examine the association between 
IUD use and pelvic inflammatory disease (PID). It is estimated that 20% of 
the controls are current IUD users. Further, it is desirable to have a sample 
size large enough to detect a ratio as large as 2 of the proportions of IUD 
users who develop PID relative to the proportion of non-IUD users who 
develop PID. A level of significance of 0.05 and power of 0.80 are required.






0 = 1 - 0  = Z* =
n = per group
(b) Calculate the sample size for an unbalanced design where r = 2.
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6. In a study that compared the complication level of two interval tubal
sterilization procedures, electrocoagulation and silastic bands, the investigators 
suspected that electrocoagulation was not as safe as silastic bands. They 
preferred to set the statistical significance at the 0.05 level for detecting a 
doubling of risk. The acceptable power of the comparison is 0,95. They 
assumed that the current complication level among the women sterilized by 
silastic bands is 1 per 100; they do not expect any patients to drop out.
(a) What type of study is this?




a  = Z a =
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7. After reading the following paragraph, answer 7a - g by circling true (T) or 
false (F).
The annual pregnancy rate for a commonly used spermicide A is 16%. 
Researchers want to compare this spermicide with a new spermicide B to see 
if the pregnancy rate is reduced by half (i.e., to 8%). They are willing to 
tolerate an a error of 0.05 and a 0 error of 0.10. It is assumed that 15% of 
the subjects will drop out of the study before its completion. Our goal at this 










(l  - f )
2 * (Z. + Z , ) 2 ♦ p * ( l - P)
( Po -  p . y
7.1 Calculate the sample size for this example.
184
Chapter 5
8. In comparing a new IUD and a standard IUD, the investigators are equally 
interested in the expulsion rate and the pregnancy rate accumulated over six 
months. Assume that a = 0.05 and that the expected drop out rate is 20%. 
Further, assume that the standard IUD has a six-month expulsion rate of 10 
per 100 women and a six-month pregnancy rate of four per 100 women. The 
investigators would like to be able to detect as different the expulsion and 
pregnancy rates in the new IUD as small as 5 and 2, respectively. They would 
like to detect a halving of rates with statistical power (1 - 0 )  of 0.80.
(a) Calculate the power for the expulsion rate and the pregnancy rate, 









(b) What would these powers mean? What sample size would be needed to 
achieve the 0.80 power desired by the researchers?
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9. Investigators planning a cohort study would like 80% power (0 = 0.20) to 
show a difference between an incidence in the exposed of 8.0% and an 
incidence in the unexposed of 5.0%, when testing at a level of significance of
0.05. The risk ratio that is considered important is 1.6. They therefore 
calculate that 1,058 participants are necessary in each group; the total sample 
size should be 2,116. Compensating for a 20% loss to follow-up they calculate 
that they need to enroll a  total of 2,645 participants. However, they anticipate 
that they can enroll only 600 participants in the exposed group. They would 
like the study to be balanced, so they will enroll a total of 1,200 volunteers in 
the study.
(a) Based on the sample size limitations, calculate the power.




10. Circle true (T) or false (F).
(a) T /F  Statistical significance can be defined as a = .05 or a  = .01 or any
other small value the researcher chooses.
(b) T /F  The purpose of hypothesis testing is to distinguish no effect from
some effect.
(c) T /F  If the null hypothesis is false, the likelihood that the study decision
rejects the null hypothesis depends primarily on statistical power.
(d) T /F  Statistical power does not apply to descriptive studies because they
are not comparative.
(e) T /F  Checking the power can help prevent the researcher from
conducting a study too small to provide conclusive results.
(f) T /F  The power of a study design may confirm a nonsignificant test
result, affirming the truth of the null hypothesis.
(g) T /F  Power calculations may clarify that a completed study with results
' indicating no difference did not have sufficient power to detect a 
difference.
(h) T /F  In a two-sided comparison, we are interested in detecting a
difference in performance only if the new treatment is better than 
the control.
11. All of the following are constraints on the sample size except:
(a) time and costs
(b) dropout rate
(c) interviewer skills
(d) number of subjects available
(e) ability to draw conclusions
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12. Fill in the blanks. Complete the following decision table with one of the 
labels given at the right.
Study
Decision
 Actual State of Nature
Null Hypothesis Null Hypothesis 











b. Type I error, a
c. Type II error, ß
d. Confidence level
13. If you were conducting a study and would like to detect an incidence ratio of
3.0 with a significance level of 0.05, you would compute a sample size. 
Assume that you expect to find an incidence of about 7% in the unexposed 
groups and that you want a power of 80% (0 = 0.20).
(a) What type of study is this?
(b) What is the formula for n?
(c) Is this a one- or two-sided test?
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(d) Calculate the sample size, using Tables 5.3 and 5.5.
(e) If you could enroll 150 participants in the exposed group, how would that 
affect the power of the test?
(f) If you have not already done so in Question 13.5 above, calculate the 
power of the test with 150 participants in each group.
(g) What would you do in this situation?
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14. A household survey is being considered in country Y to estimate the extent of 
sexual activity among female adolescents 13 to 19 years old. Studies in other 
countries with similar populations have found that 33% of females aged 13 to 
19 years have reported being sexually active. It is desired that the estimate be 
within 1% of the actual level with 95% confidence. The response rate is 
estimated to be 85%.
(a) What size sample would be required?
d =






(b) Suppose a recent census indicated that Country Y has approximately
80,000 female adolescents aged 13 to 19 years in the population. Is it 
necessary to apply the finite population correction (fpc) to estimate the 
sample size? If so, what is the corrected sample size?
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Suggested Answers to Practice Exercises
1. True or false.
(a) T Introduction
(b) F Sample Size and Power; no, because it has low power.
(c) T  Sample Size and Power
(d) F  Descriptive Studies; no, it is based on confidence intervals.
(e) F  Sample Size and Power; no, but too small a sample size will.
(f) F  Sample Size and Power; no, it would indicate a negligible difference.
(g) T  Sample Size and Power
2. Matching.
2.1 c Tests of Hypotheses
2.2 e Tests of Hypotheses
2.3 d Tests of Hypotheses
2.4 f Tests of Hypotheses
2.5 b Tests of Hypotheses
2.6 a Tests of Hypotheses
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3. Assess the level of maternal mortality.
(a) Using the estimate of maternal mortality from all deliveries in previous 
studies as a guess at the level of maternal mortality for cesarean deliveries 
in the proposed study.
d = 2/1,000 = 0.002 
1 —a = 0.90
a  = 0.10 
Z a = 1.65 (two-sided comparison)
p = 10/1,000 = 0.01
n = p * (1 - p )  * (Z a /d )2 = 0.01 * 0.99 * (1.65/0.002)2
= 6,738.2 =  6,738
4. Calculate a sample size.
(a) In two-sided comparisons, two values are available for p t . We should 
choose the value closer to 0.5 so we do not underestimate the appropriate 
sample size. The two values for p , were 0.5 and 0.7. We used 0.5 in our 
calculation to get a sample size of 520 per group. If we had used 0.7, the 
sample size would be:
If pt later actually turned out to be 0.5, then our sample size (calculated 
with pj = 0.7) would not be large enough to meet our statistical 
requirements.
2 * (1.96 + 1.28)2 * 0.65 * 035  
(0.6 — 0.7)2
! 478 per group
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5. Calculate sample size for a balanced and imbalanced design.
(a) po = 0.2
OR = 2
then,
P! = 0.2 * 2 /  [1+0.2 * (2 -1)]
= 0.33
p = (0.2 + 0.33)/2 = 0.265
a  = 0.05 Z„ = 1.65 (one-sided comparison)
0 = 0.20 1 - 0 = 0 . 8 0  Zp = 0.84
(b) r = 2
p = (2 * 0.2 + 0.33) /  3 = 0.243
The number of controls would be 2 * 102 = 204.
6. Determine the type of study and calculate sample size.
(a) Cohort study
(b) po = 0.01; we treat the silastic band participants as the unexposed group.
w 2 » (1.65 » 0.84)2 » 0.265 » 0.735 143 per group
(02 -  033)2
2 » (1.65 » 0.84)2 » 0.243 * 0.757 -  102 cases
(02  —  033)2
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P! = 0.02; we want to detect a doubling of the risk of complication
among the women who were sterilized by the electrocoagulation
procedure.
p = (0.01 + 0.02) /  2 = 0.015
a  = 0.05 Z 0 = 1.65 (one-sided comparison)
0 = 0.05 power = 1 — 0 = 0.95 = 1.65
f  = 0
7. True or false.
(a) F No, it is one-sided; we are interested only in detecting a reduced 
pregnancy rate.
(b) F No, 1 - 0  = 1 -  0.10 = 0.90 (or 90 percent).
(c) T Table 5.3, under one-sided comparison for a -  0.05.
(d) T Table 5.5, for 0 = 0.10.
(e) F This is a randomized clinical trial.
(f) T See sample size formula for randomized clinical trials.
(g) T See sample size formula for randomized clinical trials.
7.1 Sample size for the example:
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8. Compare new and standard IUDs.
(a) Pregnancy rate comparison: 
a  = 0.05 
Z a = 1.65, a one-sided comparison 
Po = 0.04
p ! = 0.02
I Po -  Pi I = 0.02
p = (0.04 + 0.02)/2 = 0.03 
f = 0.2 
n = 400
Z 400 * (1 -  0.2) * 0.02 -  1.65 ♦ y/2 * 0.03 » 0.97 _
>¡2 * 0.03 * 0.97
Z p -  — 0.17; from Table 5.5 the power 1 — 0 is < 0.50.
For expulsion rate comparison all values are the same except:
Po = 0.1 
p t = 0.05
I Po— Pi I = 0.05
p = (0.1 + 0.05)/2 = 0.075
Z a = y/ 400 * (1 -  0.2) ♦ 0.05 -  1.65 * y/2 * 0.075 ♦ 0.925 = Q75
<J 2  * 0.075 * 0.925
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Z f = 0.75; from Table 5.5, the power 1 — 0 is between 0.70 and 0.80.
(b) The power for the expulsion rate is almost sufficient but the power for the 
pregnancy rate comparison is not. A power (1 —0  ) less than 0.50 is very 
poor because there is less than one chance in two that the study could 
distinguish a difference in pregnancy rates of the order that the researcher 
specified. To achieve the 80% power (Z ff = 0.84) that the researcher 
desires for both comparisons, use values for the pregnancy rate 
comparison because there is more power for an expulsion rate 
comparison. The sample size will have to be increased substantially from 
400 per group to about 1,130 per group.
( l -  0.2)
2 * (1.65 + 0.84)2 » 0.03 * 0.97
(0.04 -  0.02)2
1,128 per group
9. Calculating power
(a) a - 0.05, Z„ = 1.65, (one-sided comparison)
Po = 0.05
Pi * 0.08





Z a  -  V 600 * (1 -  0.2) * 0.03 — 1.65 ♦ V2 » 0.065 ♦ 0.935 = fl24
•J 2 «■ 0.065 * 0.935
From Table 5.5, the power is 60%.
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(b) A power (1 -  0 ) of 0.60 is not very good because there is about a three- 
in-five chance that the study could distinguish a difference in incidence 
rates between the exposed and unexposed groups of the order that the 
researcher specified. Having only 600 subjects available for each group 
puts serious limitations on the power of the study and thus limits the 
conclusions that may be drawn from the study. It is probably not worth 
pursuing the study.
10. True or false.
(a) T Sample Size and Power
(b) T  Tests of Hypotheses
(c) F  Decision making and Sample Size and Power; no, it depends on
sample size.
(d) T  Assessing Statistical Power
(e) T  Sample Size and Power
(f) F  Decision making and Sample Size and Power; you only know you
can’t reject the null hypothesis.
(g) T  Sample Size and Power
(h) F  Determining the Sample Size; this describes a one-sided comparison.
11. c Introduction





Sample Size and Power
13. Computing sample size, 
(a) Cohort study
(b) n = a  - f )
(c) One-sided test
2 * (ztt ♦ z g y  * p * g  -  p)
( Po -  p . ) 2
(d) 2 ■» (1.65 + 0.84) 2 *  0.14 *  0.86 
(0.07 -  0 .21)2
= 76 per group.
(e) Because 150 persons per group is more than 76, the power of the test 
would be improved to a level higher than the 80% specified by the 
researcher.
(f) z V 150 *  0.14 -  1.65 *  ij 2 * 0.14 *  0.86
v /2  *  0.14 *  0.86
Zp = 1.84 (from Table 5.5, the power is between 0.95 and 0.975).
(g) More participants are available. Therefore, if the cost or effort to do 
the study with more participants is not appreciably increased, the 
improved power might make using 150 participants per group more 
appealing. If an 80% power level is acceptable to the researcher, then 
there is no need to use more than 103 participants per group.
14. Estimate the extent of sexual activity among female adolescents.
(a) Using the level of sexual activity in a neighboring country as a guess for 
the level of sexual activity in country Y, the sample size is calculated as 
follows:
d = 0.01
1 — a  = 0.95
198
Chapter 5
a  = .05 
Z a = 1.96 (two-sided comparison) 
p = 0.33 
f = 0.15
n =
( i - 0 *  P *  (1  -  P) *  (Z a /d ) 2 = 1 -0 .1 5
*  (0.33) *  (0.67) * 1.96
0.01
(b) Yes, because a sample of 10,000 comprises 12.5% of a population of 
80,000, the finite population correction is needed.
fpc n _ 10,000 = 8,888.8





Sample Size and Power
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Chapter 6 - Learning Objectives
After completing this chapter, you should be able to:
1. Recognize appropriate uses of descriptive studies.
2. Describe three types of comparisons often made by descriptive studies:
population subgroup comparisons 
geographic comparisons 
temporal comparisons
3. Specify descriptive characteristics of person data.
4. Describe different types of geographic comparisons.
5. List various reasons for a geographic difference in exposure or disease occurrence.




7. Describe sources of data and methods of collecting data for descriptive studies.
8. Recognize advantages and disadvantages of descriptive studies.





Descriptive epidemiologic studies describe patterns of disease 
occurrence or exposure to risk factors in relation to person, place, 
and time. Person refers to who is affected, place refers to where 
the health problem is more or less common, and time refers to 
when the health problem is occurring. This information is valuable 
to public health personnel: administrators, clinicians, 
epidemiologists, and researchers. Knowing which population 
subgroups are most likely to be affected allows targeting of 
particular population segments for education, preventive programs, 
and resources. Identifying descriptive characteristics can be the 
first step in identifying risk factors that can be altered or 
eliminated to reduce or prevent disease and other health 
problems. Descriptive studies can also provide valuable clues for 
generating specific hypotheses that can be tested subsequently in 
analytic studies (Hennekens and Buring, 1987).
Descriptive studies serve many purposes. For example, a 
descriptive study of the demographic characteristics and 
socioeconomic factors of women who died of pregnancy-related 
causes can determine which population subgroups are at highest 
risk. A study describing women who develop pelvic inflammatory 
disease (PID) among women who use intrauterine devices (IUD) 
can identify potential risk factors and provide information for 
hypothesis testing in future analytic studies. Descriptive studies 
are also used to monitor long-term time trends in the occurrence 
of health outcomes or exposures (e.g., the prevalence of 
breast-feeding over the last ten years).
Although descriptive studies do not, by definition, include a 
formal comparison group, valid comparisons are possible. For 
example, a descriptive study of an entire population or geographic 
area will include people with and without the risk factor or health 
outcome of interest. Therefore, it is possible to compare the 






outcome. For example, in a descriptive study of maternal mortality in 
hospitals in Chile, rates and causes of pregnancy-related deaths in 
rural hospitals could be compared with urban hospitals. A descriptive 
study of births in a single hospital could compare the characteristics 
of women who have had stillbirths with women who have had live 
births. Again, information from these comparisons can provide 
important leads for subsequent analytic studies. Example 6.1 
illustrates the type of comparisons that can be made by using 
information from the World Fertility Study (WFS), a multinational 
descriptive study.
Example 6.1
Birth Spacing and Infant Mortality
Research Question: Does birth spacing have an important effect on child 
survival?
Study Design: The World Fertility Survey (WFS) was an international 
research project that conducted surveys in 41 countries in Asia, Africa, the 
Middle East, and Latin America to provide high-quality data on fertility and 
family planning.
Data Collection Methods: The WFS questionnaire included a core of basic 
questions that were asked in every survey so that comparable data would be 
available for all countries. Optional modules were used by many countries to 
tailor the survey to the need and social setting of the particular country. The 
WFS core questionnaire contained two sections: the household schedule and 
the individual questionnaire. The household schedule asked the age, sex, and 
marital status of all members of the household. The individual questionnaire 
collected data on the background of the respondent (age, level of education, 
literacy, work history), marital and maternity history, and knowledge and use 
of contraception. As a result, comparisons of knowledge, use, and availability 
of family planning services among countries were possible.
Results: Several multicountry findings revealed highly relevant information 
about the determinants of fertility and mortality. For example, Figure 62  
demonstrates the dear and consistent relationship between birth spacing and 
infant mortality.
(Rinehart et al., 1984)
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Death Rates for Infants Bom After Short or Long Birth Intervals to 





■ M  Long Birth Interval: Children bom 2-6 years apart 
i i Short Birth Interval: Children bom < 2 years apart
AMca Asia Latin America & Caribbean
"Women wtth 1-3 years of education were uaed becauee too taw women had no education 
(Hobcraft at 1983; Nnehwt et al.. 1flM)
In the 25 countries surveyed for the WFS (Figure 6.2), analysis 
indicated that infants bom soon after another birth were more 
likely to die than infants bom  after a longer interval. To minimize 
socioeconomic differences that might affect birth spacing and 
mortality, these data cover only the children of mothers with no 
formal education. This study highlights the relevance of family 
planning to maternal and child health programs, whether or not 
population control is a motive. Closely spaced births is a high-risk 
situation that affects infant mortality and causes other maternal 
health problems. Spacing of less than two years can mean lower 
birthweights, poorer nutrition, shorter periods of breast-feeding, 
and more competition for family resources and care. Other 
comparisons of fertility by age, education, and urban/rural 
residence were possible from the WFS data and provided 










Types of Descriptive Studies
Descriptive studies address three basic types of comparisons: 
population, geographic, and temporal. Public health personnel need 
to formulate the research questions to be answered by the descriptive 
study in terms of person, place, and time measures.
Population comparisons are the who or person measure.
Descriptive data related to person address questions such as Who is 
developing the disease or health problem? or Who is at higher risk o f 
exposure? People affected or exposed are characterized by basic 
demographic and social characteristics, such as age, sex, marital status, 
race or ethnic origin, religion, and measures of socioeconomic status.
Geographic comparisons are the where or place measure. 
Descriptive characteristics related to place consider Where are the rates 
o f disease highest and lowest?, (i.e., Are cases equally distributed with 
respect to country, state or district within country, urban-rural residence, 
or area within an affected local community?)
Temporal trends are the when or time measure. Descriptive data 
on time address such questions as When does the disease occur 
commonly or rarely? and Is the frequency o f the disease at present 
different from the corresponding frequency in the past? For example, is 
there any unusual feature of the distribution of cases by year, season, 
month, or day of occurrence?
Note that descriptive studies can cover a wide range of time spans, 
from a study conducted at a single point in time to a surveillance 
study that monitors long-term trends in the occurrence of health 
outcomes or exposures.
Population Subgroup Comparisons
Comparisons of disease rates by who is most and least affected 
involve collecting descriptive data on the persons affected. Who is 
affected is an important determinant of outcome, and a careful 
description of the types of people affected can be helpful in 
delineating causes of disease as well as in targeting population 
subgroups for health programs and resources.
The characteristics of person must include age and sex. Marital 
status, race, ethnicity, and measures of socioeconomic factors such as 
occupation and literacy are other important factors that relate to 
disease occurrence. In less developed areas, variables that indicate
the availability of running water, electricity, and sanitation may be 
used to measure socioeconomic status. Important characteristics 
that affect reproductive outcomes are parity, family size, birth 
order, child spacing, prenatal care, contraceptive usage, and 
maternal age.
Age should always be considered in an epidemiologic study. 
With most health outcomes, the variation in occurrence by age is 
greater than that found with any other variable. Information 
about the relationship between age and outcome occurrence is 
important for two reasons: first, study of variation in the 
frequency of an outcome with age may assist in understanding the 
factors responsible for its development; second, associations 
between age and the frequency of a health outcome are usually so 
strong that age may produce indirect effects that must be 
considered in interpreting differences in outcome patterns among 
different populations (MacMahon, 1970).
The association of disease frequency with age is usually 
measured by relating the number of cases of the disease in each 
age group to the population in the same age group and deriving a 
succession of age-specific incidence or prevalence rates 
(MacMahon and Pugh, 1990). These rates are useful for 
delineating specific age groups that are most affected or at highest 
risk. Rates for reproductive outcomes for developed countries are 
generally restricted to ages 15 to 44 years. The age may extend to 
49 years for developing countries.
Figure 6.3 shows the strong effect of maternal age on the risk of 
childbearing in Chile, Sri Lanka, Mexico, and France. When 
plotted against age, maternal mortality rates form a J-shaped 
curve. This figure shows that among these four countries, 
childbearing is safest for women in their 20s. Maternal mortality 
rates are highest for older women and young adolescents. This 
same pattern has been observed in countries with greatly differing 
maternal mortality rates and socioeconomic conditions (Rinehart 
et al., 1984; National Research Council, 1989).
Since some outcomes occur more frequently in males and 
others occur more frequently in females, sex should be considered 
in an epidemiologic study. For example, the greater occurrence of 
coronary heart disease in young men than in young women is 
partly explained by sex differences in known risk factors—such as 








Maternal Death Ratesf by Maternal Age
Maternal Age in Years
*  Excludes abortion-related deaths 
(Ttetze, 1977; Rinehart et al., 1984)
obesity—and partly due to possible protection of the female by 
estrogens before menopause (Freidman, 1980). Differences by sex 
can have an important impact on reproductive health outcomes. 
Descriptive studies of reproductive health issues can provide valuable 
information on the differences between men’s and women’s attitudes 
toward contraception, childbearing, and accessibility to health care 
services. Example 6.4 describes a survey that provided valuable 
insights about husbands’ attitudes and behaviors concerning issues 
related to fertility and family planning in Jordan. Any population 
policy related to family planning in Jordan should take these attitudes 




Jordan Husbands9 Fertility Survey
Research Question: What are husband's attitudes and behaviors toward 
family planning and fertility-related issues? How do these attitudes and 
behaviors differ from their wives?
Study Design: The 1985 Jordan Husbands’ Fertility Survey interviewed the 
husbands of women who were currently married when interviewed in the 1983 
Jordan Fertility and Family Health Survey.
Data Collection Methods: The questionnaire consisted of a short household 
screening form and a detailed individual form. The individual husband’s 
questionnaire asked information on marriage background, respondent’s 
background, contraceptive knowledge and attitudes, the wife’s recent fertility 
and birth planning, and the husband’s and wife’s use of contraception. Three 
hundred and thirty interviews were completed from a sample of husbands of 
women interviewed in the 1983 Jordan Fertility Survey.
Results: Nearly 40% of husbands did not believe in using contraception and 
over 50% viewed family size as "up to God." Husbands gave very different 
reasons for not using fertility control (religion) than their wives (want to get 
pregnant). Many wives did not appear to be in control of their fertility 
behavior. Nearly one-third of women who did not want an additional child in 
1983 had a birth between the two surveys.
(Warren et al., 1987)
their efforts on younger males, among whom attitudes were less 
rigid).
Ethnic or racial groups often differ in disease experience. In 
some cases, the differences are genetically determined, such as the 
black-white differences in sickle cell anemia. With other 
outcomes, the explanation may not be so simple, especially when 
racial or ethnic differences are accompanied by differences in 
socioeconomic or environmental factors. A  difference in disease 
occurrence between cultural groups may reflect a difference in risk 
factors, such as common exposure to infectious agents, diet, 
prenatal care, or personal hygiene. Also, access to or acceptability 
of medical care can explain the patterns observed. Nevertheless, 
descriptive studies of disease rates among ethnic, racial, or tribal




subgroups of a single population may be useful for applying specific 
preventive measures and may be particularly helpful in providing 
leads for further epidemiologic study (Fox et al., 1970; Hennekens 
and Buring, 1987).
Overall, in Example 6.5 and Table 6.6, black infants had twice the 
risk of dying in their first year of life as white infants. This gap was 
more pronounced for infants weighing 2,500 grams or more. Part of 
the black-white gap is related to the relatively disadvantaged status of 
blacks in the United States. However, the widespread differences 
between black and white infant mortality across all maternal 
characteristics suggest that there may be other problems, including 
lack of access to effective health care for black infants and pregnant 
black women. Public health strategies should aim to decrease the 
incidence of low birthweight to increase neonatal survival for black 
infants weighing 3,000 grams or more and to increase postneonatal 
survival for all black infants.
Example 6.5
Black-White Differences in Infant Mortality
Research Question: Is there a black-white difference in infant mortality in 
the United States, and if so, does this difference vary by birthweight?
Study Design: The National Infant Mortality Surveillance (NIMS) project for 
the 1980 U.S. birth cohort provided neonatal, postneonatal, and infant 
mortality risks for blacks, whites, and all races in 12 categories of 
birthweights.
Data Collection Methods: Fifty states, New York City, and the District of 
Columbia participated in this national surveillance project. All reporting 
areas linked birth and death certificates for infants who were bom alive in 
1980 and who died within the first year of life in 1980 or 1981. Information 
on all resident births for each state serves as the denominator for infant 
mortality risks. States also provided the number of infant deaths by 
birthweight, age at death, race, and other infant and maternal characteristics.
Results: Neonatal mortality decreased sharply with increasing birthweight up 
to 4,000 grams for both blacks and whites; for all races, neonatal deaths per
1,000 live births decreased from 647.6 for infants weighing 500 to 999 grams 
to 1.4 for infants weighing 3,500 to 3,999 grams (Table 6.6). Black infants 




mortality than whites, whereas heavier black infants had a much higher 
birthweight-specific neonatal mortality. Postneonatal mortality decreased 
with increasing birthweight up to 4,000 grams for all races, although the 
slope was not as steep as for neonatal mortality, postneonatal deaths per
1,000 neonatal survivors decreased from 135.2 for infants weighing 500 to 
999 grams to 1.9 for infants weighing 4,000 to 4,499 grams. Blacks had 
higher postneonatal mortality than whites within all birthweight categories. 
Infant deaths included neonatal deaths and postnatal deaths. The risk of 
infant mortality for blacks (18.9) was 2.0 times the risk for whites (9.3).
(Hogue et al., 1987)__________________________________________________
Marital status appears on medical and civil records almost as 
regularly as age and sex. Marital status (e.g., never married, 
married, widowed) is particularly useful in epidemiologic studies of 
reproductive outcome. For example, studies of breast and cervical 
cancers have shown substantial differences by marital status.
Breast cancer is more apt to develop in single women or women 
who marry late in life, whereas cervical cancer is associated with 
early marriage. Analytic studies based on these observations have 
suggested that cervical cancer is associated with sexual activity at 
an early age and that having a first pregnancy at an early age is 
protective against breast cancer (Freidman, 1980).
Socioeconomic status is not in itself a measurable characteristic, 
but a theoretical concept. It is usually measured indirectly by 
occupation, educational level, income, and other factors. For 
example, the standard socioeconomic variables collected in the 
WFS were the educational attainment of the respondent and her 
partner, their present and childhood places of residence, the 
partner’s occupation and work status, and the employment of the 
respondent both before and after her first marriage (her 
occupation, work status, and place of work) (Singh and Casterline, 
1985). Because social class is often a reliable predictor of health 
experience, classification of persons into groups according to 
socioeconomic characteristics is particularly useful for planning 
health care resource allocations. For example, a marked 
socioeconomic gradient in infant mortality has long been noted.







Infant Mortality Risk, by Birthweight,*
Age at Death, and Race of Single-Delivery Infants Born During 1980,
United States
1,000 1,500 2,000 2,500 3,000 3,500 4,000 4,500g
Race than 500c to 999e to 1.499a to 1.999a to 2.499b to 2.999e to 3.499b to 3.999b to 4.499a or more Total
Blacks 1,000.0 615.6
Neonatal Deaths+per 1,000 Live Births 
131.3 36.1 10.6 3.6 2.4 2.5 2.8 8.7 12.5
Whites 1,000.0 660.8 212.1 61.6 18.3 4.2 1.8 1.3 1.4 3.0 6.2
All races* 1,000.0 647.6 186.5 53.9 16.0 4.0 1.9 1.4 1.5 3.5 7.3
Blacks 157.1
Postneonatal Deaths* per 1,000 Neonatal Survivors 
49.8 24.2 11.6 6.5 4.4 3.2 3.3 4.1 6.5
Whites 115.0 43.7 18.9 9.4 4.4 2.5 1.8 1.7 2.0 3.1
All races* 135.2 45.8 20.7 10.2 4.9 2.9 2.0 1.9 2.2 3.7
Blacks 1,000.0 676.0
Infant Deaths * per 1,000 Live Births 
174.6 59.4 22.1 10.0 6.8 5.7 6.1 12.8 18.9
Whites 1,000.0 699.8 246.5 79.3 27.5 8.5 4 3  3.1 3.1 5.1 9.3
All races* 1,000.0 695.2 223.7 73.5 26.0 8.9 4.8 3.5 3.4 5.7 11.0
*Number of infanta with unknown birthweight were redistributed according to percentage o f infants with known birthweight. 
includes the number of deaths <  28 days per 1,000 live births.
^Includes unknown race and infants of other races.
Ilncludes the number of deaths from 28 days to under one year per 1,000 neonatal survivors.
^Includes the number of deaths <  1 year per 1,000 live births.
Source: National Infant Mortality Surveillance Report.
(Hogue et al., 1987)
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both of living standards and of availability of medical services for 
comparisons between countries and comparisons of areas within 
countries (Freidman, 1980).
Other information can be used to indicate socioeconomic status, 
such as the possession of various household durables (e.g., 
refrigerator, television) and the type of residence (e.g., number of 
rooms, toilet, source of drinking water, electricity). Specific 
socioeconomic indicators must be considered within the individual 
setting, since each society has its own type of economy, cultural 
traditions, and social structure (Singh and Casterline, 1985).
Socioeconomic status is often measured by occupation and work 
status. This information is easy to collect and often appears on 
routinely collected records. Occupation is often categorized by 
type, such as professional or technical, clerical, skilled or unskilled, 
agricultural, and domestic. In developing countries, work status is 
sometimes categorized as working or not working outside the 
home. It may be important to separate collected data according to 
urban or rural status before stratifying by occupation because 
occupation distributions often differ substantially in urban and 
rural areas.
Income may seem a more direct measure of socioeconomic 
status than occupation. However, income data are often not 
readily available or are irrelevant in cultures that barter for 
required goods. Educational level and literacy status are also 
indicators of socioeconomic standing and, like occupation, often 
differ significantly between urban and rural areas. Literacy status 
can be assessed by asking those with minimal schooling whether 
they can read a letter or newspaper (Zimbabwe National Family 
Planning Council, 1985). Information on the occupation and 
educational level of both partners among married couples should 
be collected, since in many societies the occupation or education 
of the husband has a greater effect on the socioeconomic status of 
the family than that of the wife.
Geographic Comparisons
Descriptive characteristics related to place can serve two 
important purposes: they can provide major insights into disease 
etiology (Hennekens and Buring, 1987), and they can provide 
















making (e.g., planning the location and size of medical-care facilities). 
Geographic comparisons of health outcomes can be made at many 
levels—between countries, between regions in a country, between 
regions in a city, or between states, provinces, or counties. For 
example, maternal mortality rates vary substantially among different 
countries (Table 6.7).
International differences should always be interpreted cautiously. 
Countries differ substantially in the reliability of diagnosis, 
completeness of reporting, and validity of population census data.
Any or all of these issues may affect reported estimates, mask real 
differences in the health problem under study, or even show a 
difference where none exists.
Table 6.7
Maternal Mortality and Maternal Deaths as a Proportion o f all 
Deaths o f Women of Reproductive Age, Various Countries
Percentage o f Maternal Mortality
Deaths from Rate per 100,000
Countrv Maternal Causes Live Births Year
Bangladesh (Rural Jamalpur) 46 623 1982-1983
India (Rural Andhra Pradesh) 45 874 1984-1985
Bangladesh (Rural Tangail) 33 566 1982-1983
India (Urban Andhra Pradesh) 28 545 1984-1985
Paraguay 27 275 1984
Bangladesh (Matlab) 26 510 1983
Indonesia (Bali) 23 718 1980-1982
Egypt (Menoufia) 23 190 1981-1983
Egypt (South) 21 300 1984-1985
Ecuador 15 190 1980
Romania 10 149 1984
Mexico 10 88 1984
El Salvador 8 70 1984
Mauritius-Maurice 6 103 1985
Costa Rica 5 26 1983
Cuba 3 45 1983
Japan 1 16 1985
United States 1 8 1983
Hong Kong 1 5 1985
Sweden 0 2 1984
(Royston and Lopez, 1987)
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Example 6.8 provides information about infant mortality and 
maternal risk factors from a survey conducted in northeastern 
Brazil during 1980. As can be seen in the last column of Table 
6.9, children who had never been breast-fed were more likely to 
die in infancy than breast-fed children. However, the association 
between breast-feeding and infant mortality was much stronger in 
rural areas than in urban areas. When the data were stratified 
according to urban and rural status, certain important relationships 
were discovered (Table 6.10). For example, in urban areas, the 
association between infant mortality and breast-feeding was 
weaker.
In rural areas however, not only was infant mortality higher, but 
the association between infant mortality and failure to breast-feed 
was much stronger. In rural areas, the use of both maternal and 
child health services further adjusted the effect. This information 
suggested that for the greatest public health impact in
Example 6.8
Infant Mortality and Breast-Feeding in Northeastern Brazil
Research Question: What is the prevalence of breast-feeding in northeastern 
Brazil, and how does breast-feeding affect infant mortality in this area?
Study Design: The data for this analysis came from the Northeast Brazil 
Family Planning/Maternal Child Health Survey of 1980. Northeastern Brazil 
is the poorest region in Brazil.
Data Collection Methods: This survey covered four of the nine states in the 
northeastern region of Brazil. These four states contain over 20 million 
inhabitants, roughly one-sixth of Brazil’s population. This survey consisted of 
interviews with 7,852 women of all marital statuses between the ages of 15 
and 44. Each respondent was asked about the breast-feeding experience of 
her most recently born child; such information was obtained for 5,190 
children. For children no longer alive at the interview date, women were 
asked the age (in months) at which the child had died. Other social, 
economic, and demographic information was also collected by interview.
Results: Children who had never been breast-fed were almost twice as likely 
to die in infancy as breast-fed children (Table 6.9).








Percentage of Children Dying During First Year of Life,
by Breast-Feeding Status and Selected Variables,
Family Planning/Maternal and Child Health Survey,
Northeastern Brazil, 1980
Not Breast-Fed
Total Breast-Fed Not Breast-Fed -r Breast-Fed
Total 4.9 (3,457) 4.4 (2,674) 6.9 (783) 1.6
Residence
State capitals 1.0 (814) 1.6 (621) 3.1 (193) 1.9
Other urban 5.2 (1,386) 5.1 (1,051) 55  (335) 1.1
Rural 6.1 (1,257) 4.9 (1,002) 11.4 (225) 2.3
Maternal-child health services
No service 6.6 (793) 5.6 (652) 12.2 (141) 2.2
1 service 6.4 (1,127) 5.7 (886) 9 3  (241) 1.6
2 services 2.5 (1,524) 2.4 (1,127) 2.8 (397) 1.2
Note: Figures in parentheses are unweighted numbers of cases.
(Goldberg et al., 1984)
northeastern Brazil, educational efforts to increase breast-feeding 
should be concentrated in rural areas.
When comparing rates in smaller geographic areas, such as 
between villages or townships, it becomes more important to have an 
accurate measure of the population at risk of the health problem. 
When the population at risk (the denominator) is small, morbidity 
and mortality rates become less stable. For example, in a town with
1,000 births per year, there is a substantial difference in the maternal 
mortality rate if there is one maternal death per year or three 
maternal deaths per year (Hogue et al., 1985). In an area with a 
large population at risk, three maternal deaths would not significantly 
alter rates.
A geographic association can be explained in many ways. Different 
geographic areas can vary by climate, geology, socioeconomic 
conditions, nutrition, and culture. Geographic areas can also differ in 
the quality and availability of medical services, the attitude of the
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Table 6.10
Percentage of Children Dying During First Year of Life, 
by Breast-Feeding Status, Residence, and Selected 
Variables, Family Planning/Maternal and Child Health 
Survey, Northeastern Brazil, 1980
Urban Rural
Not Not Breast-Fed 
Breast-Fed Breast-Fed +  Breast-Fed
Not Not Breast-Fed 
Breast-Fed Breast-Fed +  Breast-Fed
Total 4.0 (1,665) 4.8 (526) 1.2 4.9 (1,009) 11.3 (157) 2.3
Mother’s education 
No school 5.5 (397) 6.0 (113) 1.1 5.6 (483) 17.4 (107) 3.1
<  Completed
primary 5.8 (493) 5.8 (132) 1.0 5.2 (483) 7.9 ( 89) 1.5
¿C om pleted 
primary 1.9 (281) 3.7 (281) 1.9 1.5 (158) 2 .9 (61 ) 1.9
Mother’s work status 
Currently
employed 4.4 (467) 7.0 (140) 1.6 8.3 (303) 23.6 ( 76) 2.8
Not currently
employed 3.8 (1,195) 4.0 (383) 1.1 3.5 (702) 6.5 (180) 1.9
Maternal Health Services 
No service 7.8 (235) 9 .6 (5 7 ) 1.2 4.4 (417) 13.7(84) 3.1
1 service 5.8 (500) 7.1 (140) 1.2 5.6 (386) 13.1 (101) 2.3
2 services 1.8 (928) 2.7 (328) 1.5 5.4 (199) 3 .5 (6 9 ) 0.6
Note: Figures in parentheses are unweighted numbers o f cases. 
(Goldberg et al., 1984)
different segments of the population toward these services, and the 
quality of the medical and vital statistics (Lilienfeld et al., 1967).
K there is a demonstrated association between the health problem 
and place, the following reasons should be considered: 1) the 
inhabitants of the particular place possess characteristics of 
etiologic importance to the development of the outcome that differ 
from such characteristics of inhabitants of other places (e.g., age 
distribution, ethnic differences, cultural practices, diet); 2) there 
are etiologic factors present in the biologic, chemical, and physical 
environment of the people inhabiting the affected places (e.g., 








species); 3) there are differences in the availability of medical care; 
and 4) there are differences in the reporting of medical and vital 
statistics (MacMahon and Pugh, 1970).
Temporal Comparisons
Descriptive studies of disease occurrence by time are useful for 
suggesting possible etiologic hypotheses and for planning future trends 
in medical needs. These changes over time, or temporal trends, have 
been useful to reproductive epidemiology in the study of such diverse 
outcomes as infant mortality, ectopic pregnancy, and teenage 
pregnancy. Three major kinds of temporal change can be identified: 
short-term fluctuations (e.g., weeks in an epidemic), cyclic changes 
(e.g., seasonal changes), and secular trends (e.g., changes over many 
years).
Short-term changes or fluctuations in disease rates are measured in 
hours, days, weeks, or months. These are most often observed in the 
study of infectious disease epidemics or foodborne outbreaks. 
Examples include brief bacterial contaminations of water supplies, 
acute air pollution episodes resulting in epidemics of asthmatic 
attacks and increases in the daily number of deaths, or foodborne 
outbreaks due to bacterial or chemical contamination (Fox et al., 
1970).
The incidence of some diseases shows cyclical or regular recurring 
increases and decreases. The pattern may exhibit cycles that last 
several years or occur annually and represent seasonal variation in 
disease occurrence (Freidman, 1980). Although seasonal fluctuations 
are most often associated with infectious diseases, reproductive 
outcomes also show cyclic changes. For example, there is a persistent 
seasonal pattern in the United States in the average daily number of 
live births, and presumably also in conception rates (National Center 
for Health Statistics, 1966). For diseases of early life, variation in risk 
by season of birth may suggest environmental factors operating during 
intrauterine or very early postnatal life (MacMahon and Pugh, 1970). 
In reproductive epidemiology, examining secular or long-term trends, 
or changes in frequency that take place over years or decades, can be 
particularly useful. For example, an interesting secular trend is the 
change in age at menarche between 1840 and 1970 (Figure 6.11). In 
Figure 6.11, changes in nutrition probably account for the striking 













(Tanner, 1973) Calendar Year
A major source of information on secular trends has been death 
certificate data. Variations in death rates over time are most 
informative if they can be shown to reflect real changes in 
incidence rates. However, several other factors can be responsible 
for a change in death rates over time. These include:
• Improved medical techniques resulting in improved diagnoses 










• Medical care becoming available to larger segments of 
populations and to outlying areas and increasing recognition of 
disease or health problems.
• Changes in rules and procedures for recording causes of deaths.
• Changes in the collection of vital statistics data (e.g., greater 
coverage in remote areas and greater accuracy in recording).
• Changes in the availability and accuracy of population size 
estimates.
• Changes in populations at risk (e.g., a population is composed of 
persons at different ages, and the age distribution is likely to 
change as time passes).
However, only one-third of the world’s population live in countries 
where the registration of births and deaths is reasonably complete and 
the certification of causes of death is reasonably reliable (Royston and 
Lopez, 1987). In many areas, periodic surveys may be the only 
practical method to measure secular changes. For example, the 
potential of surveys for studying reproductive health has been 
demonstrated on an international scale with the WFS and the 
Contraceptive Prevalence Surveys. Both promote a series of surveys 
in a large number of countries and use comparable survey 
methodology and content. These programs have provided substantial 
information on comparative contraceptive-use patterns over time 
(Hermalin and Entwisle, 1982). Example 6.12 illustrates the use of 
repeated surveys to measure long-term trends.
Table 6.13 presents estimates of total fertility rates (TFR) and 
age-specific fertility rates (ASFR) in Jordan. These data indicate that 
total fertility in Jordan fell from 7.7 to 6.6 lifetime births per women 
between 1976 and 1983. The most pronounced decrease in fertility 
occurred among younger women; for example, the fertility rate for 20- 
to 24-year-olds decreased by 34 percent, from 344 births per 1,000 
women during the period 1971 to 1975 to 228 per 1,000 by 1983. 
Among women who were at least 40 years old, there were no declines 
in fertility.
Fertility rates in Jordan between 1976 and 1983 declined somewhat 
(Table 6.13). However, the approximately seven lifetime births per
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Example 6.12 
Fertility Trends in Jordan
Research Question: What are the fertility trends and determinants in Jordan? 
Study Design: Household surveys
Data Collection Methods: Fertility estimates were based on several surveys: 
the 1976 Jordan National Fertility Survey, the 1979 Jordan Fertility Survey, 
the 1981 Jordan Demographic Survey, the 1982 Jordan Manpower Survey, and 
the 1983 Jordan Fertility and Family Health Survey. The 1983 survey sampled 
6,068 housing units from the East Bank area of Jordan. The questionnaire 
consisted of a household form and an individual questionnaire administered to 
all ever-married women living in the household. The individual questionnaire 
included questions on the health and immunization status of all children in 
the household, on infant feeding practices, on the use of maternal and infant 
health services and family planning.
Results:
Table 6.13
Total Fertility Rate and Age-Specific Fertility 
Rates per 1,000 Women
Rfltç 1976 197? 1981 1983
TFR 7.7 7.5 7.1 . 6.6 6.6
ASFR (years)
15-19 133 66 87 40 49
20-24 344 280 252 219 228
25-29 358 361 340 332 335
30-34 336 331 316 321 305
35-39 245 262 239 245 233
40-44 104 141 134 117 127
45-49 11 50 49 45 40
Period 1971- 1978- 1979- 1981- 1980-
covered 1975 1979 1981 1982 1983
(Anderson et al., 1985)
Descriptive Studies
woman still represents a very high level of fertility. Further analyses 
suggested that Jordan’s fertility decline was mainly due to later 
marriage, not to increased contraceptive use. Because there is 
probably a limit to the effect that changes in age at marriage can have 
on fertility decline, improved contraceptive practice is the factor most 
likely to bring about greater fertility reduction. Besides reducing the 
high rate of population growth, higher levels of contraceptive use will 
also benefit women’s and infants’ health by increasing the duration of 
intervals between births. Additionally, Jordanian women, on average, 
gave birth approximately two years (26.7 months) after a previous 
birth (Table 6.14). The average interval increased with age, and 
women living in urban areas had longer intervals between births than 
women living in rural areas.
Table 6.14
Mean Interval Between Live Births in the Five 
Years Preceding Interview and Length of Interval in Which 
25%, 50%, and 75% of Jordanian Women Had Their Next Birth, by 





(months) 25% 50% 75%
No. of 
Intervals
Total 26.7 18.1 24.9 38.9 5,755
Age (years)
15-19 21.4 15.3 22.4 25.3 144
20-24 21.6 15.5 21.7 215 1,003
25-29 24.0 16.2 23.7 32.3 1,467
30-34 25.9 18.5 24.4 36.3 1,154
35-39 31.3 21.8 29.1 45.5 1,129
40-49 39.7 23.9 36.2 t 858
Residence
Urban 28.4 18.1 25.8 43.7 3,839
Rural 25.2 18.2 24.2 34.1 1,916
* Weighted average of the length of the interval based on the 25th, 50th, and 
75th percentiles.
+ By the time of interview, fewer than 75% of 40- to 49-year-olds who gave 
birth in the preceding five years had another child. An estimated value for 
the 75th percentile was used to calculate the trimean for 40- to 49-year-olds,




Epidemiologic surveillance is the ongoing systematic collection, 
analysis, and interpretation of health data essential to planning, 
implementing and evaluating public health practice (Centers for 
Disease Control, 1986). A surveillance system is a series of 
descriptive studies over time that provides useful long-term 
descriptive information for planning and evaluating health services 
for a given population. A  surveillance system can also provide 
information to evaluate the feasibility of conducting a particular 
analytic study. For example, in a case-control study of oral 
contraception and liver cancer, one needs to know whether there 
is a sufficient number of histologically diagnosed liver cancer cases 
in age groups that are likely to have used oral contraceptives. 
Accurate surveillance systems are expensive and complicated and 
have been instituted in only a few countries. Efforts to establish 
surveillance systems in less developed areas will inevitably be 
accompanied by changes in the coverage and quality of diagnostic 
services. When surveillance systems are established, it will be 
important to consider whether observed changes in rates simply 
reflect changes in the availability of diagnostic services (Lilienfeld 
et al., 1967).
Sources and Methods of Collecting Data
Data for descriptive studies can be derived from existing 
systems, such as the vital statistics records systems, or can be 
collected from health surveys. As mentioned previously, most 
countries do not have vital record systems that are complete and 
accurate (Royston and Lopez, 1987). Consequently, other sources 
of information may have to be used, including health interview 
surveys, medical records from hospital or clinic files, medical 
ledgers or logs, and direct observations or measurements (e.g., 
physical examinations, anthropometric measurements).
Health interview surveys are especially valuable for countries 
that do not have established systems for recording morbidity and 
mortality and that have a high prevalence of the health problem 
under study. Health interview surveys also permit the collection of 









the health problem under study in relation to person, place, and time. 
The types of data available for study and the methods of collection 
usually depend on the available resources and the extent of the 
problem.
Descriptive studies of maternal or infant mortality, for example, 
use various sources of data to estimate the extent of the problem and 
to describe relevant associations. Example 6.15 illustrates the use of 
a survey to collect information about maternal mortality in rural 
Bangladesh. The overall maternal mortality rate was 62.3 per 10,000 
live births and accounted for 46.0 percent of all deaths to women of 
reproductive age (Table 6.16). Maternal mortality rates were lowest 
among women aged 20 to 24 years and increased substantially with 
increasing age (Table 6.16).
Example 6.15 
Maternal Mortality in Rural Bangladesh
Research Question: What is the rate and pattern of maternal mortality in rural 
Bangladesh?
Study Design: Household survey
Data Collection Methods: The study was conducted in two rural areas of the 
Jamalpur district in Bangladesh. The two areas comprised 240 villages with a 
population of about 267,000. The study employed 109 combined traditional 
birth attendants on a part-time basis as the primary reporters of births and 
maternal deaths in their study area; each attendant covered an average of two 
villages with a total population of about 2^00. The birth attendants were 
required to visit their areas once every 2 weeks to collect information on 
maternal deaths, live births, and neonatal deaths. Because the birth attendants 
were generally illiterate or semiliterate, the collected mortality information was 
reported verbally to literate supervisors, who recorded their findings. In a 
second step, the supervisors routinely visited all houses where the birth 
attendants had reported a maternal death. During the follow-up visit, the 
supervisors interviewed the family or close relatives of the deceased woman to 
collect additional information on the woman's health and the circumstances 
surrounding her death. To ensure complete reporting, all deaths among women 
of reproductive ages were reviewed to identify the cause of death. Menstrual 
status immediately prior to death was also recorded to identify possible cases 
of induced abortion performed early in pregnancy. A  single one-page form 




relation to pregnancy termination or childbirth, and medical care received by 
the woman before death. Data were collccted for a period of 12 months from 
September 1982 to August 1983.
Data Analysis: The maternal mortality rate was calculated in this example as 
the number of deaths of any woman of any cause while pregnant or within 42 
days of termination of pregnancy, irrespective of the duration or site of 
pregnancy, per 10,000 live births (Table 6.16).
(Khan et al., 1986)
Table 6.16
Number of Total Births, Live Births, and Deaths Among 
Women of Reproductive Age (WRA) and Maternal Deaths, 
by Mother’s Age, 1982-1983
Maternal Deaths Maternal Deaths
Maternal Total Live Deaths Maternal as « % of WRA per 10,000
Ace (Years) Births Births to WRA Deaths Deaths Live Births
<20 1,827 1,744 27 10 37.0 573
20-24 3,118 3,006 17 8 47.1 26.6
25-29 2,435 2337 22 11 50.0 47.1
30-34 1,255 1,221 14 9 643 73.7
35-39 767 729 16 13 813 1783
40+ 309 280 30 7 233 250.0
Total 9,711 9,317 126 58 46.0 623
(Khan et al., 1986)
Data on maternal deaths are often obtained from vital records 
or from hospital record abstractions (Rochat, 1987). However, not 
only are vital record systems in many countries incomplete, but 
certification of the cause of death is rarely reliable (Royston and 
Lopez, 1987). Hospital data are commonly used as an alternative 
to death registration data for estimating the maternal mortality 
rate. However, hospital rates may not be representative of the 





hospital. Data for women who deliver in a hospital may include a 
higher proportion of high-risk women (e.g., the rate will be inflated if 
women who intend to deliver at home are transported to the hospital 
for emergency care). Conversely, if the hospital is fee-paying, it will 
attract economically advantaged women; the measured maternal 
mortality rate may thus be lower than that prevailing in the 
community. However, hospital-based studies can give valuable 
cause-of-death information that can suggest specific interventions 
(Royston and Lopez, 1987).
Consider Example 6.17. Of the 36 maternal deaths following 
cesarean sections, only 27 had case records available for review. The 
probable causes of death for these 27 cases are presented in Table 
6.18. Maternal sepsis was responsible for 81.5% of the maternal 
deaths after cesarean section. Examination of the data according to 
time of death revealed that the majority of patients dying from sepsis 
(40.8%) did so between the second and fourth day after cesarean 
section.
Example 6.17
Characteristics of Maternal Deaths 
Following Cesarean Section
Research Question: What are the causes of maternal mortality after cesarean 
section in the University of Ilorin Teaching Hospital, Nigeria?
Study Design: Hospital record abstractions
Data Collection Methods: The University of Ilorin Teaching Hospital serves 
as a referral center for Kwara State, in the middle belt of Nigeria. Data were 
obtained from hospital records covering a five-year period from 1982 to 1986.
Results: During the five-year study period, of 48,974 deliveries, 1,992 were by 
cesarean section. The total number of maternal deaths was 125, with 36 
deaths following cesarean section (Table 6.18). The fatality rate for cesarean 
section was thus 18.1 per 1,000 deliveries. The total number of vaginal 
deliveries was 46,982 with 89 maternal deaths—a fatality rate of 1.89 per 1,000 
deliveries.
(Ojo et al., 1988)
226
Table 6.18
Probable Cause of Maternal Death After Cesarean Section,
Cause
by Time of Death
Time of Death 
iDavs After Delivery) Number (%)




















(Ojo et al., 1988)
The high maternal mortality after cesarean section reported in 
this study reflects the general pattern seen in developing countries. 
Reasons cited for the higher mortality rates included delays in 
admission (i.e., doctors live at a long distance from the hospital, 
and there are no telephone facilities for immediate summons of 
doctors; also, patients seek medical care late in labor) and the 
failure to use prophylactic antibiotics (some patients were not on 
antibiotics until the third postoperative day). Recommendations to 




department policy for the management of high-risk patients 
(especially in the early stages of labor), appropriately using 
prophylactic antibiotics, and educating traditional birth attendants to 
recognize the need for early referral of high-risk pregnancies.
Finally, other approaches to data collection for studying maternal 
and infant mortality include careful investigation of causes of death 
among all women of reproductive age and prospective surveillance of 
pregnant women and pregnancy outcomes. These options may be 
feasible only where the prevalence of maternal or infant mortality is 
high.
Advantages and Disadvantages of 
Descriptive Studies
Descriptive studies may be the most frequently conducted type of 
epidemiologic study (Hennekens and Buring, 1987). The advantages 
for conducting descriptive studies include the following:
• They are generally easy to conduct.
• They are less expensive to conduct than other epidemiologic 
study designs.
• They can reveal patterns of disease occurrence and trends over 
time.
• They permit the collection of information on important potential 
risk factors, such as age, race, sex, and geographic location. 
These data may be used to compare prevalence and to develop 
hypotheses for future analytic studies.
• They provide a basis for planning, providing, and evaluating 
health services for a given population.
• They raise few ethical problems.
The disadvantages of descriptive studies include the following:
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• They do not test etiologic hypotheses. There is no formal 
comparison group and therefore no valid method to assess 
whether the study prevalence is greater or less than would be 
expected.
• The temporal relationship between the health problem under 
study and potential exposures cannot be easily determined. 
This fact plus the lack of a formal comparison group 
prohibits the assessment of causality. The evaluation of 
causality requires analytic study designs, such as experimental 





1. Circle true (T) or false (F).
(a) T /F  Descriptive studies provide information to administrators on patterns
of disease occurrence.
(b) T /F  Descriptive studies are designed to test epidemiologic hypotheses.
(c) T /F  Descriptive studies may tell epidemiologists who is affected.
(d) T /F  Information from descriptive studies provides clues for generating
hypotheses.
(e) T /F  Descriptive studies provide useful comparison data through use of
control groups.
(f) T /F  Descriptive studies help target specific population subgroups most
likely to be affected by disease.
(g) T /F  Descriptive studies are easy to conduct but relatively expensive.
(h) T /F  Descriptive studies provide a basis for planning, providing, and
evaluating health services to a population.
(i) T /F  Descriptive studies provide a way of determining whether prevalence
is greater or less than expected.
(j) T /F  Descriptive studies can be used to evaluate trends over time.
(k) T /F  Causality cannot be determined by descriptive studies because there 
is no formal comparison group.
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2. Multiple Choice. Select one response.














2.3 Of the choices given in Question 2.2, which almost always 
accounts for more variation than any other characteristic?_________
2.4 All of the following are types of geographic comparisons except:
(a) Between countries
(b) Between states or provinces
(c) Among socioeconomic groups
(d) Among regions in a city
(e) Urban versus rural areas





(d) Availability of care
(e) Reporting of statistics
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2.6 Changes in all the following may explain changes over time in death rates 
except:
(a) Quality of diagnosis
(b) Accuracy of records




3. Matching. Match the study with the type of temporal change by filling in a 




3.1 __  Asthma attacks caused by air pollution
3.2 __  Bacterial contamination of water
3.3 __  High risk of retardation among children bom  in February
3.4 __  Decrease in menarche age over the past 30 years in Europe
3.5 __  Foodbome outbreaks due to bacterial contamination
3.6 __  Seasonal pattern of average daily number of births
4. Consider the data in Table 6.19.
Table 6.19
Percentage of Maternal Deaths,
by Category and Specific Cause of Death, 1982-1983
Category and Cause Percentage (and Number)
of Death of Maternal Deaths







Category and Cause Percentage (and Number)






Septic abortion 20.7 (12)
Postpartum 103 (6)
Difficult labor 17.2 (10)
Obstructed 103 (6)
Retained placenta 6.9 (4)
indirect obstetric 13.8 (8)
Cardiovascular 8.6 (5)
Suicide 1.7 (1)
Not diagnosed 3.5 (2)
All causes 100.0 (58)
Note: Percentage subtotals and total do not agree because of rounding. 
(Khan et al., 1986)
(a) What were the most common causes of death?
(b) How many and what percentage of deaths were due to difficult labor?
(c) What specific actions can be taken to reduce the levels of maternal 
mortality?
Descriptive Studies
5. Consider Table 6.20 from a study of contraceptive procedures performed in 
the People’s Republic of China during 1971 to 1977.
Table 6.20
Birth-Planning Operations in the 
People’s Republic of China, 1971-1977*
IUD Sterilizations Induced
Year Insertions Female Male Abortions Total
1971 6,173 1,745 1,224 3,910 13,052
1972 9,220 2,087 1,716 4,814 17,837
1973 13,950 2,956 1,933 5,110 23,949
1974 12,580 2,276 1,445 4,985 21,286
1975 16,744 3,260 2,653 5,084 27,741
1976 11,620 2,700 1,490 6,570 22,380
1977 12,974 2,776 2,616 5,229 23,595
*In thousands
(Chen and Kols, 1982; Zhang, 1980)
(a) Describe the comparison groups.




(c) What are some reasons for the trends in contraception that are exhibited 
in the data?
6. Consider the data summarized in Figure 6.21, from a study of maternal 
mortality conducted in Bangladesh during 1968 through 1970.
 ,
Figure 6.21
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(a) Describe the comparison groups.
(b) Summarize the information provided in Figure 6.21.




7. Consider the contraceptive use data summarized by survey year and urban- 
rural residence in Table 6.22.
Table 6.22
Percentage of Currently Married Women 
Aged 15-49, by Current Contraceptive Use Status and Residence
Contraceptive 1976 1983
Use Status Total Urban Rural Total Urban Rural
Currently using 22.8 293 7.0 26.0 31.7 123
Pill 11.9 15.4 3.8 7.8 9.2 4.4
IUD 2.0 2.7 03 8.3 0.9 2.1
Sterilization 1.9 22 12 3.8 4.2 2.7
Rhythm 2.1 2& 0J 2.9 3.4 1.6
Withdrawal 33 43 1.0 2.4 2.8 1.4
Condom 1.4 1.9 02 0.6 0.8 0.2
Injectable NA* NA* NA* 0.2 0.3 0.0
Other 0.1 02 0.0 0.1 0.1 0.0
Not using T12 70 5 93.0 74.0 68.4 87.7
Total
•Not applicable 
(Anderson et al., 1985)
100.0 100.0 100.0 100.0 100.0 100.0
(a) Describe the comparison groups.
(b) Summarize the information provided in Table 6.22.
(c) What are some possible explanations for the observed geographical 
differences in contraceptive use?
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Suggested Answers to Practice Exercises
1. True or false.
(a) T Introduction
(b) F Introduction. No, analytic studies such as experimental studies,




(e) F Introduction. No, descriptive studies do not have a formal
comparison group.
(f) T Introduction
(g) F Advantages #1  and #2
(h) T Introduction
(i) F Introduction and Disadvantage #1. Descriptive studies cannot assess
whether the study prevalences is greater or less than would be 
expected. However, descriptive studies permit comparisons between 
subgroup populations.
(j) T Advantage #3
(k) T Disadvantage #1
2. Multiple choice.
2.1 a Types of Descriptive Studies
2.2 e Types of Descriptive Studies
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2.3 Age Population Subgroup Comparisons
2.4 c Geographic Comparisons
2.5 b Geographic Comparisons








4. Consider data in Table 6.19.
(a) The most common causes of death were sepsis and eclampsia.
(b) Ten deaths (17.2%) were due to difficult labor.
(c) More than one-fifth of all maternal deaths in this study were due to 
septic abortion. In most cases the abortion was induced by indigenous 
practitioners using unsanitary and unscientific procedures leading to 
infection and death. Wider availability of safe fertility regulation services 
can substantially reduce the level of maternal mortality. Deaths from 
postpartum sepsis can be prevented with the provision of aseptic birth 
care services and antibiotics. Deaths caused by difficult labor, 
hemorrhage, and toxemia can be prevented by timely management and 
referral to the nearest health care facility. Only 4 out of 51 mothers 
were admitted to an institutional facility before death. Since more than
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95% of all deliveries in rural areas take place at home and are mostly 
managed by traditional birth attendants, appropriate training of the 
attendants to recognize high-risk cases for timely referral to clinical 
facilities would be a practical preventive measure. Moreover, providing 
women with available contraceptive methods and educational programs 
on the advantages of limiting and spacing births through the practice of 
contraception could help reduce the number of women at risk of 
maternal mortality.
5. Consider data from Table 620.
(a) The numbers and types of birth planning procedures performed in China 
during 1971 to 1977 are compared.
(b) In general, the number of birth-planning procedures performed in China 
during 1971 to 1977 increased from the lowest counts in 1971 to the 
highest counts during 1975. The IUD was the most frequently used 
birth-planning operation in China, outnumbering sterilizations and 
induced abortions two to one.
(c) In general, three factors affect the availability and use of various 
contraceptive procedures: political/legal, religious, and cultural. The 
Chinese government has actively supported contraceptive services and 
emphasized low-cost, highly effective methods such as the IUD and 
sterilization. Their comprehensive policy reduced the birthrate from 34 
per 1,000 in 1970 to 18 in 1979. Although difficult to quantify, cultural 
factors and religious prohibitions both have important effects on 
contraceptive use. For example, the acceptance of vasectomy is low in 
areas of the world where women are presumed to have greater 
responsibility for contraception than men.
6. Consider the data in Figure 6.21.
(a) Maternal death rates are examined according to birth order.
(b) In Matlab, Bangladesh, during 1968 through 1970, there was an 
increasing risk of maternal death with increasing birth order. The 
number of maternal deaths per 100,000 live births was lowest for mothers
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delivering their second or third infant; the maternal death rate increased 
to approximately 750 deaths per 100,000 live births among women 
delivering at least their eighth infant.
(c) One should always consider the effects of age when interpreting disease 
or reproductive health outcomes. Women who are delivering their eighth 
infant will, as a group, be older than women delivering their second or 
third infant. Because maternal mortality increases with age, some of the 
association between maternal deaths and birth order is probably age 
related.
7. Consider data in Table 6.22.
(a) Current methods of contraception among currently married women aged 
15 to 49 years are described according to year of survey and urban or 
rural residence status.
(b) For most methods of contraception, usage is higher in urban areas than 
in rural areas. In 1976, contraceptive use in urban areas was more than 
4 times greater than in rural areas; by 1983, the difference was reduced, 
and contraceptive use was only 2.5 times higher. In 1976, women used 
the pill more than 4 times more frequently than other methods. By 1983, 
the percentage of women using the IUD was slightly greater than the 
percentage using the pill.
(c) One possible explanation for the observed differences between 
contraceptive use in urban versus rural settings is access to medical care. 
If health services that dispense contraceptive services are unavailable in 
specific areas, or if women have to travel long distances to receive 
contraceptive services, levels of use may be lower. Other explanations 
might include socioeconomic reasons (pill prescriptions and IUD 
insertions are expensive), local culture (some subgroups of the population 
may desire more children), and education (some subgroups of the 
population may not know about specific methods of contraception or how 
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Chapter 7 - Learning Objectives
After completing this chapter you should be able to:




primary sampling unit (PSU)












2. Recognize general principles guiding sample design.
3. Recognize when the principle of self-weighting may be ignored.
4. Identify factors influencing sample size.
5. Order the steps in carrying out sampling operations.
6. Identify advantages and disadvantages of using a preexisting sample.
7. Identify factors influencing size of clusters.
8. Identify advantages and disadvantages of listing and segmentation and their 
alternatives.
9. Identify safeguards to prevent biased selection of sample segments and dwellings.
10. Specify how to estimate the number of households needed in a survey.
11. Recognize the importance of documenting the sample.
12. Recognize how to introduce weights into an analysis.
13. Carry out a systematic sampling procedure.
14. Recognize how to use weights to:
compensate for unequal selection probabilities 
compensate for nonresponse
compensate for a difference between the distribution in the sample and the 
population distribution of a characteristic.
15. Recognize the impact of disproportionate sampling.
16. Recognize when weighting is necessary.
17. Carry out PPS interval-based selection.
18. Identify ways to reduce coverage error.
19. Recognize what may be done when coverage must be restricted.




This chapter presents guidelines and general recommendations 
for designing samples, using sampling frames, weighting, and 
implementing sampling plans. When possible, a survey statistician, 
or someone experienced in survey design, should be involved in 
planning and executing a sample survey.
This chapter specifically addresses sampling issues in surveys, 
but much of the information can be generalized to other types of 
data collection activities, such as abstracting medical records or 
sampling hospital discharge and physician office records. Its focus 
is primarily on multistage household-based surveys in which 
households or residences are selected, and in which respondents 
from these residences are chosen for the survey. The methodology 
is also applicable, with some modifications, to surveys based on the 
selection of individuals from other populations (e.g., schools or 
clinics, instead of households). The methodology can be applied 
to innumerable types of populations (i.e., infants, women of 
reproductive age, agricultural workers), as long as the researcher 
has adequate information on the population of interest to select a 
representative sample of that population.
General Principles of Sampling Design
Sample design for cross-sectional and descriptive surveys should 
be guided by several general principles, although some 
modifications of these principles may be required in specific 
situations. First, scientific probability sampling must be used. A 
probability sample is a sample in which all members of the 
population of interest have some known probability of selection 
and in which this probability is greater than zero. A 
nonprobability sample, on the other hand, is one in which 
probabilities of selection are unknown or, for some population 

















information intended to be representative of an entire population 
would in fact be collected only from clinic attendees or people visiting 
the local marketplace. Clearly such samples may differ in important 
ways from the population as a whole. Nonprobability methods are 
often less expensive and easier to use than probability samples, but 
they should be avoided because the quality of the estimates obtained 
from a nonprobability sample is usually impossible to determine. 
Certainly, nonprobability methods cannot provide the confidence 
necessary to adequately explain unexpected findings. The use of 
nonprobability methods may also lead to criticism of the survey design 
when unexpected findings occur.
Second, samples should be self-weighting unless there is good 
reason to depart from this approach. A self-weighting sample is one 
in which no component of the population intentionally makes up a 
larger or smaller proportion of the total sample than its proportion of 
the population. Samples that are not self-weighting require the 
computation of weights to make the sample representative of the 
population. Computing weights can be an appreciable burden. The 
investigator must carry them as part of the data base, assess when and 
how they should be applied to statistical tests on weighted data, and 
correctly report their use. Alternatively, these considerations may be 
counterbalanced by certain advantages of adopting unequal sample 
weights in some circumstances.
Third, if an adequate preexisting sampling frame is available, it 
should be used. Integrating study activities with other survey activities 
is economical and helps in the coordination of survey activities.
Fourth, the sample design should be as simple and straightforward 
as possible to facilitate planning and data collection and to simplify 
analyses.
In the following sections, general recommendations are presented 
for a number of specific aspects of sample design. In the first part of 
the chapter, technical issues are treated briefly. The second part 
presents these issues in greater detail and includes a number of 
examples.
Sample Size
The determination of sample size involves both technical and 
practical decisions. The larger the sample the more elaborate and 
detailed are the analyses that can be sustained. The choice of
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sample size involves balancing the demands of analysis against the 
capability for data collection, funding, and resource constraints.
Larger samples are more difficult to manage and supervise. If 
the fieldwork period cannot be extended, and if survey resources 
are limited, inflated sample sizes should be avoided.
As the number of subpopulations or strata for which stable 
estimates are required increases, so does the overall required 
sample size. If any of the objectives of the survey include the 
study of rare events, the sample size may have to be increased.
For instance, the size of a sample may have to be increased for an 
analysis of mortality of a population with low mortality rates or for 
a characterization of individuals who exhibit an unusual condition. 
The size requirements of a sample also increase if a  primary goal 
of the survey is to detect whether a statistically significant change 
in a parameter has occurred over time.
Various factors may affect sample size. First, the key variables 
must be considered. If the survey is a multipurpose one, as most 
cross-sectional surveys are, no simple formula can be used to 
determine the optimum sample size.
One suggestion for designing multipurpose surveys is to base 
sample size calculations on the key variables that require the 
largest sample and to use a preliminary estimate for the expected 
level of that variable in the population to be sampled. When 
sample size is based on the expected occurrence of a particular 
variable, standard sample size formulas can be used.
Basic Sample Design
Most population-based surveys employ a multistage design. In 
a typical survey, geographic areas are selected first, then 
households are chosen within the selected geographic areas, and 
finally individual respondents are chosen from the selected 
households. At each stage the selection procedures can differ 
greatly from each other, and each stage has different potential 
problems and considerations.
Sampling Frames
























survey personnel must have a valid sampling frame—a recent 
compilation of population sizes, numbers of households, or other 
appropriate units for all subareas constituting the geographic area(s) 
to be included in the study. Most countries possess convenient area 
sampling frames in the form of the enumeration or census districts 
(EDs) from the most recent population census. Sketch maps and 
population size estimates are often available for the EDs. In most 
countries, EDs do not vary greatly in population size. However, many 
developing countries have no satisfactory lists of dwellings, 
households, or individuals, and no address system outside the more 
affluent parts of cities. In general, survey personnel have to make 
their own lists or maps. Sometimes these lists or maps can be 
obtained from other surveys or by selecting a subsample from a 
master sample. If EDs do not exist or if they are not suitable as a 
sampling frame, other frames, such as populations for administrative 
districts or records from government agencies and service providers, 
may be available.
Once an adequate sampling frame has been obtained, sampling 
may begin. In the first stage, primary sampling units (PSUs), which 
are usually EDs or other suitably small geographic or administrative 
units, are selected. Selection is usually done with probability 
proportional to size (PPS)—the probability of selecting a given unit is 
determined by its proportion of the entire population under study.
For example, a unit that is twice the size of another unit has twice the 
probability of being selected as the smaller unit. PPS selection 
ensures that every individual unit (people or households) within the 
population has an equal probability of selection. Examples of how 
PPS sampling is implemented are presented in the second part of this 
chapter.
PSUs (most often census EDs) are often too large (typically 1,000-
2,000 persons) to be economically feasible for survey personnel to list 
all households in the sample of PSUs. The survey personnel, 
therefore, must often segment PSUs into smaller areas before 
households are listed and selected. In many cases, the census maps 
are not accurate enough for segmentation to be done in the office. A 




A preexisting sample can be used only when the investigators 
are confident that it was well designed and that it meets the needs 
of the new survey. The investigators must also be aware of the 
weighting and stratification procedures used in the preexisting 
sample or of any unconventional sampling procedures that may 
result in a different number of interviews than are needed for the 
survey. The survey statistician must design a subsampling 
procedure (i.e., sampling from the preexisting sample) that 
produces a suitable sample for the survey. Although this will not 
always be possible, investigators are afforded more flexibility in 
developing a subsample design when the parent sample is larger 
than the desired subsample.
The decision to use a preexisting sample depends on whether 
the listing of dwellings, households, or other appropriate units is 
relatively current or whether it needs to be updated. If updating is 
required, the use of a preexisting sample may not be worthwhile.
Using a preexisting sample has two potential advantages: 
economy and increased analytic power through cross-analysis of 
two or more surveys. The disadvantages are adapting the sample 
to survey requirements and repeating interviews with the same 
households or individuals, which can result in respondent fatigue 
and contamination—answers to follow-up interviews are influenced 
by answers given in the first survey.
Often, investigators can use all but the final stage of sampling 
(selection of households or individuals) from a preexisting sample. 
Then a new cluster of households can be selected from the PSUs 
selected in the first survey. This eliminates any problems that 
might result from selecting the same households in both surveys.
Stratification
Stratification consists of dividing the population into mutually 
exclusive groups or strata according to some key variable or 
characteristic and then selecting separate samples for each 
stratum. Samples are commonly stratified according to factors 
such as sex, place of residence (urban or rural), or regions of a 
country. In Table 7.1, to study the relationship between maternal 







used birth certificate data (birthweight and race) to stratify infants 
who were bom  in State A in 1990. A simple random sample (n = 
400) was selected within each stratum, except for the stratum of birth 
certificates with unknown birthweights. Because the frequency of 
certificates with unknown birthweight was low, the investigators 
included in the sample all certificates with unknown birthweight. The 
overall sample size was 1,765 birth certificates.
Table 7.1 
StratiG cation by Birthw eight and Race
State A
B irthw eieht bv Race B irths (% ) Sam nle Size
< 2,500 g Black 3363 ( 2 S ) 400
>_2^ 00g 20,648 (1 5 3 ) 400
< 2,500 g Nonblack 6,150 (4 .6 ) 400
i  2,500 g 104,500 (77-5) 400
Unknown 165 ( -1) 165
T ota l 134,826 1,765
Stratification is generally performed as a part of the first phase of 
selection. Before this selection, all PSUs are divided into strata. A  
sample of PSUs is then selected from each stratum to obtain the 
proportionate mix of the desired strata.
Stratification helps ensure that groups of particular interest have 
large enough samples for analytic purposes and increases efficiency. 
When stratified samples are used, appropriate weights must be 
applied to the data for tabulations that include the total population, 
since probabilities of selection differ for units in different strata. In 
Table 7.1, the probability of selection varied from 0.0038 
(400/104,500) among nonblack infants weighing at least 2,500 g to 
0.1189 (400/3,363) among black infants weighing less than 2,500 g to
1.0 (165/165) for infants with unknown birthweights.
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In the ideal situation, survey sampling consists of simple 
random selection of households or respondents. For practical 
reasons related to cost, time, and management, however, a simple 
random selection is rarely possible. The types of surveys discussed 
in this chapter usually use cluster sampling. This type of sampling 
involves selecting groups of households within chosen sampling 
units, such as EDs. Although clustering reduces the cost and 
effort involved in collecting data, the technique has its own costs. 
Because individuals who live near each other tend to be more 
similar than individuals who live far apart, clustering increases the 
standard error and sample variance and functionally reduces 
sample sizes. The use of cluster sampling also requires that 
certain questions be addressed before the sampling takes place. 
For example, How large should the clusters be? How is the cluster 
starting point selected? How does one choose succeeding sample 
points after starting? How many interviews should be expected 
from a cluster that contains a given number of households?
The design effect is the ratio of the variance or standard error 
of a sample (for a given variable) to the variance for a randomly 
selected sample. This measure is commonly used to quantify the 
effect of using a clustered sample. The actual sample size divided 
by the design effect gives the effective sample size—the size of a 
simple random sample required to yield the same variance or 
standard error (depending on which was used to estimate the 
design effect).
The optimum number of potential respondents to be selected 
per cluster depends on the variables under consideration. 
Geographic clustering refers to the tendency for persons who live 
near each other to be more similar than randomly selected 
individuals with regard to the variables of interest. As a general 
rule, when clustering of the primary variable of interest is 
extensive, the cluster size should be small. For highly clustered 
variables, such as immunization status or use of health care 
services, calculations from past surveys suggest an optimum 
average number of completed interviews, or take, of 15 to 20 
respondents per cluster. For variables that tend to be less 
clustered, larger clusters can be used.















travel, staff time, and logistics. However, extremely large cluster 
takes should be avoided in multipurpose surveys, or in those surveys 
in which many different variables are being measured, but no one 
variable has greater importance than the other.
For multipurpose surveys, a cluster take of about 40 respondents is 
recommended in the rural sector and of approximately 20 respondents 
in the urban sector. The cost advantage of large takes is generally 
smaller in the urban sector than in the rural sector. Costs can be 
further reduced when a preexisting, recent household list is available 
because a major factor favoring a large take is savings in listing 
operations. If the overall sample size is small (fewer than 2,000 
interviews), the size of the clusters should also be small in order to 
increase the number of clusters, thereby ensuring that the variation 
within a population is adequately represented.
Listing and Segmentation
Listing households or constructing maps of neighborhoods before 
selecting a sample is an appreciable but essential field cost. 
Investigators should avoid having the interviewers combine listing, 
sampling, and interviewing into a single operation while they work 
through the sample area. Even less acceptable is avoiding listing 
altogether by having the interviewers create clusters as they go along 
or by having them select a sample at fixed intervals during a random 
walk up to a predetermined quota of households or to individuals who 
have completed interviews. Although designed to eliminate conscious 
choice in selection, these methods fail to meet the requirement that 
the sample be selected to give a known and nonzero probability to 
every potential respondent. They also permit bias through intentional 
or unintentional avoidance of households. For example, interviewers 
may avoid houses with poor accessibility, houses that are not seen 
from the road, or houses that look uninviting. An independent listing 
can serve to determine the completeness of the interviewers’ work, 
and the investigators can determine if the interviewers covered the 
whole sampling segment or if they omitted or substituted households.
The cost of listing can be reduced by using segmentation—breaking 
sectors into two or more roughly equal-sized pieces to decrease the 
size of the area that has to be listed. One of the segments is then 
randomly chosen. However, segmentation generates its own costs and 
requires skills in map making and in map interpretation. Because
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it is usually difficult to delineate the natural boundaries of very 
small segments, segmentation becomes progressively harder as 
segments become smaller. A point is reached where additional 
segmentation is not useful. In planned urban areas, listing is much 
easier. Usually, an address system is in effect and segmentation is 
not needed.
Sometimes listing can be avoided by making segments so small 
that they are equal to the required cluster size. One could then 
use a take-all rule at the last stage of sampling. In urban areas, 
the difficulty of delineating small segments can be reduced by 
defining blocks or single buildings as segments.
The Sampling Operations
After the primary sampling units have been selected (EDs or 
other areas) and the dwellings have been listed, the survey 
personnel must determine which dwellings will be included in the 
sample. During this step, investigators should provide safeguards 
to prevent biased selection. Preferably, the selection process 
should be performed in the office or in the field by a senior staff 
member. The selection of dwellings from the list can be done by 
either clustering consecutive dwellings with a random start or by 
systematically selecting from the list.
The first option is preferable, especially in rural areas, in terms 
of cost, time, and logistics. The second option, however, reduces 
the clustering effect by incorporating more variation within 
clusters. Systematic selection involves numbering the dwellings 
from 1 to N, randomly selecting one sample unit from the first k 
units, and subsequently selecting every kth sample unit to obtain a 
sample of predetermined size n (Cochran, 1963).
Finally, the interviewing team visits the area and an interviewer 
is assigned to each selected household. The interviewer generally 
begins with a brief household interview, lists the household 
members, and identifies all persons who usually live in the 
household. The purpose of this listing is twofold. First, it yields a 
roster of household residents who are eligible for an interview, and 
second, it permits comparisons of basic characteristics (such as 
age) of the individuals who are interviewed and those who are not.
Opinions differ as to whether only one person or all people 
within a household who meet the predetermined eligibility








requirements (e.g., all males, all married females, all teenagers, all 
users of a given health program) should be targeted for interview. 
From a statistical and a cost perspective, all potential respondents 
Contami- should be interviewed. However, contamination —interviewing more
nation than one person in a household—may bias the responses on sensitive
issues. If only one respondent is chosen per household, this person 
must be randomly selected from the household list of individuals 
eligible to be respondents. Household members who are home when 
the interviewer first visits or who are willing to be interviewed may 
differ substantially from other household members (e.g., housewives 
or the unemployed are most likely to be home) and thus may bias the 
results.
Interviewer If the members of a household or an eligible person are not
callbacks available, the interviewer must make callbacks, when feasible, on
different days and at different times of the day before the interview is 
abandoned. When and how many callbacks are made depends on a 
number of factors, including time and budget constraints and the ease 
with which the household can be visited.
Estimating the Number of Dwellings to Visit
The survey design must also include an estimate of the number of 
dwellings1 or households that must be visited in order to achieve the 
Vacant desired sample size. Estimates must take into account the number of
dwellings, vacant dwellings that are likely to be encountered, the proportion of
refusal rates, dwellings without eligible respondents, refusal rates, noncontact rates
noncontact (i.e., when no one is home or when the selected individual is not
rates home), and the number of eligible respondents per dwelling (if all
eligible persons are to be interviewed in the dwellings). By starting 
with the desired number of interviews, we can multiply by each of the 
relevant rates to estimate the number of dwellings to visit. In 
Example 7.2, we illustrate this procedure by using a hypothetical 
survey.
1 The terms household and dwelling can have different meanings in different societies. Dwellings generally refer 
to physical entities that would normally contain a household or family, although one dwelling could conceivably 
contain more than one household. Households can be defmed in many ways but are generally viewed as one 
or more people sharing a dwelling and functioning as a unit (e.g., sharing the same cooking fire or sleeping under 
the same roof). In practice, in countries where extended families are the norm, households and dwellings are 
not always easy to identify. Survey researchers must determine the most appropriate units for sample selection 
based on their knowledge of the population and of the principles of survey sampling.
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Estimating the Number of Dwellings to Visit 
All Eligible Women or One Eligible Woman per Dwelling
In Country X, public health officials decided to interview approximately 
1,000 married women 15 to 49 years old. Five hundred interviews would be 
conducted in urban areas and 500 in rural areas. How many dwellings must 
be visited to obtain the required number of interviews if all eligible women in 
each selected dwelling are to be interviewed? How many if one eligible 
woman in each dwelling is to be interviewed?
Selected Dwellings
All Eligible Women 
Urban Rural
One Elieible Woman 
Urban Rural
Required number of 
completed interviews 500 500 500 500
Percentage of 
Dwellings occupied* .98 .98 .98 .98
Mean number of women 
or percentage of 
occupied dwellings* .90* 1.10* .65* .65*
Percentage o f  
eligible women contacted* .90 .95 .75 .75
Percentage o f contacted 
women interviewed* .98 .99 .98 .99
Estimated dwellings to visit 643 493 890 723
*Percentages listed are hypothetical but are similar to those typically observed in 
developing countries.
*Mean number of eligible women 
survey, or other data source.
l per occupied dwelling. From census, earlier
Percentage o f dwellings occupied by eligible women.
Survey Sampling
EPSEM
To obtain the desired number of completed interviews, we estimate 
that about 643 urban dwellings (500 .98 -s- .90 -î- .90 -5- .98 = 643)
and 493 rural dwellings (500 4- .98 -f- 1.10 -j- .95 -r .99 = 493) must 
be visited under the given set of assumptions (Example 7.2). These 
sample size estimates are based on the estimates of the percentage of 
occupied dwellings in each setting, an estimate of the mean number 
of women per occupied dwelling, the expected percentage of women 
who can be contacted, and the expected interview completion rate.
As expected, if only one woman is selected from each household, 
more dwellings would have to be visited to obtain the desired number 
of interviews. A  significant increase in cost may result because of the 
additional time needed to visit more dwellings.
Documenting the Sample
The task of the survey sampler is not complete until every step and 
detail of the sampling operation has been carefully documented. 
Documentation is required to compute sampling errors, to link other 
data sources, and to perform various checks and supplementary 
studies. Experience has shown that special efforts are needed during 
this operation to ensure that the work is carried out effectively. 
Documentation is particularly important at the time of sample design, 
at the end of the field work, and at the completion of the data file. If 
documentation is delayed, considerable effort will be required to 
reconstruct the missing information when it is needed.
Selected Sampling Techniques and Issues
Disproportionate Sampling
It is usually preferable to design surveys so that each final unit of 
selection in the population (e.g., every patient, every child, every 
household) has an equal probability of selection. This sample design 
is known as the equal probability of selection method (EPSEM), and 
results in a self-weighting sample. The results of a self-weighting 
sample can be treated as directly representative of the entire 
population under study, and weights are not needed in the analysis.
This section deals with departures from this simple model and, in 
particular, with the deliberate introduction of different probabilities
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of selection in different strata of the sample. Even in these 
departures, however, EPSEM should be used whenever possible 
within strata.
There are two main motives for disproportionate sampling 
between strata or domains:
• Cost efficiency is increased if a larger sampling fraction (f) 
(see 7.4.1) is used when the population variance is greater 
and the unit costs are lower. Thus, sampling fractions may 
be manipulated to reach an optimum design. For instance, if 
stratum A  is very homogeneous relative to stratum B with 
regard to a key variable, stratum A may be undersampled 
relative to stratum B, since researchers might assume that a 
larger sample from A  would yield little additional 
information.
• The survey planner may wish to report findings for a 
population subgroup that constitutes only a small percentage 
of the whole population. If a fixed sampling fraction (i.e., 
EPSEM) is used everywhere, this small group will be 
allocated a correspondingly small sample (possibly too small) 
on which to base valid conclusions. TTie problem can be 
resolved by oversampling the small subpopulation, thus 
reducing its sampling error. When considering the whole 
population, introduce a weight to compensate for the 
unbalanced sampling.
Example 7.3 illustrates disproportionate sampling. The basic 
idea is first to allocate the sample proportionately to the strata 
and then to adjust these allocations by some factor based on the 
amount of oversampling done.
To determine the size sample necessary to maintain the same 
sampling precision for the total-country estimate as existed with 
the proportionate sample, we use the disproportionate sampling 
rates in column 3. In general, disproportionate sampling would 
increase the standard error for the total-country estimate. 
Furthermore, an increase in sample size would be needed to 








D isproportionate Sam pling  
A  Hypothetical Survey
A  country has an urban population of 1 million and a rural population of 4 
million. We wish to select a nationwide sample of 5,000 people. To ensure 
more precision in the estimates for the relatively small urban sector, we 
decide to double the urban sampling fraction but maintain the same total 











Urban 1,000,000 1,000 2,000 k = 1,667
Rural 4,000,000 4,000 4,000 k = 3,333
Total 5,000,000 5,000 6,000 k = 5,000
Column 1 gives the population estimates, N h.
Column 2 allocates the given total sample, n, of 5,000 between urban n t and 
rural n3 in proportion to the population in column 1.
In Column 3, to ensure more precision for estimates for the urban domain, 
we begin by doubling the sample size for the urban domain (1,000 * 2 = 
2,000) and leave the rural domain unchanged (4,000). This would yield a 
total of 6,000 interviews, 1,000 interviews more than the predetermined 
sample size of 5,000. To adjust the sample size back to 5,000, which we 
consider a fixed number, we introduce a factor k. k is computed as the ratio 
of the total sample size (in this example 5,000) to the sum of n 'h (in this 
example, 6,000). Each n'his then multiplied by the factor k (5,000/6,000) to 
obtain the disproportionate sample sizes (1,667 for the urban domain and 
3,333 for the rural domain).
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Neither the advantages nor the disadvantages of dispro­
portionate sampling are very substantial unless the sampling 
fractions depart considerably from equality. In Table 7.4, the 
two-to-one oversampling reduced the urban sampling error 
substantially but increased the rural and total sampling errors 
slightly. In general, if strata vary by population size, the effects of 
using disproportionate samples instead of equal samples in all 
regions are still minor. The relatively few benefits of a 
disproportionate sample need to be balanced against the 
disadvantages of a weighted sample. In many cases, the benefits 
of proportional sampling will not justify the inconvenience.
Sample Weighting
If a sample of size n is selected from a population of size N, 
then the probability (PR) of selection for any sample unit is:
(7.4.1)
PR { selection for any sample unit } = iL = f
N
The probability of selection or the sampling fraction (f) is the 
proportion of the population that is included in the sample. Any 
population or stratum total can be estimated by multiplying the 
corresponding sample total by the inverse of the selection 
probability N/n. The multiplier N /n  is called a weight:
(7.4.2)
Weight = H  
n
For example, if one stratum is oversampled by a factor of 2 
(i.e., twice the number of interviews are conducted as would have 
been in a proportional sample), the weight for that stratum would 
be the inverse of 2 (i.e., 1/2 or 0.5). Every interview in that 
stratum would only be counted 0.5 times when results for the 
entire population are calculated. In Table 7.4, we demonstrate the 
use of weights in making population estimates. Weights may be 
introduced at all stages of the sampling process. They are most 
often used in first-stage sampling to compensate for undersampling 
or oversampling of the strata.
In Table 7.4, column 1 displays the sampling fraction for each








Comparison of Weighted and Unweighted Results 
for a Hypothetical Population






Samóle Data Women 
(%) Married 
(Unweighted)











East 1/1,000 1,000 900 810 90 900,000 810,000 90
West 1/2,000 2,000 1,000 800 80 2,000,000 1,600,000 80
Coast 1/2,500 2,500 1,200 900 75 3,000,000 2,250,000 75
Total 3,100 2,510 81 5,900,000 4,660,000 79
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stratum. Column 2 lists the weights that are used to inflate the 
sample data of columns 3 and 4 to population estimates in 
columns 6 and 7. Comparing columns 5 and 8, we see that the 
weights do not affect the estimates within strata because the 
weight within any stratum is constant. However, the total in 
column 8, which is obtained by dividing the total of column 7 by 
the total of column 6, shows 79 percent instead of the 81 percent 
obtained from the unweighted sample data. The differential 
weighting has lowered the estimate slightly. Because an area of 
high prevalence (the East) was oversampled, unweighted estimate 
(81%) exceeds the weighted estimate (79%).
Because the weights appear in the numerator and the 
denominator of the final estimates, we can remove any common 
factor from the weights. For example, all the weights in column 2 
can be divided by 1000 and become 1, 2, and 2.5. Thus, only the 
relative values of the weights must be considered when estimating 
means, rates, proportions, percentages, or ratios. However, 
weights should not be reduced if absolute numbers of individuals 
with a characteristic in the population are of interest. Weights are 
often used to estimate the total number of individuals in the 
population who have some characteristic or condition, who are at 
risk of some condition, or who use specified services.
If only one eligible person per household is interviewed, rather 
than all eligible people, a second weight must be included. This 
weight is equal to the number of eligible respondents living in the 
household and is necessary because the interviewed individual 
represents all eligible individuals in the household. Furthermore, 
this weight compensates for the reduced selection probability of 
individuals in households with more than one eligible person.
Weighting fo r  Nonresponse. Weights can also be used to 
compensate for nonresponse or the failure to obtain data for some 
of the sampled units. In Table 7.5, suppose that column 1 
represents only the individuals actually interviewed and column 2 
represents individuals selected for interview (see column 3 from 
Table 7.4). The completion rates—respondents as a percentage of 
these selected—are presented in column 3 of Table 7.5 and can be 
factored into the weighting system.
To compensate for nonresponse, the inflating factors could be 
increased from 1,000 to 1,000/0.9 = 1,111 for the East, from 2,000 
to 2,000/0.8 = 2,500 for the West, and from 2,500 to 2,500/0.85
Weighting when 











W eighting fo r Nonresponse
1_________ 2__________ 3 4 5__________ 6
Combined Combined 
Geographic Individuals Individuals Completion Design Weight Weight 
Area Interviewed Selected Rate Weight (Unadjusted) (Adjusted)
East 900 1000 .90 1.00 1.11 1.00
West 1000 1250 .80 2.00 2.50 2.25
Coast 1200 1412 .85 2.50 2.94 2.65
=2,941 for the Coast. The combined design and nonresponse weights, 
equal to (1/Completion Rate) * Design Weight, are shown in column 
5 of Table 7.5. If these weights are adjusted and East is set to 1.0, 
the combined weights are: 1 for the East; 2.5/1.111 = 2.25 for the 
West; and 2.941/1.111 = 2.65 for the Coast. The combined weights 
differ from the sampling weights (1, 2, and 2.5) alone because they 
also compensate for unequal rates across the three regions. The West 
and Coast have lower completion rates than the East, so their weights 
have been increased relative to the rates for the East.
Noncompletion or nonresponse adjustments are an attempt to 
counteract potential biases by increasing the weights of the 
respondents to represent the nonrespondents. These adjustments, 
however, do not compensate for any bias that may result from 
systematic differences between respondents and nonrespondents 
within the strata.
Another form of weighting, known as poststratification weighting, 
compensates for differences between the sample distribution and the 
known population distribution for some characteristic(s). For 
example, even with a perfectly implemented equal probability sample, 
the age distribution in the sample will differ somewhat from the 
population age distribution because of sampling fluctuations. If the 
population age distribution is known (from the census, for example) 
the sample can be reweighted, age group by age group, to 
approximate the population distribution. The same type of weights 
N h /n h are used, where h designates the age group.
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When Is Weighting Necessary? The overall effect of weighting 
on results is usually small. The main purpose is to provide the 
best possible estimates of a wide variety of population 
characteristics from the sample. K varying sampling fractions have 
been used in the sample design, these should be reflected in the 
estimates; in these circumstances, weighting should be considered 
obligatory even if the effects are small. Such weights are termed 
design weights. In an equal probability sample, no design weights 
are required, which is why such a sample is termed self-weighting. 
For nonresponse weights, the weighting adjustment corrects only a 
part of the nonresponse bias. Corrections will nearly always be 
trivial in developing countries, where response rates tend to be 
high. It is reasonable to omit nonresponse weighting if the sample 
is otherwise self-weighting. Alternatively, if design weights are to 
be used for strata, little complexity is added in modifying these 
weights to account for variations in nonresponse rates between 
strata. The combined weight for stratum h will be the design 
weight times the inverse of the completion rate.
Finally, poststratification weighting or weighting to compensate 
for differences between the sample and the population is best 
avoided in most circumstances. This type of weighting is 
recommended only when the investigator is confident that the 
census or other data used as a standard are accurate or if the 
investigator strongly believes that severe undercoverage of people 
or areas with certain characteristics in the survey sample occurred.
In general, self-weighting samples are recommended. When the 
sample is not self-weighting, design weights, combined with 
nonresponse weights for the same strata, should be entered in the 
data record and used in all analyses. The standard method for 
introducing weights into the analyses is to include one or more 
weight variables on each individual record. In Table 7.5, for 
instance, the data records for each woman sampled in the East 
would have a value of 1 for the design weight variable, those in 
the West would have a value of 2, and those in the Coastal 
domain a value of 2.5. If there were weights for eligible 
household members, they would be included as a second weight on 
the data record. Finally a combined, or overall, weight should be 
included. If a weight variable is included as a separate variable on 









Systematic sampling is the selection of units (e.g., PSUs, 
households, individuals, clinics) at fixed intervals from a list.
Typically, the starting point for selection is randomly determined. 
Systematic sampling can be used at any stage of sampling. Compared 
with random selection, systematic sampling has three advantages:
• It is easier to perform.
• It allows the selection to be easily checked.
• It provides a degree of stratification with respect to the variable 
on which the list is based, if the list is in some order. That is, it 
helps ensure that no large segments of the population are 
omitted from the sample.
Because of these advantages, systematic selection is used much 
more often than random selection for choosing PSUs.
Systematic sampling is implemented in the following manner.
First, the sampling interval I is calculated. If the sample design 
specifies the number of units to be selected (e.g., 100 enumeration 
districts), then
(7.6.1)
j m N  Number o f units o f population 
n Number o f units o f sample""
Alternatively, if the sample design specifies a sampling fraction (f) 




After the sampling interval is calculated, a random start is selected. 
This start consists of selecting a random number, R, between 1 and I. 
On the complete list of units in the population, the Rth unit is the 
first one selected. I is then added to R  to determine the second unit 
to be selected. The third unit is R  + 2 I. This process continues 
until the list is exhausted, at which point n units will have been
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chosen. In systematic sampling with probability proportional to 
size, any unit whose size equals or exceeds I is certain to be 
selected. In some cases, units larger than the interval may be 
selected two or more times. Table 7.6 shows an example of 
systematic selection of enumeration districts for a hypothetical 
survey.
T a b le  7 .6
System atic Selection o f Sam pling U nits  
( I  =  4  and R  =  2)











The area to be surveyed consists o f 20 enumeration districts. It has been 
previously decided that five o f them will be sampled. Therefore, the sampling 
interval, I, is 2 0 /5 -4 . R has been selected at random from numbers 1 through 
4; R =  2 has been selected. Thus, the following districts are selected:
R = 2  
R + I =  6 
R +2I =  10 
R +3I =  14 
R +4I =  18
After the fifth selection, number 18, the list is exhausted.
’ X denotes the enumeration district selected.














Sampling with Probability Proportional to Size
Systematic selection of sampling units has a serious deficiency 
when the populations of sampling units vary substantially. Systematic 
selection gives every unit an equal probability of selection, regardless 
of its size. Thus, systematic sampling without regard to size 
overrepresents smaller units relative to larger ones. Therefore, 
smaller units have larger selection probabilities relative to their 
population.
A  common way to avoid this problem is to select sampling units 
with a probability proportional to their population size. Thus, if unit 
A  is estimated to be ten times as large as unit B, it is given a ten 
times greater chance of being selected. This method is called 
sampling with probability proportional to size, or PPS sampling. After 
selected areas have been sampled with PPS, we can use clusters of the 
same size within each area. Selecting areas with PPS and using a 
fixed number of households within these areas approximates the 
sampling objective that all individuals in the population have the 
same probability of selection.
When the same number of households or individuals to visit in 
each area have been selected, the fieldwork can be organized so that 
each interviewing area requires about the same amount of time, 
personnel, and resources. Equalizing the work load in each area unit 
constitutes the main attraction of PPS sampling. The fieldwork is 
easier to organize if work loads do not vary substantially from area to 
area. This advantage is particularly significant when sampling ordinary 
administrative units (e.g., villages, neighborhoods, political 
jurisdictions), which may vary in population size.
Selection using PPS may be performed as follows:
1. l is t  the area units, with the estimated size M's shown for each.
2. Cumulate the values of M ^and record this cumulative figure— 
cumulative M 'j —for each unit. Cumulative M 'jfor the last 
entry should equal the population of the entire survey area.
3. Compute the sampling interval I = M '/a , where a is the 
number of area units to be selected.
4. Select a random number R  between 1 and I.
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5. Compute the sampling numbers: R; R + I; R + 2*1;
R + 3*1; and so on.
6. For the first sampling number, find the first cumulative M 
that equals or exceeds it. The corresponding unit is the one 
selected.
7. For each succeeding sampling number, follow the same 
procedure as number 6.
Table 7.7 and Example 7.8 describe systematic sampling with 
probability proportional to the values M/, the populations of the 
PSUs. Table 7.7 describes the first stage of selection (area units) 
for the urban part of the sample. For the second stage of the 
selection (households), selection is to be interval-based, rather 
than determined by choosing adjacent households. For each 
selected area unit, compute the household sampling interval (I) as 
follows:
(7.7.1)
I. =  i/p., =  a * M'; /  f  * M' 
where
Pi = probability of selection in area i
a = 7 0  (number of PSUs) 
f = 1/30.55 = .0327 (sampling fraction)
M ' = 38,500 (population of eligibles in survey area) 
M '; = estimated PSU sizes from Table 7.7.
Ii = 0.0555 *M ' i .
For the three units selected in Table 7.7 this gives: 
Unit 001 L = 0.0555 * 150 = 8.3
Unit 007 I 
Un i t o l i  I
= 0.0555 * 110 = 6.1 







Selection of Area Units Using Systematic Sampling With
Probability Proportional to Size
Area Size Cumulative Sampling
Unit M \ M \ Numbers Area Units
001 150 150 90 Area units in survey area:
002 60 210 A =  350.
Planned sample size:
003 80 290 a =  70 units. Sum of unit
004 70 360 sizes: M' =  38,500.
005 130 490 Interval: I =  M7a =  550.
006 90 580
007 110 690 640 Random number selected
008 140 830 between 001 and 550:
009 150 980 R =  090.
010 70 1,050
O il 140 1,190 1,190 Units selected into the




Thus, in unit 001 every eighth household is chosen (after rounding
8.3 to 8), in unit 007 every sixth is chosen, and in unit Oil every 
eighth is chosen. The final steps involve listing all households in the 
selected areas, choosing a random starting point, and selecting a 
systematic sample of households using the above intervals.
If clusters of adjacent households are selected, the procedure is 
much simpler. A  number between 1 and M '; is randomly selected. 
The household on the area map or list corresponding to this number 
becomes the starting point. Each succeeding household on the map 
or list is visited until the designated number of households in each 




Estimating the Desired Number of Clusters
Given:
Desired sample size
Number of women aged 15 to 49 years in 
entire country (extrapolated from 
census or survey data)
5,000 women aged 15 to 49 
years 168,000 (N)
Number of women aged 15 to 49 years 
in urban sector
47,100
Sample selected to achieve 
desired sample size (allowing 
approximately 10% nonresponse)
5,500 women aged 15 to 49 
years (n)
Desired cluster take (urban) 20 women interviewed/cluster
Computed: Sampling fraction f  
5,500/168,000 =  1/30,55 
= .0327
Women selected in urban sector 47,100/30.55 =  1,542
Number of clusters selected 
(average of 22 women per cluster)
1,542/22 =  70
Errors of Coverage and Nonresponse
Coverage error refers to any lack of correspondence between 
the sample design and attempted interviews. Nonresponse refers 
to interviews attempted but not achieved. Thus, undercoverage 
occurs if the interview is erroneously not even attempted, and 
nonresponse occurs if the interview is unsuccessfully attempted.
Undercoverage. There are two main sources of undercoverage. 
The first occurs at the listing stage. In some surveys, listings do 
not completely cover the designated sample area for many possible 
reasons. As a result, large geographic areas and individual 














eligible persons can be excluded from the sample if the eligibility 
criteria for the interview, such as an age interval or other charac­
teristic, is inaccurately reported. Both types of undercoverage errors 
can be caused by field-workers who seek to reduce their work load. 
Intentional errors can only be controlled by intensive training and 
close supervision. However, errors that result from inaccurately 
reporting an eligibility characteristic are not necessarily conscious or 
deliberate. For example, in many developing countries field-workers 
often have to estimate the ages of older respondents because their 
date of birth is unknown. Training interviewers to guess objectively, 
without bias, is difficult. In such instances, bias cannot be eliminated 
entirely.
An outdated sampling frame can also produce errors in coverage. 
These errors can be reduced by taking special steps to update the 
frame, especially in areas of known new or expanded settlement, such 
as new housing developments, squatter areas, and refugee camps (if 
they are to be included in the survey).
Deliberate Restriction o f Coverage. In many surveys, especially 
nationwide ones, investigators deliberately exclude territories that are 
difficult to access or that would be excessively costly to survey. Two 
distinct situations exist:
• Exclusion of clearly identified areas from the sampling frame. 
The coverage limitations should be stated in the survey report, 
which then becomes a report on the remainder of the country. 
Such exclusions are not regarded as coverage or response error 
but simply as part of the definition of the survey domain. For 
example, areas where military conflict is ongoing, where the 
safety of survey workers may be jeopardized, or where sparsely 
or widely dispersed populations require an undue amount of 
time and resources to cover may be deliberately excluded from 
the sample. If areas must be excluded, they should constitute a 
coherent domain. For example, if some areas of a country are 
to be excluded because of inaccessibility, the exclusions should 
be done as complete provinces, enumeration districts, or other 
entities for which population estimates are available. A survey 
from which a number of scattered zones have been excluded is 
difficult to interpret and to use.
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• Ad Hoc exclusions that are decided during or just before 
fieldwork. In developing countries, survey organizations 
often abandon fieldwork in certain sample clusters for 
various reasons such as, floods, civil disturbance, or practical 
constraints. These exclusions usually occur after sample 
selection. If the excluded areas form a meaningful domain, 
the exclusion problem may be managed by redefining the 
survey domain. More commonly, however, the excluded 
areas will not make sense and will have to be accepted as 
constituting error. This type of error should be classified as 
nonresponse rather than coverage error. Substituting new 
areas for those excluded is not recommended.
Nonresponse. The concept of nonresponse seems simple and 
clear. Specifically, nonresponse refers to the percentage of 
persons who should have been interviewed but were not.
However, the seemingly straightforward distinction between 
nonresponse and undercoverage becomes somewhat unclear in 
practice. For example, the use of multistage samples and the 
replacement policy for nonrespondents complicate this simple 
issue.
First, in most household surveys the final interviews are 
identified through a multistage process. For example, in the 
typical survey, the researcher selects PSUs, lists and selects 
dwellings, collects information on the household members who live 
in the dwellings, and then interviews any eligible respondents in 
the households. If failure occurs at the second or third step, the 
information that permits accurate classification of nonresponse at 
the final level would not be available. For example, if the 
interviewer cannot find the selected dwelling, then whether it 
contains anyone eligible for interview is unknown. If the dwelling 
does not contain eligible individuals, the failure has no effect on 
the interview response rate. If the head of the household refuses 
to provide information on household members, the interviewer 
does not know if the household contains eligible persons for 
interview. Therefore, calculating nonresponse becomes 
problematic. There is no standard way of managing this and 
determining a single nonresponse rate.
Some surveys propose a policy on replacing nonrespondents. 
However, replacement of nonrespondents is generally not
A d Hoc 
exclusions
Sources o f 
nonresponse











recommended because replacement tends to bias the survey results 
toward the characteristics of those individuals who are most easily 
located or most cooperative. Preferably, procedures should be setup 
to improve efforts to locate hard-to-find individuals. If families, 
instead of dwellings, are selected, and if the selected family has 
moved away between the listing and the interview, interviewing the 
family (if any) that moves in as a replacement sample unit is 
acceptable. Such situations do not require any special treatment since 
the target family sample is defined as the set of families found at the 
time of interviewing in the dwellings selected from the dwelling list.
Quota sampling. Interviewing until the target number of interviews 
has been achieved, called quota sampling, should be avoided. Often, 
surveys will be designed to ensure that the exact number of interviews 
needed for each PSU and for the entire survey are obtained.
However, this procedure can introduce substantial biases into survey 
results. The problem stems from the fact that the survey quota is 
likely to have a disproportionately large number of easily found and 
easily interviewed respondents, who may tend to differ in relevant 
ways from the overall population. Although some uncertainty is 
introduced, interviewing only in preselected households is preferable.
Sampling Errors
After data collection is complete, the sample design should be kept 
in mind during data analysis.. The sample designs for most surveys 
involve features such as stratification, clustering, and weighting. All 
these features affect the sampling errors of the survey estimates. The 
standard formulas for sampling errors found in statistical texts and 
used in most computer programs do not take these features into 
account; consequently, (most of) these programs are often 
inappropriate. Formulas for the estimated standard errors of 
proportions and means are usually intended for application only to 
simple random samples. These formulas tend to understate the 
sampling errors of the survey estimates, sometimes to an appreciable 
degree.
The computations required to estimate sampling errors of survey 
estimates based on complex sample designs are more burdensome 
than those based on simple random samples. In recent years, a 
number of computer programs have been developed to perform these
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computations (e.g., the R H  SESUDAAN procedure calculates 
standard errors for weighted, stratified, and clustered samples).
The correct computation of sampling errors with complex sample 
designs requires knowledge of weights and of the stratum and 
primary sampling unit to which each sampled individual belongs. 
Therefore, this information must be recorded on each respondent’s 
computer data record if survey estimates will be derived using 
survey software.
Nonsampling Errors
Typically, survey researchers focus on sampling errors during 
the analysis of data to estimate the likely range of the rates, 
proportions, and means within the population. As noted above, 
sampling errors, when calculated correctly, take into account the 
design of the survey—clustering, weighting, and stratification. 
However, sampling errors describe the range of overall population 
values if the sample and the population’s only difference is that 
the entire population is not being interviewed. In fact, a variety of 
other potential sources of survey error, referred to as nonsampling 
errors, can influence the results. Nonsampling errors can originate 
from any source other than the design of the sample. Some 
common nonsampling errors include:
• Intentionally faulty information from respondents
• Unintentionally faulty information from respondents
• Poor questionnaire design resulting in lack of clarity 
(regarding exactly what information is being sought) by 
interviewers or respondents
• Intentional or unintentional interviewer errors
• Coverage errors
• Nonresponse
• Data entry and data processing errors
Without going into a detailed discussion of each of these, we 
can make some general recommendations for minimizing 
nonsampling errors. Thorough training of interviewers and other 
field staff is an essential component. Effective supervision of 
interviewers by well-motivated and capable supervisors is also vital. 









questions and to reduce anxiety about providing information on highly 
personal topics. Coding and data entry procedures should be 
uncomplicated. This includes designing forms to make these 
tasks as easy as possible. Unfortunately, the extent of nonsampling 





1. Circle true (T) or false (F).
(a) T /F  A probability sample involves the selection of units with known
probability.
(b) T /F  In a probability sample, it is generally acceptable for some area
units to have a zero probability of selection.
(c) T /F  Using preexisting samples is usually more expensive than designing
a new sample.
(d) T /F  Sampling frames are theoretical constructs that list all units of the
population under study.
(e) T /F  If one enumeration district is twice as large as another and has
twice the chance of being selected, this is probability proportional 
to size.
(f) T /F  Stratification is dividing and sampling a population according to a
characteristic of interest.
(g) T /F  Cluster sampling requires a random starting point and saves money
and time.
(h) T /F  It is generally agreed that selecting all adults at home when the
interviewer arrives does not introduce potential bias.
(i) T /F  Weights can be used to inflate sample data to population estimates.
(j) T /F  Design weights are required for analyzing data from a 
self-weighting sample.
(k) T /F  If an interview is erroneously not attempted, coverage error occurs.
(1) T /F  Nonresponse relates to interviews attempted but not achieved.
(m) T /F  If available time and resources were unlimited, simple random 
samples would usually be the best survey design.
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(n) T /F  In a multipurpose study, no simple formula can determine sample 
size.
(o) T /F  In a multipurpose study, sample size calculations should be based 
on the variable requiring the smallest sample.
(p) T /F  Continuing from house to house until a predetermined number of 
interviews have been obtained is a recommended strategy for 
conducting a household survey.
2. Multiple choice. Select one response.
2.1 Which of the following is generally not an acceptable reason for exclusion 
from a survey?
a. Excluding a sparsely populated desert province that would require 
extensive resources to cover
b. Excluding villages that have been inaccessible due to flooding
c. Allowing an interviewer to omit a household because of safety 
concerns
d. Excluding villages that are difficult to get to because of a lack of 
public transportation
2.2 Which general principle is probably violated when the researcher selects a 
sample from among clinic workers when he is seeking information for the 
entire population?
a. Scientific probability sampling
b. Self-weighting sample
c. Using preexisting sampling frame
d. Using simple, straightforward design
2.3 The principle of self-weighting may be overridden when a population of 
interest
a. is a small proportion of the population.
b. comes from a previous study.
c. uses predetermined segments of the population.
d. is known to have high refusal rates.
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2.4 All of the following are likely to require a larger than usual sample size 
except:
a. More strata
b. Study of rare event
c. Self-weighting sample
d. Multi-purpose study
3. Circle true (T) or false (F).
(a) T /F  Use of a preexisting sample of a population is almost always
advisable.
(b) T /F  If the characteristic of major interest is extremely variable within
clusters, very small clusters must be used.
(c) T /F  The larger the number of interviews per cluster, the less expensive
the design.
(d) T /F  Combining listing, sampling, and interviewing into a single operation
is an appropriate way to reduce costs.
(e) T /F  Interviewers should be trained to create clusters while in the field.
(f) T /F  Segmentation meets the requirement that the sample be selected to
give a known nonzero probability to every potential respondent.
(g) T /F  Household selection procedures should be designed to prevent
interviewers from avoiding uninviting households.
(h) T /F  Nonsampling errors can derive from sources beyond the control of
survey researchers.
(i) T /F  Segmentation reduces listing costs.
(j) T /F  Listing can be avoided by using small clusters and a take-all rule.
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(k) T /F  Most survey researchers agree that interviewing all potential
respondents in a household is always preferable to interviewing only 
some.
(1) T /F  Those not available to be interviewed should be dropped and 
replaced by others who are available.
(m) T /F  Respondents may be selected from a household based on who is at 
home at the time the interviewer comes.
(n) T /F  The number of households to be visited can be calculated by
multiplying the required number of interviews by the expected rates 
of vacancy, refusal, and other key factors.
4. Multiple choice. Select one response.
4.1 All of the following are reasons to preserve sampling documentation 
except:
a. Computation of sampling errors
b. Linkage with other data sources
c. Various checks and supplementary studies
d. Estimating sample sizes
4.2 All of the following are needed to introduce weights into the analysis 
except:
a. Include weight variable on each individual record.
b. Use computer program capable of handling weights.
c. Weight respondent according to eligible respondents in house.
d. Allocate weights according to a predetermined random scheme.
4.3 All of the following will reduce coverage error except:
a. Intensive training
b. Close supervision
c. Excluding parts of selected areas that are hard to reach
d. Updating area frames
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4.4 Exclusions of clearly defined areas from the sample frame are:
a. Generally not problematic when analyzing data
b. Considered to be coverage errors
c. Classified nonresponse
d. Replaced by new areas
5. Circle true (T) or false (F).
Weighting can compensate for nonresponse by multiplying 
respondents in a stratum by the inverse of the response rate.
Each age group can be weighted by its proportional distribution in 
the population.
Gains and losses resulting from disproportionate sampling may be 
significant when changes in sampling fractions are small.
Because the overall effect of weighting is usually small, the design 
weights can be ignored.
Nonresponse weights can sometimes be overlooked.
Poststratification weighting is best avoided in many situations.
R H  SESUDAAN is recommended for computing standard errors 
of survey data that are not self-weighting.
Standard errors for complex sample designs are easy to derive 











6. Arrange in order from 1 to 7 the steps in designing a sample:
(a) _ Select area units (for example, EDs).
(b) _ Interview eligible respondents in a household.
(c) _ Segment areas into smaller areas.
(d) _ Get a sampling frame.
(e) _ Select segments for listing.
(f) — List and select dwellings.
(g) __ Interview households in a dwelling.
7. For the selection of a systematic sample from a list of enumeration districts, 
describe the steps used in the selection. Assume that there are 24 
enumeration districts (EDs) that are approximately the same size and that 
there are eight EDs in the sample.
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8. Select a systematic sample using PPS from the list of villages below. The 
sample should include five EDs.
Table 7 .9  
Systematic Sampling
Village Pooulation Villace Pooulation
1 90 11 30
2 20 12 120
3 240 13 20
4 60 14 580
5 400 15 90
6 10 16 160
7 190 17 100
8 180 18 220
9 70 19 50




9. Assume that the map in Figure 7.10 is available for your use and that all 
households are numbered from 1 to 32 in a village that was selected for a 
survey. Select a sample of eight households in two different ways. Describe 





Suggested Answers to Practice Exercises
1. True or false.
(a) T  Introduction
(b) F  Introduction. No, in a probability sample, area units have a known
nonzero probability of selection.
(c) F Use of a Preexisting Sample. No, use of preexisting samples is less
expensive if it can meet the needs of the survey being planned.
(d) F Basic Sample Design. No, sampling frames are recent compilations of
population sizes, numbers of households, or other appropriate units 
for all subareas composing the geographic area to be included in the 
study.
(e) T Basic Sample Design
(f) T  Stratification
(g) T  Cluster Sampling and Sampling Operations
(h) F  Sampling Operations. No, opinions differ regarding whether all
persons having the predetermined interview eligibility requirements 
within a household should be interviewed. Interviewing all potential 
respondents in a households may bias responses.
(i) T  Sample Weighting
(j) F Disproportionate Sampling Between Strata. No, design weights are 
not required for analyzing data from a self-weighting sample.
(k) T  Errors of Coverage and Nonresponse
(1) T  Errors of Coverage and Nonresponse
(m) T  Cluster Sampling
(n) T  Sample Size
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(o) F Sample Size. No, sample size determinations should be based on both 
technical and practical considerations.
(p) F Quota Sampling. No, quota sampling should be avoided since this 
procedure can introduce substantial biases into survey results.
2. Multiple choice.
2.1 d Deliberate Restriction of Coverage
2.2 a Introduction
2.3 a Stratification
2.4 c Sample Size
3. True or false.
(a) F  Use of a Preexisting Sample. No, updating an out-of-date preexisting
sample may not be economical.
(b) F Cluster Sampling. No, when clustering of the primary variable of
interest is extensive, the cluster size should be small.
(c) T  Cluster Sampling
(d) F Listing and Segmentation. No, listing should not be performed by the
interviewer.
(e) F  Sampling Operations. No, clusters should be formed in the office or
by senior survey personnel in the field.
(f) T  Listing and Segmentation
(g) T Listing and Segmentation.
(h) T  Sampling Errors
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(j) T Sample Weighting
(k) F Sampling Operations. No, see 1. (h).
(1) F Sampling Operations. No, study subjects who are not available for 
interview should not be replaced by others who are available. 
Callbacks must be made at different times and on different days.
(m) F Sampling Operations. No, respondents must be selected from all 
eligible members of the household.
(n) T Sampling Operations
4. Multiple choice.
4.1 d Documenting the Sample
4.2 d Sample Weighting
4.3 c Errors of Coverage and Nonresponse
4.4 a Deliberate Restriction of Coverage
5. True or false.
(a) T  Sample Weighting
(b) T  Sampling Operations
(c) F Sample Size
(d) F Sample Weighting. No, usually design weights are considered
obligatory even if the overall effect of the weights is small.
(e) T Sample Weighting
(i) T Listing and Segmentation
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(f) T Sample Weighting
(g) T Sampling Errors
(h) F Sampling Errors. No, standard errors for complex sample designs are
difficult to derive and require using complex computer programs.








7. The selection steps follow:
a. Calculate sampling interval (24/8 = 3).
b. Choose a random start (1, 2, 3).
c. Beginning with the random start, cumulate by 3s to select 8 EDs.
8. The systemic sample may be selected as follows:
a. Calculate sampling interval (3,000/5=600).
b. Choose a random start between 1 and 600.
c. Cumulate populations and select the village when cumulative total is 
greater than RS, RS+600, RS + 1200, RS+1800, RS + 2400.
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9. You would select the sample by:
1. Selecting a cluster of 8 contiguous households by making a random start 
between 1 and 32.
2. Design an interval sample:
a. Calculate a sampling interval (32/8=4).
b. Select a random start.
c. Select every 4th household from the random start. (When 
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Kish L. Survey sampling. New York: John Wiley & Sons, Inc., 1965.
Shah BV. SESUDAAN: standard errors program for computing standardized 
rates from sample survey data. Research Triangle Park, North Carolina: 1963.
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Chapter 8 - Learning Objectives
After completing this chapter you should be able to:
1. Distinguish between parallel and successive treatment designs.
2. For clinical trials recognize how to:
select a study population
assign study volunteers to study groups
achieve blinding
3. Understand the rationale behind defining comparison groups.
4. Recognize the importance of sample size in a randomized clinical trial.
5. Recognize the impact on study validity of exclusions before randomization.
6. Recognize the impact on study validity of exclusions after randomization.
7. Distinguish baseline data analysis from follow-up data analysis.
8. Identify methods used in analyzing data for clinical trials with a short follow-up.
9. Identify methods used in analyzing data for clinical trials with a long follow-up.
10. Recognize advantages and disadvantages of clinical trials.
11. Design a hypothetical randomized clinical trial in outline form.

8 Randomized Clinical Trials
Introduction
The clinical trial is a  controlled experiment that is used to assess 
the safety and efficacy of treatments for human diseases and 
health problems. The clinical trial is essential to the process of 
developing and accepting new treatments. When several approved 
treatments are available for the same condition, the clinical trial is 
used to determine if one treatment, usually a new treatment, is 
superior to the standard treatment(s). Two stages are involved in 
the development of new treatments.
Stage 1. The first stage of development involves laboratory 
experiments. These studies, also called preclinical studies, are 
conducted in vitro and with animals. Preclinical studies provide 
information on pharmacology and toxicology in preparation for 
studies planned in humans.
Stage 2. The second stage involves studies that use human 
participants. This stage is usually categorized into four phases:
• Phase I studies comprise the initial evaluation among human 
participants (20-100 subjects). The primary objective is to 
assess the safety and tolerance of the treatment.
• Phase II studies (100-200 subjects) evaluate the potential 
effectiveness of the treatment. Frequently, several competing 
new treatments are screened to select the one with the most 
potential. The optimal method of administering the 
treatment is determined in Phase II.
• Phase HI studies evaluate the new treatment in a large 
number of subjects (500-1500) to establish the treatment’s 
effectiveness and to gather additional safety information.











trials in which the comparison groups are the new treatment 
group (the treatment of interest) and the control treatment 
group. The research team assigns each study subject to one of 
these treatment groups. Ideally, treatment is assigned at 
random, and both the research team and the study subjects are 
unaware of, or blinded to, the exact treatment assignment.
• Phase IV studies, or postmarketing studies, investigate the long­
term effects of the treatment; these studies are conducted after 
the treatment is approved for general use.
If the investigator assigns treatments at random, the study is known 
as a randomized clinical trial (RCT). From a scientific perspective, 
the RCT, with adequate sample size and blinding, is the preferred 
study design. Randomization should eliminate bias and is the 
preferred method of assigning individuals to treatment and control 
groups. The treatment groups are followed for the same time period 
to observe the occurrence of a  particular event or outcome (Figure 
8.1). Research hypotheses should be stated in terms of the 
anticipated outcome in the new treatment group. For analysis, the 
research team compares the rate of the outcome in the new treatment 
group and the rate of the outcome in the control treatment group.
Figure 8.1
Definition of Comparison Groups in Randomized Clinical Trials
___ Treatment of Interest I '^ >
Study Subjects Outcome




In Example 8.2, investigators designed a randomized clinical trial 
to test whether multivitamins taken daily with oral contraceptives 
(OCs) reduced the side effects associated with the pill.
Example 8.2 
Multivitamins With Oral Contraceptives
Women were assigned at random to the treatment group that took Norinyl 
with a daily multivitamin supplement or to the control group that took 
Norinyl with a placebo. Neither the investigator nor the study subjects knew 
which treatment was being taken. The study subjects were followed at 
3-month intervals for one year. During the 3-, 6-, 9-, and 12-month follow-up 
visits, the investigator collected information about the frequency and severity 
of certain side effects.
(Basnayake et al., 1983)
Often, several treatments are available for the same condition. 
To prevent pregnan<y, for example, several contraceptive methods 
are available (e.g., different doses of pills, different types of 
intrauterine devices (IUDs), barriers, sterilization). Decision 
makers in government health programs and donor agencies must 
sometimes choose among treatments; in general, they want to 
provide treatments that are safe, effective, and also relatively 
inexpensive. Phase III clinical trials provide decision makers with 
scientific evidence about the relative effectiveness and safety of 
competing treatments.
Design and Data Collection Methods
Randomized Clinical Trial Designs
Clinical trial designs have two basic forms: the parallel design 
and the successive treatment design. Again, adequate sample size, 
random assignment to treatment groups, and blinding are 
preferable design features.
Randomized Clinical Trials
Parallel designs. The structure of the parallel design is illustrated 
in Figure 8.1. In this design, study subjects remain with the treatment, 
to which they are randomly assigned, as long as they continue in the 
trial. Both groups are followed forward in time to observe the 
outcome of interest. The basic comparison groups are the patients 
receiving the new treatment and the patients receiving the control 
treatment. In Example 8.3, we present details of a parallel 
randomized clinical trial that compares expulsion rates for two 
different IUDs.
Example 8.3
Expulsion Rates of TCu200*and Progestasert Intrauterine Devices
Expulsion rates following postpartum insertion of the T C u200 and the 
Progestasert intrauterine devices (IUDs) were compared in an RCT among 400 
women.
Background: The Progestasert, a T-shaped IUD releasing crystalline 
progesterone, was designed to reduce bleeding and pain, improve effectiveness» 
and decrease expulsion. Expulsion rates are higher for all devices inserted 
immediately after delivery, but insertions performed at this time are easier and 
motivation may be high.
Research Hypothesis: Among postpartum women, expulsion rates for the 
Progestasert IUD are less than expulsion rates for the T C u200 IUD.
Study Design: Parallel randomized clinical trial.
Eligibility Criteria: Postpartum women who delivered in Santiago, Chile, during 
November 1978 through February 1980.
Treated: Two experimental groups: 100 women receiving a Progestasert that was 
inserted by hand, and 100 women receiving a Progestasert that was inserted with 
an inserter. Insertions were performed within 10 minutes of the delivery of the 
placenta.
Not Treated: Two control groups: 100 women receiving a TCu200 that was 
inserted by hand, and 100 women receiving a TCu200 that was inserted with an 
inserter. Insertions were performed within 10 minutes of the delivery of the 
placenta.
•Throughout this manual, the use of trade names is for identification and does not imply 
endorsement by the U.S. Department of Health and Human Services, Family Health International, 




Outcome: Expulsion of IUD.
Follow-up: Study subjects were followed for up to 12 months to observe 
bleeding, pain, expulsion, and other relevant symptoms.
Data Collection Methods: Sociodemographic, medical, and follow-up data 
were recorded on standard forms.
Randomization Scheme: IUD and insertion techniques were randomly 
assigned, but the methods of assignment were not reported.
Blinding: The investigators did not provide information about blinding.
Data Analysis: Age, parity, education, and sododemographic characteristics 
were compared to determine similarity of groups. At the end of 12 months, 
the investigators compared expulsion rates for the four groups.
(Lavin et al., 1983)
Successive treatment designs. In this type of design, each study 
subject is randomly assigned to a group that follows a predefined 
sequence of treatments where each person receives more than one 
treatment. The most common form of the design, the two-period 
successive treatment design, features one treatment that is 
followed by a second treatment. Frequently, a treatment-free 
period is introduced between treatments to allow any carryover 
effects from the first treatment to dissipate. The length of follow- 
up for each treatment should be the same so that events have the 
same time to manifest for either treatment. The successive 
treatment design has two variations: the replacement treatment 
design (Figure 8.4) and the crossover design (Figure 8.5).
The replacement treatment design is used to collect data about 
the effect of changing from treatment A to one of a pair of 
alternative treatments — for example, treatment B or treatment C. 
In the replacement treatment design, the study subjects are equally 
divided into two groups. Both groups receive treatment A for the 
first period. After completing the first period, the study subjects in 
one group are switched or changed over to treatment B and those 
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followed forward in time to observe the outcome of interest. The 
outcomes among patients treated with A  and B are compared with 
the outcomes among patients treated with A and C. Example 8.6 
describes a replacement treatment clinical trial conducted in 
Indonesia.
Example 8.6
Switch from Standard Oral Contraceptives to Low-dose 
Oral Contraceptives in Indonesia
In many clinics, women who are taking a standard dose oral contraceptive 
(OC) regimen are later switched to a low-dose regimen, either to reduce side 
effects or because of changes in the availability of pills. A  replacement 
treatment clinical trial in Indonesia was designed to assess changes in short­
term side effects, including breakthrough bleeding, which accompanied the 
change from a standard dose to one of two low-dose combination pills.
(Badan Keija Sama Penelitian Fertilitas et al., 1986)
In the crossover design, Group 1 receives treatment A  in the 
first period and treatment B in the second period. Group 2 
receives the treatments in the reverse order of Group 1 
(Example 8.7).
Participants in clinical trials vary considerably in their initial 
state of health and in their reaction to treatment. One advantage 
of the crossover design is that it adjusts for person-to-person 
variation by having each individual serve as his or her own control. 
In effect, each study subject is used to gather information on two 
treatments. Because of this attribute, the crossover design 
frequently requires fewer study subjects than parallel designs.
Successive treatment designs are not appropriate or even 
possible in many situations because study subjects receive more 
than one treatment over both periods of the study. Some 
outcomes may preclude receiving more than one treatment. 
Surgical procedures are usually not suitable for study by a 
successive treatment design. Any clinical trial that has death as a 
primary outcome (e.g., cancer trials) cannot use the successive 





Example 8.7  
Oral Contraceptives and Sickle Cell Disease
A common belief among physicians is that women with sickle cell disease 
should not use oral contraceptives (OCs), but there is no evidence to support this 
concern. On the contrary, progesterone (similar to one of the steroids contained 
in oral contraceptives) has been shown to have a beneficial effect on sickle cell 
disease by inhibiting the sickling of red blood cells, thereby reducing the 
frequency of painful crises and the number of irreversible sickled cells and 
significantly increasing total hemoglobin and red blood cell mass, count, and 
survival.
An 18-month study was undertaken to evaluate the effects of OCs on the 
progression of sickle cell disease. Using a crossover design, the investigators 
compared OCs and a placebo. The effects of OCs were assessed by monitoring 
blood parameters that would indicate sickling and red blood cell turnover and by 
recording the frequency of painful crises, infections associated with sickle cell 
disease, and other physical complaints.
Thirty women were recruited who had sickle cell disease, who attended sickle 
cell clinics, and who either had been sterilized, were using lUDs, or were using 
barrier methods of contraception. The medications—oral contraceptive or 
placebo—were prescribed by random assignment for each woman during the first 
24 weeks of the trial. The women took the assigned medication for 24 weeks, 
discontinued the medication for 12 weeks, and then received the alternate 
medication for 24 weeks.
(Bonhomme, 1984)
which pregnancy is the primary outcome, the successive treatment 
design is not appropriate.
Clinical trials that are likely to have a substantial percentage of 
subjects who drop out are not suited for the successive treatment 
design. Participants who drop out during the first period are not 
available for evaluation in the second period. In general, as the 
treatment period lengthens, the probability that study participants will 
drop out increases. To minimize dropout, investigators should design 
successive treatment trials as short-term studies with period lengths 
of three months or less.
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The study population, a subset of the general population, 
consists of the individuals defined according to unambiguous study 
criteria. The group of actual study subjects in the trial may be a 
sample or a subset of the study population. For example, the 
general population in City A includes 3,000,000 women. The study 
population in City A is defined as 500,000 healthy women aged 18 
to 44 years who reside in City A during a specified time period, 
and the RCT includes a sample of 500 women from the study 
population.
Investigators need to specify which individuals were studied and 
how they were selected. The scientific community needs to know 
the characteristics of the individuals who responded or failed to 
respond to the treatment, regardless of the success of the 
treatment. This information is essential for assessing whether the 
study results can be generalized to the study and general 
populations.
Eligibility Criteria. These criteria are the characteristics of the 
study population used to determine which individuals are eligible 
for inclusion in the clinical trial. Precise eligibility criteria and the 
reasons for their specification should be detailed in the planning 
stages of the trial. The impact that these criteria will have on the 
study design, on the recruitment of study subjects, and on the 
ability to generalize the findings from the trial must be considered. 
Eligibility criteria are most often described in two lists: inclusion 
criteria and exclusion criteria. In general, the number of 
exclusions should be minimized. In Examples 8.8 and 8.9, detailed 
inclusion and exclusion criteria for RCTs involving IUDs are 
provided.
Selection of Study Subjects
Defining the comparison groups is a critical step in designing 
the RCT. Treatment definition should focus on the most 
important question that the investigators think they can answer. 
The control treatment may be no treatment (a placebo) or the 











Pelvic Inflammatory Disease and Intrauterine Devices 
With and Without Strings
Background: An RCT was designed to evaluate the rate of pelvic in f la m m a to r y  
disease (PID) over a 12-month period among women who received intrauterine 
devices (IUDs) with strings (control group) and among women who received 
lUDs without strings (treatment group).
Eligibility criteria
Inclusion criteria: Women in good physical health who want IUDs and can be 
followed for at least 12 months. Each woman must:
•  Be a first-time IUD user.
• Be sexually active.
•  Have terminated last pregnancy at least 42 days before IUD insertion.
•  Have had at least one normal menstrual period since termination of last 
pregnancy.
Exclusion criteria: Before the IUDs were inserted, women provided a medical 
history and submitted to a physical examination that included a detailed pelvic 
examination, cultures for gonococcus from the cervix and anal crypts, and 
cultures for chlamydia from the cervix. Women with any of the following 
conditions were excluded from the study:
•  Uterine abnormalities, abnormalities that distort the uterine cavity or 
cervical canal, evidence of adnexal mass or pelvic adhesive disease, 
suspicious pelvic mass.
• Abnormal uterine bleeding, menstrual irregularities, history of 
hyperplastic endometrial disease, polyps, or carcinoma.
•  Postpartum endometritis or infected abortion, septic course after 
incomplete abortion or delivery.
•  Using antibiotics or having used antibiotics within three months.
•  Pelvic inflammatory disease:
- fever at time of IUD insertion ( ^  38° C)
- pelvic pain: excessive tenderness on pelvic palpation.
- purulent vaginal, urethral, or Skene’s glands discharge, 
detected either visually or by urethral massage; enlarged 
Bartholin’s glands (PID did not include mild vaginitis or 
cervicitis).
(Wheeler et al., 1985)
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Example 8.9  
Comparison of Two Copper Intrauterine Devices
Background: Long-term intrauterine device (IUD) use has the advantages of 
convenience and low cost. One of the newer IUDs, the TCu380Ag, may be 
as effective or more effective than other popular copper IUDs, such as the 
Multiload Cu375.
Research Hypothesis: The TCu380Ag performs as well or better than the 
Multiload Cu375.
Study Design: Parallel randomized clinical trial.
Eligibility Criteria: Healthy, sexually active women who gave informed 
consent were eligible to participate in the trial. Their last pregnancy 
terminated at least 40 days before the IUD insertion.
(Cole et al., 1984)
comparison group. For example, in contraceptive trials, the use of 
placebo controls is not ethical (Example 8.10).
Comparison of only two groups in any trial is the most efficient 
design and gives the maximum chance for being able to make 
some definitive conclusions for a limited number of study subjects 
(Peto et al., 1976). Pressures will always be exerted from various 
sources to study more than two groups. Efforts to include more 
than two groups should be resisted. Sometimes, investigators 
desire to evaluate the equality of more than one new treatment, 
perhaps because of lower cost, lower toxicity, fewer side effects, 
and other factors. Even in these instances, studying more than two 
groups tends to dilute study power and produce a less informative 
result. With two groups, a positive result is more likely, and a null 
result is more informative (Example 8.11). Treatments must be 
sufficiently different from each other so that it is biologically 
plausible that the outcome related to one treatment could be 
substantially different from the outcome related to others. Ideally, 
only treatments likely to differ substantially should be compared in 
an RCT (Peto et al., 1976).
Exclusions before randomization. Individuals who are excluded 
from the study before randomization do not affect the treatment
Randomized Clinical Trials
Example 8.10
Early Oral Contraceptive Research 
No Suitable Comparison Group
On May 11, 1960, the U.S. Food and Drug Administration (FDA) approved 
the marketing of oral contraceptives (OCs). Preclinical studies had begun nine 
years earlier. Between 1954 and 1956, clinicians assessed the pill’s safety and the 
dosage necessary to prevent pregnancy. In 1956, approximately 1,000 women were 
enrolled to use the pill for at least one year in a large efficacy study. Although 
the trial had several objectives, the most important objective was to demonstrate 
that the pill would be very effective in preventing pregnancy. A  convincing 
demonstration would help gain approval for marketing from the FDA. The 
demonstration was successful and approval was granted even though the study of 
OCs did not include a control group. There was no standard hormonal 
contraceptive against which to compare the effectiveness of the pill. Once the 
original pill was marketed, however, a standard existed to serve as a control for 
future experimental studies of OCs.
(McLaughlin, 1982)
Example 8.11
Randomized Clinical Trial Comparing Penicillin G 
and Kanamycin in the Treatment of Endometritis
A  variety of antibiotics can be used to treat endometritis (infection of the lining 
of the uterus) after childbirth. Consider a hypothetical study of the comparative 
effectiveness of several drugs that are used alone to treat endometritis: penicillin 
G, ampicillin, tetracycline, and kanamycin. Although it is tempting to study all 
four drugs in a single RCT, a definitive conclusion is more likely when comparing 
only two drugs at a time. Kanamycin is the standard treatment, but judging from 
antimicrobial coverage and cost factors, the researchers chose penicillin G as the 
most promising alternative. Hence, the preferred RCT design would compare 
penicillin G with kanamycin.
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comparison and do not introduce bias. Subjects might have to be 
excluded because they have a condition for which the treatment 
assigned in the trial may be contraindicated, because they are not 
likely to remain observable or because they are taking other 
medication.
However, exclusions made before randomization may affect the 
ability to generalize the results. As the number of excluded study 
subjects increases, the less generalizable the results become. 
Although the trial may be perfectly executed, it may have no 
relevance to the persons to whom the researchers wish to relate 
the findings.
The investigators must make sure that the inclusion and 
exclusion criteria are clearly specified and that they are applied 
before randomization. If they are applied before randomization, 
bias is not introduced. Criteria must be evaluated for sources of 
selection that would make the study sample atypical or 
nonrepresentative. Selection criteria that are too restrictive result 
in the selection of study subjects who are such a restricted subset 
of the study population that the results will have little meaning. 
Example 8.12 illustrates problems with restrictive eligibility 
criteria.
Example 8.12
Intrauterine Devices and Menstrual Blood Loss 
Restrictive Eligibility Criteria
An RCT was designed to evaluate the menstrual blood loss associated with 
two different intrauterine devices (IUDs). Since the investigator knew that 
menstrual blood loss increased substantially in users of most inert, 
nonmedicated IUDs, he established rigorous exclusion criteria based on 
hemoglobin levels. Women with even mild anemia were excluded from 
participation. Consequently, most women in his region were ineligible for 
enrollment in the trial. These strict criteria meant that it took a long time to 
recruit sufficient numbers of women for study and that only affluent, well- 
nourished women were enrolled. Thus, the generalizability of the findings of 
the study to the general population of women in the region was limited.
Randomization. Study subjects should be assigned to treatment 





and confounding biases, it is the preferred method of assigning 
individuals to treatment and control groups. Randomization ensures 
that study subjects have an equal chance of being assigned to either 
group and enhances the likelihood of comparability between the 
groups on all factors, known and unknown, measured and 
unmeasured. Allocating patients to treatment groups by random 
chance rather than by the clinician’s choice is essential to avoid 
selection bias. Without effective randomization, clinicians with a 
preference for or against a particular therapy may subconsciously or 
consciously exclude a subject or alter a study subject’s treatment 
assignment. Failure to randomize will likely introduce differences 
between the treatment groups and invalidate the results.
Randomization ensures that subjects are equally likely to be 
assigned to the treatment or control group. However, not all 
randomization schemes are equivalent (Table 8.13). Certain schemes 
that investigators label random are not really random and are 
therefore ineffective for controlling bias. In particular, some 
commonly reported methods are based on alternate assignment of 
patients, on chart number (odd or even), or on date of birth. These 
methods may influence the assignment decision, since personnel who 
assign treatment or refer patients may know in advance which 
treatment is next and may therefore decide a patient’s eligibility or 
schedule the patient’s referral according to treatment preferences. 
These are not truly random allocation schemes. Schemes such as 
shuffling a deck of cards or flipping a coin are random, but these 
methods can tempt investigators to intervene. For example, they may 
think, "We have had too long a series of heads," and decide to change 
the next assignment. Also, these schemes cannot be checked or 
reproduced. Using a table of random numbers is a preferred method 
because the table is random and reproducible. Even if the method of 
selecting study subjects is random, the investigators and the study 
subjects must not be able to suspect which treatment is next. That is, 
the randomization must be blinded. See the section on blinding in 
this chapter for more detail.
Balanced randomization, sometimes called pseudorandomization or 
restricted randomization, can be used to ensure that the number of 
study subjects allocated to each treatment group is approximately 
equal during the entire trial. Not only is this statistically efficient, but 
it ensures that no time trend in the allocation rates will exist and that 
bias is minimized even if a time trend in the prognosis of the patients
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Table 8.13
An Evaluation of Randomization Schemes
Scheme Evaluation
None reported by authors Poor
Alternate assignment
(chart number, date-of-birth, etc.)
Poor
Coin flipping or card shuffling, 
without blinding of the randomization
Fair
Coin flipping or card shuffling, 
with blinding of the randomization 
(e.g., sealed opaque envelopes)
Good
Random number table, with 
blinding of the randomization
Excellent
Random number table, balanced 
randomization with blinding and 
disguised block length
Excellent
exists for any reason. Balanced randomization is usually achieved 
by first determining the number of study subjects per block', then 
individuals are randomly assigned within each block so that half 
are in the treatment group and half are in the control group.
Balanced randomization is the preferred method of randomi­
zation as long as the investigators do not allow the block lengths 
to become known. Predicting the next treatment is more difficult 
with long block lengths (block lengths of ten are better than four) 
and with randomly varying the block lengths.
By design, randomization improves the balance of potentially 
confounding variables. The equal distribution of the measured 
and unmeasured variables in the treatment groups minimizes 
confounding bias. If randomization does not produce balanced 
groups, statistical techniques exist that allow the investigator to 
adjust for factors that are measured. However, we cannot adjust 
for confounding by factors that have not been measured.
Randomized Clinical Trials
Finally, investigators need to completely describe in their research 
reports the randomization scheme used in their RCT. Failure to 
describe the randomization scheme should cause readers to question 
the methods and results.
Steps for determining a balanced randomization include using 
blocks, using a random number table to select blocks, and concealing 
the treatment assignment. The following eight steps describe a 
method that randomizes and allocates approximately the same 
number of patients to each treatment group during the trial (Adapted 
from Peto et al., 1976).
Step 1. List all possible randomization blocks for a specified block 




For the present example, A  represents treatment assignment A, and B 
represents treatment assignment B. Blocks are set up to make sure that the 
randomization balances with every sixth patient; the block size equals 6. All 
combinations of 3 As and 3 Bs are listed. After every 6th patient, the number of 
patients assigned to treatment A  will approximately equal the number of patients 
assigned to treatment B.
All possible permutations or treatment sequences have to be listed. To 
determine how many different sequences are possible, use the following formula:
(8.14.1)
Number of (Block Size)!
possible sequences = -----------------------------------------
(Block Size/2) !*(Block Size/2)!
For the present example, a block size of six generates 20 sequences, which are 
listed in Table 8.15.
Number of 6! 6*5*4*3*2*1





AAABBB ABABAB BAAABB BABBAA
AABABB ABABBA BAABAB BBAAAB
AABBAB ABBAAB BAABBA BBAABA
AABBBA ABBABA BABAAB BBABAA
ABAABB ABBBAA BABABA BBBAAA
(Adapted from Peto et al., 1976)
Step 2 . Assign sampling numbers to each block of treatment 
sequences. Every block must have an equal number of sampling 
numbers so that each block has an equal probability of selection. 




Sampling Treatment Sampling Treatment Sampling Treatment Sampling Treatment
Number Sequence Number Sequence Number Sequence Number Sequence
00-04 AAABBB 25-29 ABABAB 50-54 BAAABB 75-79 BABBAA
05-09 AABABB 30-34 ABABBA 55-59 BAABAB 80-84 BBAAAB
10-14 AABBAB 35-39 ABBAAB 60-64 BAABBA 85-89 BBAABA
15-19 AABBBA 40-44 ABBABA 65-69 BABAAB 90-94 BBABAA
20-24 ABAABB 45-49 ABBBAA 70-74 BABABA 95-99 BBBAAA
(Adapted from Peto et al., 1976)
Step 3. Before you turn to a random number table, you must 
decide, once you have obtained a starting number, whether you 
will proceed up, down, left, or right in the chosen row or column 
in the random number table. For the present example, we 
decided to proceed down the column.
Randomized Clinical Trials
Step 4. Shut your eyes and, at random, make a mark on the 
random number table with a pencil dot. Select the two-digit number 




41 82 79 37 00 45 98 54 52 89 26 34
66 18 76 82 11 18 61 90 90 63 78 57
42 34 00 49 97 53 33* 16 26 91 37 58
90 84 22 16 26 96 54 11 01 96 58 91
33 43 01 32 58 39 19 54 56 37 23 38
17 89 37 04 18 32 13 45 59 03 91 08
36 87 98 73 77 64 75 19 05 61 11 64
15 58 19 68 95 47 25 69 11 90 26 19
45 52 27 35 86 81 16 20 37 60 39 35
72 72 81 84 36 58 05 10 70 50 31 04
06 68 52 50 39 35 92 28 18 89 64 37
95 73 80 92 26 49 54 30 41 21 06 62
96 23 16 46 15 51 60 31 55 27 84 14
34 96 32 68 48 22 40 17 43 25 33 31
07 19 94 46 17 51 03 73 99 89 28 44
.37 08 08 46 56 76 29 48 33 87 70 79
18 01 67 19 29 49 58 67 68 56 27 24
08 79 18 78 00 32 86 74 78 55 55 72
(Adapted from Peto et al., 1976)
Step 5. From the two-digit starting point, list the series of two-digit 
random numbers from that point down (up, right, left) the column 
(row). The number of random numbers to list is equal to the total 
sample size desired divided by the block size.
For the present example, the required sample size is 60 partici­
pants, or 30 in each treatment group. Therefore, the required 
number of two-digit random numbers needed to establish a treatment 
sequence for 60 participants is the number of participants (60) divided 
by block size (6). Thus, starting with the number 33 (Step 4) list the 
ten random numbers down the column in Table 8.17: 33 54 19 13 75 
25 16 05 92 54.
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Step 6. For each random number (Step 5), find the corres­
ponding block or treatment sequence (Table 8.16). For our 
example, the treatment sequences are:
(33) (54) (19) (13) (75)
ABABBA BAAABB AABBBA AABBAB BABBAA
(25) (16) (05) (92) (54)
ABABAB AABBBA AABABB BBABAA BAAABB
Step 7. Consecutively number opaque envelopes for the number 
of participants in the trial. Then, in sequence, insert the letter (A 
or B: the treatment group assignment corresponding to the letter) 
into the envelopes.
For the present example, 60 envelopes were numbered from 
1 to 60. Letters corresponding to the indicated treatments were 




Envelope Treatment Envelope Treatment Envelope Treatment
Number Assigned Number Assigned Number Assigned
1 A 9 A 17 B
2 B 10 A 18 A
3 A 11 B 19 A
4 B 12 B . . .
5 B 13 A . . .
6 A 14 A • « ■
7 B 15 B 59 B
8 A 16 B 60 B
Step 8. As each participant is entered into the trial, determine 
treatment assignment by opening the next envelope in sequence.
Blinding. In any clinical trial, bias is a major concern and 




















several points in time during a clinical trial, from the design stage 
through data analysis and interpretation. The general solution for 
managing bias in an RCT is to keep study subjects and the 
investigator blinded to the exact treatment assignment. Blinding can 
be applied to the randomization process, the administration of the 
treatment, and to the assessment, classification and evaluation of the 
outcome.
The randomization process must be blinded. The investigator, the 
evaluator, and study subjects must not be able to suspect which 
treatment is next. Several processes may be used to blind the 
investigator, clinicians, and study subjects about the randomization of 
treatment assignments:
• Inserting assignments in consecutively numbered, opaque 
envelopes.
• Making assignments by telephone from a central office.
• Having drugs prepackaged and numbered for consecutive patients 
according to the randomization scheme.
The use of consecutively numbered, opaque envelopes is one of the 
most practical methods. Persons who implement the randomization 
process must not be involved in the enrollment of study subjects, 
treatment, or evaluation.
Single blinding occurs when the treatments have been concealed 
from trial participants. Double blinding occurs when the treatments 
have been concealed from both the investigator and the study 
subjects. Triple blinding occurs when the clinician who is evaluating 
outcome (the evaluator) is not the investigator and when the study 
subjects, the investigator, and the evaluator are unaware of the 
treatment assignments. Because both investigators and study subjects 
are likely to have strong hopes and prejudices about a trial, biases are 
likely to occur unless precautions are taken.
Blinding study subjects about the treatment assignment is desirable. 
Blinding study subjects is necessary if dropout or noncompliance is 
likely to result from patients’ knowing their therapy and becoming 
discouraged.
Blinding investigators about the treatment assignment is also 
important. Knowing that a patient is receiving what is suspected to be 
the less effective treatment may lead to compensatory efforts that 
would be detrimental to the study. For example, the investigator may
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institute some additional adjunctive therapy not specified in the 
protocol, or an assistant may decide or be given orders to monitor 
study subjects receiving certain treatments more closely than 
required in the protocol. The most serious problem involves the 
investigator who is inclined to make sure that the study subject 
who is more severely ill receives the treatment suspected to be the 
most effective.
Blinding study subjects and the evaluator about the outcome is 
also critical, especially if the outcome is subjective. In some 
situations, blinding about the outcome is not possible (e.g., if the 
outcome is death). A study subject who has knowledge of the 
expected outcomes may be more likely than an uninformed subject 
to report data that support the desired outcome. Evaluators who 
have prejudices about the conclusions of the trial may be inclined 
to diagnose borderline symptoms and situations as the outcome 
that supports their expectations about the proposed new treatment.
Of course, in some trials not all types of blinding are possible. 
For example, if an operative treatment is being compared to a 
drug treatment, it is impossible to blind the surgeon and patient 
about the treatment. In this case, using a blinded evaluator may 
be the most appropriate approach. Examples 8.19 and 8.20 
illustrate blinding the study subject and blinding the clinician who 
evaluates the outcome.
Example 8.19 
Estrogen In jection and Postpartum  Breast Engorgement
A  hypothetical study is designed to compare the efficacy of an injection of 
estrogen immediately after delivery with no therapy in preventing the pain of 
postpartum breast engorgement among women who choose not to nurse. The 
outcome measure is the amount of pain reported by the women each day 
after delivery. For a given level of discomfort, women who receive the 
injection may report less pain because they know they have been given a 
treatment they believe to be effective. This bias (called ascertainment or 
information bias) may be avoided by using a placebo injection instead of no 












Daikon Shield Versus Lippes Loop and Pelvic Inflammatory Disease
A hypothetical study compares rates of pelvic inflammatory disease (PID) 
among women who use the Daikon Shield and women who use the Lippes Loop. 
The outcome measure is the physician’s diagnosis of PID. Since the type of 
intrauterine device (IUD) can be determined by viewing the tail protruding from 
the cervix, the physician evaluating a patient with symptoms would know the 
patient’s treatment group. If the physician had read or heard that the Daikon 
Shield was associated with more infections than other devices, this information (or 
clinical hunch) might influence the diagnosis. Given the same symptoms, a 
patient known to have a Daikon Shield in place might be more likely to be 
diagnosed with PID than a patient with a Lippes Loop. The physician could be 
blinded by using the same type of tail for both IUDs and by having different 
persons do the insertions and the follow-up examinations.
Sam ple Size
The need to determine the requisite sample size is critical in the 
design of an RCT. (Sample size and power estimation are discussed 
in Chapter 5.) This is especially true because RCTs are held in such 
high esteem. Yet many researchers do not design sufficient statistical 
power into their studies (i.e., their sample sizes are too small to 
answer, with assurance, the questions posed). A review of 71 negative 
randomized clinical trials revealed that 67 had a greater than 10% 
chance of missing a true 25% improvement in therapy. Many 
treatments were labeled as no different from the standard or control 
treatments in trials that had inadequate samples (Frieman et al., 
1978).
Ethical Concerns
Unlike other studies, RCTs allow the investigator to assign study 
subjects to the comparison and treatment groups. This scientific 
meddling in the course of individual lives forces the investigator to 
confront important issues concerning the ethics of human 
experimentation.
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The term human experimentation recalls for many persons sad 
chapters in human history when experiments were carried out on 
unwilling human subjects (e.g., prisoners of war or men and 
women institutionalized for diagnoses of mental illness). On the 
other hand, the development of modern medicine has been due, in 
large part, to human experimentation. Since the first treatment 
was given to the first patient, practitioners of medicine have been 
experimenting empirically on patients in uncontrolled settings and 
have been changing treatments as dictated by the response of the 
patient. The development of RCTs has been a major 
advancement for medicine because when properly conducted,
RCTs provide valid, useful, and reproducible results. Where 
disagreement exists concerning choice of treatments, a 
well-conducted and well-reported RCT offers hope of determining 
the preferred treatment. In this sense, it may be unethical not to 
perform an RCT to answer an important medical question 
(Schafer, 1982).
Conflict of Obligations
RCTs may present a conflict of obligations to the clinician or 
investigator. Most western physicians are bound by an oath (often 
a modern version of the Hippocratic Oath) to make the welfare of 
the individual patient of paramount importance. An RCT may 
appear to be in direct conflict with this obligation. Although the 
patient’s welfare is the principal responsibility of the clinician, the 
clinician-investigator has the long-term perspective—the pursuit of 
knowledge may help other patients in the future.
Conflict exists between the obligation to the individual and the 
obligation to the groups. In an RCT, individual treatment, 
considered the patient’s right in western medicine, may have to be 
compromised to adhere to random allocation and other RCT 
rules. This has been interpreted by some to be a violation of the 
clinician’s obligation to the individual patient. The question can 
be stated as "When, if ever, is it morally justifiable to sacrifice the 
patient’s right to completely individualized treatment for the 
benefit of scientific progress?" (Schafer, 1982). When contem­
plating this question, one must consider two types of RCTs:
Randomized Clinical Trials
• One of the treatments is the accepted best therapy available today, 
and the other is a new therapy that shows promise to be even 
more effective.
• One treatment is a placebo and the other is a new therapy that 
shows promise for treating a disease for which no effective 
therapy existed in the past.
There are consequences to not performing RCTs. Studies 
performed without adequate controls may seriously mislead clinicians 
regarding choices of therapy. Clinicians may feel obligated to provide 
treatments that are, in fact, inferior. Thus, the investigator should 
carefully consider the potential risks and benefits of a given RCT.
Informed Consent
Informed consent is required for prospective study subjects in an 
RCT. Study subjects must be informed about all aspects of the trial 
that might influence their participation. They need to be aware of the 
known risks and benefits of the proposed treatments. They have a 
right to choose not to participate, or if enrolled, they have a right to 
withdraw at any time without penalty. Study subjects being recruited 
into an RCT clearly have a right to know that they are taking part in 
an experiment and that their treatment is decided by chance. It is 
unethical not to advise prospective study subjects of the method by 
which their treatment will be chosen. Some investigators fear that 
this disclosure will discourage patients from cooperating. Patients 
seek out clinicians who will base their therapy on training and clinical 
experience, not on the luck o f the draw. Some investigators feel that 
adequate numbers of patients cannot be recruited if this disclosure is 
made. However, since the outcome from the proposed therapy is 
admittedly unknown (excluding placebo studies), no material 
information is withheld.
When investigators plan an RCT, they likely have doubts about the 
effectiveness of a treatment but may have a treatment preference (a 
hunch about which treatment is better, based on clinical experience). 
When investigators have a treatment preference, it is difficult for 
them to be truly indifferent to the alternatives being tested. Can they 
ethically withhold their opinions from patients considering entering 
the study? On the other hand, clinical impressions in the absence of 
scientific controls are highly questionable. What are the ethical
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consequences of providing well-intended, but possibly incorrect, 
advice to a patient considering taking part in an RCT?
In summary, the ethical issues need careful consideration before 
implementing an RCT. Many needed RCTs have not been done 
because of ethical considerations based on suggestive evidence.
This suggestive evidence frequently consists of clinical impressions, 
small inconclusive studies, or merely bias. In other words, ethical 
considerations can provide an easy justification for not doing an 
RCT—an action that can in itself be unethical.
Data Analysis Methods
The RCT study design determines the types of analyses that may 
be performed. In clinical trials, treatment data are collected for 
groups of study subjects who are comparable except for the 
treatment assigned. The eligibility criteria are used to select study 
subjects based on a specific select set of characteristics. For other 
characteristics, investigators rely on randomization to help ensure 
the comparability of study subjects. However, even when eligibility 
criteria are used and randomization is properly implemented, there 
is no guarantee that comparison groups will be homogeneous in 
characteristics other than the treatments.
Baseline and Follow-up Data
Data from clinical trials can be divided into two types: 
information collected from study subjects when they are admitted 
to the study (baseline data), and information collected from study 
subjects during follow-up (follow-up data). The baseline data 
provide researchers with health or demographic profiles of study 
subjects and with a description of the study group(s). With follow- 
up data, researchers are able to evaluate each participant’s 
response to his or her assigned treatment and to determine the 
overall response of each treatment group. Together, baseline and 
follow-up data provide information on changes in a study subject’s 
health that could be attributed, for example, to a treatment or, 
alternatively, to a consequence of a baseline characteristic.
Randomized Clinical Trials
Baseline Data Analysis
Baseline data are collected and analyzed to assess comparability 
between the treatment groups. The distributions of the baseline 
characteristics in the study groups should be compared. When a 
difference in outcomes between study groups is observed, this 
difference may have one of two causes: one treatment may be 
superior to the alternative treatment, or the group that exhibited the 
superior performance may be composed of subjects who would have 
done better regardless of the treatment they had been assigned.
Analysis table o f characteristics o f study subjects. Comparison of 
baseline characteristics between treated and untreated study subjects 
may be visual. Statistical testing to determine if the distributions are 
different is not essential. Even the successful use of randomization is 
compatible with some differences in variable distributions; and if 
distributions of important (prognostic) baseline variables differ, 
regardless of whether or not the differences are statistically 
significant, the differences may be related to the outcome.
Table 8.21 presents arithmetic means for patient characteristics 
according to treatment groups (doxycycline and placebo) and women 
lost to follow-up in an RCT designed to evaluate the effectiveness of 
200 mg of doxycycline given orally at the time of IUD insertion in 
reducing the incidence of PID. Treatment groups and women lost to 
follow-up had similar ages, education, number of live births and 
spontaneous abortions, and coital frequency per week (Sinei et al., 
1990). Statistically significant but practically unimportant differences 
existed for education and live births.
Follow-up Data Analysis
In most Phase III clinical trials of contraceptives, the primary 
outcome variable provides incidence data: the number of 
pregnancies, the number of discontinuations of specific contraceptives, 
the number of IUD expulsions, etc. Outcome frequencies, the 
number of individuals receiving the study treatments, and how long 
the individuals participated in the study are used to evaluate the 
treatments. Some contraceptive clinical trials have a relatively short 
period of follow-up—days or a few weeks.
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Age 25.5 25.3 25.6 0J51
Education 9.5 9.7 9.2 0.02
Live births 2.5 2.3 2.4 0.03
Spontaneous
abortions 0.2 0.2 0.2 0.78
Coital
frequency/week 2.4 2.4 2.5 0.48
•One-way analysis of variance on the three groups. 
(Sinei et al., 1990)
Short period o f follow-up. Contraceptive clinical trials, which 
are generally designed to evaluate long-term contraceptive use, 
may produce results within a few days or weeks after study 
subjects have received their treatment. Clinical trials of 
sterilization techniques, for example, represent an important class 
of contraceptive studies, in which evaluations after a short period 
of follow-up are important. These studies typically focus on 
complications associated with various sterilization techniques or 
their use by different types of family planning professionals. In 
other clinical trials, secondary outcome variables may produce 
results within a few days or immediately. For instance, in an IUD 
study focusing on expulsion as the primaiy variable, investigators 
may be interested secondarily in the percentage of women 
reporting pain at IUD insertion.
Lengthy period o f follow-up. Most contraceptive clinical trials 














these studies, how the events were distributed throughout the follow- 
up period is important. For clinical trials with a lengthy follow-up 
(three months or more), the investigators are interested not only in 
whether the event of interest occurs but also in how long it takes for 
the event to occur. The analysis of the time until the occurrence of 
the outcome of interest is called life-table analysis. The methods for 
conducting a life-table analysis are described in detail in Appendix 3.
Analysis table fo r  proportions and relative risk. The symbol p  
represents a proportion calculated from the study data and the symbol 
n represents the sample size used in the calculation of the proportion. 
p  is number of study subjects who exhibited the primary outcome 
event divided by the total number of study subjects. The proportions 
(or percentages) of the primary outcome event for the different . 
treatment groups and the relative risks are calculated as shown in 
Table 8.22.
In Example 8.23, the proportion of women with postoperative 
morbidity who were sterilized by a physician is 9/149 = 0.06. For 
women sterilized by a nurse-midwife, the proportion with post­
operative morbidity is 10/143 = 0.07. Thus, 1% of the women who 
had had sterilization surgery by a nurse-midwife had a postoperative 
complication, whereas 6% of the women who had had sterilization 
surgery by a physician had a complication.
In RCTs, the relative risk may be used to measure the magnitude 
of the association between the treatment and outcome under study. 
Relative risk is the incidence of the outcome among the study subjects 
who received the specified treatment (8.22.1) divided by the incidence 
of the outcome among the study subjects who received no treatment 
(placebo) or who received the standard treatment (8.22.2). This 
relative risk, also known as cumulative incidence relative risk (CIR), 
measures the risk of the study subjects developing the outcome during 
the entire study period (8.22.3). In Example 8.23, the CIR =
0.07/0.06 = 1.2. Because the confidence interval includes 1.0, we 
would conclude that women who had a tubal sterilization performed 
by a nurse-midwife had the same risk for postoperative morbidity as 
women who had a tubal sterilization performed by a physician.
Sometimes, person-time of observation is used as the denominator 
in the relative risk calculation instead of the number of people 
enrolled in the study. This type of relative risk is known as incidence 
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Tubal Sterilization by Nurse-Midwives and by Physicians
In a study of complications occurring with postpartum minilaparotomous tubal 
sterilization procedures, those performed by nurse-midwives were compared with 
procedures performed by physicians. The event of interest was a postoperative 
problem including mild pyrexia, respiratory infection, cystitis, or wound 
breakdown. Volunteers who had requested sterilization before delivery were 
randomly allocated to a nurse-midwife or a physician for surgery. The evaluation 





bv nurse-midwife bv nhvsician
Women with 
postoperative 
morbidity 10 (a) 9 (b)
Women without
postoperative
morbidity 133 (c) 140 (d)
Total 143 (n .)  149 (n0) 192(t)
Proportion with
postoperative
morbidity 10/143 = 0.07 9/149 = 0.06
CIR = 0.07/0.06 = 1.2 (95% Cl: 0.5 - 2.8)
(Dusitin et al., 1980)
simultaneously considers the number of persons under observation 
and the duration of observation for each person; that is, the actual 
time of observation must be computed for each individual in the 
group (Table 8.24). For example, if 10 persons participate in a study 
for 10 years, they are said to have contributed 100 (10 persons * 10 
years) person-years of observation. The same figure may be derived 




Analysis Table for Incidence Density Relative Risk
Treatment No Treatment Total





Incidence Density Relative Risk (IDR) = a/n,
b /n 0
where
a is the number of study subjects with the outcome in the treatment group, b 
is the number of study subjects with the outcome in the group that received 
no treatment, n 1 is the person-time in the treatment group, and n 0 is the 
person-time in the group that received no treatment.
(Rothman and Boice, 1979)
six months. This method allows the investigator to more 
satisfactorily manage the situations in which the dates when the 
study subjects enter the trial vary, or in which some study subjects 
are no longer under observation during the course of the study 
because of death, loss of contact, or other reasons.
Exclusions after randomization. As a general rule, all patients 
who are randomized should be analyzed. Furthermore, the 
patients should be analyzed as part of the treatment group to 
which they were initially assigned. Every effort must be made to 
determine the outcome for all study subjects randomized. 
Exclusions after randomization (e.g., withdrawals, losses, and 
deviations) can bias the randomized treatment comparison and 
thus should be carefully scrutinized. Inappropriate approaches to 
the handling and analysis of these patients can lead to subtle, well 
disguised, yet serious errors in research design and results.
Investigators have given ineligibility as a stated reason for 
exclusion after randomization when they have eventually 
discovered that the study subject did not meet the inclusion 
criteria. Decisions to withdraw study subjects under these 











clinicians who have a treatment preference for a specific patient may 
withdraw the patient if randomized to the wrong group. As another 
example, the patient whose health continues to decline on the 
assigned treatment would likely attract more attention and therefore 
be more likely to be categorized as ineligible. The valid approach is 
not to allow any exclusions after randomization for the eventual 
discovery of patient ineligibility.
One exception is when differential diagnosis of eligibility criteria is 
difficult. The investigators might develop a process so that 1) the 
same information is collected from each patient at the time of 
randomization, 2) the information is reviewed at a central location, 
and 3) the clinician is blinded to the treatment allocated to the 
patient. Patients not satisfying the eligibility criteria could then be 
withdrawn.
Postrandomization pretreatment outcome pertains to any outcome 
(such as death) that occurs after randomization but before the 
treatment begins, before the treatment regimen is completed, or 
before the treatment theoretically could produce an effect. Decisions 
to withdraw study subjects who were diagnosed with the outcome 
after randomization but before treatment also introduce bias. For 
example, in an RCT of the effect of a drug on death, the investigator 
decided to withdraw as not anafyzable all patients who died after 
randomization but before treatment began and also all patients who 
died without receiving at least seven days of the treatment. This rule 
is called the 7-day rule since the drug would not have any effect, 
theoretically, for at least seven days. This seems intuitively attractive, 
since none of the deaths could be attributable to the treatment. In 
essence, however, the same argument could be used to exclude all the 
deaths during the entire study interval in the placebo group, since 
none of them, theoretically, would be related to treatment.
When such rules are instituted as part of the protocol before the 
trial has begun, only the impact of the randomization may be reduced. 
If rules are instituted after the trial has begun, the actions may lead to 
biased and invalid results. Therefore, all randomized patients should 
be analyzed. This is especially true since it is often difficult to 
determine whether the rules were instituted before or after the start 
of the trial. Planned or unplanned, the exclusion of not anafyzable 
outcomes is not acceptable in the analysis of randomized clinical trials 
(Meier, 1981).
When study subjects are followed up, sometimes they are lost to
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farther involvement in the trial for various reasons, such as moving 
away or disinterest. The study must retain as many study subjects 
as possible. Bias is likely to occur if the two treatments differ in 
unpleasantness, toxicity, efficacy, or any way that affects loss 
differently. There are no acceptable reasons for losing study 
subjects.
Although losses may not be completely eliminated, methods to 
minimize them must be developed. For example, study subjects 
who are likely to be lost should be excluded before randomization. 
When study subjects do not return, extensive procedures can be 
implemented to locate them by telephone inquiries, letters, or 
special visits by research assistants. Analysis should consider 
differential rates of loss between the treatment groups. If losses 
do occur, analyses should include their outcomes up to the time 
of loss.
Some investigators suggest that if a study subject deviates from 
the protocol or the assigned treatment, that person should not be 
included in that treatment group in the final analysis (or should be 
included only up to the point of deviation). Again, this approach 
is intuitively attractive. However, omitting study subjects who 
deviate from the protocol is a serious error, since the group that 
deviates from one protocol and the group that deviates from the 
other protocol may be so different that the treatment comparison 
in the remaining study subjects may be seriously biased (Peto et 
al., 1976).
All the study subjects who deviate from the protocol should be 
followed and analyzed in the group to which they were originally 
assigned. In Example 8.25, the study subjects who deviated from 
the antibiotic group, therefore, must be categorized in the 
antibiotic group for the analysis. The correct procedure is to 
compare the group that was randomly assigned to antibiotics with 
the group that was randomly assigned to placebo, no matter what 
happened to them after assignment. Then the results address the 
issue of whether a policy of antibiotics for PID is superior to a 
policy of no antibiotics (Figure 8.26).
It might seem difficult to deal with exclusions, withdrawals, 
losses, and protocol deviants because of the many options that 
seem logical, ethical, and medically sound. However, with rare 
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Oral Antibiotics and Pelvic Inflammatory Disease Febrile Morbidity
To determine whether the incidence of febrile morbidity from pelvic 
inflammatory disease (PID) is decreased by oral antibiotic treatment, patients 
with PID are randomly assigned to either the antibiotic group or the placebo 
group. However, 25% of the patients in the antibiotic group deviated from the 
protocol and did not take their medication. In effect, the patients in the antibiotic 
control group who deviated from the protocol received the same treatment (i.e., 
nothing as the placebo group). Should the patients who deviated from the 
protocol then be excluded totally or should they be merged with the placebo 
group and compared only to the antibiotic patients who adhered to the protocol? 
The response for both options is emphatically negative because the members of 
the two groups would no longer be comparable. The patients who did not take 
the antibiotics were likely to be in better health generally or were likely to have 
felt better because of less serious PID. Exclusion of the patients who deviated 
from the protocol potentially would leave only the more serious cases in the 
antibiotic group and produce a bias in the treatment comparison. If these 
patients were included in the placebo group, then not only do the more serious 
cases remain in the antibiotic group, but the placebo group has been infiltrated 
with potentially less serious cases. Again, the treatment comparison is biased.
The appropriate paths for treatment assignment and analysis for patients who 
have been randomized is illustrated in Figure 8.26.
Figure 8.26
Flow Diagram of Patients Randomized in a Randomized Clinical Trial 
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analyzed in the group to which they were randomized. Failure to 
follow this rule may introduce bias (Examples 8.27 and 8.28).
The exclusions described in Example 8.27 biased the results.
The study reported a 32% reduction in death from cardiac causes 
(Anturane Reinfarction Trial Group, 1978). When ineligible and 
unanafyzable subjects were included, the effect was adjusted to a 
21% reduction (Temple and Pledger, 1980). Subsequently, the 
Food and Drug Administration (FDA) advisory committee 
announced that sulfinpyrazone could not be labeled and advertised 
for the prevention of death in the critical months after a heart 
attack. The detailed review of the study indicated that the original 
exclusions were inappropriate (Temple and Pledger, 1980).
In Example 8.28, the authors concluded that one can justify 
almost any conclusion, depending on the analysis chosen (Coronary
Example 8.27
Anturane and Myocardial Infarction
Anturane (sulfinpyrazone) is a drug used to treat gouty arthritis; it also 
appears to have antithrombotic (anticlotting) effects. To test the ability of 
this drug to prevent repeat myocardial infarction (heart attack) in persons 
having had a recent myocardial infarction, a randomized clinical trial was 
conducted to compare Anturane and a placebo. Subjects were followed for a 
mean of eight months, and rates of death from cardiac causes were compared 
for the two groups.
This apparently well-conceived and well-executed RCT contains good 
examples of inappropriate exclusions. For example, seven patients who had 
received treatment until or almost until the day of death were withdrawn as 
ineligible. Six were in the sulfinpyrazone group and one in the placebo group. 
Moreover, in a detailed Food and Drug Administration (FDA) staff review, 
auditors found that patients from the placebo group who could have been 
declared ineligible, based on similar criteria, had not been declared ineligible. 
The study plan never mentioned an intent to exclude ineligible patients after 
entry, particularly patients who had died. Also, the Anturane Trial used the 
7-day rule. Any death to a patient who had not received treatment for at least 
seven days or who died more than seven days after termination of treatment 
was declared as not anafyzable.
(Anturane Reinfarction Trial Research Group, 1978)
Randomized Clinical Trials
Drug Project Research Group, 1980). Clearly, when analyses are 
conducted on subgroups of randomized patients, the many advantages 
provided by randomization are lost. The only valid comparison 
includes all randomized patients.
Example 8.28
Cloflbrate and Cardiac Deaths
An RCT compared the effectiveness of various cholesterol-lowering drugs for 
preventing cardiac deaths in men who had survived a myocardial infarction. 
Clofibrate was compared with a placebo. The five-year total mortality rate among 
cloflbrate patients was 20.2%; this rate was not significantly different (p = .55) 
from the placebo patients (20.9%). Had patients who deviated from the protocol 
in the cloflbrate group been eliminated (80% adherence), the resulting rate,
15.0%, would have been significantly different from the placebo group. However, 
these exclusions were demonstrated to be unacceptable when elimination of the 
patients who deviated from the placebo group resulted in a mortality rate of 
15.1% —approximately equal to the 15.0% for the clofibrate group.
(Coronary Drug Project Research Group, 1980)
Controlling for Confounding in the Analysis
By design, confounding will not likely occur in an RCT, especially 
one that has been well conceived and carefully conducted. In general, 
the random assignment of study subjects to treatment groups 
effectively balances potential confounding variables by equally 
distributing the measured and unmeasured variables between the two 
groups. Although confounding could result from disparate 
distribution that occurred by chance, the possibility that confounding 
could occur is small. If the investigator suspects that the association 
between the treatment and the outcome is confounded by a third 
variable, standard statistical methodologies may be used to check and 
adjust for the confounding.
Effect Modification
Each subject who enters a clinical trial brings a set of personal 
characteristics (age, parity, etc.) that may be related to the study
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subject’s response to the treatment. We have already discussed 
these concepts in the section on baseline data. It is often 
informative to compare the effectiveness of treatments in 
subgroups of study subjects whenever we have reason to suspect 
that the reaction to the treatments may be different among these 
subgroups. Table 8.29 presents the relative risks of unscheduled 
IUD-related visits according to sexually transmitted disease (STD) 
culture status at time of IUD insertion: no gonorrhea and no 
chlamydia, gonorrhea positive only, and chlamydia positive only 
(Sinei et al., 1990). For this RCT of doxycycline prophylaxis at 
time of insertion and the risk of IUD-related pelvic infection, the 
risk of an unscheduled IUD-related visit differed according to STD 
culture status at the time the IUD was inserted. Among the 
women whose cultures were negative for both gonorrhea and 
chlamydia, those who were treated with doxycycline had a 
statistically significant lower risk of an unscheduled IUD-related 
visit [CIR = 0.62 (95% Confidence Interval: 0.45 - 0.86)] than 
women who received the placebo. Among the women whose 
cultures were positive only for gonorrhea, the treated women also 
had a reduced risk of an unscheduled visit, although the estimate 
was not statistically significant. Finally, among the women whose
Table 8.29
Rates and Relative Risks of Unscheduled Intrauterine Device—Related Visits 
During the First Month by Culture Status at the Time of 
Intrauterine Device Insertion and by Treatment Group
Culture Status







or chlamydia 8.1% 13.0% 0.62 (0.45 - 0.86)
Gonorrhea 
positive only 10.5% 25.9% 0.41 (0.10 - 1.7)
Chlamydia 
positive only 10.4% 11.1% 0.94 (0.41 - 2.1)
(Sinei et al., 1990)
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cultures were positive only for chlamydia, the treated women had 
approximately the same risk of an unscheduled IUD-related visit as 
women who received the placebo. Each STD culture status group 
was analyzed separately. Because the risk of an unscheduled IUD- 
related visit differed according to culture status at the time of IUD 
insertion, STD culture status is considered an effect modifier.
Advantages and Disadvantages of 
Randomized Clinical Trials
Clinical trials have more advantages than disadvantages:
• First and foremost, randomization is the only effective method 
known to control selection bias.
• Randomization will also likely balance the potential confounding 
variables.
• An RCT allows standardization of eligibility criteria, the 
exposures, and outcome assessments.
• An RCT is statistically efficient since equal numbers of exposed 
and unexposed are studied.
• An RCT is statistically efficient since not much statistical power 
is lost if and when confounding is controlled for in the analysis.
• An RCT is theoretically attractive since many statistical methods 
are based on the assumption that subjects are randomly assigned 
or selected.
• An RCT has concurrent comparison groups; any outside 
intervention is less likely to influence results since it should affect 
both groups equally.
Disadvantages include the following:
• Design and implementation of RCTs may be complex and 
expensive.
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• RCTs can be subject to a lack of representativeness: patients 
who volunteer may differ substantially from the general 
population and the study population.
• An RCT may be open to ethical challenges: is it ethical to 
withhold a treatment from one group?
• Sometimes RCTs are impractical.
Scientifically, RCTs with blinding and adequate sample size and 
power are the ideal study design. Although an RCT is 
conceptually a more difficult design than a cohort study, it is 
probably easier to conduct correctly. In other epidemiologic study 
designs, selection bias and confounding may be difficult to manage. 
In general, a simple analysis suffices in the RCT, and selection and 
confounding bias are addressed adequately. Hence, the increased 
complexity in designing and implementing an RCT (including the 
randomization process, blinding, and the need for an adequate 
sample size) is more than compensated for by the ease of analysis 
and by the potential for increased validity of the results.
Randomized Clinical Trials
Practice Exercises
1. Circle true (T) or false (F).
(a) T /F  Study subjects are allowed to select their treatments.
(b) T /F  In the crossover design, each subject receives both treatments.
(c) T /F  A potential problem with the parallel design is the carryover effect.
(d) T /F  A major appeal of the crossover design is its efficiency.
(e) T /F  In a randomized clinical trial, the study population is composed of
study subjects randomly assigned as treatment or control.
(f) T /F  In a randomized clinical trial, inclusion and exclusion criteria are
implemented after randomization but before treatment.
(g) T /F  Random assignment to a treatment or a control group takes place
after screening for eligibility and consent to participate.
(h) T /F  With a limited number of patients, a definite conclusion is more
likely if the main comparisons are between two treatment groups.
(i) T /F  When attempting to determine if a new treatment is better than the
standard treatment, it must be biologically plausible that the 
outcomes are substantially different from each other.
(j) T /F  Sample size issues minimally affect conclusions in a randomized 
clinical trial.
(k) T /F  Exclusions before randomization do not bias randomized treatment 
comparison.
(1) T /F  Exclusions before randomization do not affect the extrapolation of 
the results.




(n) T /F  Bias can result if study subjects in a randomized clinical trial are lost 
to follow-up.
(o) T /F  Study subjects who deviate from protocol in a randomized clinical 
trial need not be followed.
(p) T /F  Study subjects who do not adhere to the prescribed treatment in a 
randomized clinical trial should be analyzed as a separate group.
2. Multiple choice. Select one response.
2.1 Which two of the following approaches to randomization are 
recommended?
(a) Alternate assignment of patients by chart number
(b) Alternate assignment of patients by date of birth
(c) Coin flipping
(d) Card shuffling
(e) Use of random number table
(f) Balanced randomization
2.2 Which type of blinding is recommended and feasible when a surgical 
treatment is being compared to a drug treatment? Choose one.
(a) Single blinding: surgeon
(b) Single blinding: clinician
(c) Double blinding: patient and clinician
(d) Double blinding: patient and surgeon
(e) Triple blinding: surgeon, patient, and clinician
3. Arrange these steps of the recommended randomization method in the correct 
order by numbering them 1 through 4.
  Use a random number table to select blocks from the master list of
randomization blocks.
  Based on the randomly selected blocks, put individual treatment
allocations in opaque envelopes.
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As study subjects enter trial, open envelope. 
Set up a master list of randomization blocks.
4. For an RCT that compares a new treatment A with a standard treatment B, 
answer the following questions:
(a) Calculate the number of possible sequences of block size four.
(b) List all possible sequences for treatments A and B with the block size of 
four and number the sequences consecutively, using integers beginning 
with the number 1.
(c) Your study requires 20 subjects in each of two treatment groups. 
How many blocks will you need to select from the master list?
Chapter 8
(d) The following is a list of one-digit random numbers. Beginning with the 
first number, underline the numbers you can use to select blocks from the 
master list.
8 7 4  1 8 2 7 9 3 7 0 0 4 5 9 8 5 4 5 2 7 9 0
(e) Using the random numbers in (d), list the blocks from (c) in the order 
you selected them.
5. Circle true (T) or false (F).
(a) T /F  Follow-up data describe the characteristics of the study subjects.
(b) T /F  Baseline data analysis evaluates whether study groups are
comparable.
(c) T /F  Follow-up data analyses allow researchers to evaluate the response
to treatment.
(d) T /F  Statistical tests are important for comparing the baseline
characteristics in the treatment and the control groups.
(e) T /F  When the 95% confidence interval for the difference in proportions
includes zero, the results are not statistically significant.
(f) T /F  The RCT is an inexpensive type of research design.
(g) T /F  One disadvantage of RCTs is that they do not ensure that each
eligible subject has an equal chance of being in the treatment or the 
control group.
(h) T /F  Outside intervention is unlikely to affect results, since it would
affect treatment and control groups equally, especially if the 
investigator uses balanced randomization.
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6. Consider the following randomized clinical trial of oral contraceptives and 
possible side effects and continuation of use.
Example 8.30
Norinyl Versus Brevicon in Sri Lanka
Background: It has been hypothesized that low-dose oral contraceptives (OCs) may be more 
suitable for Asian women who, in general, have a smaller body mass index than women who live 
in developed countries.
Research Hypothesis: Low-dose OC users are more likely to continue using OCs than standard-
dose OC users.
Study Design: Randomized parallel clinical trial that is to be conducted in Colombo and two 
rural sites in Sri Lanka.
Eligibility criteria: Physically healthy women 18 to 40 years old were eligible for inclusion. 
Women were excluded if they were currently using OCs for therapeutic reasons, had beenUsing 
OCs six months before the study, or had any known or suspected contraindications to OC use. 
Women were also excluded if they were currently breast-feeding or if their last pregnancy ended 
within three months before the study.
Treated: Brevicon (low-dose OC).
Not treated: Norinyl (standard-dose OC).
Outcome: Termination of OC use.
Follow-up: Follow-up data were collected at 1*, 3-, 6-, 9-, and 12-month visits.
Data Collection Method: Study subjects were visited at home to discuss possible side effects.
All data were recorded by the study subject on a symptom calendar.
Randomization Scheme: Study subjects were assigned at random.
Blinding: OCs were packaged similarly. Study subjects were not aware of which OC they 
received.
(Basnayake et al., 1983)
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(a) In Colombo, Sri Lanka, women who used Norinyl were significantly more 
likely to continue use than women who used Brevicon. However, in 
Colombo the follow-up staff were aware of treatment assignment and 
exclusively followed study subjects treated with one OC. Fewer Norinyl 
users were lost to follow-up; Norinyl users completed the symptoms 
calendar more frequently; and more home visits were made to homes of 
Norinyl users. In retrospect, how could procedures be modified to 
eliminate the problems that occurred here?
(b) In this study, Norinyl and Brevicon were compared at three locations in 
Sri Lanka. At the two rural locations, continuation rates for Norinyl and 
Brevicon were similar. In Colombo, Norinyl users were more likely to 
continue use than Brevicon users. Considering these results and the 




7. Consider the following randomized clinical trial of the effectiveness of 
perioperative Cefazolin in preventing infection after hysterectomy.
Example 8.31
Perioperative Cefazolin and Preventing Infection After Hysterectomy
Background: Approximately 700,000 elective hysterectomies are performed in the United States 
each year. The morbidity rate for these procedures ranges from 20% to 60% and is primarily 
related to postoperative infections. Several clinical trials have shown prophylactic antibiotics to 
be effective at reducing the number of infections after vaginal hysterectomy. Minimal 
information exists on the efficacy of antibiotic prophylaxis for elective abdominal hysterectomy.
Research Hypothesis: Perioperative Cefazolin by injection reduces pelvic and wound infections 
after elective abdominal hysterectomy.
Study Design: Randomized clinical trial.
Eligibility Criteria: All patients booked for elective nonradical abdominal hysterectomy were 
eligible. Patient refusal, physician refusal, evidence of infection, use of antibiotic within two 
weeks of hysterectomy, and a history of hypersensitivity to penicillin or any cephalosporin were 
reasons for exclusion.
Treated: Patients received Cefazolin 1.0 g intramuscularly one to two hours before surgery and 
again at 6 and 12 horn's after surgery.
Not treated: Patients received equal volume of placebo by same route on same schedule. 
Outcome: Infection.
Follow-up: Hospital records were reviewed daily until discharge. Letters were sent to physicians 
6 weeks after discharge to inquire about subsequent infection.
Data Collection Methods: Patients and records were reviewed daily for data relevant to 
infection. When catheter was removed, urine specimen was obtained from catheter. A urine 
culture was performed on day of discharge.




Blinding: Physicians and patients were unaware of treatment assignment.
Data Analysis: The data were treated as a clinical trial with a short follow-up. Percent 







Number infected 29 47
Number not infected 177 176
Totals 206 223
Percent infected 14% 21%
No weaknesses were described. This study was based on several earlier studies and could 
thus avoid their difficulties. However, some of the points raised below may indicate potential 
problems with the study and perhaps should have been addressed.
This study included vaginal and abdominal hysterectomies (elective, nonradical). The majority 
of the patients received abdominal hysterectomies (85%) and their results were the focus of our 
outline of the study.
During the study period, 1,511 women were eligible for the study, but only 567 (38%) were 
enrolled. The primary reasons for nonenrollment were patient refusal (32%), physician refusal 
(30%), recent antibiotic therapy (14%), drug allergy (8%), and other (16%). Of the 567 who 
were enrolled, 52 (9%) were withdrawn (26 treatment, 26 control) and given other treatments, 
usually because of prolonged or complicated surgery.
(Polk et al., 1980)_______________________________________________________________________
(a) Do you think the women enrolled in the trial were a random sample of 
those eligible for the study? Why or why not?
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(b) Were they a sample that was representative of those eligible? Why or 
why not?




8. Design an RCT to test whether the Today sponge is as safe a method of 
contraception as other vaginal methods. State the problem and the 
hypothesis. Describe the eligibility criteria. Define the treatments and the 
outcome in measurable terms. Describe randomization, blinding, and follow- 

















Suggested Answers to Practice Exercises
1. True or false.
(a) F Introduction. Investigators assign treatments to study subjects.
(b) T Successive Treatment Designs
(c) F Successive Treatment Designs. Carryover effect is a problem of
crossover design.
(d) T Successive Treatment Designs. Since study subjects receive more
than one treatment, a crossover design requires fewer subjects than a 
parallel design.
(e) F Study Population. No, the study population are the individuals from
the general population defined according to the study criteria, and the 
study subjects in the trial are usually a sample of the study 
population.
(f) F Eligibility Criteria. No, inclusion and exclusion criteria must be
defined and implemented before randomization.
(g) T Selecting the Study Subjects
(h) T  Defining Comparison Groups. Comparison of only two groups gives
the maximum chance of being able to make some definitive 
conclusions for a limited number of patients.
(i) T Defining Comparison Groups
(j) F Sample Size. No, many researchers design studies that are too small 
to answer the questions posed.
(k) T Exclusions Before Randomization
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(1) F Exclusions Before Randomization. No, exclusions before
randomization do affect the extrapolation of results. As the number 
of excluded study subjects increases, the results become less relevant 
to the general population.
(m) F Exclusions After Randomization. No, exclusions after randomization 
can bias the randomized treatment comparison and can affect the 
extrapolation of results.
(n) T Exclusions After Randomization
(o) F Exclusions After Randomization. No, study subjects who deviate
from protocol should be followed and analyzed in the groups to which 
they were originally assigned.





3. Steps of recommended randomization method.
2, 3, 4, 1
4. Comparing treatments A  and B.
4! 24




(b) Number sequence. (Note: You may have listed your sequences in a 
different order.)
1 A  A B B
2 A B  A B
3 B A A B
4 B A B  A
5 B B  A A
6 A B B A
(c) Ten blocks required.
(d) 8 7 4 1 8 2 7 9 2 . 7 0 0 4 £ 9 8 i £ I 2 7 9 0
(e) 4) B A B  A
1) A  A B B
2) A B A B
3) B A A B
4) B A B  A
5) B B A A  
5) B B A A
4) B A B  A
5) B B A A  
2) A B A B
5. True or false.
(a) F Follow-up Data Analysis. No, follow-up data provide the incidence
data—the number of study subjects treated and the number of study 
subjects not-treated who develop the outcome or health problem of 
interest.
(b) T Baseline Data Analysis
(c) T Follow-up Data Analysis
(d) F Baseline Data Analysis. No, differences in distributions of prognostic




(e) T Follow-up Data Analysis
(f) F Advantages and Disadvantages
(g) F Advantages and Disadvantages
(h) F Advantages and Disadvantages
6. Randomized Clinical Trial—Norinyl and Brevicon
(a) Apparently the follow-up staff for Norinyl users was more effective in 
locating study subjects than the follow-up staff for Brevicon users. This 
difference likely affected study results. To avoid this problem, study 
subjects followed by clinic staff should be evenly divided between Norinyl 
and Brevicon users.
(b) The investigators were not able to demonstrate a convincing difference in 
continuation between Norinyl and Brevicon users.
7. Randomized Clinical Trial—Cefazolin
(a) No. Women volunteered for the study and as volunteers were not 
selected at random.
(b) They are not likely to be representative of those eligible because they are 
volunteers.
(c) Very little. The withdrawal was balanced (same number in each group) 
and the reasons for withdrawal appear to be the same for both treatment 
and control groups. If randomization had been delayed until the surgery 
was completed, prolonged or complicated surgery could have been used 
as an exclusion criterion.
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8. Randomized clinical trial—Today Sponge. The answer given here is a 
suggested answer and is based on the report of the actual study.
Example 8.32 
A Trial of the Contraceptive Sponge and Diaphragm
Background: The Today sponge was designed to be easy to use, provide 24-hour protection 
against pregnancy, and be available without prescription.
Research Hypothesis: Sponge users are not as likely as diaphragm users to be compliant users. 
Study Design: Randomized multiclinic trial.
Study Population: At least 50 volunteers attending each of 13 clinics.
Eligibility criteria: Women aged 18 to 40 years who were in good health, had no anatomic 
abnormalities, were sexually active, had had at least one menstrual period since the termination 
of last pregnancy, and agreed to return for regular follow-up visits were eligible for participation 
in the trial. Women were excluded after randomization if they were not sexually active, had had 
no menses since last pregnancy, or were older than 40 years.
Treated: Sponge.
Not Treated: Diaphragm.
Outcome: Product-related problems, discontinuation, pregnancy.
Follow-up: Every three months for one year.
Data Collection Methods: Common protocol. Data were recorded on standard forms using a 
common protocol. Lab tests on admission to study and at the final 12-month clinic visit provided 
hematocrit, complete blood count, urinalysis, Veneral Disease Research Laboratories (VDRL), 
gonorrhea culture, Papanicolaou smear, and pregnancy test.
Randomization Scheme: Study subjects were volunteers who were randomized to use the sponge 
or diaphragm.
Blinding: Other details about the randomization were not provided.
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Chapter 9 - Learning Objectives
After completing this chapter you should be able to:
1. Define the terms:
prospective cohort study 





2. Describe how study subjects will be identified with respect to exposure status.
3. Define the study outcome in measurable terms.
4. Specify the data collection methods to be used in the study.
5. Develop a data table for analysis of the association between the exposure and 
outcome.
6. Calculate relative risk and confidence limits for cumulative incidence relative risk 
and incidence density relative risk.
7. Interpret relative risk.
8. Recognize advantages and disadvantages of cohort studies.
9. Design a hypothetical cohort study in outline form.
9 Cohort Studies
Introduction
The cohort study is an analytic epidemiologic research design in 
which the study population is composed of individuals who are 
classified as exposed or not exposed to a particular risk factor 
(comparison groups). These groups are followed forward for a 
specific period of time to estimate the incidence rates of an 
outcome or the development of a health problem (Figure 9.1).
The exposed group is composed of individuals who have been 
exposed to a postulated causal or protective factor for a health 
problem. The unexposed group is composed of individuals who 
are similar to the exposed group but who are known not to have 
been exposed to the causal or protective factor. Depending on 
whether the study is designed to examine a postulated causal or 
protective factor, the individuals in the exposed group are 
hypothesized to be at greater or lesser risk of developing the
Figure 9.1
Definition of Comparison Groups in Prospective Cohort Studies
t - .  Exposed















health problem than the individuals in the unexposed group. In 
designing a cohort study, investigators should clearly state the 
research hypothesis and specify the expected relationship between the 
exposure groups and the health problem of interest.
Cohort studies are similar to randomized clinical trials in that they 
proceed from exposure to outcome. Unlike the randomized clinical 
trial, however, the investigator observes rather than assigns exposure 
status. The study groups are identified by exposure status before 
outcome status. Each person in both the exposed and unexposed 
groups (study subjects) is followed in an identical manner until one of 
the following outcomes occurs:
• The study subjects develop the health problem under study.
• The study subjects die.
• The study ends.
• The study subjects are lost to follow-up.
In the randomized clinical trial, the investigator determines the 
exposure status. In the cohort study, the exposure status is 
determined by:
• genetics or biology (i.e., male or female, presence or absence of 
sickle cell anemia)
• a conscious choice made by the subject (smoker or nonsmoker; 
contraceptive user or nonuser)
• circumstances (living in a poorly served rural area or in a large 
city).
Cohort studies may be either prospective or historical. In a 
prospective cohort study, exposure status is determined when the 
study begins, and the exposed and unexposed groups are followed 
forward in time to observe whether they develop the study outcome. 
In a historical cohort study, the study subjects have developed the 
health problem or outcome and have been exposed before the study 
begins. The exposure and the health problem are determined from 
existing records. A  historical cohort study is essentially the 
reconstruction of a cohort study that has already taken place. In 
Example 9.2, we use a hypothetical study of maternal thalassemia and 




Maternal Thalassemia and Fetal Death in Utero
A  hypothetical cohort study is to be conducted to assess the association 
between maternal thalassemia and fetal death in utero.
Design 1: A Prospective Cohort Study
In a hypothetical prospective cohort study, women with thalassemia who 
come to a clinic for their first prenatal visit would compose the exposed 
group. The unexposed group would be women without thalassemia who also 
come to the clinic for their first prenatal visit. In both groups, each woman 
would be followed throughout her pregnancy to observe the occurrence of 
fetal death in utero (outcome).
Design 2; A Historical Cohort Study
The association between maternal thalassemia and fetal death in utero 
could also be evaluated using a historical cohort study design, if the quality of 
the records and the follow-up procedures at the study site were good. Using 
this design, investigators would identify all women with thalassemia who came 
to the clinic for their first prenatal visit at some specified time in the past 
(exposed), and all women without thalassemia who had their first prenatal 
visit during the same time period (unexposed). The medical records of these 
women would be reviewed to determine whether fetal death in utero 
(outcome) had occurred. In a historical study, the exposure (thalassemia) 
would be identified first; then the outcome (fetal death) would be ascertained. 
Both the exposure and outcome may have occurred months or even years in 
the past. This design is a cohort study because exposed and unexposed 
groups are the comparison groups; it is retrospective because both exposure 
and outcome occurred before the study was initiated.
In cohort studies, investigators can examine more than one 
health problem that may be the result of the exposure under study. 
For example, in a study of the effects of oral contraceptives, 
investigators may be primarily interested in cardiovascular disease, 
but the study could provide the opportunity to examine a variety of 
other outcomes hypothesized to be related to oral contraceptive 






Design and Data Collection Methods
Population Sources and Follow-up
An important step in designing a cohort study is selecting exposed 
and unexposed populations that can be adequately followed over time. 
A high rate of follow-up for both exposed and unexposed study 
subjects is needed if the conclusions of the study are to be considered 
valid. Both exposed and unexposed groups will need to be followed 
in an identical manner to determine if they develop the study 
outcome. For example, if the exposed subjects are followed up with 
in-person interviews and physical examinations, the unexposed 
subjects should be followed up by identical data collection methods to 
minimize bias in the detection of the health problem.
The population used in a given study will depend on the exposure 
and outcome of interest and on the ease of gathering sufficient 
information on exposure and outcome in the population. The choice 
of the study population may be affected by the delay between 
exposure and outcome (latency). If latency is long, extensive follow- 
up will be necessary. Potential sources for the study population may 
include the general population, a sample of the general population, 
special groups (such as nurses or government employees who can be 
readily followed over time), attendees to clinics with good record­
keeping and follow-up procedures, or occupational groups with 
different levels of exposure. Populations or samples of populations 
are most appropriate for a cohort study design when the exposure is 
relatively common. If the study exposure is uncommon, investigators 
should select special groups who have experienced a higher level of 
exposure than the general population. For example, investigators who 
study a possible association between injectable contraceptives and 
cancer might use a population of family planning clinic attendees 
instead of women in the general population, especially if the 
prevalence of contraceptive use is low in the population.
Selection of the Exposed Group
The exposed group in a cohort study are the individuals who have 
the exposure of interest. Before the exposed individuals can be 
identified, the investigators must develop an unambiguous and 
objective description of what constitutes exposure. Where applicable,
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the definitions should include the minimal acceptable levels of the 
exposure (e.g., more than ten cigarettes per day) and the minimal 
duration of exposure (e.g., use of oral contraceptives continuously 
for at least a year). Other eligibility criteria for entry in the study, 
such as age, sex, and absence of preexisting medical problems, 
should also be determined. In particular, the individuals should 
not have a history of the outcome.
A cohort study may have more than one exposed group; the 
merits of using more than one exposed group should be considered 
in the initial study design. For example, in a study of smoking and 
intrauterine growth retardation (IUGR), the investigators may 
wish to compare the effects of heavy smoking ( >  20 cigarettes per 
day) with the effects of lighter smoking (< 20 cigarettes per day) 
on IUGR. The study could include two exposure groups: the 
group that smokes < 20 cigarettes per day, and the group that 
smokes > 20 cigarettes per day. In the analysis, both exposure 
groups would be compared with the women who do not smoke 
during pregnancy (unexposed group). However, the number of 
heavy smokers may be too small to make valid conclusions about 
the association. In general, if detailed information about the 
effects of different levels of exposure is needed, the investigators 
should consider using more than one exposure group. Example 9.3 
presents a cohort study of the association between oral 
contraceptive use and breast cancer among nurses (Romieu et al., 
1989). In this study, women who were current users of oral 
contraceptives (OC) and women who were past users were 
followed up and compared to women who had never used OCs.
Preferably, only the study subjects who are potentially at risk 
for the outcome of interest should be enrolled in the study. For 
example, investigators studying smoking and adverse pregnancy 
outcomes should exclude women who have had a tubal ligation 
because these women are not at risk of pregnancy. The decision 
to include or exclude individuals from the study population will 
depend on the exposure and outcome of interest and on whether 
heterogeneity is managed by restricting admission to certain groups 
or by performing stratified analyses after the data are collected.
In general, the more restrictive the admission criteria, the more 
difficult it is to assemble an appropriate cohort.
Cohort Studies
Example 9.3 
Oral Contraceptives and Breast Cancer
Problem: Are oral contraceptives associated with an increased risk of breast 
cancer?
Research Hypothesis: Women who use oral contraceptives have a higher risk of 
breast cancer than women who have never used oral contraceptives.
Study Design: Prospective cohort study of 121,700 female registered nurses 30 to 
55 years old who are living in 11 states of the United States.
Exposed: Women who had used oral contraceptives for at least one month in the 
past and who had never experienced angina pectoris, myocardial infarction, or 
stroke before the beginning of the study in 1976. Women who had used oral 
contraceptives were further categorized as women who were currently using oral 
contraceptives and women who had used oral contraceptives in the past but were 
no longer currently using them.
Unexposed: Women who had never used oral contraceptives and who had never 
experienced angina pectoris, myocardial infarction, or stroke before the beginning 
of the study in 1976.
Outcome: All breast cancer cases reported by the woman (or next of kin for 
decedents) for whom relevant hospital records confirmed the diagnosis.
Follow-up: The follow-up was conducted every two years using a mailed 
questionnaire. A repeat mailing was done for those who did not respond. 
Approximately 5% of the women were lost to follow-up.
Data Collection Methods: Self-administered questionnaires included information 
on medical conditions and life-style practices. Follow-up data were collected with 
self-administered questionnaires every two years. Outcomes reported by women 
were verified by review of medical records; deaths were reported by next of kin or 
postal authorities (when the questionnaires could not be delivered) or identified 
from vital records.
Results: Oral ContraceDtive Use
Current Past Never
Breast cancer 32 685 1,041
Person-years 22,622 472,828 592^64
Rate/1,000 person-years 1.41 1.45 1.76
Crude IDR 0.8 0.8
95% Cl (0.6,1.1) (0.7, 0.9)
(Romieu et al., 1989)
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Selection of the Unexposed Group
The unexposed subjects should be similar to the exposed in all 
ways except they should not have the exposure under study. The 
unexposed group is used to determine the incidence of the health 
problem among those without the exposure. Then, the 
investigators compare the incidence of the outcome among the 
individuals in the exposed and unexposed groups. Thus, the 
exposed and unexposed populations should be as similar as 
possible.
In a cohort study, the unexposed subjects should have the same 
general criteria for entry into the study as the exposed (e.g., age, 
sex, absence of preexisting medical problems, no history of the 
outcome of interest). They should also be at potential risk of 
developing the outcome under study. Finally, the unexposed study 
subjects should have the same opportunity as the exposed to be 
diagnosed with the outcome.
Ideally, the unexposed study subjects should be chosen using 
the following criteria:
• Take the total population or a sample of the population (e.g., 
all the attendees at a specific clinic or a random sample of the 
population in a rural village).
• Determine the exposure status of each individual.
• Classify each individual into the appropriate exposure category.
By using these built-in or internal comparison groups, 
investigators are afforded considerable advantages that include 
decreasing the potential for bias attributable to differences in the 
study populations and to differences in ascertaining the outcome 
between the exposed and unexposed study subjects. In the study 
outlined in Example 9.3, participants were asked on the initial 
questionnaire whether they currently used or whether they had 
ever used oral contraceptives (Romieu et al., 1989). Based on this 
information, the investigators divided the cohort into women who 
had ever (currently or in the past) used oral contraceptives 








Consider the following hypothetical cohort study that also uses an 
internal comparison group to examine the effect of low birthweight on 
infant survival. The investigator designed a study in which all live- 
born infants in five villages were weighed at birth by midwives using 
simple scales and followed for one year. The total population of 
babies could be divided into an exposed group (birthweight 
< 2,500 g) and an unexposed group (birthweight ^  2,500 g) and 
followed at monthly intervals to determine the outcome of survival at 
the end of the study period (the child’s first birthday). Alternatively, 
all the low-birthweight babies could be used as the exposed group and 
only a sample of the >  2,500 g babies would be used as the 
unexposed group, since these larger babies will considerably 
outnumber the low-birthweight babies.
In another hypothetical cohort study, investigators used an internal 
comparison group to investigate the effects of anemia on premature 
births among a population of women who attend a prenatal clinic.
The investigators could screen all women for anemia who come to the 
clinic for the initial prenatal exam in their first trimester during a 
specified year. Those women with low hemoglobin could comprise 
the exposed group, and those with normal hemoglobin could comprise 
the unexposed group. The women in both groups could be followed 
to determine who delivered premature infants.
When an appropriate unexposed group cannot be selected within 
the same population, two less-than-ideal methods are sometimes used. 
The first method compares the exposed group with another group that 
is similar in composition but does not have the exposure. In Example 
9.4, investigators used this method to select a sample of unexposed 
women.
The second method compares the outcomes among exposed study 
subjects and a population rate. Using this method, investigators 
compare the outcomes in a study cohort and the experience of the 
general population while the cohort is being followed. For example, 
investigators could compare the mortality rates of women who have 
used oral contraceptives and died of thromboembolism and the 
mortality rates of women of comparable age in the general 
population. This method is only possible when population rates are 
available (e.g., death rates).
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Example 9.4
Selection of an Unexposed Group from a Different Population
Investigators designed a study to examine the effects of malaria on 
placental weight among women in certain villages; almost all of the women 
are infected with malaria. To obtain the unexposed group, the investigators 
select women from villages located in nonmalarious areas. Although the 
selected villages are demographically similar, and the villagers have access to 
comparable health services, the investigators’ decision to use women from 
different villages is not ideal. The exposed and unexposed populations may 
differ in tangible and intangible ways, and they may not be strictly 
comparable. There may not be other options in this situation, and the 
investigators may have difficulty determining whether differences in the 
relative risk for the health problem under study are related to the exposure or 
to differences in the two populations.
Matching
Matching refers to procedures for selecting a study group and a 
comparison group so that they are comparable with respect to 
extraneous factors (Last, 1988). Individual matching involves 
identifying individuals for the comparison group such that each 
resembles a certain study subject on the matched variable(s). 
Frequency matching involves matching on selected variables so that 
the frequency distributions of the matched variables are similar in 
the study and comparison groups (Last, 1988) (Example 9.5). In 
frequency matching, the investigator estimates the number of 
exposed subjects in a  given subgroup before the study begins. The 
estimate is based on a preliminary analysis of the distribution of 
individuals with the exposure of interest; then the requisite 
number of unexposed subjects in the subgroup is enrolled in the 
study (Last, 1988).
In most circumstances, the preferred approach to matching is 
simply to take a population or population sample, separate the 
selected individuals into exposed and unexposed groups, and then 
in the analysis stratify by other variables that are likely to affect 
the relationship between exposure and outcome. Investigators 










Individual and Frequency Matching
A Hypothetical Study
Investigators design a study to examine the effects of anemia on pregnancy 
outcome among women at a certain prenatal clinic. They decide that parity is 
likely to affect the relationship between the two variables and that matching may 
be necessary. Two methods of matching are considered.
Frequency m atching. The investigators determined in a preliminary study that 
20% of the women with anemia who come to the clinic for their first prenatal visit 
have had no previous pregnancies. They decide to enroll 100 women with anemia 
and 100 women without anemia. For the unexposed group, they would identify 
women without anemia who have had no previous pregnancies as they come into 
the clinic, until 20 women (with no children) are enrolled.
Individual m atching  If this method is used, the investigators could match the 
first woman diagnosed with anemia who has had no previous pregnancy (exposed) 
with the next woman seen at the clinic who is not anemic and who has had no 
previous pregnancy (unexposed). If the next woman to be seen at the dinic has 
anemia and has had three children, she would be matched with the next woman 
who has had three children but who is not anemic. This enrollment process 
would continue until the required number of women is obtained for the study.
• Matching on a particular variable prohibits studying its 
association with the outcome.
• Matching may greatly increase the amount of work required 
to find appropriate unexposed individuals with the same 
characteristics as the exposed.
• A matched variable that is in the causal pathway between 
exposure and disease, or a variable that is related to the 
outcome but not the exposure may cause problems in 
interpreting the results of a study.
• Individual matching requires a matched analysis to ensure that 




Since matched analyses can be difficult, matched designs should 
be used only when the advantages outweigh the disadvantages.
Measuring Exposure
In a prospective cohort study, investigators measure exposure at 
the time of enrollment. In some studies, persons may be enrolled 
at the time they first experience the exposure (e.g., at the time 
they begin using a certain contraceptive or have a sterilization 
procedure). More commonly, the exposure has been occurring for 
some time (e.g., smoking), and both current and historical 
exposure data are generally collected. Exposure status may be 
determined from interviews, self-administered questionnaires, or 
existing records, such as clinic or hospital charts and laboratory or 
employment records. To adequately describe the relationship 
between an exposure and an outcome, investigators should include 
measures related to frequency, duration, dose, and timing (e.g., 
dates of first and last exposure).
Some exposures are one-time events (e.g., a surgical procedure 
such as a tubal ligation or vasectomy) or are biologically 
determined and unchangeable (e.g., hemoglobinopathies or 
maternal height). Others, however, may change after an individual 
is enrolled in the study. For example, a woman who is using an 
intrauterine device (IUD) might decide to change methods or 
might choose not to use a contraceptive; a person classified as a 
smoker at the beginning of the study may quit during the study. 
Alternatively, an initially unexposed person may begin to use an 
IUD or may begin smoking after being enrolled in the unexposed 
group. In these instances, maintaining the original designation of 
exposed or unexposed is a conservative approach that tends to bias 
the results toward the null effect.
From a conservative perspective, the exposure status of the 
study subjects should not be changed, for purposes of analysis, 
after initial classification, but investigators should note changes in 
exposure status over time. If such information is available, 
investigators can look at the effect of differing durations or 
intensities of exposure on the health problem under study. For 
example, it might be interesting to determine if the development 
of a myocardial infarction is dependent on the length of time a






woman uses OCs or how long the risk of an infarction persists after a 
woman stops using them.
Determination of Outcome
When the study begins, the outcome must be defined precisely and 
as unambiguously and objectively as possible. The definition must be 
applied uniformly for both the exposed and unexposed. If many 
medical providers will be diagnosing the health problem or identifying 
the outcome under study in a number of different study sites, the 
investigators should consider the skills of the providers and the 
likelihood that certain diagnostic tests will be performed when they 
define the outcome. If possible, the processes by which an outcome is 
defined and diagnosed should be standardized and outlined in a. 
training program. However, such a program must be designed 
carefully. If the medical providers are made aware of the hypothesis 
under study, they may be more likely to diagnose the outcome among 
the individuals in the exposed group than among the individuals in the 
unexposed group.
In a historical cohort study the medical providers who diagnose the 
outcome should be unaware of the exposure status of the study 
subjects since such knowledge may potentially bias the investigators’ 
determination of the outcome. Restricting knowledge of any aspect of 
the study from anyone involved in the study is referred to as blinding.
Determining outcome may be logistically more complicated in a 
prospective cohort study. For example, if the disease (e.g., cancer) 
has a long latency period, the follow-up will have to be conducted 
over a prolonged period of time. When the study is designed, the 
investigators must develop methods to ensure the highest possible 
follow-up rates for both exposed and unexposed study subjects.
The specific methods used to determine outcome will depend on 
the outcome under study. If the outcome involves changes in 
behavior or minor illnesses that are unlikely to require hospitalization, 
for example, follow-up would involve recontacting the subjects on a 
periodic basis. For individuals with more severe outcomes that 
typically require hospitalization, investigators may periodically review 
the admissions records at the hospitals where the study subjects are 
likely to go if they become ill. For outcomes such as death or cancer, 
the best method of follow-up may be to review death certificates or 
cancer registries on a regular schedule.
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In the design of the study, the investigators must carefully 
consider the methods that will be used to adequately ascertain the 
outcome, since the resources required to perform the study and 
the validity of the study’s results are highly dependent on the 
follow-up methods. If the follow-up is to be conducted through 
regular reviews of vital records (or cancer registry records), the 
detailed personal identifiers for each individual should be collected 
at the beginning of the study and attempts should be made 
periodically to update this information. If follow-up is conducted 
through contact with the study subjects or their health care 
providers, the investigators may want to gather not only personal 
identifiers on the individual but the names of relatives or friends 
who are likely to know where to locate the individual in the future. 
Well-documented specifications on what constitutes adequate 
follow-up is not available, but if more than 40% of the study 
subjects are lost to follow-up, results of the study are likely to be 
seriously questioned. Even a 20% loss to follow-up may introduce 
doubts about a study’s validity. As in historical cohort studies, the 
outcome should be ascertained without knowledge of the exposure, 
and identical methods must be used to follow up and ascertain 
outcomes for individuals in both the exposed and unexposed 
groups. These measures are necessary to avoid biases that may 
lead to erroneous conclusions.
Examples 9.6 and 9.7 illustrate follow-up procedures and 
methods used to ensure the complete and accurate assessment of 
outcomes.
Example 9.6  
Risk Factors for Maternal Mortality in Bangladesh
Problem: Is increased maternal age associated with a higher risk of maternal 
death in Bangladesh?
Research Hypothesis: In Bangladesh, women who are at least 30 years old at 
delivery have a higher risk of maternal death than younger women.
Study Design: Prospective cohort study
Exposed: Women in the study population who are at least 30 years old. 






Outcome: Death from any cause during pregnancy, at delivery, or in the 42 days 
after termination of the pregnancy.
Follow-up: Follow-up was conducted through personal interviews every two weeks 
until 42 days after delivery to determine pregnancy outcomes.
Data Collection Methods: Interviewers identified pregnant women during visits to 
each of the study villages and tracked their outcomes.
(Alauddin, 1986)
Example 9.7 
Instillation Methods for Second Trimester Abortion
Problem: Is urea-prostaglandin instillation a safer method than saline instillation 
for second trimester abortion.
Research Hypothesis: Women who undergo urea-prostaglandin abortions have 
less risk of complications than women who undergo saline instillations.
Study Design: Prospective cohort study
Exposed: Women at least 20 years old who had had urea-prostaglandin 
instillation abortions at one of 13 study institutions during 1975-1978.
Unexposed: Women at least 20 years old who had had saline instillation 
procedures at the same institutions.
Women in both groups who had concurrent sterilization procedures, ectopic 
pregnancies, and hydatidiform moles were excluded from the analysis.
Outcome: The study outcomes were defined as the following major 
complications: fever >_38*C for 3 or more days, hemorrhage requiring 
transfusion, or unintended abdominal surgery.
Follow-up: Complications were recorded on routine follow-up visits 2 to 6 weeks 
after abortion.
Data Collection Methods: Data were collected through regular reviews of records 
from participating clinics.




When conducting epidemiologic studies, investigators must be 
concerned about making false conclusions that are a result of the 
research methodology used. The purpose of the cohort study 
design is to allow the investigator to determine what effect the 
exposure has on the outcome. If the methodology used by the 
investigator alters the true effect of an exposure, this 
misrepresentation is called bias. If no bias is present in the study, 
the measure of effect calculated is said to be a valid estimate of 
the effect of the exposure on the health problem.
Two important types of bias can occur in cohort studies— 
selection bias and information bias. Potential sources of bias 
should be carefully considered in the design of a study. Except for 
the exposure of interest, the study subjects should have 
comparable risks of developing the outcome of interest.
Selection bias. This type of bias may be present if the 
individuals who are enrolled in the study have different 
characteristics than the population they are supposed to represent. 
Selection bias occurs if the individuals selected for participation in 
the study differ somehow from the individuals who were not 
selected (Examples 9.8 and 9.9).
Example 9.8
Delivery During the Harvest Season and the Risk of Complications
Selection Bias
A Hypothetical Study
A physician observes that women who deliver their infants during the 
harvest season tend to have more labor and delivery complications than 
women who deliver their infants at other times of the year. He hypothesizes 
that the complications may be attributed to high levels of physical activity in 
the weeks before labor since most women are working in the fields up to 12 
hours per day during the harvest season. He designs a hospital-based study to 
compare women who have their infants during the harvest (the exposed) and 
women who deliver 3 months after the harvest, when routine daily activities 
have returned to normal (unexposed); the women are matched on age and 
parity. He finds that complications are, in fact, greater for women who 
deliver during the harvest. He also notes that the number of hospital-based
Potential 






deliveries declined considerably during the harvest months. In a discussion with 
local midwives and trained birth attendants, he discovers that during the harvest 
season, women tend to deliver in their villages to minimize the time away from 
work. Most of the women who do make the long trip to the hospital during this 
period are those with prolonged or difficult labor.
This study provides an example of selection bias. Although women who 
deliver in the hospital after the harvest may be fairly representative of the women 
in the hospital’s catchment area, those women who deliver in the hospital during 
the harvest season are not representative of all women who have their babies 
during this time period. As a result, the study probably overestimates the risk of 
complications related to increased physical activity. To conduct this study 
properly, the physician should conduct a population-based study to examine 
complication rates among women who deliver at hospitals, at health centers, and 
at home.
Example 9.9
Intrauterine Devices and Pelvic Inflammatory Disease 
Selection Bias
Another example of potential selection bias is a hypothetical cohort study in 
which an association between intrauterine device (IUD) use and pelvic 
inflammatory disease (PID) is investigated. If women using oral contraceptives 
and barrier methods composed the unexposed group, an erroneous conclusion 
might be made, since both methods of contraception are known to reduce the risk 
of PID. A better alternative for the unexposed group would be women who are 
sexually active but not using contraceptives. The study could be matched or 
stratified by number of sexual partners and any other variables that may be 
different between IUD users and women who do not use contraceptives, or by 
variables that may affect the incidence of PID independent of exposure to IUDs.
Information bias. If information on exposure or outcome is 
obtained differently for the exposed and unexposed groups, 
information bias may result. In prospective cohort studies, 
information bias related to exposure is minimal because exposure 
status is determined before the disease occurs. However, in 
prospective cohort studies, the outcome may be subject to information 
bias because exposure status is known before the outcome is
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determined. In historical cohort studies, both exposure and 
outcome information are potentially subject to this bias because 
information on both variables is collected after the outcome has 
occurred. For example, information bias might occur if 
ascertainment of outcome among the individuals in the exposed 
group was based on periodic attempts to recontact the individual 
and a review of death certificates, while outcome for the 
unexposed individuals was obtained by only reviewing death 
certificates. Information bias is best avoided by ensuring that the 
same attention is given to each study subject in the exposed and 
the unexposed groups. Preferably, the persons who collect 
outcome information should be blinded to the exposure status of 
the study subjects (Example 9.10). Information bias generally is 
best managed while the study is in the field and not during the 
analysis phase.
Example 9.10
Ora! Contraceptives and Cervical Carcinoma in Situ 
Information Bias
In a hypothetical study of oral contraceptive (OC) use and cervical 
carcinoma in situ> women who use OCs compose the exposed group and 
women who use the barrier method compose the unexposed group. The 
women are identified through visits to a family planning clinic. Women with 
cancer in situ  are identified from hospital laboratory records. A potential 
concern is that OC users who return more frequently for prescription 
renewals are more likely to receive a Pap smear and to be diagnosed with 
cancer in situ  than women who use barrier methods. To overcome this 
problem, the study protocol states that women in both the exposed and 
unexposed groups should receive Pap smears at the same intervals.
Another form of information bias could occur if, during the study, results 
showing a positive link between OC use and carcinoma in situ  were published 
by other investigators. As a result, physicians might be more likely to 
perform Pap smears more often on women using OCs. Additionally, the 
pathologists who read the Pap smears may be more likely to read borderline 
smears in an OC user as positive if they are aware of the woman’s contra­
ceptive status. The former problem is best prevented by requiring that the 
Pap smears be done at comparable intervals for women in the exposed and 
unexposed study subjects. The problem of exposure status affecting the 
pathologist’s reading is best managed by having the pathologist read the 
smears without knowledge of the exposure status.
Cohort Studies
Data Analysis Methods
Ideally, the analytic methods are determined concurrently with the 
design of the study protocol and the data collection forms to ensure 
that information is collected for all required variables and that the 
sample size is adequate. After data collection is complete, the first 
steps of the analysis are to organize the data into the tables 
developed when the analysis was planned. Several types of tables are 
used to organize cohort study data and to make comparisons between 
exposed and unexposed study subjects. The first tables presented for
Table 9.11
Characteristics of Women Undergoing Abortion by
Intra-Amniotic Instillation
Urea-nrostaelandin Saline Solution
Characteristic (n= 2,805) (n = 4,778)
% %
Age (year)





Black and other 453 40.4
Marital status




1 or more 43.7 463
Prior abortions
None 82.4 83.4
1 or more 17.6 16.6
(Binkin et al., 1983)
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the analysis of cohort studies are usually demographic 
characteristics and risk factors for the study subjects in the exposed 
and unexposed groups (Table 9.11). Additional tables present 
information about the magnitude of the association between the 
exposure and the health problem under study and information 
about the risk of the health problem among subgroups of the 
exposed and unexposed study subjects.
Analysis Table of Characteristics of Exposed and 
Unexposed Study Subjects
The analysis should begin with a description of the demographic 
and medical characteristics of the exposed and unexposed study 
subjects. These data permit a comparison of the individuals in the 
exposed and unexposed groups. For example, in Table 9.11 
women who underwent abortion by intra-amniotic instillation 
differed slightly by age, race, and type of instillation (Table 9.11). 
Otherwise, the two groups of women were similar with respect to 
marital status and pregnancy history.
Cohort Study Analysis Table for Relative Risk and 
Confidence Interval
Analysis of data from cohort studies involves the comparison of 
rates of the health problem among the exposed and unexposed 
study subjects. Relative risk is the most commonly used measure 
of association between exposure to a particular factor and risk of 
specified outcome. Relative risk is the incidence of the outcome 
among the exposed study subjects divided by the incidence of the 
outcome among the unexposed study subjects. The relative risk 
shown in Table 9.12 is known as cumulative incidence relative risk 
(CIR); it measures the risk of the study subject developing the 
health problem during the entire study period.
For example, pregnant women in Bangladesh who were at least 
30 years old had almost two times the risk (CIR = 1.8) of 
maternal death as pregnant women who were younger than 30 
years old (Example 9.13). In the study of the relationship between 
complications after abortion and the type of instillation procedure, 
the overall risk of serious complications was more than two times 








Cohort Study Analysis Table for Cumulative Incidence Relative Risk














The proportion of the outcome 
= among the exposed study subjects 
The proportion of outcome among 
the unexposed study subjects
= a/s., 
b /n 0 (9.12.1)
where a is the number of persons with the exposure who have the outcome, b is 
the number of persons without the- exposure who have the outcome, c is the 
number of persons with the exposure who do not have the outcome, and d  is the 
number with neither the exposure nor the outcome, n 2 represents the total 
number of persons exposed, and n 0 the total number of persons unexposed, m j 
represents the total number of persons who have the outcome, m 0 represents the 
total number of persons who do not have the outcome, and t is the total number 
of persons under study.




Risk Factors for Maternal Mortality in Bangladesh 
Results:
Maternal Age (years) 
Outcome ^  30_________ < 30
Number of pregnant
women who died within 42 18 11
days of delivery
Number of pregnant
women still living 42 4,318 4,774
days after delivery
Total 4,336 4,785
CIR = Incidence of maternal deaths in women 5: 30 years
Incidence of maternal deaths in women < 30 years
=  18/4330 
11/4,785
= 1.8 (95% Cl: 0.9 - 3.8)
(Adapted from Alauddin, 1986)
Table 9.14
Complication Rates and Additional Treatments Associated 
with Urea-Prostaglandin and Saline Solution Instillations
________ Rate*_________
Complication Urea- Saline Adjusted 95% Confidence
or Treatment Prostaglandin Solution Relative Riskt Interval
Serious
complications: 1.03 2.18 23 (1.4 - 3.6)
Hemorrhage 
necessitating
transfusion 0.32 1.72 5.9 (2.7 - 13.0)
Fever >_ 38° C










Complication Urea- Saline Adjusted 95% Confidence
or Treatment Prostaelandin Solution Relative Riskt Interval
Other complications:
Hemorrhage 6.20 2.20 0.23 (0.17 - 030)
Fever 38° C
for J>. 1 day 6.27 4.96 0.77 (0.61 - 0.96)
Endometritis 5.31 3.26 0.53 (0.41 - 0.69)
Cervical injury 1.32 0.42 0.12 (0.06 - 0.25)
Treatments:
Uterine evacuation 10.34 14.82 1.4 (1.2 - 1.6)
* Per 100 abortions
t  Adjusted for follow-up, previous pregnancies, use of laminaria, prophylactic 
antibiotics, and use of oxytocin at or before instillation 
t  Numbers too small for logistic regression analysis; using an exact procedure, 
relative risk = 2.3 with a 95% confidence interval of 0.23 to 120
(Binkin et al., 1983)
glandin instillations (Table 9.14). The risk of hemorrhage requiring 
transfusion was approximately six times greater (CIR = 5.9).
Some studies use person-time as the denominator in the relative 
risk calculation instead of the number of persons enrolled in the 
study. This type of relative risk is known as incidence density relative 
risk (IDR). The person-time denominator simultaneously considers 
the number of persons under observation and the duration of 
observation for each person. For example, if 10 persons participate in 
a study for 15 years, they are said to have contributed 150 (10 persons 
* 15 years) person-years of observation. The same figure may be 
derived if 150 persons were under observation for one year or 300 
persons for six months. This method allows the investigator to more 
satisfactorily manage situations when the dates the study subjects 
enter the cohort study vary, or when, during the course of the study, 
some study subjects are no longer under observation because of 
death, loss of contact, or other reasons. The basic analytic table for 




Cohort Study Analysis Table for Incidence Density Relative Risk
Exnosed Unexnosed Total
Cases a b m ,
Person-time n t n0 t
IDR « a /  n.!
b / n 0
(9.15.1)
where a is the number of cases among the exposed, b is the number of cases 
among the unexposed, n2 is the person-time in the exposed group, and n 0is the 
person-time in the unexposed group, m ; represents the person-time among the 
cases and t  is the person-time for all study subjects.
(Rothman and Boice, 1979)
The confidence interval for the CIR and the IDR is given in 
formula 9.15.2.
(9.15.2)
Confidence Interval = RR^ * ^ z / *  )
where RR =  CIR or IDR, z is a normal variate, x •  , and
(9.153)
,  .  (t -  1) ♦ [(» ♦ d) -  (b ♦ c)]2 , .  (a ♦ m , /  t)2
™ n, * n0 * m , * m 0 XmR n, * n0 * m , /  t 2
(Rothman and Boice, 1979). In Example 9.13, the CIR of 1.8 was 
not statistically significant since the 95% confidence interval (0.9 - 
3.8) includes 1.0. Using the data in Example 9.13, the confidence 
interval for the CIR is computed by performing the following 
steps:
Studies
s te p  1: _ 9)12o * (18 * 4,774 -  11 * 4,318)2
4,336 * 4,785 * 29 * 9,092
= 2.46
= 1.57
Step 2: For 95% confidence interval, z = 1.96
Step 3: Lower limit = CIR^1 _ z /*  )
m c [In CIR * (1 -  z / x  )]
m e [In 1.8 * (1 -  1.96 /1.57 )]
= 0.9
Upper limit = CIR ^  + z / *  )
= e [In 1.8 * (1 + 1.96 /1.57 )]
= 3.8
For Example 9.3, the unadjusted IDR for past users compared to 
never users was 0.8 with 95% confidence interval (0.7 - 0.9). This 
estimate suggests that women who have used OCs in the past have a 
statistically significant reduced risk of breast cancer than women who 
have never used OCs. The estimate is statistically significant since the 
confidence interval does not include 1.0.
Controlling for Confounding in the Analysis
Confounding is a form of bias that occurs when an extraneous 
factor related to both the exposure and outcome obscures the true 
relationship between exposure and outcome. To be a confounder, a 
variable must be associated with, but not a consequence of, the 
exposure and independent of its association with the exposure, be 
associated with the outcome. Stratified analysis is often used to 
correct for confounding. The relative risk estimate, which has been 
adjusted by the confounding variable, is computed and compared with 
the crude estimate. If the difference between the crude and adjusted 
estimates is more than some percentage specified before analysis,
Neonatal Outcome by Maternity Clinic or District Hospital
Table 9.16









Early neonatal mortality rate 7.S IQtQ
1,000 1,000
CIR = 0.8
then the variable may be considered a confounder and should be 
controlled for in the analyses. Details of calculating the adjusted 
relative risk and confidence intervals are introduced in Chapter 4.
In a hypothetical historical cohort study, investigators designed 
a study to examine whether delivery at the maternity clinic in a 
certain district is associated with a higher risk of early neonatal 
mortality than at the district hospital. Records from the maternity 
clinic and the district hospital are abstracted; the results are shown 
in Table 9.16. Instead of finding a higher risk of early neonatal 
mortality associated with delivering in the maternity clinic, the 
investigator finds the risk is actually lower in the maternity clinic 
than in the district hospital.
The district has a referral system in which a score system has 
been developed to identify high-risk pregnancies. Women seen at 
the maternity clinic for prenatal care are referred to the district 
hospital for further care and delivery if they have a high maternal 
risk score. Thus, the investigator decides to examine whether 
maternal risk score may be confounding the comparison of early 
neonatal mortality rates at the clinic and the hospital (Table 9.17).
For both strata, the risk of early neonatal mortality is higher for 
the maternity clinic. The relative risk adjusted for maternal risk 
score also reflects the higher risk for the maternity clinic. In this 
example, maternal risk score is a confounder: it is associated with, 
but not a consequence of, the delivery sites, independent of its
Cohort Studies
Table 9.17
Neonatal Outcome by Risk Score for Maternity Clinic and District Hospital
Maternity District
Earlv neonatal outcome Clinic Hosnital




Early neonatal mortality rate 2
1,000 1,000
CIR = 1.2




Early neonatal mortality rate 5,7
1,000 1,000
CIR = 1.8
Crude CIR = 0.8
CIR adjusted for maternal risk score = 1.4
association with delivery site, it is associated with poor early neonatal 
outcome.
There are essentially three ways to manage potentially confounding 
variables in a cohort study:
• Restrict admission to the study (e.g., admit only exposed and 
unexposed women with a maternal risk score lower than some 
specified level).
• Match on the potentially confounding variable.
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• Control for the confounding variable in the analysis by 
calculating an adjusted measure of effect.
The risk estimate in Table 9.17 after adjusting for the confounding 
effect of maternal risk score is 1.4; the unadjusted risk is 0.8. 
Adjusted measures of relative risk can be computed using formula
4.12.1 or 4.12.4.
Effect Modification Analysis Table
Effect modification is a phenomenon that is frequently 
discussed in conjunction with confounding, although it is not a 
form of bias. Effect modification is present when the relationship 
between exposure and outcome is different for various subgroups 
in the population. Effect modification is detected by stratifying by 
the variable of interest, calculating a measure of association for 
each stratum, and looking for differences in the relative risks 
among strata. Differences may reflect biologic or other factors 
that can modify the relationship between exposure and outcome. 
For example, measles vaccine may result in a much lower risk of 
contracting measles when administered to children older than one 
year than to younger children. These differences are related to 
the interference of maternally transmitted antibodies with 
development of immunity in the infant and have important 
implications for vaccine policy.
Both confounding and effect modification can occur at the same 
time. When both are present, the effect modification should be 
noted, the confounding should be controlled for in the analysis, 
and the findings should be stratified by the variable that confounds 
and modifies the association under study.
Consider the analysis of the relationship between anemia and 
birthweight (Table 9.18). The overall crude CIR is 1.7 and the 
adjusted CIR is 1.6. These results indicate that maternal age is 
not a confounder. However, maternal age appears to modify the 
effect of anemia on low birthweight; young anemic women are 
twice as likely to have a low-birthweight baby than those without 
anemia (CIR = 2.2). Among older women, however, anemia is 




Anemia and Low Birthweight According to Maternal Age
Maternal Ace < 25 Years Anemia No Anemia
Low Birthweight 13 4
Normal Birthweight 18 17
Total 31 21
CIR = 2.2 (95% Cl: 0.8 - 5.8)
Maternal Ace ^ 25 Years Anemia No Anemia
Low Birthweight 5 4
Normal Birthweight 37 31
Total 42 35
CIR = 1.0 (95% Cl: 0.3 - 3.6)
Advantages and Disadvantages of 
Cohort Studies
Cohort studies have several advantages:
• They allow a complete description of the individuals’ 
experiences subsequent to exposure, including the natural 
history of disease.
• They provide a clear temporal sequence of exposure and 
disease.
• They provide an excellent opportunity to study rare exposures.
• They permit the assessment of multiple outcomes (risks and 
benefits) that may be related to a specific exposure.
• They permit the direct estimation of the rate of the health 




• They present generally more understandable information to 
nonepidemiologists.
• They do not require withholding treatment as in a 
randomized clinical trial.
Disadvantages include the following:
• Large numbers of subjects are required to study rare diseases 
in cohort study designs.
• Long-term follow-up may be necessary when the latency 
period for the outcome of interest is long.
• Follow-up may be difficult and loss-to-follow-up may affect 
the study’s results.
• The studies may be relatively expensive to conduct.
• The exposure status, which is present at enrollment into the 




1. Consider the following study of the risk of dehiscence among obstetric patients 
who were not seen at the hospital before delivery.
Example 9.19
The Risk of Dehiscence Among Women Who Were Not Seen at the Hospital Before Delivery
Problem: Is the risk of dehiscence (wound disruption) after cesarean section different for 
obstetric patients who were booked (seen at the hospital one or more times before delivery) or 
unbooked  (seen for the first time when in labor)?
Research Hypothesis: Obstetric patients who were unbooked have a greater risk of dehiscence 
than patients who were booked.
Study Design: Cohort study
Exposed: Women who were not seen at the hospital before having a cesarean section.
Unexposed: Women who were seen at the hospital before having a cesarean section.
Outcome: Dehiscence (i.e., an abdominal wound breakdown involving all layers, including the 
peritoneum) at any time after cesarean section.
Follow-up: Information on dehiscence was collected at the 6-week follow-up visit.
Data Collection Methods: Data were abstracted from medical records for all cesarean deliveries 





Number of women with dehiscence 
Number of women without dehiscence 







CIR = 1.7 (95% Cl: 0.9 - 33) 
(Chukudebelu and Okafor, 1978)
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(a) Considering the 95% confidence interval, is it possible that women who 
were unbooked have less risk of dehiscence than women who were 
booked?
(b) What differences between the booked and unbooked patients might 
account for the results?
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2. Consider a hypothetical study of maternal education and the risk of neonatal 
death.
Example 9.20 
Maternal Education and Neonatal Death
Problem: Is maternal education related to neonatal death?
Research Hypothesis: Women with less than six years of schooling have an increased risk of 
delivering an infant who will die during the neonatal period than do women with at least six years 
of schooling.
Study Design: Cohort study
Exposed: Women who had had less than six years of formal education.
Unexposed: Women who had had six or more years of formal education.
Outcome: Neonatal death (defined as death occurring between birth and 28 days following birth).
Follow-up: Information on neonatal deaths was collected at the 6-week follow-up visit.
Data Collection Methods: Personal interview data were collected from all women coming to the 
Maternity Clinic between January 1 and December 31,1985.
(a) What characteristics might differ between the women in the exposed 
group and those in the unexposed group?
Cohort Studies
(b) Which of these characteristics might also be related to neonatal death?
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(c) Eighty percent of the women who had had at least six years of schooling 
returned for follow-up, whereas only 65% of the less educated women 
returned for follow-up. How might this affect the results? What might 
be done about this problem?
(d) Construct a data analysis table for computing the cumulative incidence 
relative risk.
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3. Consider an analysis from the Collaboration Review of Sterilization Study.
Cohort Studies
Example 0.21
Interval Sterilization Procedures by Electrocoagulation and Silastic Bands
Problem: Are interval tubal sterilization procedures (TSP) by electrocoagulation less safe than 
sterilization using silastic bands?
Research Hypothesis: TSP by electrocoagulation has a greater risk of surgical complications 
than TSP using silastic bands.
Study Design: Prospective cohort study
Exposed: Women having interval TSP by electrocoagulation.
Unexposed: Women having interval TSP by silastic bands.
Outcome: Unintended major surgery, hemorrhage requiring blood transfusion, febrile morbidity, 
cardiopulmonary crisis, hospitalization, and death occurring in relation to the tubal sterilization 
procedure.
Follow-up: Subjects were followed up with a standard questionnaire two to 12 weeks 
postoperatively.
Data Collection Methods: Data were collected at nine hospitals in the United States from 
1978-1980. Information was obtained from standard questionnaires administered to all study 
subjects and from medical charts.
Data Analysis:
___________Exposure_____________





Total Subjects: 2397 1,109
(Adapted from DeStefano et al., 1983)
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(a) Compute the CIR and the 95% confidence interval and interpret the 
results.
(b) Reverse exposed and unexposed groups in Table 9.21 to obtain Table 
9.22; that is, let the exposed be the silastic band group and let the 
unexposed be the electrocoagulation group. Compute the CIR and the 
95% confidence interval and interpret the results.
Table 9.22
Interval Sterilization and Silastic Bands Versus Electrocoagulation
Exoosure





Total subjects 1,109 2397
(Adapted from DeStefano et al., 1983)
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4. Design a prospective cohort study in outline form based on the following 
problem situation. Briefly state the problem, define the exposed and 
unexposed groups, and describe how study subjects for each group will be 
identified. Specify the measurable outcome and the data collection methods. 
Develop an analysis table. Describe potential strengths and limitations of your 
study design.
Background: Voluntary female sterilization is the most prevalent method of 
contraception in the world. Approximately 100 million couples use this 
method, and the demand is expected to increase during this century. One 
concern is that female sterilization may cause changes in menstrual patterns. 
For this exercise we will focus on an increase in the severity of dysmenorrhea 
as our outcome. The level of dysmenorrhea could be subjectively reported or 
measured in any way you choose. While designing this study, consider 
previous contraceptive use, the age of study subjects, the reasons for 
sterilization, potential losses to follow-up, and the appropriate length of follow- 










Potential Strengths and Weaknesses:
5. Circle true (T) or false (F).
(a) T /F  In a cohort design, the study groups are identified by exposure status
before ascertaining disease status.
(b) T /F  In a historical cohort study, the researcher selects individuals based
upon outcome and then determines exposure.
(c) T /F  In a prospective cohort study, the exposure has not happened before
the study begins.
(d) T /F  Instead of using an unexposed group, investigators may compare the
frequency of an outcome in the exposed study population with that 
of the general population.
(e) T /F  If a person’s exposure status changes after initial assignment to an
exposed or unexposed group, the person should remain in the group 
to which he or she was originally assigned.
(f) T /F  The process by which an outcome is defined needs to be
standardized without making staff aware of the hypothesis under 
study.
(g) T /F  Cohort studies are well adapted for studying rare diseases.
(h) T /F  A  20% loss to follow-up may make study results questionable.
(i) T /F  Relative risk is the incidence rate for those who were exposed to




A relative risk greater than 1 occurs when the risk in the unexposed 
group is greater than in the exposed group.
Information bias is greater in prospective cohort studies than in 
historical cohort studies.
Frequency matching involves enrolling an exposed individual and 
then selecting the next unexposed person with characteristics similar 
to the exposed individual.
6. Consider the hypothetical data presented below:
Table 9.23
Outcome Z and Exposure Q
Outcome
Exoosure 
ExDosed to O Not exnosed to O
Health problem Z 225 75
Person-years 22,750 24,250
(a) Compute the EDR and the 95% confidence interval.






Suggested Answers to Practice Exercises
1. The risk of dehiscence among obstetric patients.
(a) Yes, it is possible that patients who were unbooked have less risk 
than patients who were booked, since the lower confidence limit for 
CIR is 0.9. However, it seems reasonable that patients who were 
unbooked would be at greater risk.
(b) Possible problems with interpretation include the fact that, besides 
not receiving antenatal care, the unbooked patients are more likely 
to represent emergency cases with prolonged labor and have greater 
potential for preadmission complications. They are also more likely 
to be from a lower socioeconomic class. Additionally, because they 
may be more likely to be from rural areas, they may have begun 
physical labor sooner than women from urban areas and thus may 
have increased their risk of dehiscence. The same women who are 
not booked may be less likely to seek medical attention for 
problems such as wound infections and thus may have increased 
their risk of dehiscence. These differences could explain the study 
results.
2. Maternal education and the risk of neonatal death.
(a) Income, nutritional status, access to health services (including 
prenatal care, maternity services, and care for the infant) differences 
in cultural practices affecting infant outcome (e.g., management of 
the umbilical stump in a way that may increase the risk of neonatal 
tetanus), intrapartum interval, infant feeding practices, etc.
(b) Virtually all of the above are also associated with poor infant 
outcome.
(c) It may underestimate the risk in the less educated women, if failure 
to return for follow-up is associated with adverse infant outcome.
To correct the problem, arrange active follow-up on both the 
exposed and unexposed to ensure the highest possible response rate 
in both groups. Alternatively, select a random sample of those who 










Neonatal death a b
Survival to 28 days c d
Total Hi n o
3. Interval sterilization procedures by electrocoagulation and silastic bands.
(a) CIR = 2.2/1.1 = 2 (95% Cl: 1.1 - 3.8). In this study, TSP by
electrocoagulation appears to be associated with an increased risk 
(two times) of surgical complications than silastic bands. Since the 
confidence interval does not include 1.0, the CIR is a statistically 
significant increased risk; that is, TSP by electrocoagulation appears 
to be associated with a statistically significant 2-fold increased risk 
of surgical complications compared with TSP by silastic bands. The 
data analysis confirmed the research hypothesis.
(b) If you reverse the "exposed" and "unexposed", the relative risk
becomes less than one; the cumulative incidences would be 1.1% 
and 2.2%, and the CIR = 1.1/2.2 = 0.5 (95% Cl: 0.3 - 0.9). Since 
the confidence interval does not include 1.0, this finding is 
statistically significant. TSP by silastic bands appears to be half as 




4. These are only suggested answers. The exposure groups and outcome you 
choose will vary, and many responses will be acceptable. The answer provided 
is based on the report of the actual study referenced.
Example 9.24
Female Sterilization and Dysmenorrhea
Problem: Does dysmenorrhea increase after female sterilization?
Research Hypothesis: More women who have had sterilization surgery report dysmenorrhea 
after surgery than women who did not undergo sterilization surgery.
Study Design: Cohort study
Exposed: Healthy women aged 25 to 34 years who are at least six months postpartum, are 
menstruating, and have not used hormonal or intrauterine contraception in the three months 
before seeking voluntary sterilization.
Unexposed: Healthy women aged 25 to 34 years who are at least six months postpartum, are 
menstruating, and have not used hormonal or intrauterine contraception in the three months 
before admission to the study and who are presently using barrier contraceptives.
Outcome: Dysmenorrhea is classified as none, mild, moderate, or severe as subjectively reported 
by the study subject in response to a standard set of questions.
Follow-up: Two years after the procedure, follow-up data were collected by telephone interviews 
with each woman.
Data Collection Methods: At admission to the study, subjects reporting dysmenorrhea will be 
given gynecologic examinations to determine the cause of the condition. If the cause is not 
idiopathic, the women will be dropped from the study. Each subject will be asked about the 
characteristics of her most recent menstrual period at admission; one and two years later, each 
women will be reinterviewed about the characteristics of her menstrual periods over the last 6 
months. The interviewer will not know whether the subject is in the exposed or unexposed 
group.














Since we are able to establish accurately the time since sterilization for exposed groups and the 
time from entry into the study for barrier users, we will use incidence density as our incidence 
measure. The incidence density and confidence limits will be calculated from the data in the 
table. Finally, we will need to determine if the age and parity distribution differ in the two 
comparison groups.
Potential Strengths and Weaknesses:
Strengths —Voluntary sterilizations have been separated from medically indicated ones. The 
effects of prior contraceptive use have been controlled. The evaluator of dysmenorrhea will 
not know the exposure status of the subjects.
Weaknesses —Level of dysmenorrhea is a subjective outcome. Many subjects may be lost 
from the unexposed group because they change contraceptives or become pregnant.
(DeStefano et al., 1983)
5. True or false.
(a) T Introduction
(b) F In a historical cohort study, exposure and outcome have occurred
before the study begins; as in prospective cohort studies, the subjects 
are selected according to exposure status rather than outcome.
(c) F In a prospective study, exposure status is determined when the study
begins, and the exposed and unexposed groups are followed forward in 
time to observe whether they develop the study outcome. Often, the 
exposure has been going on for some time when the study begins.
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(d) T  Population Sources and Follow-up
(e) T  Measuring Exposure
(f) T  Determination of Outcome
(g) F  Advantages and Disadvantages. Cohort studies are well adapted for
studying rare exposures.
(h) T Population Sources and Follow-up
(i) T  Relative Risk
(j) F  Relative Risk. A relative risk greater than 1 occurs when the risk in 
the exposed group is greater than the risk in the unexposed group.
(k) F Validity and Bias. Information bias is likely to be larger in historical 
cohort studies than in prospective cohort studies.
(1) F Matching. Frequency matching involves enrolling exposed individuals 
and categorizing them into subgroups and then enrolling a specified 
number of unexposed individuals with the appropriate characteristics 
for the subgroup.
6. Outcome Z  and exposure Q.
6.1 IDR = 3.2 (95% Cl: 2.5 - 4.1)
6.2 Women exposed to Q have an approximately threefold increased risk of 
developing health problem Z as women who have never been exposed to 
Q. This finding is statistically significant because the 95% confidence 
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Chapter 10 - Learning Objectives
After completing this chapter, you should be able to:




2. Describe how to select cases and controls.
3. Define the exposure variable in measurable terms.
4. Construct different measures of exposure.
5. Specify the data collection methods to be used in the study.
6. Describe types of bias.
7. Identify data analysis methods for case-control studies.
8. Describe why the measures of association used for cohort studies do not apply to
case-control studies.
9. Construct analysis tables for a case-control study.
10. Calculate and interpret the odds ratio and the confidence interval for the odds
ratio.
11. Interpret analysis tables for a case-control study.
12. Recognize advantages and disadvantages of case-control studies.
13. Design a hypothetical case-control study.

1  A  Case-Control 
A  \ /  Studies
Introduction
The case-control study is an analytic epidemiologic research 
design in which the study population consists of groups who either 
have or do not have a particular health problem or outcome. 
Comparison groups for case-control studies are formed on the 
basis of disease or health problem status. The study subjects with 
the health problem are called cases, and the study subjects without 
the health problem are called controls. In a case-control study we 
look back in time to measure exposure(s) of the study subjects 
(Figure 10.1). We compare the exposure among cases to the 
exposure among the controls to determine if the exposure could 
account for the health condition of the cases. The research 
hypotheses should clearly specify the expected relationship 
between the health problem and the exposure of interest.
Figure 10.1















The case-control study differs from the cohort study in that 
individuals are categorized by their health problem or outcome; 
epidemiologists then look back in time to determine each individual’s 
exposure status. In a cohort study, individuals are categorized by 
their exposure status; then epidemiologists look forward in time to 
determine the outcome. In Example 10.2 investigators examined the 
risk of myocardial infarction among women who were current users of 
oral contraceptives (OCs) and women who had discontinued using 
OCs (Slone et al., 1981). The cases were diagnosed with myocardial 
infarction during 1976 through 1979. The controls were admitted to 
the same hospitals during the same time period as the cases. The 
investigators looked back in time to measure exposure to 
contraceptives. Interviewers collected information about each 
woman’s lifetime use of contraceptives, specifically OCs, before her 
diagnosis in 1976 through 1979.
Example 10.2 
Oral Contraceptive Use and Myocardial Infarction
Problem: Is oral contraceptive (OC) use associated with myocardial infarction?
Research Hypothesis: Current OC use is positively associated with myocardial 
infarction.
Study Design: Multicenter hospital-based case-control study
Cases: Women who were hospitalized with a diagnosis of myocardial infarction 
(World Health Organization criteria).
Women 25 to 49 years old who were admitted to 155 hospitals in the northeastern 
United States between July 1, 1976, and June 30, 1979. Cases who had had a 
myocardial infarction, coronaiy-bypass surgery, cardiac-valve prosthesis, rheumatic 
heart disease, an occurrence of infarction after admission, or sickle-cell crisis 
preceding infarction were excluded from the study.
Controls: Women with no previous history of myocardial infarction who were 
admitted to the same hospitals and diagnosed during the same time period as the 
cases.
Four women, aged 25 to 49 years with diagnoses judged to be unrelated to 




considered unrelated to contraceptive choice included fractures, dislocations, 
soft-tissue injuries, gastroenteritis, appendicitis, disk disease, lower-back pain, 
renal calculus, hiatal hernia, reflux esophagitis, inguinal or femoral hernia, 
duodenal ulcer, gastric ulcer, and nontoxic thyroid nodules.
Exposure: Current OC use (OC use in the month before hospital admission).
Data Collection Methods: Hospital records were abstracted and cases and 
controls were interviewed by nurses in the hospital or at home after discharge.
(Slone et al., 1981)
Design and Data Collection Methods
Case Selection
The cases are the study subjects who have the health problem 
or outcome to be investigated. The definition of a case requires 
two specifications:
• An unambiguous and objective description of the health 
problem, including how the health problem is to be 
diagnosed (i.e., diagnostic procedures, laboratory tests, and 
clinical signs and symptoms),
• The eligibility criteria that will be used to select cases for the 
study (i.e., ages, no history of selected diseases and 
conditions, etc., and how, when, and where cases are 
identified) (Schlesselman, 1982). Cases may be all persons 
who are newly diagnosed with disease during a specified 
period of time (also known as incident cases).
Example 10.3 presents the case definition from a case-control 
study of pelvic inflammatory disease (PID) and current use of an 
intrauterine device (IUD) (Burkinan et al., 1981). Clinically, cases 
were defined as women who received a hospital discharge 






Use of Intrauterine Devices and Pelvic Inflammatory Disease
Problem: Is current intrauterine device (IUD) use associated with pelvic 
inflammatory disease (PID)?
Research Hypothesis: Current IUD use is positively associated with the 
development of PID.
Study Design: Multicenter hospital-based case-control study
Cases: Women with a hospital discharge diagnosis of PID. The diagnosis of 
PID was classified as m ost certain, moderately certain, and least certain. Women 
with anatomic findings of PID at laparoscopy, laparotomy, culdoscopy, or 
colpotomy (either the adnexa were visualized or an abscess cavity was drained) 
were classified as most certain. Women who were hospitalized with a diagnosis 
of PID for seven days or longer or who had a temperature greater than 100.4 
degrees F on two or more days, and who did not undergo the operative 
procedures listed for the certain cases were classified as moderately certain. 
Women with a discharge diagnosis of PID who did not fit the criteria for the 
most certain and moderately certain cases were categorized as least certain.
Women 18 to 44 years old with a discharge diagnosis of PID between October 
1976 and August 1978 were identified through a systematic review of admission 
lists, operative logs, ward census records, and discharge logs at one of 16 
hospitals in nine cities in the United States. Women were excluded if they had 
not been sexually active during the previous year, had had sterilization surgery 
(or if partner had had sterilization surgery), had been pregnant during the 
previous six weeks, or had not menstruated in the past year.
Controls: Women who were admitted for acute conditions or elective surgery 
to the surgical and medical services of the same hospitals during the same time 
period as the cases.
Controls were selected using the same eligibility criteria as the cases, but they 
were not diagnosed with PID. Women with diagnoses of gallbladder disease; 
vascular, pelvic, or breast surgery; and other conditions that could influence 
contraceptive choice were excluded. Women with diagnoses of epilepsy, 
thromboembolism, cerebrovascular disease, or cancer were also excluded.
Exposure: Current IUD use (contraceptive method used during the 30 days 
before hospital admission). Women who had an IUD when admitted to the 
hospital or who had one removed within 30 days before being admitted to the 




Data Collection Methods: Information about the women enrolled in the 
study was abstracted from medical records, and a standardized interview was 
conducted during each woman’s hospital stay. If a woman was discharged 
from the hospital before an interview was conducted, she was interviewed by 
telephone or in her home.
(Burkm an et al., 1981)
assess the certainty o f diagnosis. The investigators based their 
judgment on whether specific procedures necessary for 
confirmation of a diagnosis of PID had been performed and on 
the presence of selected signs and symptoms likely to indicate a 
diagnosis of PID. The criteria for defining cases of PID in this 
study were categorized as certain, moderately certain, and least 
certain.
Eligibility criteria for the cases in this study included a specific 
age range, sexual activity during the previous year, absence of 
sterilization surgeries (woman or her partner), menses during the 
past year, and no pregnancy during the six weeks before admission 
to the hospital. Study personnel described how, when, and where 
the cases were identified; admission logs were used to enroll 
women as potential cases. All women were interviewed before 
they were discharged from the hospital. Final eligibility was 
determined after discharge.
The eligibility criteria identify groups of women who could have 
experienced the exposure under study (Schlesselman, 1982). 
Women with conditions that might have limited their choices of 
contraception were excluded. For example, women who are not 
sexually active or who have had a tubal ligation sure not likely to 
have recently used any contraceptive method including IUDs.
Good sources of cases include admissions and discharge logs in 
physician offices, clinics, and hospitals; surgical logs; disease or 
tumor registries; and for deaths, vital statistics records 
(Schlesselman, 1982). Potential sources of cases should be 
evaluated to understand the case identification process, the 
potential for identifying all cases, and the likely referral patterns 
for cases. For example, seriously ill cases who live a long distance








from the medical care facility may be unable to travel to the facility, 
and thus may be missed as potential cases for study. Alternatively, 
cases from outside the defined study settings may be referred to the 
medical care facility for treatment and included for study. Failure to 
consider and manage these possibilities may bias risk estimates.
Control Selection
The controls are the study subjects who do not have the health 
problem or outcome under investigation. Controls should be similar 
to the cases with respect to the potential for exposure, since case- 
control analyses compare the rate of exposure among the cases to the 
rate of exposure among the controls (Schlesselman, 1982). The 
criteria used to select controls should be comparable in all ways with 
the criteria used to select cases, except the controls should not have 
the health problem under study. If controls are selected in this 
manner, differences in the rates of exposure are likely to reflect a true 
association between exposure and disease. If controls are not selected 
in this manner, then measures of the association between the health 
problem and the exposure may reflect the differences in the ways the 
cases and controls were selected and therefore may be biased.
The eligibility criteria for both cases and controls in Example 10.3 
were similar and the likelihood that both groups of women were 
potential users of contraception was increased. Importantly, controls 
chosen from hospital admission records did not have diagnoses that 
were related to contraceptive use.
Alternatively, consider a case-control study in which the cases are 
identified from the discharge logs of a  public hospital located in a 
large urban area. Assume that the controls are selected at random 
from the general population in the same urban area. These controls 
would be inappropriate because the general population probably 
includes many persons who would always use a private instead of a 
public hospital. These controls are not likely to be comparable to the 
cases with respect to access to medical care, diseases and conditions, 
socioeconomic status, education, and other factors.
The most common sources of control subjects are hospitals, clinics, 
physicians’ offices, the community, or the general population.
Selecting controls from the same hospital where cases are selected is 
often practical and cost efficient; these patients are referred to as 
hospital controls. However, hospital controls should be selected from
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diagnostic categories that are unrelated to the exposure of interest. 
Controls may also be selected from the community or geographic 
area where the hospitalized cases reside; these controls are 
referred to as community or population controls. In some studies, 
neighbors, associates, friends, or relatives of cases have served as 
controls. Using the relatives of cases as controls will likely result 
in matching on variables such as diet, life-style behaviors, and 
family history of diseases.
Controls may be selected in several ways. Selection may 
involve sampling or may include the total population (excluding 
cases). Controls may be randomly or systematically selected from 
the total population. Finally, controls may be matched to cases on 
specific variables to make controlling for confounding in the 
analysis more efficient. Matching may be desirable if there is an 
unusual distribution of cases compared to controls with respect to 
a specific variable (e.g., age). Matching may be individual 
matching (also known as one-to-one matching) or frequency 
matching. If individual matching is used, one or more study 
subjects without disease is matched with a specific study subject 
who has disease. Alternatively, frequency matching involves 
matching several study subjects without disease in a given 
subgroup with study subjects who have disease.
Exposure Definition
The intensity of the exposure is assessed through measures 
related to frequency and time. Measures of expdsure that relate 
to frequency may be dichotomous, polytomous, or continuous:
• Dichotomous: categorized as exposed or unexposed (e.g., 
never and ever diaphragm use)
• Polytomous: measured on more than two levels (e.g., never, 
occasional, and frequent condom use; number of 8-ounce 
drinks of alcohol per week; days per week when calcium is 
taken)
• Continuous: measured on the continuum of a unit of 















Exposure may be intermittent (i.e., exposure to a risk factor is 
interspersed with periods of nonexposure) or continuous (i.e., 
exposure to a risk factor is constant where a single episode of 
exposure is not interrupted by exposure to an alternative risk factor or 
to no risk factor). Measures that relate to time include duration of 
exposure (e.g., total months of IUD use), time since first exposure 
(e.g., number of months since first OC use), time since last exposure 
(e.g., number of months since last pregnancy), and ages at first or last 
exposure. For some health problems, exposure before, during, or 
after selected reproductive events or events that are related to the 
health problem under study is important. For example, McPherson 
and colleagues (1983) suggested that OC use before the first term 
pregnancy might increase the risk of breast cancer. Exposure to 
alcohol, smoking, and various drugs during pregnancy has been 
related to adverse fetal, neonatal, and infant outcomes. Whether the 
exposure is current or past may also be important for studying 
selected health problems or outcomes. In Example 103, the 
definition of current exposure is precisely specified with respect to 
number of days and includes criteria about recent discontinuations.
Since measures of risk are expressed in terms of the exposure, 
minimum exposure must be defined. The cases and controls with the 
minimum exposure are the comparison or referent group. Minimum 
exposure may be defined as no exposure or as some low level of 
exposure judged to be insufficient to be related to disease.
The primary sources of exposure data are 1) hospital or clinic 
records, 2) vital statistics, 3) employment, insurance, or social service 
records, and 4) direct contact with study subjects. Exposure data 
should be collected from existing documents when possible. When 
collecting exposure data, the same data collection methods should be 
used for both cases and controls. If existing sources are unavailable 
or inadequate, exposure data must be collected by contacting the 
study subjects directly (in person, by telephone, or by mail).
Data Collection Methods
In-person and telephone interview questionnaires, self-administered 
questionnaires, and forms designed to abstract information from 
medical records are used to collect and organize data for study and 
analysis. Careful form design and wording of the questions affect 
data quality. Questions used in other studies of the same health
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problem or exposure are useful for planning and constructing 
questions for new studies. Using questions that provided valid 
data in other studies minimizes the time required to test question 
wording and promotes comparability of data across studies.
Questionnaire construction should begin with a list of variables 
needed for study. The list is best developed from a thorough 
review of the medical literature and should contain all the risk 
factors for the health problem and the exposure under study. A 
description of all possible ways to measure each variable should 
also be included. All data collection forms should be pretested, 
and data collection personnel (e.g., interviewers, abstractors) 
should be trained to use the forms correctly.
In Example 10.3, data collection involved medical record 
abstracts and personal interviews. The interview questionnaire 
contained questions to confirm the eligibility criteria, demographic 
questions, questions about factors that might be related to the 
occurrence of PID or to contraceptive choice, and histories of 
gynecologic conditions, chronic diseases, contraceptive use, 
pregnancies and menstrual events. (For additional sources on 
questionnaire design and data collection methods, see Bennett and 
Ritchie, 1975, Schlesselman, 1982, and Sudman and Bradbum, 
1983.)
Bias
In the design of a case-control study, the methods by which 
study participants are selected and classified as diseased, not 
diseased, exposed, and unexposed affect validity (Schlesselman, 
1982). Errors in design may cause the overrepresentation or 
underrepresentation of study participants into these categories and 
distort the measure of the association between the health problem 
and the exposure. Bias refers to the systematic errors that 
produce an inaccurate estimate of the association between the 
health problem and the exposure. Three types of bias can 
influence the results of the case-control investigation: selection 
bias, information bias, and confounding bias.
Selection bias. This type of bias refers to the process in which 
cases or controls are selected in a way that is related to exposure. 
Biased estimates of the association between the exposure and the
Questionnaire
construction








Length o f 
hospital stay 
bias
health problem can occur when the exposure is related to 
nonresponse, length of stay, survival, differential surveillance, 
diagnosis, referral, or selection of study participants.
Nonresponse bias is a type of selection bias that refers to the 
respondent’s refusal or inability to participate in the study or to the 
field personnel’s inability to contact potential study participants. 
Nonresponse bias occurs when the rate of exposure among nonpartici­
pating cases is different from the rate of exposure among nonpartici­
pating controls. While the study is being conducted, every effort 
should be made to locate study participants, to enlist their partici­
pation, and to minimize refusals. Interviewers may need training on 
how to locate difficult-to-find study participants. When refusal rates 
are high, several actions are needed to identify ways to reduce 
nonparticipation. Introductions and information about the study that 
is provided to study participants may need to be revised. Interviewers 
with high refusal rates may need specialized training about how to 
persuade reluctant participants to cooperate. Convening regular 
meetings for interviewers permits exchange of ideas about locating 
difficult-to-find participants and eliciting cooperation.
However, if nonresponse is high at the conclusion of the study, 
some measure of the possible effects of nonparticipation on the 
results is needed. The investigator may perform a worst-case analysis 
in which all nonparticipating cases are assumed to be exposed and all 
nonparticipating controls are assumed to be unexposed. If the 
conclusions about the association between the health problem under 
study are unchanged with the worst-case analysis, nonparticipants are 
unlikely to have affected the results. The investigator may also 
compare characteristics of the participating and nonparticipating cases 
and controls.
Bias related to length of hospital stay, another type of selection 
bias, may occur if cases are selected from a registry of current 
hospital patients instead of from admission or discharge logs. If cases 
are selected from a registry of current hospital patients, then cases 
who have been hospitalized for the longest period of time have a 
higher probability of being selected than cases admitted for minor 
conditions or cases who died. Furthermore, these cases may have 
other diseases and conditions that may be related to the disease or 
exposure under study. Therefore, use of admission or discharge logs 




Two additional types of selection bias are survival bias and 
surveillance bias. Bias related to survival may occur if only the 
survivors of the outcome are selected as cases and if survival is 
related to the exposure of interest. Surveillance bias may occur 
when health problems that are mild or asymptomatic are 
diagnosed as a result of more frequent or thorough follow-up 
examinations and when more frequent or thorough examinations 
are conducted among study participants who have been subjected 
to suspected exposures. To assess whether surveillance bias is 
present in the data, cases and controls with frequent medical 
surveillance can be analyzed separately from cases and controls 
with infrequent surveillance.
Diagnostic bias and referral bias are also types of selection bias. 
Diagnostic bias may occur if knowledge of the exposure status 
inappropriately alters the diagnosis. Assuming that diagnostic bias 
decreases as the severity of disease or the certainty of diagnosis 
increases, analysis of cases according to the certainty of diagnosis 
permits some assessment of the presence of this type of bias. 
Referral bias may occur if knowledge of the exposure status or if a 
variable (e.g., socioeconomic status) related to exposure 
inappropriately affects referral patterns. Referral bias is most 
likely to occur when a study is based in the hospital, clinic, or 
physician’s office.
Potential biases introduced in selecting cases and controls may 
be reduced by designing the study so that selections are not 
necessary. The ideal study design involves the enrollment of all 
cases of a disease occurring in a defined geographic region during 
a specified period of time and the random selection of controls 
from the general population of the same area. Exclusions that are 
applied to the cases must also be applied to the controls. Since 
the purpose of the control group is to determine the rate of 
exposure expected in the case group, if no association between the 
exposure and the health problem is present, the controls should be 
comparable with the cases in all relevant ways except that they do 
not have the health problem.
Example 10.4 describes a population-based case-control study. 
The cases were all women diagnosed with histologically confirmed 
primary breast cancer who resided in one of eight geographic 
regions in the United States (The Cancer and Steroid Hormone 









Oral Contraceptive Use and Breast Cancer
Problem: Is OC use associated with the risk of breast cancer?
Research Hypothesis: There is an association between OC use and breast cancer.
Study Design: Multicenter population-based case-control study
Cases: All women 20 to 54 years old with newly diagnosed breast cancer who 
reside in one of eight geographic regions in the United States. The women were 
identified through population-based tumor registries.
Controls: Women of the same ages selected at random from the general 
population of the same eight geographic regions during the same time period 
when cases were diagnosed.
Exposure: OC use before cancer diagnosis for cases and before interview for 
controls.
(The Cancer and Steroid Hormone Study, 1986)
based tumor registries, which are agencies that collect information on 
all new cases of cancer diagnosed in the region. The controls were 
selected at random from the general population of the same 
geographic regions as the cases. Since the controls were selected 
from the general population, the data on their contraceptive history 
will likely provide an accurate measure of the expected rate of 
exposure to oral contraceptives in these geographic regions. Although 
population-based case-control studies are ideal, they may not always 
be feasible. Identifying all case patients may be difficult if they do 
not routinely seek medical attention for the disease under study. 
Identifying controls from the general population may be expensive or 
logistically impossible. Furthermore, not all hospitals in the specified 
geographic regions or metropolitan areas will necessarily consent to 
participate in the study.
When studying certain mild conditions or outcomes for which only 
selected patients, such as more affluent patients, would be 
hospitalized, use of neighborhood or general population controls may 
pose problems that relate to selection bias. (Under these
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circumstances, general population controls may not be comparable 
to cases, since controls with middle to lower socioeconomic status 
may never be hospitalized for the mild condition.) Preferably, the 
controls should be restricted to individuals who would likely have 
been hospitalized if they developed the condition under study.
Hospital-based case-control studies maximize similarities 
between cases and controls. In the hospital-based case-control 
study, controls should be selected from patients admitted to the 
same hospitals for other minor conditions that are known not to 
be associated with the exposure. If such measures are taken, cases 
and controls are more likely to have similar socioeconomic status, 
life-style behaviors, religion, and other traits that can determine 
patterns of hospitalization. Although this selection procedure 
promotes comparability between cases and controls, the results 
may not be generalizadle to the entire population.
If the control group is chosen from hospitalized patients, it 
seems best to include individuals with many different illnesses, 
none of which is known to be associated with the exposure being 
studied. In this way, even if one of the diseases is found to be 
associated with the exposure under study, it will likely have little 
effect on the study results since the number of patients with one 
specific illness is small (Example 10.5).
Example 10.5 
Selection Bias in  Hospital-Based Studies
One of the first case-control studies of OC use and cardiovascular disease 
included many women with gallbladder disease in the control group. Shortly 
after the study was concluded, several reports indicated that women using 
OCs were at increased risk of gallbladder disease. Thus the control group 
contained women who had developed gallbladder disease because they had 
used OCs. As a result, a spuriously high rate of exposure to oral 
contraceptives was noted among the controls, and the study artificially 
underestimated the relative risk of cardiovascular disease in oral contraceptive 
users.
(Boston Collaborative Drug Surveillance Program, 1973)
Case-Control Studies
Recall bias
Information bias. This type of bias refers to the collection of 
incorrect information about exposure that results in an incorrect 
measurement of the exposure. Obtaining an accurate exposure 
history from the cases and controls is one of the major difficulties in 
conducting a valid case-control study. Participants’ recall of past 
exposures may be inconsistent and inaccurate. Exposure information 
may be difficult to remember, particularly when the exposures 
occurred in the distant past. To improve recall, memory aids such as 
calendars, diaries, photographs, or other visual materials may be 
helpful. Exposure information should be validated whenever possible, 
using sources independent of the study subject’s report (Example 
10.6).
Example 10.6
The Use o f M em ory Aids to Reduce Inform ation  Bias
In studies of the association between oral contraceptive use and reproductive 
cancers, accurate information on use of specific formulations of oral 
contraceptives and use in the distant past was essential. Researchers in Great 
Britain designed a study to compare self-reported oral contraceptive histories 
collected during personal interview with data collected prospectively from the 
Oxford Family Planning Association cohort study. Two memory aides were used 
to assist recall during interview; a calendar of important life events to which the 
study participant might relate her use of oral contraceptives, and a book of color 
photographs of all oral contraceptive preparations marketed in Great Britain. 
Interview data collected with the calendar and photographs consistently had better 
agreement with the cohort records data than interview data collected without the 
aids. Agreement between self-reported data and cohort records within six months 
was 56.2% for total duration, 81.2% for date of first use, 66.7% for date of last 
use, and 79.2% for date of use prior to first term pregnancy. For interviews 
conducted without the memory aids, the rate for total duration was 39.2%, for 
date of first use, 80.4%, for date of last use, 52.9%, and for date of use prior to 
first term pregnancy, 70.6%.
(Coulter et al., 1986)
More important than forgetfulness, however, is whether cases 
remember exposures to risk factors in the past differently than 
controls. Recall bias refers to the effect of cases remembering 
exposures differently than controls. In some case-control studies,
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recall bias may be of such concern that it influences the choice of 
a control group (Example 10.7).
Example 10.7
The E ffect o f Potential Recall Bias on the Choice o f Controls
Investigators of congenital malformations seek information on exposures 
early in pregnancy. Because of the psychological trauma of giving birth to a 
child with defects, mothers of cases may be more likely than mothers of 
controls to recall exposures to potential risk factors during pregnancy; they 
may, in fact, search for an explanation of the malformation. This 
enhancement of recall could result in bias, and spuriously create a difference 
between the cases and the controls in their reported exposure histories.
Recall bias in studies of malformations may be minimized by choosing control 
infants with different birth defects than the birth defect of interest.
In a case-control study of the relationship between birth defects and 
maternal consumption of caffeine, six groups of case patients (inguinal hernia, 
cleft lip, cardiac defect excluding murmur, pyloric stenosis, isolated cleft 
palate, and neural tube fusion defect) were compared to all other malformed 
infants. Mothers of malformed infants who did not have one of the six case 
defects would likely have similarly enhanced recall as mothers of the case 
patients.
(Rosenberg et al., 1982)
A similar rationale has been used in the defense of hospital- 
based case-control studies. Since the controls in hospital-based 
studies are also ill, they would be expected to have a similar 
enhancement of memory as the cases.
Confounding bias. This bias refers to the effect of an 
extraneous factor that distorts an apparent association between the 
health problem and the exposure under study or that obscures an 
underlying true association (Schlesselman, 1982). That is, the 
association between an exposure and the health problem under 
study may actually be due to another variable. Alternatively, the 
lack of an association could result from failure to control for the 
effect of some extraneous factor. To be a confounder, a variable 
must be associated with, but not a consequence of, the exposure, 
and be a risk factor for the health problem under study
Case-Control Studies
(Schlesselman, 1982). Confounding may be controlled in the data 
analysis phase if the relevant information has been collected.
Data Analysis Methods
Analyses should be planned concurrently with designing the study 
protocol and data collection form or questionnaire to ensure that 
information is collected for all important variables in a manner that is 
appropriate for analysis. The first steps of the analysis begin with 
organizing the data into tables that are used to make comparisons 
between cases and controls. Typical tables presented for the analysis 
of case-control studies include characteristics (demographics and risk 
factors) of the cases and controls (Table 10.8), information about the 
magnitude of the association between the health problem and the 
exposure under study (Tables 10.14 and 10.16), and information about 
the risk of the health problem according to various subgroups of the 
cases and controls (Table 10.18).
Analysis Table of Characteristics of Cases and Controls
Careful examination of differences of various characteristics 
between cases and controls provides important information about the 
comparability between the case patients and the controls. First, these 
data permit comparisons with studies published in the literature. The 
risk factors present in the data under study can be compared with 
known risk factors in other studies. When known risk factors are not 
present in the data under study, the researcher should evaluate and 
question his data collection procedures and findings. Second, analysis 
of known risk factors may provide information about which variables 
will potentially confound an association between the health problem 
and the exposure under study. Third, evaluation of similarities or 
dissimilarities between the cases and controls may provide 
information that may indicate if cases and controls were selected or 
interviewed in a comparable manner. For example, in multicenter 
studies, are the geographic, hospital, or clinic distributions of the 
cases and controls similar?
Table 10.8 presents selected percentage distributions of 
demographic characteristics and risk factors for cases and controls 
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Obesity [(Weight (g)/Height \cm )]
<2.25 48.8 56.0
2.25-2.49 26.2 21.5
2.50 + 24.8 22.1
Unknown 0.2 0.4
(The Cancer and Steroid Hormone Study, 1987)
epithelial ovarian cancer (The Cancer and Steroid Hormone Study, 
1987). Cases were more likely than controls to be younger, have 
lower parity, and be obese.
The Odds Ratio as an Estimate of the Relative Risk
Data collected from case-control studies do not permit a direct 
calculation of the relative risk. Because the proportion of the 
population that the cases and the controls represent is usually not 
known, we cannot derive incidence rates in the exposed and 





the relative risk. When the health problem is rare among the exposed 
and unexposed persons in the general population, the odds ratio 
closely approximates the relative risk. Historically, case-control 
studies have been the preferred study design when the incidence of 
the study outcome is rare, such as in cancer studies. Example 10.9 
and Table 10.10 permit the comparison between the use of the 
relative risk in a hypothetical cohort study and the use of the odds 
ratio in a case-control study with similar hypotheses.
Example 10.9
Oral Contraceptive Use and Cervical Intraepithelial Neoplasia 
Cohort Study
Problem: Is OC use related to the risk of cervical intraepithelial neoplasia 
(CIN)?
Research Hypothesis: OCs are associated with the risk of CIN.
Study Design: Multicenter cohort study
Exposed: Women 18 to 44 years old who were using OCs when they visited any 
of 20 family planning clinics.
Not Exposed: Women of the same ages who were not using OCs when they 
visited the same family planning clinics.
Outcome: Exposed and unexposed women were followed for one year to observe 
occurrences of biopsy-proven CIN.
Data Collection Methods: Clinic records for the current visit were abstracted for 
each visit during one-year follow-up.
Clinic records indicated that the one-year incidence of cervical 
dysplasia among the exposed women would be 5% and unexposed 
women would be 2%. The cumulative incidence relative risk (Table 
10.10) was:
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If this problem had been investigated in a case-control study 
(Table 10.10), the 140 cases of cervical dysplasia would constitute 
the group of cases. An equal number of controls would have been 
selected at random from the 1,900 + 1,960=3,860 women who did 
not have cervical dysplasia (69 = 1,900 * 140/3,860 controls who 
had used OCs, and 71 = 1,960 * 140/3,860 controls who had never 
used OCs). Information about exposure to oral contraceptives 





The odds ratio was:
r»x> _ a/b  100/40 _ 100 * 71 _ *
c/d  69/71 69 * 40
Because the incidence of cervical dysplasia was low in the general 
population, the case-control study yielded an odds ratio of 2.6. This 
ratio is approximately equal to the cohort study cumulative incidence 
relative risk of 2.5. However, the case-control design required a 
substantially smaller study size (280) than the cohort study (4,000).
Alternatively, if the incidence of the health problem under study is 
high, the odds ratio will be an inadequate estimate of the relative risk 
(Example 10.11). In the cohort design, the proportion of the exposed 
with the outcome (1,000/2,000) is the same as the proportion of cases 
exposed in the case-control study (1,000/2,000). A similar 
relationship exists among the unexposed women in the cohort study 
(1,000/10,000) and the controls who were exposed in the case-control 
study (200/2,000). The unbiased estimate of the cumulative incidence 
relative risk from the cohort study is CIR=5.0. Because the incidence 
of the outcome was high in the general population the estimate of 
relative risk from the odds ratio, O R =9.0, is a poor estimate.
Case-Control Study Analysis Table for the Odds Ratio and 
Confidence Interval
In case-control studies, the odds ratio (OR) estimates the relative 
risk as a measure of the magnitude of the association between the 
exposure and the health problem under study. Table 10.12 presents 
the analysis table for the odds ratio. Table 10.12 is similar to the 
tables used to estimate the relative risk (RR) and the incidence 
density ratio in cohort studies and randomized clinical trials.
However, the risk measures applicable for cohort studies cannot be 
calculated from data gathered by the case-control design because, in a 
case-control study, the health problem or outcome is sampled, not the 
exposure. The ratio of risks in a case-control study may be estimated 
by dividing the odds o f disease among the exposed ( a /c  ) by the odds o f 
disease among the unexposed ( b /d  ) (See 10.12.1). An OR larger 
than 1.0 implies that the risk of the health problem is increased if the 
study participant was exposed. An OR smaller than 1.0 implies 
protection as a result of the exposure (i.e., the risk of the health 
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The confidence interval (Cl) for the odds ratio (Mantel and Haenszel, 
1959, Miettinen, 1976) is given by the formula 10.12.2.
( 10.12.2)
Confidence Interval for OR = O R ^ ^ 
where z is a normal variate, and 
(10.12.3)
(t -  1) * (a * d -  b * c)2 
n, * n0 * m, + m 0
This confidence interval provides a good estimate when the OR is 
close to 1.0 but becomes less stable for ORs greater than, say 3.
Table 10.13 presents the risk of epithelial ovarian cancer among
= Jxtm , and * m h  "
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women who have ever used oral contraceptives (The Cancer and 
Steroid Hormone Study, 1987). Women who have ever used OCs 
have a 40 percent [( 1 — 0.6 )*100 ] decreased risk of developing 
epithelial ovarian cancer than women who have never used OCs. 
Oral contraceptive use protects against ovarian cancer.
Using the data in Table 10.13, the confidence interval for the 
odds ratio is computed by performing the following steps:
Step 1. 2 _ (t - l )  * (a *d - b * c ) 2
XMH n ! *  n 0 *  m i *  m 0
= 4 ^ 0  -  (250 * 1,532 -  242 * 2,696)2 
2,946 * 1,774 * 492 * 4,228
= 31.51
= 5.61
Step 2: For 95% confidence interval, z = 1.96
Step 3:
Lower limit = OR^1 " z/ *  )
= e Pn OR * (1 -  z/x )]
= e [In 0.6 * (1 -  1.96/5.61)]
= 0.5
Upper limit = OR ^  + z / x  )
= e [In OR * 1 + z /x  )]
= e [In 0.6 * (1 + 1.96/5.61)]
= 0.7
Because the confidence interval does not include 1.0 in Table 
10.13, the odds ratio is considered statistically significant. That is, 
OC use protects against ovarian cancer, and the estimate of the 
relative risk is significantly less than 1.0.
Case-Control Studies
Table 10.13
Oral Contraceptive Use and Epithelial Ovarian Cancer
Epithelial Ever OC Use
Ovarian Cancer Yes Ns. Total
Yes 250 242 492
No 2,696 1,532 4,228
Total 2,946 1,774
OR « 0.6 (95% Cl: 0.5 - 0.7)
(The Cancer and Steroid Hormone Study, 1987)
In Example 10.14, compared with women who have no history of 
legal abortion, women with a previous legal abortion have a relative 
risk of 1.4 of having placenta previa in a later pregnancy (Grimes and 
Techman, 1984). In this analysis, because the confidence interval 
includes 1.0, the investigators concluded that legal abortion appeared 
to have little effect on the development of placenta previa in a later 
pregnancy.
Evaluating some frequency or time-related measure of the 
exposure may be important for some health problems. That is, does 
the risk of the health problem differ for different levels of exposure? 
Does the risk of the health problem increase (decrease) with 
increasing (decreasing) levels of the exposure? Table 10.15 presents 
the risk of ovarian cancer according to years duration of OC use (The 
Cancer and Steroid Hormone Study, 1987). An odds ratio is 
computed for each duration grouping of years of OC use, with never 
users as the referent group. The risk of ovarian cancer decreased 
from 0.6 among women who use OCs for less than one year to 0.3 
among women who use OCs for at least 10 years.
Other possible measures for evaluating the association between 
ovarian cancer and OC use might include years since first (last) use of 




Legal Abortion and the Risk of Placenta Previa
Problem: Is legal abortion associated with placenta previa in a later 
pregnancy?
Research Hypothesis: Legal abortion increases the risk of placenta previa in 
a later pregnancy?
Study Design: Hospital-based case-control study
Cases: Women who gave birth to infants weighing >499 g at Grady Hospital 
(Atlanta, Georgia) between January 1,1975 and December 31, 1979. The 
women were diagnosed either with complete placenta previa (documented by 
ultrasonography) that necessitated cesarean delivery of the infant or with 
placenta previa (documented by ultrasonography) that led to bleeding and 
required hospitalization during pregnancy.
Controls: Women without placenta previa who delivered infants weighing 
>499 g at Grady Hospital during the study period; they were randomly 
selected.
Exposure: A  history of one or more previously induced abortions.
Data Collection Methods: At the first prenatal visit, information about the 
cases and controls was collected through personal interview; and abstracts of 
computerized medical records and charts were used to collect information for 
the remainder of the pregnancy. Data obtained at each interview was 
validated, when possible, through linkage of family planning clinic records.
Results:  Exposure______________
Previous No Previous




OR = 1.4 (95% Cl: 0.5 - 3.6)
(Grimes and Techman, 1984)
Case-Control Studies
Table 10.15
The Risk of Epithelial Ovarian Cancer by 
Duration of Oral Contraceptive Use
Crude 95%
Duration of Odds Confidence
Use (Years) Cases Controls Ratio Interval
Never 242 1,532 1.0 Referent
< 1 40 414 0.6 (0.4 - 0.9)
1-2 65 602 0.7 (0.5 - 0.9)
3-4 40 397 0.6 (0.4 - 0.9)
5-9 39 594 0.4 (0.3 - 0.6)
>_ 10 13 328 0.3 (0.1 - 0.4)
(The Cancer and Steroid Hormone Study, 1987)
Controlling for Confounding in the Analysis
Unlike selection and information bias, we can adjust for 
confounding in the analysis phase. During data collection, we should 
collect information on potentially confounding variables so that they 
can be addressed during analysis. To control for confounding, we 
arrange the data in strata according to levels of the potentially 
confounding variable. Then, the Mantel-Haenszel method may be 
used to compute a summary (adjusted) relative risk and summary x2 
(Mantel and Haenszel, 1959). The adjusted relative risk is a weighted 
relative risk that takes into account the relative risk estimates for 
each stratum.
To determine whether or not a variable confounds the association 
between the outcome and the exposure, the crude (unadjusted) 
relative risk (Formula 10.12.1) is compared with the adjusted relative 
risk. If the adjusted relative risk estimate differs from the crude 
relative risk by more than some previously specified percentage, the 
variable may be considered a confounder. Under these 
circumstances, the adjusted relative risk estimate should be presented 
instead of the crude estimate.
In Table 10.16, the relative risk adjusted for age ( 3.1) differs from 




Current Oral Contraceptive Use and Myocardial Infarction 
Adjustment for Confounding by Age
Aye
OC Use
Yes No OR 95% Cl
<40 Cases 21 26
Controls 17 59 2.8 (1 .3-6 .1)
40-44 Cases 8 44
Controls 2 50 4.5 (1 .0 -2 0 3 )
Total Cases 29 70
Controls 19 109
Crude RR = 2.4 (95% Cl: 1.2 - 4.5)
R R mh = 3.1 (95% Cl: 1.6 - 6.3)
(Hogue et al., 1985)
age is a confounding variable in this study. Because age confounds 
the association between current OC use and the risk of myocardial 
infarction, the adjusted relative risk ( 3.1) should be reported. 
Current OC use is associated with a statistically significant 
increased risk of myocardial infarction; overall, women who 
currently use OCs have three times the risk of myocardial 
infarction as women who are not currently using OCs.
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Effect Modification Analysis Table
Some health problems or outcomes require analyses of subgroups 
of study participants. That is, does the risk of the health problem for 
the exposure of interest vary for different ages or is the risk greater 
for some racial or ethnic groups? Do women with a particular 
characteristic have a different risk than women without the 
characteristic? When the association between a health problem and 
an exposure varies according to categorizations of a particular 
variable, that variable is considered an effect modifier. In Table 
10.16, age is not only a confounder but also an effect modifier. The 
relative risks differ according to age. Among women who are 40 to 
44 years old, current OC users have 4.5 times the risk of a myocardial 
infarction as women of the same ages who were not currently using 
OCs. Among younger women the risk is 2.8.
Table 10.17 presents the risk, of developing epithelial ovarian 
cancer among women who have used OCs and women who have 
never used OCs, by age and parity (Cancer and Steroid Hormone 
Study, 1987). The risk of epithelial ovarian cancer does not appear to 
vary by age among women who had ever used OCs and women who 
had never used OCs. However, the risk of epithelial ovarian cancer 
varied slightly for different levels of parity. For example, nulliparous 
women had a risk of 0.7, women with parity 1 to 4 had a statistically 
significant reduced relative risks of 0.4 or 0.5, and women with parity 
5 or more had a relative risk of 1.2.
Although effect modification seems similar to confounding, the two 
are very different. A variable can be an effect modifier of the 
association between the outcome and an exposure, a confounder of 
the association, both, or neither. When effect modification appears to 
be present, Woolfs x2 test for heterogeneity may be used to test 
whether the variations in stratum-specific relative risks are real or due 
to chance (Woolf, 1955).
Advantages and Disadvantages
Advantages:
• Case-control studies are useful for studying health problems 
that occur infrequently.
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O varian Cancer by Age and P arity
Odds 95% Confidence
Table 10.17
Characteristic Cases Controls Interval
Age (years)
<30 15/ 32f . 53/206+ 0.5 (03  -1 .1)
3 0 -3 4 114/40 695/414 0.6 (0.4 - 0.9)
3 5 -3 9 6 1 /2 9 454/515 0.4 (03  - 0.7)
4 0 -4 4 3 3 /3 3 199/474 0.4 (03  - 0.7)
4 5 -4 9 10 /3 3 81/462 0.6 (03  - 12)
5 0 -5 4 9 /3 8 50/351 0.6 (03  - 13)
Parity
NuUiparous 6 3 /5 4 231/302 0.7 (0.4 - 1.0)
1 3 0 /3 4 135/292 0.5 (03  - 0.9)
2 6 0 /5 3 324/672 0.4 (03  - 0.6)
3 5 2 /3 7 305/578 0.4 (0.2 - 0.6)
4 22 / 10 245/294 0.4 (0.2 - 0.8)
5+ 15/ 17 292/284 12 (0.6 - 2.4)
* In each stratum, ever users are compared to never users. 
+Did not use/used oral contraceptives.
(The Cancer and Steroid Hormone Study, 1987)
• Case-control studies are useful for studying health problems 
with a long latent interval.
• The relatively short study period required usually makes 
case-control studies less time consuming and less expensive 
than cohort studies.
• Case-control studies are useful for characterizing the effects 




• Because cases and controls may be selected from two separate 
populations, it is difficult to ensure they are comparable with 
respect to extraneous risk factors and other sources of bias.
• Exposure data are collected from records or by recall after the 
disease has occurred. Records may be incomplete, and recall of 
past events is subject to human error and the possibility of 
selective recall.
• Case-control studies cannot be used to determine incidence 
rates.
• If the health problem is relatively common in the population 
(i.e., > 5%-10%), the odds ratio is not a reliable estimate of 
the relative risk.
• Case-control studies cannot be used to determine the other 
possible health effects of an exposure. By definition, case- 
control studies are concerned with only one outcome.
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Practice Exercises
1. In Example 10.3, investigators examined the association between IUDs and 
PID. Using the information presented in Table 10.18, analyze and interpret 
the data.
Table 10.18
The Risk of Pelvic Inflammatory Disease Among Women 
Who Use Intrauterine Devices and 
Women Who Use No Method of Contraception
IUD Use
Current No Method
PID IUD User Currently
Yes 841 724
No 518 967
(Burkinan et al., 1981)
(a) Compute the odds ratio and the 95% confidence interval for this study.
(b) Interpret the odds ratio and the confidence interval.
Case-Control Studies
(c) What are some questions the investigators should consider regarding the 
choice of the control group?
(d) What are some other potential risk factors for PID that need to be 
considered in the analysis?
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2. Example 10.19 presents a case-control study designed to investigate whether 
early age at first coitus is a risk factor for cervical cancer.
Problem: Is age at first coitus associated with cervical cancer?
Research Hypothesis: Age £  15 years at first coitus is positively associated with subsequent 
development of cervical cancer.
Study Design: Hospital-based case-control study
Cases: Women of any age with a histologic diagnosis of invasive cancer of cervix at one hospital.
Controls: Women of any age who were healthy and attended the hospital’s family planning 
clinic.
Exposure: The woman’s report that her age at first coitus was <  15 years.
Data Collection Methods: Questionnaires were administered to cases and controls.
Results:
Example 10.19
Early Age at First Coitus and Cervical Cancer
Cervical Cancer
Age a t F irs t Coitus 
^  IS  years >1S years
Yes (Cases) 36 78
No (Controls) 11 95
Crude OR = 4.0 (95% Cl: 2.0 - 8.1)
(Andolusi, 1977)
(a) Interpret the odds ratio and confidence interval.
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3. Example 10.20 presents a study of OC use and the risk of PID.
Case-Control Studies
Example 10.20
Current Oral Contraceptive Use and Pelvic Inflammatory Disease
Problem: Is current use of OCs associated with pelvic inflammatory disease (PID)?
Research Hypothesis: Current OC use is associated with PID.
Study Design: Hospital-based case-control study
Cases: Women 18 to 44 years old who were admitted to nine hospitals in the United States with 
an initial episode of PID.
Controls: Women 18 to 44 years old with no history of PID who were admitted to the same 
hospitals as the case patients but had acute conditions or elective procedures not related to PID.
Women in either group who reported sterility, recent pregnancy, or lack of sexual activity, as well 
as women with conditions that might contraindicate OC use, were excluded from the study.
Exposure: The woman’s report of the contraceptive method used in the three months prior to 
interview.




Outcome OC User Method Total
PID
Yes 139 170 309
No 831 558 1,389
Total 970 728
(Rubin et al., 1982)
Chapter 10
(a) Compute the odds ratio and the 95 % confidence interval.
(b) Interpret the odds ratio and confidence interval.
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4. In Example 10.21, the description of a study of depo-medroxyprogesterone 
acetate (DMPA) and the risk of breast cancer is presented:
Problem: Is DMPA use associated with the risk of breast cancer?
Research Hypothesis: DMPA is associated with the risk of breast cancer.
Study Design: Case-control study
Cases: Women 25 to 58 years old who were diagnosed with breast cancer between January 1,1982 
through March 31, 1984. The women were retrospectively enrolled using the National Tumor 
Registry records in Costa Rica.
Controls: Women 25 to 58 years old who were, selected at random from the general population with 
a multistage probability household survey.
Exposure: The woman’s report of using an injectable contraceptive.




D M P A  Use and Breast Cancer




Crude OR = 22  (95% Cl: 13  - 3.8)
(Lee et al., 1987)
(a) Interpret the odds ratio and confidence interval.
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5. Circle true (T) or false (F).
(a) T /F  In the case-control study, study subjects from the study population
are assigned to treatment or comparison groups.
(b) T /F  Cases are those who have the health problem under study.
(c) T /F  The purpose of the case-control study is to decide whether the
exposure under study could account for the health condition of the 
cases.
(d) T /F  If there is an association between the exposure and the health
problem, then the control group provides an estimate of the rate of 
exposure in the cases.
(e) T /F  To be enrolled in a case-control study, a case must clearly have the
health problem under study.
(f) T /F  Controls may be matched to cases to adjust for potentially
confounding variables.
(g) T /F  The effects of variables on which subjects have been matched
cannot be evaluated.
(h) T /F  Cases and controls should be matched on variables related to
exposure.
(i) T /F  Variables used for matching during data collection need not be
considered as matched variables for analysis.
(j) T /F  Relatives of cases may not be used for matching.
(k) T /F  The exposure variable must be defined in clear, measurable terms.
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6. Multiple Choice. Select one response.
6.1 All of the following are frequency measures of exposure except?
(a) Days per week vitamins taken
(b) Total months of condom use
(c) Parity
(d) Ever use of natural methods of birth control
(e) History of previous abortion
6.2 All of the following are measures of exposure related to time except?
(a) Age at first intercourse
(b) Time since IUD was inserted
(c) Current IUD use
(d) Duration of OC use
(e) Ever breast-fed
7. Which of the following are appropriate (True) methods to help reduce bias? 
Circle true (T) or false (F).
(a) T /F  Select all cases in a defined region.
(b) T /F  Choose controls at random from an appropriate population.
(c) T /F  If you use a hospital-based design, then the control group should
include individuals with different illnesses not associated with the 
exposure.
(d) T /F  Use memory aids to improve subject recall.
(e) T /F  Select controls whose recall bias is likely to be similar to the recall
bias of the cases.
(f) T /F  Validate recall with medical or other institutional records whenever
possible.
(g) T /F  Omit from the study any participants with poor memory.
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8. Multiple Choice. Select one response.
8.1 All the data sources listed below are useful in case-control studies except:
(a) Medical events that occur after diagnosis of the health problem of 
interest




Why do the measures of association used for cohort studies not apply to
case-control studies?
(a) Because you select controls from a different population than cases
(b) Because of selection bias
(c) Because you cannot determine rates without sampling exposure
(d) Because you sample exposed and unexposed individuals in a case- 
control design








9. Qrcle true (T) or false (F).
(a) T /F  Case-control studies are appropriate for infrequently occurring
health problems.
(b) T /F  Case-control studies are appropriate for determining incidence
rates.
(c) T /F  Case-control studies are inappropriate for studying problems with
long latency.
(d) T /F  Case-control studies are generally less expensive than cohort
studies.
(e) T /F  In case-control studies it is often difficult to ensure that cases and
controls are comparable.
(f) T /F  Data collected for case-control studies permit calculation of
relative risk.
(g) T /F  The odds ratio is an appropriate estimate of the relative risk when
the incidence rates of the health problem under study are high.
(h) T /F  Case-control studies usually require smaller study sizes than cohort
studies.
(i) T /F  A variable may be an effect modifier or a confounder, but not
both.
(j) T /F  Summary relative risk measures may mask increases or decreases
in risk that are present in subgroups.
(k) T /F  An OR greater or smaller than 1.0 implies that the risk of the
health problem is associated with the exposure.
(1) T /F  Confounding bias may be minimized or eliminated by exclusions,
matching, or analytic methods.
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10. In outline form, design a case-control study based on the following problem 
situation. State the problem and the hypothesis. Describe the cases and the 
controls and how both groups of women will be enrolled in the study. Define 
the exposure in measurable terms. Specify the data collection methods. 
Develop the analysis table for measuring any possible association between the 
outcome and the exposure.
Background: As a researcher you have a collaborative relationship with 
several health care providers that allows you to conduct scientific studies. In 
particular, you want to investigate the risk of myocardial infarction among 















11. Table 10.22 presents results from a study of ectopic pregnancy and current 
contraceptive methods (Ory et al., 1981).

























(a) Compute the odds ratios and confidence intervals for current IUD,
barrier or natural methods, and oral contraceptive use. Consider women 
who used no method as the referent category.
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(b) Interpret the odds ratios and confidence intervals.
(c) Compute the odds ratio and the 95% confidence interval for the risk of 
ectopic pregnancy among IUD users compared to OC users.
(d) Interpret the odds ratio and confidence intervals.
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Suggested Answers to Practice Exercises
1. Using the information in Table 10.18, analyze and interpret the data.
(a)
OR _ 841/724 = 2168 
518/967
n =3050
2 _ 3049 *(841 * 967 -  724 * 518)2
* ” (841 + 518) * (724 + 967) * (841 +724) * (518 * 967)
109.63
X “  10.47 
Lower Limit = 2.2^  “ L96/ 10-47) 
= 1.876




(b) Women who are current IUD users have a 2.2 times greater risk of PID 
than women who are not using any method of contraception. The 95% 
confidence interval means that the researcher was 95% confident that 
the true odds ratio is between 1.9 and 2.5. Another way of saying this is, 
we know that the OR is statistically larger than 1.0, since the lower 
confidence limit is greater than 1.0. Current IUD users are at greater 
risk of PID than women who are not currently using any method of 
contraception.
(c) Other questions the investigators might ask: Were cases and controls 
comparable? For example, perhaps controls should have been selected 
from a minor surgery clinic in the same hospital. Were other possible 
risk factors similar for cases and controls (e.g., number of sexual 
partners)?
(d) Age, marital status, education, history of sexually transmitted diseases, 
frequency of intercourse, previous episodes of PID, contraceptive history, 
previous episodes of IUD use, number of sexual partners.
2. Using Example 10.19, interpret the odds ratio.
(a) The risk of developing cervical cancer is approximately four times higher 
among women who were sexually active at age 15 years or younger than 
among women who were sexually active later in life. Since the 
confidence interval does not include 1.0, then the hypothesis that there is 
no difference between women with cervical dysplasia and controls is 
rejected.
3. Using Example 10.20, analyze and interpret the data.
(a) OR = 0.5 (95% Cl: 0.4 - 0.7)
(b) The risk of developing PID for women currently using OCs is 0.5 (half) 
that of women not currently using OCs.
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4. Interpret the odds ratio and confidence interval.
(a) The risk of breast cancer among women who use DMPA is twice the risk 
among women who have never used DM PA Since the confidence 
interval does not include 1.0, then the hypothesis that there is no 
difference in breast cancer risk between women who have used DMPA 
and women who have not used DMPA is rejected; the odds ratio is 
statistically significant.
5. True or false.
(a) F Introduction. No, groups are identified according to having or not
having a particular health problem.
(b) T Introduction
(c) T Introduction
(d) F Control Selection. No, the control group provides an estimjate of
the rate of exposure if there was no association between the 
exposure and the health problem.
(e) T  Case Selection
(f) T  Control Selection
(g) T Control Selection
(h) F Control Selection. No, cases and controls should be matched on
variables related to the exposure and the health problem.
(i) F Control Selection. No, matching during data collection must be
maintained for analysis.
(j) F Control Selection. No, matching on relatives may be important for
some investigations and will likely result in matching on other 
variables, such as diet and behaviors.




6.1 b Exposure Definition. Total months of condom use or duration of
condom use is a time-related measure of exposure.
6.2 e Exposure Definition. Ever breast-fed is a frequency measure of
exposure.
(a) T Selection Bias
(b) T  Selection Bias
(c) T  Information Bias
(d) T  Information Bias
(e) T  Information Bias
(f) T  Information Bias
(g) F  Information Bias. No, excluding study participants with a poor
memory is not a method for reducing bias. In fact, such an 
exclusion might introduce bias.
7. True or false.
(a) T Selection Bias
(b) T Selection Bias
(c) T Information Bias
(d) T Information Bias
(e) T Information Bias
(0 T Information Bias
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(g) F Information Bias. No, excluding study participants with a poor 
memoiy is not a method for reducing bias. In fact, such an 
exclusion might introduce bias.
8. Multiple choice.
8.1 a Data Collection Methods. We are interested in medical events that 
occurred prior to the diagnosis or enrollment in a case-control study.
8.2 c Data Analysis Methods
8.3 c Bias
9. True or false.
(a) T Advantages #1
(b) F Disadvantages #3. No, incidence rates cannot be computed from 
case-control data.
(c) F Advantages #2. No, case-control designs are ideal for studying 
health problems with long latency.
(d) T Advantages #3
(e) T Disadvantages # 2
(f) F Disadvantages. No, incidence rates cannot be computed from case- 
control data.
(g) F Data Analysis Methods. No, the odds ratio is an appropriate 
estimate of the relative risk when the incidence of the health 
problem is low.
(h) T Data Analysis Methods
(0 F Data Analysis Methods. A  variable may be both a confounder and 
an effect modifier.
(j) T Data Analysis Methods
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(k) T  Data Analysis Methods 
(1) T Data Analysis Methods
10. The answer given here is a suggested answer and is based on the report of the 
actual study referenced.
Example 10.23
Oral Contraceptive Use in the Past and Myocardial Infarction
Problem: Is long-term OC use in the past associated with the occurrence of myocardial 
infarction?
Research Hypothesis: Long-term OC use after discontinuation is associated with a myocardial 
infarction.
Study Design: Multicenter hospital-based case-control study
Cases: Women younger than 65 years old with an admission diagnosis of first myocardial 
infarction, defined according to World Health Organization criteria. Cases with a history of 
rheumatic valvular disease, cardiomyopathy, or cardiac surgery (including coronary artery bypass 
surgery) were excluded.
Controls: Women younger than 65 years old without a history of myocardial infarction, 
rheumatic valvular disease, cardiomyopathy, or cardiac surgery. Control women were admitted 
for nonmalignant and nongynecologic symptoms that were not related to OC use.
Exposure: The woman’s report that she used medicines including oral contraceptives and 
noncontraceptive estrogens. The timing and brands for all medicines taken were recorded.




Infarction Use Use Total
Yes 291 613 904
No 673 1,047 1,720
Total 964 1,660 2,624
(Rosenberg et al., 1990)
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11. Compute the odds ratios and confidence intervals.
(a) IUD OR = 0.4 (95% Cl: 0.3 - 0.6)
Barrier or 
natural OR = 0.3 (95% Cl: 0.25 - 0.45)
OC OR = 0.1 (95% Cl: 0.1 - 0.19)
(b) Women who are currently using IUDs, traditional methods of 
contraception, and OCs have a lower risk of an ectopic pregnancy than 
women who are currently not using any method. Since the confidence 
intervals do not include 1.0, the hypotheses of no association between 
ectopic pregnancy risk for women who use these methods compared with 
women who do not practice contraception are rejected.
(c) OR = 3.2 (95% Cl: 2.1 - 5.0)
(d) Women who are currently using an IUD have a greater risk of an ectopic 
pregnancy than women currently using OCs. Since the confidence interval 
does not include 1.0, the hypothesis of no association between ectopic 
pregnancy risk for women currently wearing an IUD compared with 
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Recommended Definitions, Standards, and Reporting 
Requirements for ICD-10 Related to Reproduction
Fetal, Perinatal, Neonatal, and Infant Mortality Definitions1
liv e  birth. Live birth is the complete expulsion or extraction from its mother 
of a product of conception, irrespective of the duration of the pregnancy, which, 
after such separation, breathes or shows any other evidence of life, such as 
beating of the heart, pulsation of the umbilical cord, or definite movement of 
voluntary muscles, whether or not the umbilical cord has been cut or the placenta 
is attached; each product of such a birth is considered livebom.
Fetal death (deadbom fetus). Fetal death is death prior to the complete 
expulsion or extraction from its mother of a product of conception, irrespective of 
the duration of pregnancy; the death is indicated by the fact that after such 
separation the fetus does not breathe or show any other evidence of life, such as 
beating of the heart, pulsation of the umbilical cord, or definite movement of 
voluntary muscles.
Birthweight. The first weight of the fetus or newborn obtained after birth.
Low birthweight. Less than 2,500 g (up to, and including 2,499 g).
Very low birthweight. Less than 1,500 g (up to, and including 1,499 g).
Extremely low birthweight. Less than 1,000 g (up to, and including 999 g).
Gestational age. The duration of gestation is measured from the first day of 
the last normal menstrual period. Gestational age is expressed in completed days 
or completed weeks (e.g., events occurring 280 to 286 completed days after the 
onset of the last normal menstrual period are considered to have occurred at 40 
weeks of gestation).
Preterm. Less than 37 completed weeks (less than 259 days) of gestation.
Term. From 37 completed weeks to less than 42 completed weeks (259 to 293 
days) of gestation.
1 World Health Organization. International Conference on the Tenth Revision of the International 
Classification o f Diseases, Geneva: World Health Organization, In Press 1991.
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Postterm. 42 completed weeks or more (294 days or more) of gestation.
Perinatal period. The perinatal period commences at 22 completed weeks (154 
days) of gestation (the time when birth weight is normally 500 g), and ends seven 
completed days after birth.
Neonatal period. The neonatal period commences at birth and ends 28 
completed days after birth. Neonatal deaths (deaths among live births during the 
first 28 completed days of life) may be subdivided into early neonatal deaths, 
occurring during the first seven days of life and late neonatal deaths, occurring 
after the seventh day but before 28 completed days of life.
Notes on Definitions
For live births, birth weight should preferably be measured within the first hour 
of life before significant postnatal weight loss has occurred. Whilst statistical 
tabulations include 500 g groupings for birth weight, weights should not be 
recorded in those groupings. The actual weight should be recorded to the degree 
of accuracy that it is measured.
The definitions of low, very low, and extremely low birthweight do not constitute 
mutually exclusive categories. Below the set limits they are all-inclusive and 
therefore overlap (i.e., low includes very low and extremely low, while very low 
includes extremely low).
Gestational age is frequently a source of confusion when calculations are based 
on menstrual dates. For the purposes of calculation of gestational age from the 
date of the first day of the last normal menstrual period and the date of delivery, 
it should be borne in mind that the first day is day zero and not day one; days 0-6 
therefore correspond to completed week zero, days 7-13 to completed week one, and 
the 40th week of actual gestation is synonymous with completed week 39. Where 
the date of the last normal menstrual period is not available, gestational age 
should be based on the best clinical estimate. In order to avoid misunderstanding, 
tabulations should indicate both weeks and days.
Age at death during the first day of life (day zero) should be expressed in units 
of completed minutes or hours of life. For the second (day 1), third (day 2), and 
subsequent days of life, age at death should be expressed in days.
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It is recognized that legal requirements for the registration of fetal deaths and 
live births still vary from country to country and even within countries. However, 
it is recommended that, wherever possible, all fetuses and infants delivered 
weighing at least 500 g, whether alive or dead, be included in the statistical 
tabulations. When birth weight is unavailable, the corresponding criteria for 
gestational age (22 completed weeks), or body length (25 cm crown-heel) should 
be used. The criteria for deciding whether an event has taken place within the 
perinatal period should be applied in the order 1) birth weight, 2) gestational age, 
3) crown-heel length. The inclusion of fetuses and infants weighing between 500 g 
and 1,000 g in national statistics is recommended both because of its inherent 
value and because this inclusion improves the completeness of reporting at 1,000 g 
and over.
In statistics for international comparison, inclusion of this group of births of 
extremely low birth weight disrupts the validity of comparisons and is not 
recommended. Countries should therefore arrange registration and reporting 
procedures so that the events and the criteria for their inclusion in the statistics 
can be easily identified. Less mature fetuses and infants not corresponding to 
these criteria should be excluded from perinatal statistics unless there are legal or 
other valid reasons to the contrary, in which case this inclusion must be explicitly 
stated. Where these characteristics are unknown, the event should be included in, 
rather than excluded from, mortality statistics of the perinatal period. Countries 
should also present standard statistics in which both the numerator and the 
denominator of all ratios and rates are restricted to fetuses and infants weighing 
1,000 g or more (weight-specific ratios and rates); where birth weight is 
unavailable, the corresponding gestational age (28 completed weeks) or body 
length (35 cm crown-heel) should be used.
In reporting fetal, perinatal, neonatal and infant mortality statistics the number 
of deaths due to malformations should whenever possible be identified for live 
births and fetal deaths and in relation to birth weight of 500-999 g and 1,000 g or 
more. Neonatal deaths due to malformations should be subdivided into early and 
late neonatal deaths. The availability of this information enables perinatal and 
neonatal mortality statistics to be reported with or without the deaths from 
malformations. A malformation is defined as a congenital morphological 




Recommended Definitions, Standards, and
Reporting Requirements Related to Reproduction
Ratios and Rates
Published ratios and rates should always specify the denominator that has been 
used, i.e., live births or total births (live births plus fetal deaths). Countries are 
encouraged to provide the ratios and rates listed below, or as many of them as 
their data collection systems permit:
Fetal death ratio: Fetal deatto * 1,000 
Live births
Fetal death rate: Feta] deaths  ̂ 1000 
Total births
Fetal death rate, weight-specific: Fetal deaths weighing l,000.g_agd over „ 1>000
Total births weighing 1,000 g and over
Early neonatal mortality rate: Early ne!onatal deaths m 1000
Live births
Early neonatal mortality rate, weight-specific:
Early neonatal deaths of infants weighing 1,000 g and over at birth  ̂ jqqq 
Live births weighing 1,000 g and over
Perinatal mortality ratio: Fetal deaths ^  SF *  neonatal deaths * 1,000
Live births
Perinatal mortality ra te1: Fetal deaths and early neonatal deaths „ lfiQQ
Total births
1 The perinatal mortality rate is the number of fetal deaths weighing at least 500 g (or, when birth 
weight is unavailable, after 22 completed weeks of gestation or with a crown-heel length of 25 cm or 
more), plus the number of early neonatal deaths, per 1,000 total births. Because of the different 
denominators in each component, this is not necessarily equal to the sum of the fetal death rate and 
the early neonatal mortality rate.
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Perinatal mortality rate, weight-specific:
Fetal deaths weighing 1,000 g and over, plus 
early neonatal deaths of infants weighing 1,000 g and over at birth +  ̂
Total births weighing 1,000 g and over
Neonatal mortality rate: Neonatal deaths * 1,000
Live births
Neonatal mortality rate, weight-specific:
Neonatal deaths of infants weighing 1,000 g and over at birth  ̂ ^qqq 
Live births weighing 1,000 g and over
Infant mortality rate: Number of deaths under one year of age ,  1(XX)
Live births
Infant mortality rate, weight-specific:
Infant deaths among live births weighing 1,000 g and over at birth ^ iQOO 
Live births weighing 1,000 g and over
Maternal Mortality Definitions
Maternal death. The death of a woman while pregnant or within 42 days of 
termination of pregnancy, irrespective of the duration and the site of the 
pregnancy, from any cause related to or aggravated by the pregnancy or its 
management, but not from accidental or incidental causes.
Late maternal death. The death of a woman from direct or indirect obstetric 
causes more than 42 days but less than one year after termination of pregnancy.
Pregnancy-related death. The death of a woman while pregnant or within 42 
days of termination of pregnancy, irrespective of the cause of death. This 
definition is provided to permit calculation of an alternative to the maternal death 
rate in countries that wish to identify deaths occurring in pregnancy, childbirth 
and the puerperium, but cannot distinguish direct and indirect maternal deaths as 
defined.
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Maternal deaths should be subdivided into two groups:
Direct obstetric deaths: those resulting from obstetric complications of the 
pregnant state (pregnancy, labor and puerperium), from interventions, omissions, 
incorrect treatment, or from a chain of events resulting from any of the above.
Indirect obstetric deaths: those resulting from previous existing disease or 
disease that developed during pregnancy and which was not due to direct obstetric 
causes, but which was aggravated by physiologic effects of pregnancy.
Reporting Requirements
For the purposes of the international reporting of maternal mortality only those 
maternal deaths occurring before the end of the 42-day reference period should 
be included in the calculation of the various ratios and rates, though the recording 
of later deaths is useful for national analytical purposes.
Late maternal deaths should not be included in the calculation of the maternal 
mortality rate.
Published maternal mortality rates should always specify the numerator 
(number of recorded maternal deaths), which can be given as:
• the number of recorded direct obstetric deaths, or
• the number of recorded obstetric deaths (direct plus indirect).
The denominator used for calculation should likewise be specified as either the 
number of live births or the total number of births (live births plus fetal deaths). 




These should be expressed as a ratio of the numerator to the denominator, 
multiplied by k (where k may be 1,000, 10,000, or 100,000 as preferred and 
indicated by the country). Maternal mortality ratios and rates can thus be 
expressed as:
Maternal mortality rate1 : Maternal deaths (direct and indirect) # k
Live births
Direct obstetric mortality ratio: Direct obstetric deaths only # k
Live births
Pregnancy-related mortality ratio: Pregnancy~ related deaths * k
Live births
Ratios and Rates






Life-table analysis is a method of summarizing the results of a study by time, 
that is, by grouping into smaller intervals the time between admission to a study 
and the end of the designated follow-up period. For each time interval, life-table 
analysis records the number of study subjects who are still in the study at the start 
of the interval, the number who experience the outcome of interest during the 
interval (e.g., pregnancy, intrauterine device (IUD) expulsion, continuation of 
contraceptive use), and the number of study subjects who discontinue participation 
during the interval without having had the outcome of interest (i.e., because they 
are lost to follow-up or no longer participate in the study for a reason other than 
the outcome of interest). From these numbers, the probability of the outcome 
event occurring in each interval is estimated.
The major advantage of the life-table approach is that it takes into account how 
long each participant is in the study. Life tables take advantage of the experience 
of individuals even though they do not complete the study. This establishes the 
period of time within the study when each participant was at risk of exhibiting the 
outcome of interest.
Grouping observations into fixed  time periods o f follow-up. In most clinical 
trials, the subjects do not enter the study at the same time. Their entry is 
staggered. In life-table analysis, however, all entry times are considered time 
zero. In Figure 1, study subjects were recruited during a one-year time period 
and followed up for one year. Their staggered entry is shown in the upper panel 
of the figure. Study subjects 1 and 4 completed the trial without experiencing the 
event of interest (i.e., pregnancy). Study subject 3 was lost to follow-up and study 
subjects 2 and 5 experienced the event of interest during the follow-up. For life- 
table analysis, the time of follow-up observation for the five study subjects are 
shown in the lower panel of Figure 1. All entry times are at time zero.
Study subjects who do not experience the event of interest while they are being 
followed up are said to survive (without the event). They could complete the 
study without the event or drop out (be withdrawn because they have an event 
that disqualifies them from the study or be lost to follow-up). Some study subjects 
enter the study near its conclusion and do not complete the full time period 
before the conclusion of the study. In these situations, the follow-up experience 
of all study subjects who survive is said to be censored before we can observe the 
event of interest. Note, however, that the term censored as used for any particular 
time period includes only those lost or discontinued during the interval for some 






Tim e Since Start of Trial Versus Follow-up Time
1
2 -- 
t 3-Z*  - 
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0  RECRUITMENT 1 2
Time Since Start of Trial (years)
l a
0  1 2 
Foftow-upTlme (years)
o = Completed trial with no event 
•  = Had the event of interest during foftow-up 
a  *  Withdrawn or lost to follow-up
The steps and formulas required for life-table calculations are:
Step 1. Group the observations into fixed time periods of follow-up.
Step 2. Compute the probability of surviving any time interval, the ith interval, 
given survival up to the beginning of the interval as:
(8.33.1)
„  _  n t “  d i "  ( c i / 2 )
» . - ( C . / 2 )
where n ; = number of subjects entering the ith interval; d; = number of events of 
interest in the ith interval; c; = number of subjects censored in the ith interval 
(lost-to-follow-up or discontinuing for a reason other than the event of interest); qj 
is also called the survival rate for the ith interval; and n. -  (c. /2) is the group at 
risk for the event of interest during the ith interval.
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Step 3. Compute the probability of not surviving the ith interval as:
(8.33.2)
P i  = 1 “  <li 
d.
n i “  ( c i / 2 )
Pi is also called the event rate for the ith interval.
Step 4. Compute the probability of surviving from the beginning of the study 
until the end of each time interval. The probability of surviving from the 
beginning of the study until the end of the ith interval is:
(833.3)
Sj = «qi
S; is also called the cumulative survival rate.
Step S. Compute the probability of experiencing the event of interest sometime 
from admission to the study until the end of the ith interval, 1 -  S i. This is also 
called the cumulative event rate.
Step 6. Compute the variance of the cumulative event rate for the ith interval
as:
(833.4)
Variance (1 -  S. ) * Variance(S. )
k * 1 nk -  dk -  (ck /2) nk -  (ck /2 )
Step 7. Compute the Standard Error (SE) for 1 -  Sj as:
(833.5)
SE (1 -  S ,)  = SE (S. )
= ^ Variance (S, )
Recall that the SE of the cumulative event rate is also known as the standard 
deviation. Steps 3, 5, and 7 are required for the life tables in Table 2. The other 
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SE ( 1 - S , )
1 723 15 104 0.0224 0.0224 0.0057
2 604 8 35 0.0136 0.0357 0.0073
3 561 12 26 0.0219 0.0568 0.0094
4 523 10 41 0.0199 0.0756 0.0109.
5 472 11 31 0.0241 0.0979 0.0125
6 430 10 31 0.0241 0.11% 0.0140
7 389 6 23 0.0159 0.1336 0.0149
8 360 6 8 0.0169 0.1482 0.0158
9 346 5 11 0.0147 0.1607 0.0165
10 330 4 24 0.0126 0.1713 0.0171






1 717 5 102 0.0075 0.0075 0.0033
2 610 9 14 0.0149 0.0223 0.0059
3 587 12 39 0.0211 0.0430 0.0083
4 536 4 49 0.0078 0.0505 0.0090
5 483 6 36 0.0129 0.0627 0.0102
6 441 7 31 0.0165 0.0781 0.0116
7 403 3 24 0.0077 0.0852 0.0122
8 376 5 16 0.0136 0.0977 0.0132
9 355 3 23 0.0087 0.1055 0.0139
10 329 3 25 0.0095 0.1140 0.0146
11 301 0 24 0.0000 0.1140 0.0146
12 277 4.
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_ n . " d. -(c,/2) 
», ~ (c, /2)
,  723 -  15 -  (104 /2)




, = 1 -  q, = 1 -  0.9776 = 0.0224 
, = q, = 0.9776 
, =0.0224
) -s* *
n i — d i — (ci / 2) “ i — (c, /2)
= 0.97762 * [------------ 1________  -   I___1
[723 -  15 -  (104 /2) 723 -  (104 /2) J
= (0.9557) * f_ L  -  — } 
v '  [656 671J
= 0.00033 
) = ^ Variance (1 -  S ,) = 0.0057
®2 d 2 ( C2 /2)
2 n2 ~ (C2 /2)
_ 604 -  8 -  (35 /2)




2 = 1 -  q2 = 0.0136 
2 = q, * q2 « 0.9776 * 0.9864 
= 0.9643 
2 = 0.0357
1► « 0.96432 *
656 -6 7 1  5785 -  5865




Table 2 contains follow-up data from the randomized parallel clinical trial of 
the contraceptive sponge and the diaphragm in Example 8.32 (Edelman et al., 
1984). The format for Table 2 is a good working format. To illustrate the 
calculations, consider the first two months of follow-up for sponge users (Use 
formulas 8.33.1 through 8.33.5).
In reporting the results of a life-table analysis, the emphasis is on the 
cumulative event rate (cumulative pregnancy probability (1 -S ; ) in Table 2).
With the cumulative event rate, the probability of having the event of interest 
within the first k months of use of a treatment can be estimated. For example, 
the probability of becoming pregnant in the first six months is 0.1196 for sponge 
users and 0.0781 for diaphragm users. The SE for the cumulative event rate 
measures the precision of the estimate.
For comparative trials, the interest is usually in comparing cumulative event 
rates or probabilities between treatments. This is the probability calculated in 
Step 5 as shown in Table 2. A  useful way to compare cumulative event rates is to 
plot them. The method of plotting is illustrated in Figure 3. Since the estimates 
of cumulative event rates are made at the end of each month, the plotted points 
are joined by steps rather than by straight lines. The joined, plotted points are 
called cumulative event rate curves.
Figure 3 
Cumulative Pregnancy Rates 









The rates are expressed as pregnancies per 100 women. For the contraceptive 
sponge, the annual pregnancy rate is estimated at about 17 per 100 women. For 
the diaphragm, approximately 13 of 100 users will become pregnant within one 
year. The plots show that throughout the follow-up, sponge users have a higher 
pregnancy rate than diaphragm users.
Point Estimates and Confidence Intervals
The primary point estimate from the life table is the cumulative event rate at 
different times during the follow-up. By combining the point estimates of the 
cumulative event rate with the corresponding standard error of the estimate of the 
cumulative event rate, a confidence interval for the cumulative event rate at a 
specific time during the follow-up can be calculated. The formula for a 95% 
confidence interval is:
(8.34.1)
Lower Limit = (1 -  -  1.96 * SE, (1 -  Sj)
Upper Limit = (1 -  S i) + 1.96 * SE-, (1 -  SO
For the contraceptive sponge data in Table 2, the 95% confidence interval for the 
12-month cumulative pregnancy probability is:
Lower Limit = 0.1741 -  1.96 * 0.0173 = 0.1402 
Upper Limit = 0.1741 + 1.96 * 0.0173 = 0.2080
Note that the values for (1 -  S ;) and SEi (1 — S j) to be used in formula 8.34.1 
are from the last line of the upper panel in Table 2.
Table 4
Condensed Life Table 
Sponge Users
95% Cl for the
Follow-up Cumulative Cumulative
Month Presnancv % Probability
1 2.24 (1.12, 336)
3 5.68 (3.84, 9.52)
6 11.96 (9.22, 14.70)
9 16.07 (12.84, 19.30)
12 17.41 (14.02, 20.80)
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Life-table Analysis
In reports and publications, it is useful to present an abbreviated version of the 
working life table that includes a column for the confidence interval for the 
cumulative event rate. The cumulative event rate and confidence intervals may 
be expressed as percentages or proportions. Table 4 presents the cumulative 
pregnancy probability and confidence intervals expressed as percentages.
Statistical Comparison. The relative effectiveness of two treatments is best 
evaluated statistically by comparing the cumulative rate curves for the total study 
period. The logrank method uses a chi-square (x2) statistic to compare the 
number of observed events for each treatment with the number of events expected 
if the treatments were equally effective. For purposes of illustration, assume that 
we are comparing treatment A with treatment B. The calculations are made 
easier by using a table that requires the following entries:
i = the number of the follow-up interval (e.g., month i where i = 1, 2, . .  .,
12).
d; = total number of events observed in interval i (both treatments combined).
nAi = number at risk in treatment group A in interval i.
= number in group A entering the interval -  1/2 the number in group A
censored during the interval.
n Bi = number at risk in treatment group B in interval i.
= number in group B entering the interval -  1/2 the number in group B
censored during the interval.
E *  = expected number of events in group A in interval i.
(836.1)
E Bi = expected number of events in group B in interval i.
(836.2)
Appendix 3
In the sponge and diaphragm example, consider the first month in Table 2: 
d j = 15 sponge pregnancies + 5 diaphragm pregnancies = 20 pregnancies.
During the first month of follow-up, 723 sponge users entered the trial, 104 quit 
the trial for a reason other than pregnancy or were lost to follow-up (censored) 
during the month.
n sl = 723 -  (104/2) = 671 where S refers to sponge usage.
During the first month of follow-up, 717 diaphragm users entered the trial, 102
quit the trial or were lost to follow-up (censored) during the month.
n m = 717 -  (102/2) = 666 where D refers to diaphragm usage.
E„ = ___—  * d, = -----— ------ f  20 = 10.04
S1 n s, + n D1 1 671 +666
E di = d 1 -  E S1 = 20 -  10.04 = 9.96
The calculations in Table 5 are used to determine E s and E „ , the expected 
number of pregnancies among the sponge and the diaphragm users, respectively. 
The expected values are compared to the observed values using the following 
chi-square (x2) statistic with 1 degree of freedom (df):
(837.1)
^  (O s - E s ) ’ A (Od - E D) 2 
"  E  -------E---------
1 1 S D
(88 — 73.79)2 ^ (61 -  7521)2 
73.79 75.21
= 5.42
where O s and O d are the observed number of pregnancies among the sponge and 
the diaphragm users, respectively (see Table 2). The example xL= 5.42 has a  p- 
value slightly less than 0.025. This is a small p-value and indicates a statistically 
significant probability that the two treatments are not equally effective. The small 
p-value taken together with the life-table displays and the plot of the cumulative 









i d, »81 n DI E» E d ,
1 20 671 666 10.04 9.96
2 17 586.5 603 8.38 8.62
3 24 548 567.5 11.79 12.21
4 14 502.5 511.5 6.94 7.06
5 17 456.5 465 8.42 8.58
6 17 414.5 425.5 839 8.61
7 9 377.5 391 4.42 4.58
8 11 356 368 5.41 5.59
9 8 340.5 343.5 3.98 4.02
10 7 318 316.5 351 3.49
11 1 296 289 0.51 0.49
12 4 246.5 245.5 2.00 
E s = 73.79
2.00 




Circle true (T) or false (F).
(a) T /F  In life table analysis, we are interested in how long persons in
the trial do not have the outcome.
(b) T /F  Life tables summarize results of the study according to time
intervals.
(c) T /F  Life tables take advantage of the experience of individuals even
though those persons do not complete the study.
(d) T /F  Life tables provide a method of recording the actual time when
study subjects enter the trial.
(e) T /F  Life-table analysis permits estimates of the probability that an
individual who follows a particular treatment regimen will have 
the outcome within 3 months.
(f) T /F  The results of life tables are usually analyzed by visual methods
alone.




Suggested Answers to Practice Exercises
1. True or false.
(a) T
(b) T
(c) T Any length of time in the study is recorded in the life table.
(d) F No. In the analysis, all participants are treated as if they enter the
study at the same time.
(e) T
(f) F  No. Visual methods and formal statistical tests are used to analyze
life tables.
(g) T
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